

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:39:17 ; Search time 0.001 Seconds
(without alignments)
41.256 Million cell updates/sec

Title: US-10-605-498-91-COPY

Perfect score: 764

Sequence: 1 ggcacgaggcagcagtcag.....aagttcaagcaaccacctg 764

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 2 segs, 27 residues

Total number of hits satisfying chosen parameters: 4

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 2 summaries

Database : estdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	11.4	1.5	13	1	BM394028
2	11.4	1.5	14	1	BM394028

ALIGNMENTS

RESULT 1
BM394028/c
LOCUS
DEFINITION 50072-2-12-E02.X.1 Chilcoat/Turkewitz cDNA (large fraction)
Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION BM394028
VERSION BM394028.1 GI:18194066
SOURCE EST.
ORGANISM Tetrahymena thermophila
Tetrahymena thermophila
Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
Hymenostomatida; Tetrahymenina; Tetrahymenidae; Tetrahymena.
1 (bases 1 to 13)
Turkewitz,A.P., Karrer,K.M., Jahn,C., Orlas,E., Kirk,K.E.,
Frankel,J. and Klobutcher,L.
EST from Tetrahymena thermophila, strain CU428.1, growing cells
Unpublished (2002)
Contact: Turkewitz AP
Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.
Location/Qualifiers

source

1. .13
/organism="Tetrahymena thermophila"
/mol_type="mRNA"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_lib="Chilcoat/Turkewitz cDNA (large fraction)"
/notes="Vector: Bluescript2 SK+; Details on library preparation can be found in Chilcoat and Turkewitz (2001) Proc. Natl. Acad. Sci USA, 98: 8709-8713."

Query Match 1.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 597 TTGGGGGGCCCGA 609

DB 13 TAGGGGGGGCCG 1

RESULT 2

BQ584787

LOCUS

DEFINITION

CDNA clone 024-002-K09-SP6R MP1Z-ADIS-024-inflorescence Beta vulgaris

ACCESSION BQ584787

VERSION BQ584787.1 GI:26114364

KEYWORDS EST.

SOURCE Beta vulgaris

ORGANISM Beta vulgaris

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyllales; Magnoliophyta; eudicotyledons; core eudicots;

Caryophyllales; Amaranthaceae; Beta.

REFERENCE 1 (bases 1 to 14)

AUTHORS Herwig,R., Schulz,B.; Weisshaar,B., Hennig,S., Steinfath,M.,

Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.

and Radelof,U.

TITLE Construction of a 'unigene' cDNA clone set by oligonucleotide

fingerprinting allows access to 25 000 potential sugar beet genes

JOURNAL Plant J. 32 (5), 845-857 (2002)

MEDLINE 22362189

PUBMED 12472698

COMMENT Contact: Weisshaar B

ADIS DNA core facility at MP1Z

Max-Planck-Institute for Plant Breeding Research

Carl-von-Linne Weg 10, 50829 Koeln, Germany

Fax: 00492215062851

Email: weisshaar@mpiz-koeln.mpg.de

Insert Length: 14 Std Error: 0.00

Plate: 2 row: K column: 09

Seq primer: SP6r; ATTAGGTGACACTATAGAAGA.

Location/Qualifiers

1. .14

/organism="Beta vulgaris"

/mol_type="mRNA"

/cultivar="KWS2320 (double haploid, monogerm breeding

line)"

/db_xref="GABI:181901"

/db_xref="taxon:161934"

/clone="024-002-K09"

/tissue_type="inflorescence"

/lab_host="EMDH108"

/clone_lib="MP1Z-ADIS-024-inflorescence"

/notes="Vector: pCMVSPORT6; Site 1: SalI; Site 2: NotI;

cDNA library from sugar beet, library provided by KWS

Kleinwanzlebener Saatgut AG Einbeck, Germany, contact:

b.schulz@kws.de; cloning sites SalI-NotI, primer sites and

orientation:

SP6-Sali-CCACGCGTCGCG-5prime-cDNA-polyA-CC-NotI-T7; Note:

Sequencing granted in the context of the GABI-Beet

project, local PI: Dr. Katharina Schneider, coordinator:

Prof. Christian Jung; Sequence submission managed by

RZPD/GABI-Primary database: http://gabi.rzpd.de"

Query Match 1.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 0;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 724 ATCTTCTGTTTTT 736
||| ||| ||| |||
Db 2 ATCTTCTGATTTT 14

Search completed: October 18, 2005, 09:39:17
Job time : 0.001 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:40:46 ; Search time 2 Seconds
(without alignments)
2.828 Million cell updates/sec

Title: US-10-605-498-91-COPY
Perfect score: 764
Sequence: 1 ggcacgaggagcagatgcag.....aagttcaagcaaccacctg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 200 seqs, 3702 residues

Total number of hits satisfying chosen parameters: 400

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 201 summaries

Database : gedb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	25	3.3	25	1	AR091050
C 2	25	3.3	25	1	AR198085
C 3	25	3.3	25	1	AR260239
C 4	24	3.1	24	1	AR091049
C 5	24	3.1	24	1	AR198084
C 6	24	3.1	24	1	AR260238
C 7	21.4	2.8	23	1	AX454996
C 8	21	2.7	21	1	AR099903
C 9	21	2.7	21	1	AR099904
C 10	21	2.7	21	1	AR099905
C 11	21	2.7	21	1	AR099906
C 12	21	2.7	21	1	AR099907
C 13	21	2.7	21	1	AR099908
C 14	21	2.7	21	1	AR099909
C 15	21	2.7	21	1	AR099910
C 16	21	2.7	21	1	AR099911
C 17	21	2.7	21	1	AR099912
C 18	21	2.7	21	1	AR099913
C 19	21	2.7	21	1	AR099914
C 20	21	2.7	21	1	AR099915
C 21	21	2.7	21	1	AR099916
C 22	21	2.7	21	1	AR099917
C 23	21	2.7	21	1	AR099918
C 24	21	2.7	21	1	AR099919
C 25	21	2.7	21	1	AR099920
C 26	21	2.7	21	1	AR099921
C 27	21	2.7	21	1	AR099922
C 28	21	2.7	21	1	AR099923
C 29	21	2.7	21	1	AR099924
C 30	21	2.7	21	1	AR099925
C 31	21	2.7	21	1	AR099926
C 32	21	2.7	21	1	AR099927
C 33	21	2.7	21	1	AR099928

C 34	21	2.7	21	1	AR099929
C 35	21	2.7	21	1	AR099930
C 36	21	2.7	21	1	AR099931
C 37	21	2.7	21	1	AR099932
C 38	21	2.7	21	1	AR099933
C 39	21	2.7	21	1	AR099934
C 40	21	2.7	21	1	AR099935
C 41	21	2.7	21	1	AR099936
C 42	21	2.7	21	1	AR099937
C 43	21	2.7	21	1	AR099938
C 44	21	2.7	21	1	AR099939
C 45	21	2.7	21	1	AR099940
C 46	21	2.7	21	1	AR099941
C 47	21	2.7	21	1	AR099942
C 48	21	2.7	21	1	AR099943
C 49	21	2.7	21	1	AR099944
C 50	21	2.7	21	1	AR099945
C 51	21	2.7	21	1	AR099946
C 52	21	2.7	21	1	AR099947
C 53	21	2.7	21	1	AR099948
C 54	21	2.7	21	1	AR099949
C 55	21	2.7	21	1	AR099950
C 56	21	2.7	21	1	AR099951
C 57	21	2.7	21	1	AR099952
C 58	21	2.7	21	1	AR099953
C 59	21	2.7	21	1	AR099954
C 60	21	2.7	21	1	AR099955
C 61	21	2.7	21	1	AR099956
C 62	21	2.7	21	1	AR099957
C 63	21	2.7	21	1	AR099958
C 64	21	2.7	21	1	AR099959
C 65	21	2.7	21	1	AR099960
C 66	21	2.7	21	1	AR099961
C 67	21	2.7	21	1	AR099962
C 68	21	2.7	21	1	AR099963
C 69	21	2.7	21	1	AR099964
C 70	21	2.7	21	1	AR099965
C 71	21	2.7	21	1	AR099966
C 72	21	2.7	21	1	AR099967
C 73	21	2.7	21	1	AR099968
C 74	21	2.7	21	1	AR099969
C 75	21	2.7	21	1	AR099970
C 76	21	2.7	21	1	AR099971
C 77	21	2.7	21	1	AR099972
C 78	21	2.7	21	1	AR099973
C 79	21	2.7	21	1	AR099974
C 80	21	2.7	21	1	AR099975
C 81	21	2.7	21	1	AR099976
C 82	21	2.7	21	1	AR099977
C 83	21	2.7	21	1	AR099978
C 84	21	2.7	21	1	AR099979
C 85	21	2.7	21	1	AR099980
C 86	21	2.7	21	1	AR099981
C 87	21	2.7	21	1	AR099982
C 88	20	2.6	20	1	AR099983
C 89	19	2.5	19	1	AR099984
C 90	19	2.5	19	1	AR099985
C 91	18.4	2.4	21	1	BD178972
C 92	18	2.4	18	1	AR099979
C 93	17.8	2.3	21	1	AR099991
C 94	17.8	2.3	22	1	BD178973
C 95	17.4	2.3	20	1	BD230260
C 96	17	2.2	17	1	AX671859
C 97	17	2.2	17	1	AX728678
C 98	17	2.2	17	1	AX738957
C 99	17	2.2	17	1	AX762937
C 100	15.8	2.1	19	1	AR099985
C 101	15.8	2.1	21	1	AR099909
C 102	15.4	2.0	17	1	CO625927
C 103	15.4	2.0	17	1	AR466990
C 104	15.4	2.0	17	1	AX735327
C 105	15.4	2.0	17	1	AX762926
C 106	15	2.0	15	1	AR180537

```
c 107 14.8 1.9 18 1 AR072210 ACCESSION:AR072210
c 108 14.8 1.9 18 1 CQ786325 ACCESSION:CQ786325
c 109 14.8 1.9 18 1 I26321 ACCESSION:I26321
c 110 14.8 1.9 18 1 AR392122 ACCESSION:AR392122
c 111 14.8 1.9 18 1 AX480662 ACCESSION:AX480662
c 112 14.4 1.9 16 1 I69196 ACCESSION:I69196
c 113 14.4 1.9 16 1 AR253794 ACCESSION:AR253794
c 114 14.4 1.9 16 1 AX696849 ACCESSION:AX696849
c 115 14.4 1.9 17 1 CQ625926 ACCESSION:CQ625926
c 116 14.4 1.9 17 1 CQ625928 ACCESSION:CQ625928
c 117 14.4 1.9 17 1 AR466989 ACCESSION:AR466989
c 118 14.4 1.9 17 1 AR466991 ACCESSION:AR466991
c 119 14.4 1.9 17 1 AR461541 ACCESSION:AR461541
c 120 14.4 1.9 17 1 AX615412 ACCESSION:AX615412
c 121 14.4 1.9 17 1 AX783872 ACCESSION:AX783872
c 122 14.4 1.9 17 1 AX783873 ACCESSION:AX783873
c 123 14.4 1.9 18 1 AR096356 ACCESSION:AR096356
c 124 14.4 1.9 18 1 AR109825 ACCESSION:AR109825
c 125 14.4 1.9 18 1 BD217404 ACCESSION:BD217404
c 126 14.4 1.9 18 1 AR294360 ACCESSION:AR294360
c 127 14.4 1.8 17 1 AX215323 ACCESSION:AX215323
c 128 14.4 1.8 17 1 AX216349 ACCESSION:AX216349
c 129 14.4 1.8 17 1 AX266839 ACCESSION:AX266839
c 130 14.4 1.8 17 1 AX266840 ACCESSION:AX266840
c 131 13.8 1.8 17 1 AR164573 ACCESSION:AR164573
c 132 13.8 1.8 17 1 BD197647 ACCESSION:BD197647
c 133 13.8 1.8 17 1 BD241652 ACCESSION:BD241652
c 134 13.8 1.8 17 1 CQ617589 ACCESSION:CQ617589
c 135 13.8 1.8 17 1 CQ617590 ACCESSION:CQ617590
c 136 13.8 1.8 17 1 CQ617591 ACCESSION:CQ617591
c 137 13.8 1.8 17 1 CQ625929 ACCESSION:CQ625929
c 138 13.8 1.8 17 1 CQ625930 ACCESSION:CQ625930
c 139 13.8 1.8 17 1 AR286401 ACCESSION:AR286401
c 140 13.8 1.8 17 1 AR398391 ACCESSION:AR398391
c 141 13.8 1.8 17 1 AR458652 ACCESSION:AR458652
c 142 13.8 1.8 17 1 AR458653 ACCESSION:AR458653
c 143 13.8 1.8 17 1 AR458654 ACCESSION:AR458654
c 144 13.8 1.8 17 1 AR466992 ACCESSION:AR466992
c 145 13.8 1.8 17 1 AR466993 ACCESSION:AR466993
c 146 13.8 1.8 17 1 AR483153 ACCESSION:AR483153
c 147 13.8 1.8 17 1 AX216972 ACCESSION:AX216972
c 148 13.8 1.8 17 1 AX498863 ACCESSION:AX498863
c 149 13.8 1.8 17 1 AX531714 ACCESSION:AX531714
c 150 13.8 1.8 17 1 AX579468 ACCESSION:AX579468
c 151 13.8 1.8 17 1 AX580066 ACCESSION:AX580066
c 152 13.8 1.8 17 1 AX580067 ACCESSION:AX580067
c 153 13.8 1.8 17 1 AX725108 ACCESSION:AX725108
c 154 13.8 1.8 17 1 AX725434 ACCESSION:AX725434
c 155 13.8 1.8 17 1 AX735751 ACCESSION:AX735751
c 156 13.8 1.8 17 1 AX736224 ACCESSION:AX736224
c 157 13.8 1.8 17 1 AX753978 ACCESSION:AX753978
c 158 13.8 1.8 17 1 AX783428 ACCESSION:AX783428
c 159 13.8 1.8 17 1 AX783429 ACCESSION:AX783429
c 160 13.8 1.7 21 1 CQ799952 ACCESSION:CQ799952
c 161 12.8 1.7 16 1 AR110507 ACCESSION:AR110507
c 162 12.8 1.7 16 1 AR137060 ACCESSION:AR137060
c 163 12.8 1.7 16 1 BD266330 ACCESSION:BD266330
c 164 12.8 1.7 16 1 CQ858645 ACCESSION:CQ858645
c 165 12.8 1.7 16 1 I69269 ACCESSION:I69269
c 166 12.8 1.7 16 1 AR253867 ACCESSION:AR253867
c 167 12.8 1.7 16 1 AR391398 ACCESSION:AR391398
c 168 12.8 1.7 16 1 AR391498 ACCESSION:AR391498
c 169 12.8 1.7 16 1 AR435928 ACCESSION:AR435928
c 170 12.8 1.7 16 1 AR451605 ACCESSION:AR451605
c 171 12.8 1.7 16 1 AR451617 ACCESSION:AR451617
c 172 12.8 1.7 16 1 AX073744 ACCESSION:AX073744
c 173 12.8 1.7 16 1 AX073745 ACCESSION:AX073745
c 174 12.8 1.7 16 1 AX132924 ACCESSION:AX132924
c 175 12.8 1.7 16 1 AX281878 ACCESSION:AX281878
c 176 12.8 1.7 16 1 AX281978 ACCESSION:AX281978
c 177 12.8 1.7 16 1 AX696922 ACCESSION:AX696922
c 178 12.6 1.6 21 1 CQ799962 ACCESSION:CQ799962
c 179 12.4 1.6 15 1 AR097225 ACCESSION:AR097225
```

```
180 12.4 1.6 15 1 E05651 ACCESSION:E05651
181 12.4 1.6 15 1 I77111 ACCESSION:I77111
182 12.4 1.6 15 1 AR180586 ACCESSION:AR180586
183 12.4 1.6 15 1 AR432576 ACCESSION:AR432576
184 12.4 1.6 15 1 AX269347 ACCESSION:AX269347
c 185 12 1.6 12 1 AX097953 ACCESSION:AX097953
c 186 12 1.6 12 1 AX138529 ACCESSION:AX138529
c 187 12 1.6 14 1 AR180644 ACCESSION:AR180644
c 188 12 1.6 15 1 AR180645 ACCESSION:AR180645
c 189 12 1.6 21 1 CQ799917 ACCESSION:CQ799917
c 190 12 1.6 21 1 CQ799916 ACCESSION:CQ799916
c 191 11.6 1.5 21 1 CQ799930 ACCESSION:CQ799930
c 193 11.4 1.5 13 1 BD263080 ACCESSION:BD263080
c 194 11.4 1.5 13 1 AX025026 ACCESSION:AX025026
c 195 11.4 1.5 13 1 AX556272 ACCESSION:AX556272
c 196 11.4 1.5 14 1 AR89531 ACCESSION:AR89531
c 197 11.4 1.5 14 1 BD209296 ACCESSION:BD209296
c 198 11.4 1.5 14 1 BD209297 ACCESSION:BD209297
c 199 11.4 1.5 14 1 AX025606 ACCESSION:AX025606
c 200 11.4 1.5 14 1 BD067044 ACCESSION:BD067044
c 201 11.4 1.5 14 1 ATH523733 ACCESSION:ATH523733
```

ALIGNMENTS

```
RESULT 1
AR091050/c 25 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 1170 from patent US 5994076.
DEFINITION AR091050
ACCESSION AR091050
VERSION AR091050.1 GI:10017805
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 25)
AUTHORS Chenchik,A., Jolkhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 5994076-A 1170 30-NOV-1999;
FEATURES
source
location/Qualifiers
source
1..25
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 3.3%, Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred.No.3.4;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 631 TGCGCCCAAGTAAAGCCTTAGCCCG 655
| | | | | | | | | | | | | | | | | | | | |
Db 25 TGCGCCCAAGTAAAGCCTTAGCCCG 1

RESULT 2
AR198085/c 25 bp DNA linear PAT 20-APR-2002
LOCUS Sequence 1170 from patent US 6352829.
DEFINITION AR198085
ACCESSION AR198085
VERSION AR198085.1 GI:20247934
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 25)
AUTHORS Chenchik,A., Jolkhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6352829-A 1170 05-MAR-2002;
FEATURES
source
location/Qualifiers
source
1..25
/organism="unknown"
/mol_type="unassigned DNA"
```

Query Match 3.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 TCCCGCCCAAGTAAGCCTTAGCCCG 655
DB 25 TCCCGCCCAAGTAAGCCTTAGCCCG 1

RESULT 3
AR260239/c AR260239 25 bp DNA linear PAT 20-DEC-2002
LOCUS AR260239 Sequence 1170 from patent US 6489455.
DEFINITION AR260239
ACCESSION AR260239
VERSION AR260239.1 GI:27310750
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 25)
AUTHORS Chenchik, A., Jokhadze, G. and Bibilashvili, R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6489455-A 1170 03-DEC-2002;
FEATURES Location/Qualifiers
source 1..25
/organism="unknown"
/mol_type="genomic DNA"

Query Match 3.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.4;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 TCCCGCCCAAGTAAGCCTTAGCCCG 655
DB 25 TCCCGCCCAAGTAAGCCTTAGCCCG 1

RESULT 4
AR091049 AR091049 24 bp DNA linear PAT 07-SEP-2000
LOCUS AR091049 Sequence 1169 from patent US 5994076.
DEFINITION AR091049
ACCESSION AR091049
VERSION AR091049.1 GI:10017804
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Chenchik, A., Jokhadze, G. and Bibilashvili, R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 5994076-A 1169 30-NOV-1999;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 3.1%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.5;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 396 ACGAGGAGCGGACGAGCAGCATG 419
DB 1 ACGAGGAGCGGACGAGCAGCATG 24

RESULT 5
AR198084 AR198084 24 bp DNA linear PAT 20-APR-2002
LOCUS AR198084 Sequence 1169 from patent US 6352829.
DEFINITION AR198084
ACCESSION AR198084
VERSION AR198084.1 GI:20247933
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Chenchik, A., Jokhadze, G. and Bibilashvili, R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6352829-A 1169 05-MAR-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 3.1%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.5;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 396 ACGAGGAGCGGACGAGCAGCATG 419
DB 1 ACGAGGAGCGGACGAGCAGCATG 24

RESULT 6
AR260238 AR260238 24 bp DNA linear PAT 20-DEC-2002
LOCUS AR260238 Sequence 1169 from patent US 6489455.
DEFINITION AR260238
ACCESSION AR260238
VERSION AR260238.1 GI:27310749
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Chenchik, A., Jokhadze, G. and Bibilashvili, R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6489455-A 1169 03-DEC-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="genomic DNA"

Query Match 3.1%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.5;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 396 ACGAGGAGCGGACGAGCAGCATG 419
DB 1 ACGAGGAGCGGACGAGCAGCATG 24

RESULT 7
AX454996 AX454996 23 bp DNA linear PAT 06-JUL-2002
LOCUS AX454996 Sequence 63 from Patent WO0208453.
DEFINITION AX454996
ACCESSION AX454996
VERSION AX454996.1 GI:21714181
KEYWORDS
SOURCE Canis familiaris (dog)
ORGANISM Canis familiaris
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.

REFERENCE 1
AUTHORS Farr, S.B., Pickett, G.G., Neft, R.E. and Dunn, R.T.
TITLE Canine toxicity genes
JOURNAL Patent: WO 0208453-A 63 31-JAN-2002;
FEATURES Phase-1 Molecular Toxicology (US)
Location/Qualifiers
source 1..23
/organism="Canis familiaris"
/mol_type="unassigned DNA"
/db_xref="taxon:9615"

Query Match 2.8%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 11;

Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 73 GGACCCCTTCGCGAGTGTGACC 95
 Db 1 GGACCCCTTCGCGAGTGTGACC 23

RESULT 8
 CQ799903/c
 LOCUS CQ799903 21 bp DNA linear PAT 28-APR-2004
 DEFINITION Sequence 1 from Patent WO2004030660.
 ACCESSION CQ799903
 VERSION CQ799903.1 GI:46848850
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
 1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
 Compositions for treatment of prostate and other cancers
 Patent: WO 2004030660-A 1 15-APR-2004;
 The University of British Columbia (CA)

JOURNAL
 The University of British Columbia (CA)

FEATURES
 Location/Qualifiers
 1..21
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 10;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGCACGAGGAGCAGTGCAC 21
 Db 21 GGCACGAGGAGCAGTGCAC 1

RESULT 9
 CQ799904/c
 LOCUS CQ799904 21 bp DNA linear PAT 28-APR-2004
 DEFINITION Sequence 2 from Patent WO2004030660.
 ACCESSION CQ799904
 VERSION CQ799904.1 GI:46848851
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
 1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
 Compositions for treatment of prostate and other cancers
 Patent: WO 2004030660-A 2 15-APR-2004;
 The University of British Columbia (CA)

JOURNAL
 The University of British Columbia (CA)

FEATURES
 Location/Qualifiers
 1..21
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 10;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 GCAGAGTCAGCCAGCATGACC 31
 Db 21 GCAGAGTCAGCCAGCATGACC 1

RESULT 10
 CQ799905/c
 LOCUS CQ799905 21 bp DNA linear PAT 28-APR-2004
 DEFINITION Sequence 3 from Patent WO2004030660.

ACCESSION CQ799905
 VERSION CQ799905.1 GI:46848852
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
 1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
 Compositions for treatment of prostate and other cancers
 Patent: WO 2004030660-A 3 15-APR-2004;
 The University of British Columbia (CA)

JOURNAL
 The University of British Columbia (CA)

FEATURES
 Location/Qualifiers
 1..21
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 10;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 CCAGCATGACCGCGCGCG 41
 Db 21 CCAGCATGACCGCGCGCG 1

RESULT 11
 CQ799906/c
 LOCUS CQ799906 21 bp DNA linear PAT 28-APR-2004
 DEFINITION Sequence 4 from Patent WO2004030660.
 ACCESSION CQ799906
 VERSION CQ799906.1 GI:46848853
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
 1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
 Compositions for treatment of prostate and other cancers
 Patent: WO 2004030660-A 4 15-APR-2004;
 The University of British Columbia (CA)

JOURNAL
 The University of British Columbia (CA)

FEATURES
 Location/Qualifiers
 1..21
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 10;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 31 CGAGCGCGCGTCCCTTCTC 51
 Db 21 CGAGCGCGCGTCCCTTCTC 1

RESULT 12
 CQ799907/c
 LOCUS CQ799907 21 bp DNA linear PAT 28-APR-2004
 DEFINITION Sequence 5 from Patent WO2004030660.
 ACCESSION CQ799907
 VERSION CQ799907.1 GI:46848854
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
 1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
 Compositions for treatment of prostate and other cancers
 Patent: WO 2004030660-A 5 15-APR-2004;

```

FEATURES
  source
    The University of British Columbia (CA)
      Location/Qualifiers
        1..21
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 41 GTCCCTCTCGCTCGGG 61
Db 21 GTCCCTCTCGCTCGGG 1

RESULT 13
LOCUS      CQ799908/c
DEFINITION Sequence 6 from Patent WO2004030660.
ACCESSION  CQ799908
VERSION     CQ799908.1 GI:46848855
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 6 15-APR-2004;
            The University of British Columbia (CA)
FEATURES
  source
    Location/Qualifiers
      1..21
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 CGTCTCTCGGGGCCAGCT 71
Db 21 CGTCTCTCGGGGCCAGCT 1

RESULT 14
LOCUS      CQ799909/c
DEFINITION Sequence 7 from Patent WO2004030660.
ACCESSION  CQ799909
VERSION     CQ799909.1 GI:46848856
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 7 15-APR-2004;
            The University of British Columbia (CA)
FEATURES
  source
    Location/Qualifiers
      1..21
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 81 TCCGCGACTGGTACCCGCATA 101
Db 21 TCCGCGACTGGTACCCGCATA 1

RESULT 17
LOCUS      CQ799912/c
DEFINITION Sequence 10 from Patent WO2004030660.
ACCESSION  CQ799912
VERSION     CQ799912.1 GI:46848859

```

```

Qy 61 GGGCCCCAGCTGGGACCCCTT 81
Db 21 GGGCCCCAGCTGGGACCCCTT 1

RESULT 15
LOCUS      CQ799910/c
DEFINITION Sequence 8 from Patent WO2004030660.
ACCESSION  CQ799910
VERSION     CQ799910.1 GI:46848857
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 8 15-APR-2004;
            The University of British Columbia (CA)
FEATURES
  source
    Location/Qualifiers
      1..21
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 71 TGGGACCCCTTCGCGACTCG 91
Db 21 TGGGACCCCTTCGCGACTCG 1

RESULT 16
LOCUS      CQ799911/c
DEFINITION Sequence 9 from Patent WO2004030660.
ACCESSION  CQ799911
VERSION     CQ799911.1 GI:46848858
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 9 15-APR-2004;
            The University of British Columbia (CA)
FEATURES
  source
    Location/Qualifiers
      1..21
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 81 TCCGCGACTGGTACCCGCATA 101
Db 21 TCCGCGACTGGTACCCGCATA 1

RESULT 17
LOCUS      CQ799912/c
DEFINITION Sequence 10 from Patent WO2004030660.
ACCESSION  CQ799912
VERSION     CQ799912.1 GI:46848859

```



```
Db      21 CCCCGCTGCCGAGAGTGG 1

RESULT 22
LOCUS   CQ799917/c
DEFINITION Sequence 15 from Patent WO2004030660.
ACCESSION CQ799917
VERSION   CQ799917.1 GI:46848864
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE    Compositions for treatment of prostate and other cancers
JOURNAL  Patent: WO 2004030660-A 15 15-APR-2004;
          The University of British Columbia (CA)
FEATURES
source   1..21
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      141 CGGAGGAGTGGTCCGAGTGGT 161
          |||||||
Db      21 CGGAGGAGTGGTCCGAGTGGT 1

RESULT 23
LOCUS   CQ799918/c
DEFINITION Sequence 16 from Patent WO2004030660.
ACCESSION CQ799918
VERSION   CQ799918.1 GI:46848865
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE    Compositions for treatment of prostate and other cancers
JOURNAL  Patent: WO 2004030660-A 16 15-APR-2004;
          The University of British Columbia (CA)
FEATURES
source   1..21
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      151 GTCGAGTGGTTCGAGCGCAG 171
          |||||||
Db      21 GTCGAGTGGTTCGAGCGCAG 1

RESULT 24
LOCUS   CQ799919/c
DEFINITION Sequence 17 from Patent WO2004030660.
ACCESSION CQ799919
VERSION   CQ799919.1 GI:46848866
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE    Compositions for treatment of prostate and other cancers
JOURNAL  Patent: WO 2004030660-A 17 15-APR-2004;
          The University of British Columbia (CA)
FEATURES
source   1..21
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"
```

```
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE    Compositions for treatment of prostate and other cancers
JOURNAL  Patent: WO 2004030660-A 17 15-APR-2004;
          The University of British Columbia (CA)
FEATURES
source   1..21
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      161 TTAGGCGGCGAGCAGCTGCGCA 181
          |||||||
Db      21 TTAGGCGGCGAGCAGCTGCGCA 1

RESULT 25
LOCUS   CQ799920/c
DEFINITION Sequence 18 from Patent WO2004030660.
ACCESSION CQ799920
VERSION   CQ799920.1 GI:46848867
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE    Compositions for treatment of prostate and other cancers
JOURNAL  Patent: WO 2004030660-A 18 15-APR-2004;
          The University of British Columbia (CA)
FEATURES
source   1..21
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      171 GCAGCTGCGCAGGCTACGTGC 191
          |||||||
Db      21 GCAGCTGCGCAGGCTACGTGC 1

RESULT 26
LOCUS   CQ799921/c
DEFINITION Sequence 19 from Patent WO2004030660.
ACCESSION CQ799921
VERSION   CQ799921.1 GI:46848868
KEYWORDS
SOURCE   Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE    Compositions for treatment of prostate and other cancers
JOURNAL  Patent: WO 2004030660-A 19 15-APR-2004;
          The University of British Columbia (CA)
FEATURES
source   1..21
          /organism="Homo sapiens"
          /mol_type="unassigned DNA"
          /db_xref="taxon:9606"
```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 181 AGGCTACGTGGCGCCCGCCCTGCC 201
      |||||
Db 21 AGGCTACGTGGCGCCCGCCCTGCC 1

RESULT 27
LOCUS      CQ799922/c
DEFINITION Sequence 20 from Patent WO2004030660.
ACCESSION  CQ799922
VERSION     CQ799922.1 GI:46848869
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 20 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 191 GCGCCCGCTGGCGCCCGCCGCGCC 211
      |||||
Db 21 GCGCCCGCTGGCGCCCGCCGCGCC 1

RESULT 28
LOCUS      CQ799923/c
DEFINITION Sequence 21 from Patent WO2004030660.
ACCESSION  CQ799923
VERSION     CQ799923.1 GI:46848870
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 21 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 201 CCCCGCGCGCCATCGAGGCC 221
      |||||
Db 21 CCCCGCGCGCCATCGAGGCC 1

RESULT 29
LOCUS      CQ799924/c
DEFINITION Sequence 22 from Patent WO2004030660.
ACCESSION  CQ799924
VERSION     CQ799924.1 GI:46848871
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 22 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 211 CATCGAGAGCCCCGCGAGTGGC 231
      |||||
Db 21 CATCGAGAGCCCCGCGAGTGGC 1

RESULT 30
LOCUS      CQ799925/c
DEFINITION Sequence 23 from Patent WO2004030660.
ACCESSION  CQ799925
VERSION     CQ799925.1 GI:46848872
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 23 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 221 CCCGCGTGGCGCCGCGCGGCC 241
      |||||
Db 21 CCCGCGTGGCGCCGCGCGGCC 1

RESULT 31
LOCUS      CQ799926/c
DEFINITION Sequence 24 from Patent WO2004030660.
ACCESSION  CQ799926
VERSION     CQ799926.1 GI:46848873
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 24 15-APR-2004;
              The University of British Columbia (CA)
FEATURES
  source
    1..21
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 231 CCGCGCCGCGCTACAGCGCG 251
Db 21 CCGCGCCGCGCTACAGCGCG 1

RESULT 32
LOCUS      CQ799927/c              21 bp      DNA              linear      PAT 28-APR-2004
DEFINITION Sequence 25 from Patent WO2004030660.
ACCESSION  CQ799927
VERSION     CQ799927.1 GI:46848874
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 25 15-APR-2004;
              The University of British Columbia (CA)
FEATURES
  source
    1..21
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 241 CTACAGCGCGCGCTCAGCGG 261
Db 21 CTACAGCGCGCGCTCAGCGG 1

RESULT 33
LOCUS      CQ799928/c              21 bp      DNA              linear      PAT 28-APR-2004
DEFINITION Sequence 26 from Patent WO2004030660.
ACCESSION  CQ799928
VERSION     CQ799928.1 GI:46848875
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 26 15-APR-2004;
              The University of British Columbia (CA)
FEATURES
  source
    1..21
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 24 15-APR-2004;
              The University of British Columbia (CA)
FEATURES
  source
    1..21
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 251 GCGCTCAGCGCGCACTCAGC 271
Db 21 GCGCTCAGCGCGCACTCAGC 1

RESULT 34
LOCUS      CQ799929/c              21 bp      DNA              linear      PAT 28-APR-2004
DEFINITION Sequence 27 from Patent WO2004030660.
ACCESSION  CQ799929
VERSION     CQ799929.1 GI:46848876
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 27 15-APR-2004;
              The University of British Columbia (CA)
FEATURES
  source
    1..21
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 261 GGCAACTCAGCAGCGGGTCT 281
Db 21 GGCAACTCAGCAGCGGGTCT 1

RESULT 35
LOCUS      CQ799930/c              21 bp      DNA              linear      PAT 28-APR-2004
DEFINITION Sequence 28 from Patent WO2004030660.
ACCESSION  CQ799930
VERSION     CQ799930.1 GI:46848877
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 28 15-APR-2004;
              The University of British Columbia (CA)
FEATURES
  source
    1..21
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 271 CAGCGGGGTCTCGGAGATCCG 291
Db 21 CAGCGGGGTCTCGGAGATCCG 1

RESULT 36
```

```
CQ799931/c
LOCUS      CQ799931          21 bp      DNA
DEFINITION Sequence 29 from Patent WO2004030660.
ACCESSION  CQ799931
VERSION    CQ799931.1  GI:46848878
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 31 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy  281 TCGGAGATCCGGCACACTGCG 301
      |||||
Db   21 TCGGAGATCCGGCACACTGCG 1

RESULT 37
CQ799932/c
LOCUS      CQ799932          21 bp      DNA
DEFINITION Sequence 30 from Patent WO2004030660.
ACCESSION  CQ799932
VERSION    CQ799932.1  GI:46848879
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 30 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy  281 TCGGAGATCCGGCACACTGCG 301
      |||||
Db   21 TCGGAGATCCGGCACACTGCG 1

RESULT 38
CQ799933/c
LOCUS      CQ799933          21 bp      DNA
DEFINITION Sequence 31 from Patent WO2004030660.
ACCESSION  CQ799933
VERSION    CQ799933.1  GI:46848880
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 31 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy  291 GGCACACTCGGACCGCTGCG 311
      |||||
Db   21 GGCACACTCGGACCGCTGCG 1

RESULT 39
CQ799934/c
LOCUS      CQ799934          21 bp      DNA
DEFINITION Sequence 32 from Patent WO2004030660.
ACCESSION  CQ799934
VERSION    CQ799934.1  GI:46848881
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 32 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy  301 GGACCGCTGGCGCGTGCCT 321
      |||||
Db   21 GGACCGCTGGCGCGTGCCT 1

RESULT 40
CQ799935/c
LOCUS      CQ799935          21 bp      DNA
DEFINITION Sequence 33 from Patent WO2004030660.
ACCESSION  CQ799935
VERSION    CQ799935.1  GI:46848882
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 33 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy  311 CGCGTGTCCTGGATGTCAC 331
      |||||
Db   21 CGCGTGTCCTGGATGTCAC 1

RESULT 41
CQ799936/c
LOCUS      CQ799936          21 bp      DNA
DEFINITION Sequence 34 from Patent WO2004030660.
ACCESSION  CQ799936
VERSION    CQ799936.1  GI:46848883
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 34 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy  321 GGCACACTCGGACCGCTGCG 341
      |||||
Db   21 GGCACACTCGGACCGCTGCG 1
```

Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 321 TGGATGTCACCACTTCGCC 341
Db 21 TGGATGTCACCACTTCGCC 1

RESULT 41
CQ799936/c
LOCUS CQ799936 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 34 from Patent WO2004030660.
ACCESSION CQ799936
VERSION .CQ799936.1 GI:46848883
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 34 15-APR-2004;
The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 331 CCACCTTCCCGCCGACGAGCT 351
Db 21 CCACCTTCCCGCCGACGAGCT 1

RESULT 42
CQ799937/c
LOCUS CQ799937 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 35 from Patent WO2004030660.
ACCESSION CQ799937
VERSION CQ799937.1 GI:46848884
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 35 15-APR-2004;
The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 341 CCGACGAGCTGACGGTCAAG 361
Db 21 CCGACGAGCTGACGGTCAAG 1

RESULT 43
CQ799938/c
LOCUS CQ799938 21 bp DNA linear PAT 28-APR-2004

DEFINITION Sequence 36 from Patent WO2004030660.
ACCESSION CQ799938
VERSION CQ799938.1 GI:46848885
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 36 15-APR-2004;
The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 351 TGACGGTCAAGACCAAGGATG 371
Db 21 TGACGGTCAAGACCAAGGATG 1

RESULT 44
CQ799939/c
LOCUS CQ799939 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 37 from Patent WO2004030660.
ACCESSION CQ799939
VERSION CQ799939.1 GI:46848886
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 37 15-APR-2004;
The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 361 GACCAAGGATGGCGTGGTGA 381
Db 21 GACCAAGGATGGCGTGGTGA 1

RESULT 45
CQ799940/c
LOCUS CQ799940 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 38 from Patent WO2004030660.
ACCESSION CQ799940
VERSION CQ799940.1 GI:46848887
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE Compositions for treatment of prostate and other cancers

```

JOURNAL Patent: WO 2004030660-A 38 15-APR-2004;
The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 371 GCGGTGGTGGAGATCACCGCG 391
| | | | | | | | | | | | | | | | | | | | |
Db 21 GCGGTGGTGGAGATCACCGCG 1

RESULT 46
CQ799941/c
LOCUS CQ799941 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 39 from Patent WO2004030660.
ACCESSION CQ799941
VERSION CQ799941.1 GI:46848888
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
AUTHORS Compositions for treatment of prostate and other cancers
TITLE Patent: WO 2004030660-A 39 15-APR-2004;
JOURNAL The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 381 AGATCACCGCGAAGCAGCAGG 401
| | | | | | | | | | | | | | | | | | | | |
Db 21 AGATCACCGCGAAGCAGCAGG 1

RESULT 47
CQ799942/c
LOCUS CQ799942 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 40 from Patent WO2004030660.
ACCESSION CQ799942
VERSION CQ799942.1 GI:46848889
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
AUTHORS Compositions for treatment of prostate and other cancers
TITLE Patent: WO 2004030660-A 40 15-APR-2004;
JOURNAL The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 391 CAAGCAGGAGGCGGCAGGA 411
| | | | | | | | | | | | | | | | | | | | |
Db 21 CAAGCAGGAGGCGGCAGGA 1

RESULT 48
CQ799943/c
LOCUS CQ799943 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 41 from Patent WO2004030660.
ACCESSION CQ799943
VERSION CQ799943.1 GI:46848890
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
AUTHORS Compositions for treatment of prostate and other cancers
TITLE Patent: WO 2004030660-A 41 15-APR-2004;
JOURNAL The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 GAGCGGCGAGGAGCATGGC 421
| | | | | | | | | | | | | | | | | | | | |
Db 21 GAGCGGCGAGGAGCATGGC 1

RESULT 49
CQ799944/c
LOCUS CQ799944 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 42 from Patent WO2004030660.
ACCESSION CQ799944
VERSION CQ799944.1 GI:46848891
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gleave, M.E., Rocchi, P. and Signaevsky, M.
AUTHORS Compositions for treatment of prostate and other cancers
TITLE Patent: WO 2004030660-A 42 15-APR-2004;
JOURNAL The University of British Columbia (CA)
FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 411 ACGAGCATGGCTACATCTCCC 431
| | | | | | | | | | | | | | | | | | | | |
Db 21 ACGAGCATGGCTACATCTCCC 1

RESULT 50
CQ799945/c
LOCUS CQ799945 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 43 from Patent WO2004030660.
ACCESSION CQ799945

```

```

VERSION      CQ799945.1  GI:46848892
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS      Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 43 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
              source
                1..21
                  /organism="Homo sapiens"
                  /mol_type="unassigned DNA"
                  /db_xref="taxon:9606"
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 421 CTACATCTCCCGTCTTCAC 441
      |||||
Db 21 CTACATCTCCCGTCTTCAC 1

RESULT 51
CQ799946/c
LOCUS       CQ799946                21 bp    DNA                linear    PAT 28-APR-2004
DEFINITION Sequence 44 from Patent WO2004030660.
ACCESSION  CQ799946
VERSION    CQ799946.1  GI:46848893
KEYWORDS   Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 44 15-APR-2004;
            The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 431 CGTGCTTCACGCGGAATAC 451
      |||||
Db 21 CGTGCTTCACGCGGAATAC 1

RESULT 52
CQ799947/c
LOCUS       CQ799947                21 bp    DNA                linear    PAT 28-APR-2004
DEFINITION Sequence 45 from Patent WO2004030660.
ACCESSION  CQ799947
VERSION    CQ799947.1  GI:46848894
KEYWORDS   Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 45 15-APR-2004;
            The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 431 CGTGCTTCACGCGGAATAC 451
      |||||
Db 21 CGTGCTTCACGCGGAATAC 1

RESULT 54
CQ799949/c
LOCUS       CQ799949                21 bp    DNA                linear    PAT 28-APR-2004
DEFINITION Sequence 47 from Patent WO2004030660.
ACCESSION  CQ799949
VERSION    CQ799949.1  GI:46848896
KEYWORDS   Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 47 15-APR-2004;
            The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 451 CACGCTGCCCCCGGTGTGGA 471
      |||||
Db 21 CACGCTGCCCCCGGTGTGGA 1

RESULT 53
CQ799948/c
LOCUS       CQ799948                21 bp    DNA                linear    PAT 28-APR-2004
DEFINITION Sequence 46 from Patent WO2004030660.
ACCESSION  CQ799948
VERSION    CQ799948.1  GI:46848895
KEYWORDS   Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 46 15-APR-2004;
            The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 451 CACGCTGCCCCCGGTGTGGA 471
      |||||
Db 21 CACGCTGCCCCCGGTGTGGA 1

RESULT 55
CQ799949/c
LOCUS       CQ799949                21 bp    DNA                linear    PAT 28-APR-2004
DEFINITION Sequence 47 from Patent WO2004030660.
ACCESSION  CQ799949
VERSION    CQ799949.1  GI:46848896
KEYWORDS   Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 47 15-APR-2004;
            The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 461 CCGGCTGTGGACCCCA 481

```

```
Db      21  CCGGCTGTGACCCCAACAA 1
|||||
RESULT 55
CQ799950/c
LOCUS      21 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 48 from Patent WO2004030660.
ACCESSION  CQ799950
VERSION     CQ799950.1  GI:46848897
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 48 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      471  ACCCCACCCCAAGTTTCCTCCT 491
|||||
Db      21  ACCCCACCCCAAGTTTCCTCCT 1

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 56
CQ799951/c
LOCUS      21 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 49 from Patent WO2004030660.
ACCESSION  CQ799951
VERSION     CQ799951.1  GI:46848898
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 49 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      481  AGTTTCCTCCTCCTCCTGTCCTCC 501
|||||
Db      21  AGTTTCCTCCTCCTGTCCTCC 1

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 57
CQ799952/c
LOCUS      21 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 50 from Patent WO2004030660.
ACCESSION  CQ799952
VERSION     CQ799952.1  GI:46848899
KEYWORDS
```

```
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 50 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      491  TCCCTGTCCCTGAGGGGCACA 511
|||||
Db      21  TCCCTGTCCCTGAGGGGCACA 1

RESULT 58
CQ799953/c
LOCUS      21 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 51 from Patent WO2004030660.
ACCESSION  CQ799953
VERSION     CQ799953.1  GI:46848900
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 51 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      501  CTGAGGGGCACACTGACCGTGG 521
|||||
Db      21  CTGAGGGGCACACTGACCGTGG 1

RESULT 59
CQ799954/c
LOCUS      21 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 52 from Patent WO2004030660.
ACCESSION  CQ799954
VERSION     CQ799954.1  GI:46848901
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 52 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
```

```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 511 ACTGACCGTGGAGGCCCCCAT 531
Db 21 ACTGACCGTGGAGGCCCCCAT 1

RESULT 60
LOCUS      CQ799955/c
DEFINITION Sequence 53 from Patent WO2004030660.
ACCESSION  CQ799955
VERSION     CQ799955.1 GI:46848902
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 53 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 521 GAGGCCCCCATGCCCAAGCTA 541
Db 21 GAGGCCCCCATGCCCAAGCTA 1

RESULT 61
LOCUS      CQ799956/c
DEFINITION Sequence 54 from Patent WO2004030660.
ACCESSION  CQ799956
VERSION     CQ799956.1 GI:46848903
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 54 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 531 TGCCCCAAGCTAGCCACGAGT 551
Db 21 TGCCCCAAGCTAGCCACGAGT 1

/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 511 ACTGACCGTGGAGGCCCCCAT 531
Db 21 ACTGACCGTGGAGGCCCCCAT 1

RESULT 62
LOCUS      CQ799957/c
DEFINITION Sequence 55 from Patent WO2004030660.
ACCESSION  CQ799957
VERSION     CQ799957.1 GI:46848904
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 55 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCGAGTCCCAACGAGAT 561
Db 21 AGCCACGCGAGTCCCAACGAGAT 1

RESULT 63
LOCUS      CQ799958/c
DEFINITION Sequence 56 from Patent WO2004030660.
ACCESSION  CQ799958
VERSION     CQ799958.1 GI:46848905
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 56 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 TCCCAACGAGATCACCATCCCA 571
Db 21 TCCCAACGAGATCACCATCCCA 1

RESULT 64
LOCUS      CQ799959/c
DEFINITION Sequence 57 from Patent WO2004030660.
ACCESSION  CQ799959
VERSION     CQ799959.1 GI:46848906
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```

```
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 57 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 561 TCACCATCCCACTCAGCTTCG 581
Db 21 TCACCATCCCACTCAGCTTCG 1

RESULT 65
LOCUS      CQ799960/c
DEFINITION Sequence 58 from Patent WO2004030660.
ACCESSION CQ799960
VERSION   CQ799960.1 GI:46848907
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 58 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 571 AGTCACCTTCGAGTCGCGGC 591
Db 21 AGTCACCTTCGAGTCGCGGC 1

RESULT 66
LOCUS      CQ799961/c
DEFINITION Sequence 59 from Patent WO2004030660.
ACCESSION CQ799961
VERSION   CQ799961.1 GI:46848908
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 59 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 57 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 581 GAGTCGCGGGCCAGCTTGGG 601
Db 21 GAGTCGCGGGCCAGCTTGGG 1

RESULT 67
LOCUS      CQ799962/c
DEFINITION Sequence 60 from Patent WO2004030660.
ACCESSION CQ799962
VERSION   CQ799962.1 GI:46848909
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 60 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 591 CCCAGCTTGGGGCCAGAG 611
Db 21 CCCAGCTTGGGGCCAGAG 1

RESULT 68
LOCUS      CQ799963/c
DEFINITION Sequence 61 from Patent WO2004030660.
ACCESSION CQ799963
VERSION   CQ799963.1 GI:46848910
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 61 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 601 GGGCCAGAGCTGCAATC 621
Db 21 GGGCCAGAGCTGCAATC 1
```

```
/db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 581 GAGTCGCGGGCCAGCTTGGG 601
Db 21 GAGTCGCGGGCCAGCTTGGG 1

RESULT 67
LOCUS      CQ799962/c
DEFINITION Sequence 60 from Patent WO2004030660.
ACCESSION CQ799962
VERSION   CQ799962.1 GI:46848909
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 60 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 591 CCCAGCTTGGGGCCAGAG 611
Db 21 CCCAGCTTGGGGCCAGAG 1

RESULT 68
LOCUS      CQ799963/c
DEFINITION Sequence 61 from Patent WO2004030660.
ACCESSION CQ799963
VERSION   CQ799963.1 GI:46848910
KEYWORDS  Homo sapiens (human)
SOURCE    Homo sapiens
ORGANISM  Homo sapiens
           Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
           Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 61 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 601 GGGCCAGAGCTGCAATC 621
Db 21 GGGCCAGAGCTGCAATC 1
```

```
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
RESULT 69
LOCUS      CQ799964/c
DEFINITION Sequence 62 from Patent WO2004030660.
ACCESSION  CQ799964
VERSION     CQ799964.1 GI:46848911
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 62 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      611 GCTGCAAAATCCGATGAGACT 631
          |||||||
Db      21 GCTGCAAAATCCGATGAGACT 1

RESULT 70
LOCUS      CQ799965/c
DEFINITION Sequence 63 from Patent WO2004030660.
ACCESSION  CQ799965
VERSION     CQ799965.1 GI:46848912
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 63 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      621 CCGATGAGACTCCGCCCAAGT 641
          |||||||
Db      21 CCGATGAGACTCCGCCCAAGT 1

RESULT 71
LOCUS      CQ799966/c
DEFINITION Sequence 64 from Patent WO2004030660.
ACCESSION  CQ799966
VERSION     CQ799966.1 GI:46848913
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
..
```

```
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 64 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      631 TGCGCCCAAGTAAAGCCTTAG 651
          |||||||
Db      21 TGCGCCCAAGTAAAGCCTTAG 1

RESULT 72
LOCUS      CQ799967/c
DEFINITION Sequence 65 from Patent WO2004030660.
ACCESSION  CQ799967
VERSION     CQ799967.1 GI:46848914
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 65 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      641 TAAAGCCTTAGCCCGGATGCC 661
          |||||||
Db      21 TAAAGCCTTAGCCCGGATGCC 1

RESULT 73
LOCUS      CQ799968/c
DEFINITION Sequence 66 from Patent WO2004030660.
ACCESSION  CQ799968
VERSION     CQ799968.1 GI:46848915
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 66 15-APR-2004;
          The University of British Columbia (CA)
FEATURES   source
            1..21
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
```

```
Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 651 GCCCGATGCCACCCCTGCT 671
Db 21 GCCCGATGCCACCCCTGCT 1

RESULT 74
CQ799969/c
LOCUS          21 bp DNA
DEFINITION     Sequence 67 from Patent WO2004030660.
ACCESSION      CQ799969
VERSION        CQ799969
KEYWORDS       CQ799969.1 GI:46848916
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE          Compositions for treatment of prostate and other cancers
JOURNAL        Patent: WO 2004030660-A 67 15-APR-2004;
               The University of British Columbia (CA)
FEATURES       Location/Qualifiers
               source
               1..21
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 661 CCACCCCTGCTCGGCCACTG 681
Db 21 CCACCCCTGCTCGGCCACTG 1

RESULT 75
CQ799970/c
LOCUS          21 bp DNA
DEFINITION     Sequence 68 from Patent WO2004030660.
ACCESSION      CQ799970
VERSION        CQ799970.1 GI:46848917
KEYWORDS       CQ799970.1 GI:46848917
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE          Compositions for treatment of prostate and other cancers
JOURNAL        Patent: WO 2004030660-A 68 15-APR-2004;
               The University of British Columbia (CA)
FEATURES       Location/Qualifiers
               source
               1..21
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 671 TGCCGCCACTGGCTGTCCTC 691
Db 21 TGCCGCCACTGGCTGTCCTC 1

RESULT 76
CQ799971/c
LOCUS          21 bp DNA
DEFINITION     Sequence 71 from Patent WO2004030660.
ACCESSION      CQ799971
VERSION        CQ799971.1 GI:46848920
KEYWORDS       CQ799971.1 GI:46848920
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Gleave,M.E., Rocchi,P. and Signaevsky,M.
```

```
LOCUS          21 bp DNA
DEFINITION     Sequence 69 from Patent WO2004030660.
ACCESSION      CQ799971
VERSION        CQ799971.1 GI:46848918
KEYWORDS       CQ799971.1 GI:46848918
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE          Compositions for treatment of prostate and other cancers
JOURNAL        Patent: WO 2004030660-A 69 15-APR-2004;
               The University of British Columbia (CA)
FEATURES       Location/Qualifiers
               source
               1..21
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 681 GGCTGTGCTCCCGCCACC 701
Db 21 GGCTGTGCTCCCGCCACC 1

RESULT 77
CQ799972/c
LOCUS          21 bp DNA
DEFINITION     Sequence 70 from Patent WO2004030660.
ACCESSION      CQ799972
VERSION        CQ799972.1 GI:46848919
KEYWORDS       CQ799972.1 GI:46848919
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE          Compositions for treatment of prostate and other cancers
JOURNAL        Patent: WO 2004030660-A 70 15-APR-2004;
               The University of British Columbia (CA)
FEATURES       Location/Qualifiers
               source
               1..21
               /organism="Homo sapiens"
               /mol_type="unassigned DNA"
               /db_xref="taxon:9606"

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 691 CCCCGCCACCTGTGTCT 711
Db 21 CCCCGCCACCTGTGTCT 1

RESULT 78
CQ799973/c
LOCUS          21 bp DNA
DEFINITION     Sequence 71 from Patent WO2004030660.
ACCESSION      CQ799973
VERSION        CQ799973.1 GI:46848920
KEYWORDS       CQ799973.1 GI:46848920
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1
AUTHORS        Gleave,M.E., Rocchi,P. and Signaevsky,M.
```

```

TITLE      Compositions for treatment of prostate and other cancers
JOURNAL    Patent: WO 2004030660-A 71 15-APR-2004;
           The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 701 CTGTGTCCTTTTGATACAT 721
Db 21 CTGTGTCCTTTTGATACAT 1

RESULT 79
CQ799974/c
LOCUS      CQ799974      21 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 72 from Patent WO2004030660.
ACCESSION  CQ799974
VERSION    CQ799974.1 GI:46848921
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 72 15-APR-2004;
           The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 731 GTTTTCTCAATAAAGTTCA 751
Db 21 GTTTTCTCAATAAAGTTCA 1

RESULT 82
CQ799977/c
LOCUS      CQ799977      21 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 75 from Patent WO2004030660.
ACCESSION  CQ799977
VERSION    CQ799977.1 GI:46848924
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE     Compositions for treatment of prostate and other cancers
JOURNAL   Patent: WO 2004030660-A 75 15-APR-2004;
           The University of British Columbia (CA)
FEATURES   Location/Qualifiers
            source
              1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 741 AATAAGTTCAAGCAACCAC 761
Db 21 AATAAGTTCAAGCAACCAC 1

RESULT 83
CQ799978/c
LOCUS      CQ799978      21 bp      DNA      linear      PAT 28-APR-2004
DEFINITION Sequence 76 from Patent WO2004030660.

```

[illegible][illegible]

Qy 26 ATGACCGAGCGCGCGTCCCC 46
Db 21 ATGACCGAGCGCGCGTCCCC 1

RESULT 88
LOCUS CQ799984/c 20 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 82 from Patent WO2004030660.
ACCESSION CQ799984
VERSION CQ799984.1 GI:46848931
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 82 15-APR-2004;
The University of British Columbia (CA)
FEATURES
source
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 13; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0

Qy 26 ATGACCGAGCGCGCGTCCCC 45
Db 20 ATGACCGAGCGCGCGTCCCC 1

RESULT 89
LOCUS CQ799989 19 bp RNA linear PAT 28-APR-2004
DEFINITION Sequence 87 from Patent WO2004030660.
ACCESSION CQ799989
VERSION CQ799989.1 GI:46848936
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 87 15-APR-2004;
The University of British Columbia (CA)
FEATURES
source
1..19
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 17; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0

Qy 556 CGAGATCACCATCCAGTC 574
Db 1 CGAGATCACCATCCAGTC 19

RESULT 90
LOCUS CQ799992 19 bp RNA linear PAT 28-APR-2004
DEFINITION Sequence 90 from Patent WO2004030660.
ACCESSION CQ799992
VERSION CQ799992.1 GI:46848939

KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 90 15-APR-2004;
The University of British Columbia (CA)
FEATURES
source
1..19
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 17; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0

Qy 26 ATGACCGAGCGCGCGTCCC 44
Db 1 ATGACCGAGCGCGCGTCCC 19

RESULT 91
LOCUS BD178972 21 bp DNA linear PAT 16-APR-2003
DEFINITION HSP inducing agent.
ACCESSION BD178972
VERSION BD178972.1 GI:30016240
KEYWORDS WO 02078705-A/1.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
1 (bases 1 to 21)
REFERENCE Terashita, Z., Naruo, K., Uchikawa, O. and Nakanishi, A.
AUTHORS HSP inducing agent
TITLE Patent: WO 02078705-A 1 10-OCT-2002;
JOURNAL TAKEDA CHEMICAL INDUSTRIES LTD.,ZENICHI TERASHITA, KENICHI NARUO,
OSAMU UCHIKAWA, ATSUSHI NAKANISHI
COMMENT OS Artificial Sequence
PN WO 02078705-A/1
PD 10-OCT-2002
PF 27-MAR-2001 JP 01P 092704
PI ZENICHI TERASHITA, KENICHI NARUO, OSAMU UCHIKAWA, ATSUSHI PI
NAKANISHI
PC A61K31/437, A61K45/00, A61K45/06, C07D471/04, A61P1/00, A61P1/04,
PC A61P1/08,
A61P1/16, A61P3/04, A61P3/06, A61P3/10, A61P5/00, A61P7/02, A61P7/06, PC
A61P9/04,
PC A61P9/06, A61P9/08, A61P9/10, A61P9/12, A61P11/00, A61P11/04, A61P11/ PC
06,
PC A61P13/08, A61P13/12, A61P19/02, A61P19/06, A61P19/10, A61P23/00,
PC A61P25/16,
PC A61P25/18, A61P25/22, A61P25/24, A61P25/28, A61P27/02, A61P29/00,
PC A61P31/00,
PC A61P35/00, A61P37/08, A61P43/00
CC PCR primer for amplifying HSP27 gene
FH Key Location/Qualifiers
FT source 1..21
FT /organism="Artificial Sequence";
Location/Qualifiers
1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 2.4%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 25;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 359 AAGACCAAGGATGGCGTGT 378
 |||||
 Db 2 AAGACCAAGGAGGCGTGT 21
 |||||

RESULT 92
 LOCUS CQ799979/c
 DEFINITION Sequence 77 from Patent WO2004030660.
 ACCESSION CQ799979
 VERSION CQ799979.1 GI:46848926
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
 TITLE Compositions for treatment of prostate and other cancers
 JOURNAL Patent: WO 2004030660-A 77 15-APR-2004;
 The University of British Columbia (CA)
 FEATURES
 1..18
 Location/Qualifiers
 source
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 2.4%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 21;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 226 AGTGGCGCGCCGCCCTA 243
 |||||
 Db 18 AGTGGCGCGCCGCCCTA 1
 |||||

RESULT 93
 LOCUS CQ799991
 DEFINITION Sequence 89 from Patent WO2004030660.
 ACCESSION CQ799991
 VERSION CQ799991.1 GI:46848938
 KEYWORDS Homo sapiens (human)
 SOURCE
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
 AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.
 TITLE Compositions for treatment of prostate and other cancers
 JOURNAL Patent: WO 2004030660-A 89 15-APR-2004;
 The University of British Columbia (CA)
 FEATURES
 1..21
 Location/Qualifiers
 source
 /organism="Homo sapiens"
 /mol_type="unassigned RNA"
 /db_xref="taxon:9606"

Query Match 2.3%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 31;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 576 CTTTCAGTCGGCGGCCGAGC 596
 |||||
 Db 1 CTTTCGTGTCGGCGGCCCTG 21
 |||||

RESULT 94
 LOCUS BD178973/c
 DEFINITION HSP inducing agent.

ACCESSION BD178973
 VERSION BD178973.1 GI:30016241
 KEYWORDS WO 02078705-A/2
 SOURCE synthetic construct
 ORGANISM synthetic construct
 other sequences; artificial sequences.
 1 (bases 1 to 22)
 REFERENCE
 AUTHORS Terashita, Z., Naruo, K., Uchikawa, O. and Nakanishi, A.
 TITLE HSP inducing agent
 JOURNAL Patent: WO 02078705-A 2 10-OCT-2002;
 TAKEDA CHEMICAL INDUSTRIES LTD, ZENICHI TERASHITA, KENICHI NARUO,
 OSAMU UCHIKAWA, ATSUSHI NAKANISHI
 COMMENT OS Artificial Sequence
 PN WO 02078705-A/2
 PD 10-OCT-2002
 PF 27-MAR-2002 WO 2002JP002946
 PR 28-MAR-2001 JP OIP 092704
 PI ZENICHI TERASHITA, KENICHI NARUO, OSAMU UCHIKAWA, ATSUSHI PI
 NAKANISHI
 PC A61K31/437, A61K45/00, A61K45/06, C07D471/04, A61P1/00, A61P1/04,
 PC A61P1/08,
 PC A61P1/16, A61P3/04, A61P3/06, A61P3/10, A61P5/00, A61P7/02, A61P7/06, PC
 A61P5/04,
 PC A61P9/06, A61P9/08, A61P9/10, A61P9/12, A61P11/00, A61P11/04, A61P11/ PC
 06,
 PC A61P13/08, A61P13/12, A61P19/02, A61P19/06, A61P19/10, A61P23/00,
 PC A61P25/16,
 PC A61P25/18, A61P25/22, A61P25/24, A61P25/28, A61P27/02, A61P29/00,
 PC A61P31/00,
 PC A61P35/00, A61P37/08, A61P43/00
 CC PCR primer for amplifying HSP27 gene
 FH Key Location/Qualifiers
 FT 1..22
 source
 /organism="Artificial Sequence".
 FEATURES
 source
 1..22
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 2.3%; Score 17.8; DB 1; Length 22;
 Best Local Similarity 90.5%; Pred. No. 35;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 413 GAGCATGGCTACATCTCCGG 433
 |||||
 Db 21 GAACATGGCTACATCTCTCG 1
 |||||

RESULT 95
 LOCUS BD230260
 DEFINITION Total genome radiation hybrid map of canine genome and its use for
 identification of interesting genes.
 ACCESSION BD230260
 VERSION BD230260.1 GI:33040030
 KEYWORDS JP 2002530091-A/129.
 SOURCE Canis familiaris (dog)
 ORGANISM Canis familiaris
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 1 (bases 1 to 20)
 REFERENCE
 AUTHORS Galibert, F. and Andre, C.
 TITLE Total genome radiation hybrid map of canine genome and its use for
 identification of interesting genes
 JOURNAL Patent: JP 2002530091-A 129 17-SEP-2002;
 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
 COMMENT OS Canis familiaris (dog)
 PN JP 2002530091-A/129
 PD 17-SEP-2002
 PF 15-NOV-1999 JP 2000582596

```

PR 13-NOV-1998 US 60/108193
PI FRANCIS GALBERT,CATHERINE ANDRE
PC C12N15/09,C12Q1/68,C12N15/00
CC A0086R
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
FEATURES
source 1..20
/organism="Canis familiaris (dog)".
/mol_type="genomic DNA"
/db_xref="taxon:9615"

Query Match 2.3%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 33;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 495 TGTCCTGAGGGGCACT 513
Db 1 TGTCCTGAGGGGCACT 19

RESULT 96
AX7671859 17 bp DNA PAT 27-MAR-2003
LOCUS Sequence 304 from Patent W003004526.
DEFINITION
ACCESSION AX7671859
VERSION AX7671859.1 GI:29330207
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and their use as
medicines
JOURNAL Patent: WO 03004526-A 304 16-JAN-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
Db 1 GATCACCATCCAGTCA 17

RESULT 97
AX728678 17 bp DNA PAT 08-MAY-2003
LOCUS Sequence 312 from Patent W003025175.
DEFINITION
ACCESSION AX728678
VERSION AX728678.1 GI:30508021
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or virus resistance and their use as
medicines
JOURNAL Patent: WO 03025175-A 312 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

PR 13-NOV-1998 US 60/108193
PI FRANCIS GALBERT,CATHERINE ANDRE
PC C12N15/09,C12Q1/68,C12N15/00
CC A0086R
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
Db 1 GATCACCATCCAGTCA 17

RESULT 98
AX738957 17 bp DNA PAT 08-MAY-2003
LOCUS Sequence 4547 from Patent W003025177.
DEFINITION
ACCESSION AX738957
VERSION AX738957.1 GI:30518247
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour
reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
JOURNAL Patent: WO 03025177-A 4547 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
Db 1 GATCACCATCCAGTCA 17

RESULT 99
AX762937 17 bp DNA PAT 25-JUN-2003
LOCUS Sequence 6258 from Patent W003040369.
DEFINITION
ACCESSION AX762937
VERSION AX762937.1 GI:32257553
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 6258 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.2%; Score 17; DB 1; Length 17;

```

Best Local Similarity 100.0%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
Db 1 GATCACCATCCAGTCA 17
|||||

RESULT 100
CQ799985
LOCUS CQ799985 19 bp RNA linear PAT 28-APR-2004
DEFINITION Sequence 83 from Patent WO2004030660.
ACCESSION CQ799985
VERSION CQ799985.1 GI:46848932

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 83 15-APR-2004;
The University of British Columbia (CA)

FEATURES
Location/Qualifiers
source
1..19
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 51;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 266 CTCACGACGGGGTCTCGG 284
Db 1 CTCGCTCGGGGTCTCGG 19
|||||

RESULT 101
CQ799909
LOCUS CQ799909 21 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 7 from Patent WO2004030660.
ACCESSION CQ799909
VERSION CQ799909.1 GI:46848856

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE Compositions for treatment of prostate and other cancers
JOURNAL Patent: WO 2004030660-A 7 15-APR-2004;
The University of British Columbia (CA)

FEATURES
Location/Qualifiers
source
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 62;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 60 GGGGCCCCAGCTGGGACCC 78
Db 3 GGGGTCCAGCTGGGCCCC 21
|||||

RESULT 102
CQ625927
LOCUS CQ625927 17 bp DNA linear PAT 02-FEB-2004

DEFINITION Sequence 10667 from Patent WO0192524.
ACCESSION CQ625927
VERSION CQ625927.1 GI:41676145

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.

TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10667 06-DEC-2001;
Aeomica, Inc. (US)

FEATURES
Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 47;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 12 CAGAGTCAGCCAGCATG 28
Db 1 CAGAGCCAGCCAGCATG 17
|||||

RESULT 103
AR466990
LOCUS AR466990 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10667 from patent US 6686188.
ACCESSION AR466990
VERSION AR466990.1 GI:42702047

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.

TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10667 03-FEB-2004;

FEATURES
Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 47;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 12 CAGAGTCAGCCAGCATG 28
Db 1 CAGAGCCAGCCAGCATG 17
|||||

RESULT 104
AX735327
LOCUS AX735327 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 917 from Patent WO03025177.

ACCESSION AX735327
VERSION AX735327.1 GI:30514604
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijnder,M.
TITLE Sequences involved in phenomena of tumour suppression, tumour

```

reversion, apoptosis and/or resistance to viruses and the use
thereof as medicaments
Patent: WO 03025177-A 917 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES
    source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
Query Match
Best Local Similarity 2.0%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
Db 1 GATCACCATCCAGCCA 17

RESULT 105
LOCUS
AX762926 17 bp DNA linear PAT 25-JUN-2003
DEFINITION
Sequence 6247 from Patent WO03040369.
ACCESSION
AX762926
VERSION
AX762926.1 GI:32257542
KEYWORDS
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS
Telerman,A., Amson,R. and Tuijinder,M.
TITLE
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or vital resistance phenomena and their use as
medicines
JOURNAL
Patent: WO 03040369-A 6247 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
    source
    1..17
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"
Query Match
Best Local Similarity 2.0%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
Db 1 GATCACCATCCAGCCA 17

RESULT 106
LOCUS
AR180537 15 bp DNA linear PAT 20-APR-2002
DEFINITION
Sequence 605 from patent US 6333152.
ACCESSION
AR180537
VERSION
AR180537.1 GI:20222570
KEYWORDS
Unknown.
ORGANISM
Unknown.
REFERENCE
1 (bases 1 to 15)
AUTHORS
Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.
TITLE
Gene expression profiles in normal and cancer cells
JOURNAL
Patent: US 6333152-A 605 25-DEC-2001;
Molecular Engines Laboratories
FEATURES
    source
    1..15
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match
Best Local Similarity 2.0%; Score 15; DB 1; Length 15;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 529 CATGCCCAAGCTAGC 543
Db 1 CATGCCCAAGCTAGC 15

RESULT 107
LOCUS
AR072210 18 bp DNA linear PAT 28-AUG-2000
DEFINITION
Sequence 13 from patent US 5948611.
ACCESSION
AR072210
VERSION
AR072210.1 GI:9998974
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 18)
AUTHORS
Prockop,D.J., Ala-Kokko,L., Williams,C.J., Ritvaniemi,P.,
Baldwin,C., Hopkinson,I. and Ahmad,N.Nina.
TITLE
Primers and methods for detecting mutations in the procollagen II
gene (COL2A1) that indicate a genetic predisposition for a
COL2A1-associated disease
JOURNAL
Patent: US 5948611-A 13 07-SEP-1999;
FEATURES
    source
    1..18
    /organism="unknown"
    /mol_type="unassigned DNA"
Query Match
Best Local Similarity 1.9%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 TGCCCGCGCTGCCGAGG 146
Db 18 TGCCCTGGCTGCAGGAG 1

RESULT 108
LOCUS
CO786325 18 bp DNA linear PAT 24-MAR-2004
DEFINITION
Sequence 133 from Patent WO2004020668.
ACCESSION
CO786325
VERSION
CO786325.1 GI:45721427
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Nakamura,Y. and Katagiri,T.
TITLE
Method for treating synovial sarcoma
JOURNAL
Patent: WO 2004020668-A 133 11-MAR-2004;
Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)
FEATURES
    source
    1..18
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Description of Artificial Sequence: synthetic
    oligonucleotide"
Query Match
Best Local Similarity 1.9%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 100 TAGCCGCGCTTTCGACCA 117
Db 1 TAACTGCGCTCTCGACCA 18

RESULT 109
LOCUS
I26321 18 bp DNA linear PAT 07-OCT-1996

```

```

DEFINITION Sequence 13 from patent US 5558988.
ACCESSION I26321
VERSION I26321.1 GI:1606191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Prockop,D.J., Ala-Kokko,L. and Ritvaniemi,P.
TITLE Primers and methods for detecting mutations in the procollagen II
JOURNAL gene that indicate a genetic predisposition for osteoarthritis
FEATURES Patent: US 5558988-A 13 24-SEP-1996;
Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 65;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 129 TCCCCCGCTGCCGAGG 146
DB 18 TCCCGCTGCTGCAGGAG 1

RESULT 110
AR392122/c
LOCUS AR392122 18 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 37 from patent US 6613567.
ACCESSION AR392122
VERSION AR392122.1 GI:40116012
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.F. and Cowsett,L.M.
TITLE Antisense inhibition of Her-2 expression
JOURNAL Patent: US 6613567-A 37 02-SEP-2003;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 65;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 123 TCGGCTGCCCGCTGC 140
DB 18 TCGGCTGCCCGCTGC 1

RESULT 111
AX480662/c
LOCUS AX480662 18 bp DNA linear PAT 12-AUG-2002
DEFINITION Sequence 50 from Patent WO248189.
ACCESSION AX480662
VERSION AX480662.1 GI:22217411
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Etzerodt,M., Holtet,T.L., Graversen,N.J. and th Gersen,H.C.
TITLE Combinatorial libraries of proteins having the scaffold structure
of c-type lectin-like domains
JOURNAL Patent: WO 0248189-A 50 20-JUN-2002;
FEATURES Borean Pharma A/S (DK)
Location/Qualifiers
source 1..18
/organism="synthetic construct"

/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="oligonucleotide"

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 65;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 86 GACTGGTACCGCATAGC 103
DB 18 GACCGGTACCGCATGCG 1

RESULT 112
I69196/c
LOCUS I69196 16 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 466 from patent US 5677149.
ACCESSION I69196
VERSION I69196.1 GI:2831318
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Bauer,S.Christopher., Abrams,M.Allen., Braford-Goldberg,S.Ruth.,
Caparon,M.Helena., Easton,A.Michael., Klein,B.Kure.,
McKearn,J.Patrick., Olins,P., Paik,K., Polazzi,J. and
Thomas,J.Warren.
TITLE Interleukin-3 (IL-3) mutant polypeptides and their recombinant
JOURNAL production
FEATURES Patent: US 5677149-A 466 14-OCT-1997;
Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 565 CATCCAGTCACCTTC 580
DB 16 CATCCAGTCACCTTC 1

RESULT 113
AR253794/c
LOCUS AR253794 16 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 466 from patent US 6479261.
ACCESSION AR253794
VERSION AR253794.1 GI:27302222
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Bauer,S.C., Abrams,M.A., Braford-Goldberg,S.R., Caparon,M.H.,
Easton,A.M., Klein,B.K., McKearn,J.P., Olins,P., Paik,K.,
Polazzi,J. and Thomas,J.W.
TITLE Methods of using interleukin-3 (IL-3) mutant polypeptides for
JOURNAL ex-vivo expansion of hematopoietic stem cells
FEATURES Patent: US 6479261-A 466 12-NOV-2002;
Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 565 CATCCAGTCACCTTC 580
DB 16 CATCCAGTCACCTTC 1

```

Db 16 CATTCCAGTCACCTTC 1

RESULT 114
AX696849/c
LOCUS AX696849 16 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 466 from Patent EP1283264.
ACCESSION AX696849
VERSION AX696849.1 GI:29419961
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Bauer, S.C., Abrams, M.A., Braford-Goldberg, S.R., Caparon, M.H., Easton, A.M., Klein, B.K., McKearn, J.P., Olins, P.O., Paik, K., Polazzi, J.O., and Thomas, J.W.
TITLE Interleukin-3 (il-3) mutant polypeptides
JOURNAL Patent: EP 1283264-A 466 12-FEB-2003;
G.D. SEARLE & CO. (US)
FEATURES
source
1. .16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 1.9%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 59;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 565 CATCCAGTCACCTTC 580
||| ||||| ||||| |||||
Db 16 CATTCCAGTCACCTTC 1

RESULT 115
CQ625926
LOCUS CQ625926 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10666 from Patent WO0192524.
ACCESSION CQ625926
VERSION CQ625926.1 GI:41676144
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 10666 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 12 CAGAGTCAGCCAGCAT 27
||||| ||||| ||||| |||||
Db 2 CAGAGCCAGCCAGCAT 17

RESULT 116
CQ625928
LOCUS CQ625928 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 10666 from Patent WO0192524.
ACCESSION CQ625928
VERSION CQ625928.1 GI:41676146

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.

TITLE Myosin-like gene expressed in human heart and muscle

JOURNAL Patent: WO 0192524-A 10666 06-DEC-2001;

Aeomica, Inc. (US)

FEATURES

Location/Qualifiers

source

1. .17

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 66;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 AGAGTCAGCCAGCATG 28

||||| ||||| ||||| |||||

Db 1 AGAGCCAGCCAGCATG 16

||||| ||||| ||||| |||||

RESULT 117

AR466989

LOCUS

AR466989

Sequence 10666 from patent US 6686188.

ACCESSION

AR466989

VERSION

AR466989.1

GI:42702046

KEYWORDS

Unknown.

ORGANISM

Unclassified.

REFERENCE

1 (bases 1 to 17)

AUTHORS

Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.

TITLE

Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle

JOURNAL

Patent: US 6686188-A 10666 03-FEB-2004;

Aeomica, Inc. (US)

FEATURES

Location/Qualifiers

source

1. .17

/organism="unknown"

/mol_type="genomic DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 66;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 12 CAGAGTCAGCCAGCAT 27

||||| ||||| ||||| |||||

Db 2 CAGAGCCAGCCAGCAT 17

||||| ||||| ||||| |||||

RESULT 118

AR466991

LOCUS

AR466991

Sequence 10668 from patent US 6686188.

ACCESSION

AR466991

VERSION

AR466991.1

GI:42702048

KEYWORDS

Unknown.

ORGANISM

Unclassified.

REFERENCE

1 (bases 1 to 17)

AUTHORS

Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.

TITLE

Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle

JOURNAL

Patent: US 6686188-A 10668 03-FEB-2004;

Aeomica, Inc. (US)

FEATURES

Location/Qualifiers

```
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 AGAGTCAGCCAGCATG 28
|||||
Db 1 AGAGCCAGCCAGCATG 16

RESULT 119
AX615411/c
LOCUS AX615411 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 218 from Patent EP1262488.
ACCESSION AX615411
VERSION AX615411.1 GI:28446457
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gu,Y. and Nguyen,C.T.
AUTHORS Human lcc1-domain containing protein
TITLE Human lcc1-domain containing protein
JOURNAL Patent: EP 1262488-A 218 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 11 GCAGAGTCAGCCAGCA 26
|||||
Db 17 GCAGAGTCAGCCTGCA 2

RESULT 120
AX615412/c
LOCUS AX615412 17 bp DNA linear PAT 20-FEB-2003
DEFINITION Sequence 219 from Patent EP1262488.
ACCESSION AX615412
VERSION AX615412.1 GI:28446458
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Gu,Y. and Nguyen,C.T.
AUTHORS Human lcc1-domain containing protein
TITLE Human lcc1-domain containing protein
JOURNAL Patent: EP 1262488-A 219 04-DEC-2002;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 11 GCAGAGTCAGCCAGCA 26
|||||
Db 16 GCAGAGTCAGCCTGCA 1

RESULT 121
AX783872
LOCUS AX783872 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2203 from Patent WO03050284.
ACCESSION AX783872
VERSION AX783872.1 GI:32951721
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Guo,J.
AUTHORS Human prostate cancer candidate protein 1
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2203 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 56 CTGCGGGGGCCCCAGCT 71
|||||
Db 2 CTGAGGGGGCCCCAGCT 17

RESULT 122
AX783873
LOCUS AX783873 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 2204 from Patent WO03050284.
ACCESSION AX783873
VERSION AX783873.1 GI:32951722
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Guo,J.
AUTHORS Human prostate cancer candidate protein 1
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 2204 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.9%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 56 CTGCGGGGGCCCCAGCT 71
|||||
Db 1 CTGAGGGGGGGCCCCAGCT 16

RESULT 123
AR096356
LOCUS AR096356 18 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 27 from patent US 6007995.
ACCESSION AR096356
VERSION AR096356.1 GI:10025093
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
```

```

Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B.F. and Cowse, L.M.
TITLE Antisense modulation of TNFR1 expression
JOURNAL Patent: US 6007995-A 27 28-DEC-1999;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 487 CTCCTCCCTGTCCTCCT 502
||| ||||| |||||
Db 2 CTTCTCCCTGTCCTCCT 17

RESULT 124
AR109825 AR109825 18 bp DNA linear PAT 14-FEB-2001
LOCUS
DEFINITION Sequence 249 from patent US 6114139.
ACCESSION AR109825
VERSION AR109825.1 GI:12826101
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.
TITLE G-protein coupled receptor protein and a DNA encoding the receptor
JOURNAL Patent: US 6114139-A 249 05-SEP-2000;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 218 AGCCCGCAGTGGCGG 233
||| ||||| |||||
Db 1 AGCCTCGCAGTGGCGG 16

RESULT 125
BD217404 BD217404 18 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Antisense modulation of TNFR1 expression.
ACCESSION BD217404
VERSION BD217404.1 GI:33027174
KEYWORDS JP 2002519015-A/27.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B.F. and Cowse, L.M.
TITLE Antisense modulation of TNFR1 expression
JOURNAL Patent: JP 2002519015-A 27 02-JUL-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002519015-A/27
PD 02-JUL-2002
PF 17-JUN-1999 JP 2000557265
PR 26-JUN-1998 US 09/106038
PI BRENDA F BAKER, LEX M COWSE
PC
C12N15/09,A61K31/7105,A61K31/711,A61K48/00,A61P29/00,A61P43/00,PC
C12Q1/68,
PC C12N15/00
CC Strandedness: Single;

CC Topology: Linear;
CC Antisense modulation of TNFR1 expression
FH Key Location/Qualifiers
FT source 1..18 /organism="Unidentified".
FEATURES Location/Qualifiers
source
1..18
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 487 CTCCTCCCTGTCCTCCT 502
||| ||||| |||||
Db 2 CTTCTCCCTGTCCTCCT 17

RESULT 126
AR294360/c AR294360 18 bp DNA linear PAT 12-JUN-2003
LOCUS
DEFINITION Sequence 6095 from patent US 6537751.
ACCESSION AR294360
VERSION AR294360.1 GI:31681644
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
disequilibrium map of the human genome
JOURNAL Patent: US 6537751-A 6095 25-MAR-2003;
FEATURES Location/Qualifiers
source
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 74;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 701 CTGTGTTCTTTTGA 716
||| ||||| |||||
Db 18 CTGTGTTCTTCTGA 3

RESULT 127
AX215323 AX215323 17 bp RNA linear PAT 07-SEP-2001
LOCUS
DEFINITION Sequence 765 from Patent WO0159103.
ACCESSION AX215323
VERSION AX215323.1 GI:15525366
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 765 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

```

```
Query Match      1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 164 GCGCGCAGCAGCTG 177
      |||||
Db 3 GCGCGCAGCAGCTG 16

RESULT 128
AX216349
LOCUS AX216349 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 1791 from Patent WO0159103.
ACCESSION AX216349
VERSION AX216349.1 GI:15526410
KEYWORDS .
SOURCE synthetic construct
ORGANISM synthetic construct
          other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
JOURNAL nogo gene expression
        Patent: WO 0159103-A 1791 16-AUG-2001;
        RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
        McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
source 1..17
        /organism="synthetic construct"
        /mol_type="unassigned RNA"
        /db_xref="taxon:32630"
        /note="Nucleic Acid"

Query Match      1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 164 GCGCGCAGCAGCTG 177
      |||||
Db 2 GCGCGCAGCAGCTG 15

RESULT 129
AX266839/c
LOCUS AX266839 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4230 from Patent WO0173002.
ACCESSION AX266839
VERSION AX266839.1 GI:16515640
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E. B., Gamper, H. B. and Rice, M. C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
        Patent: WO 0173002-A 4230 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
source 1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 38 GCGCTCCCTCTCTCGCT 54
      |||||
Db 17 GCGCTCCCTCTCTCGCT 1

RESULT 132
BD197647
LOCUS BD197647 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
ACCESSION BD197647
VERSION BD197647.1 GI:33007417
KEYWORDS JP 2002509721-A/673.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

Query Match      1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 AGCCACGCGAGTCCA 554
      |||||
Db 15 AGCCACGCGAGTCCA 2
```

```
RESULT 130
AX266840
LOCUS AX266840 17 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 4231 from Patent WO0173002.
ACCESSION AX266840
VERSION AX266840.1 GI:16515641
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E. B., Gamper, H. B. and Rice, M. C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
        Patent: WO 0173002-A 4231 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
source 1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 76;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 AGCCACGCGAGTCCA 554
      |||||
Db 3 AGCCACGCGAGTCCA 16

RESULT 131
ARI64573/c
LOCUS ARI64573 17 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 6 from patent US 6274310.
ACCESSION ARI64573
VERSION ARI64573.1 GI:16237643
KEYWORDS .
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Habener, J. F. and Stoffers, D. A.
TITLE Compositions and methods for detecting pancreatic disease
JOURNAL Patent: US 6274310-A 6 14-AUG-2001;
FEATURES
source 1..17
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 38 GCGCTCCCTCTCTCGCT 54
      |||||
Db 17 GCGCTCCCTCTCTCGCT 1

RESULT 132
BD197647
LOCUS BD197647 17 bp RNA linear PAT 17-JUL-2003
DEFINITION Method and reagent for treating diseases or conditions concerning
ACCESSION BD197647
VERSION BD197647.1 GI:33007417
KEYWORDS JP 2002509721-A/673.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
```



```
RESULT 136
CQ617591/c
LOCUS          CQ617591      17 bp      DNA          linear      PAT 02-FEB-2004
DEFINITION     Sequence 2331 from Patent WO0192524.
ACCESSION      CQ617591
VERSION        CQ617591.1  GI:41667809
KEYWORDS       .
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarhini; Homnidae; Homo.
REFERENCE      1
AUTHORS        Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
                Shannon,M.E.
TITLE          Myosin-like gene expressed in human heart and muscle
JOURNAL        Patent: WO 0192524-A 2331 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
                source
                1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 549 AGTCCAAACGAGATCACC 565
Db 17 AGTCAGCGGACATCACC 1
Query Match    1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
LOCUS          CQ625929      17 bp      DNA          linear      PAT 02-FEB-2004
DEFINITION     Sequence 10669 from Patent WO0192524.
ACCESSION      CQ625929
VERSION        CQ625929.1  GI:41676147
KEYWORDS       .
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarhini; Homnidae; Homo.
REFERENCE      1
AUTHORS        Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
                Shannon,M.E.
TITLE          Myosin-like gene expressed in human heart and muscle
JOURNAL        Patent: WO 0192524-A 10669 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
                source
                1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
LOCUS          CQ625930      17 bp      DNA          linear      PAT 02-FEB-2004
DEFINITION     Sequence 10670 from Patent WO0192524.
ACCESSION      CQ625930
VERSION        CQ625930.1  GI:41676148
KEYWORDS       .
SOURCE         Homo sapiens (human)
```

```
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarhini; Homnidae; Homo.
REFERENCE      1
AUTHORS        Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
                Shannon,M.E.
TITLE          Myosin-like gene expressed in human heart and muscle
JOURNAL        Patent: WO 0192524-A 10670 06-DEC-2001;
                Aeomica, Inc. (US)
FEATURES       Location/Qualifiers
                source
                1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"
Query Match    1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 15 AGTCAGCGGACGATGACC 31
Db 1 AGCCAGCGGATGGGCC 17
Query Match    1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
LOCUS          AR286401      17 bp      RNA          linear      PAT 10-APR-2003
DEFINITION     Sequence 773 from patent US 6528640.
ACCESSION      AR286401
VERSION        AR286401.1  GI:29723997
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Beigelman,L., Burgin,A., Beaudry,A., Karpeisky,A.,
                Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE          Synthetic ribonucleic acids with RNase activity
JOURNAL        Patent: US 6528640-A 773 04-MAR-2003;
                Location/Qualifiers
                source
                1..17
                /organism="unknown"
                /mol_type="unassigned RNA"
Query Match    1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 123 TCGGGCTGCCCGGCTG 139
Db 1 TCGGGCTGGCTCGGCTG 17
Query Match    1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
LOCUS          AR398391      17 bp      RNA          linear      PAT 18-DEC-2003
DEFINITION     Sequence 772 from patent US 6617438.
ACCESSION      AR398391
VERSION        AR398391.1  GI:40136165
KEYWORDS       .
SOURCE         Unknown.
ORGANISM       Unknown.
REFERENCE      1 (bases 1 to 17)
AUTHORS        Beigelman,L., Burgin,A.B., Beaudry,A., Karpeisky,A.,
                Matulic-Adamic,J., Sweedler,D. and Zinnen,S.
TITLE          Oligoribonucleotides with enzymatic activity
JOURNAL        Patent: US 6617438-A 772 09-SEP-2003;
                Location/Qualifiers
                source
                1..17
                /organism="unknown"
                /mol_type="unassigned RNA"
```

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 81;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 123 TCGGCTGCCCGGCTG 139
 Db 1 TCGGCTGCCCGGCTG 17

RESULT 141
 AR458652/c 17 bp DNA linear PAT 20-FEB-2004
 LOCUS Sequence 2329 from patent US 6686188.
 DEFINITION AR458652
 VERSION AR458652.1 GI:42693709
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 2329 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 81;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 551 TCCACGAGATCACCAT 567
 Db 17 TCCACGAGATCACCAT 1

RESULT 142
 AR458653/c 17 bp DNA linear PAT 20-FEB-2004
 LOCUS Sequence 2330 from patent US 6686188.
 DEFINITION AR458653
 VERSION AR458653.1 GI:42693710
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 2330 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 81;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 550 GTCCACGAGATCACCACCA 566
 Db 17 GTCCACGAGATCACCACCA 1

RESULT 143
 AR458654/c 17 bp DNA linear PAT 20-FEB-2004
 LOCUS Sequence 2331 from patent US 6686188.
 DEFINITION

ACCESSION AR458654
 VERSION AR458654.1 GI:42693711
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 2331 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 81;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 549 AGTCCACGAGATCACC 565
 Db 17 AGTCCACGAGATCACC 1

RESULT 144
 AR466992 17 bp DNA linear PAT 20-FEB-2004
 LOCUS Sequence 10669 from patent US 6686188.
 DEFINITION AR466992
 ACCESSION AR466992
 VERSION AR466992.1 GI:42702049
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 10669 03-FEB-2004;
 FEATURES Location/Qualifiers
 source 1..17
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 81;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 14 GAGTCAGCCAGCATGAC 30
 Db 1 GAGTCAGCCAGCATGAC 17

RESULT 145
 AR466993 17 bp DNA linear PAT 20-FEB-2004
 LOCUS Sequence 10670 from patent US 6686188.
 DEFINITION AR466993
 ACCESSION AR466993
 VERSION AR466993.1 GI:42702050
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 10670 03-FEB-2004;
 FEATURES Location/Qualifiers

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 81;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 14 GAGTCAGCCAGCATGAC 30
 Db 1 GAGTCAGCCAGCATGAC 17

RESULT 145
 AR466993 17 bp DNA linear PAT 20-FEB-2004
 LOCUS Sequence 10670 from patent US 6686188.
 DEFINITION AR466993
 ACCESSION AR466993
 VERSION AR466993.1 GI:42702050
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
 TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
 JOURNAL Patent: US 6686188-A 10670 03-FEB-2004;
 FEATURES Location/Qualifiers

```

source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 15 AGTCAGCCAGCATGACC 31
||| ||||| ||||| |||
Db 1 AGCCAGCCAGCATGCCC 17

RESULT 146
AX498153/c
LOCUS AX498153 17 bp DNA linear PAT 14-MAY-2004
DEFINITION Sequence 599 from patent US 6703228.
ACCESSION AR483153
VERSION AR483153.1 GI:47245676
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
1 (bases 1 to 17)
AUTHORS Landers, J., Jordan, B., Housman, D.E. and Charest, A.
TITLE Methods and products related to genotyping and DNA analysis
JOURNAL Patent: US 6703228-A 599 09-MAR-2004;
FEATURES
Location/Qualifiers
source
1..17
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 746 AGTTCAAAGCAACACC 762
||| ||||| ||||| |||
Db 17 AGTACAAAGCAACACC 1

RESULT 147
AX216972
LOCUS AX216972 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 2414 from Patent WO0159103.
ACCESSION AX216972
VERSION AX216972.1 GI:15527033
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
nogo gene expression
JOURNAL Patent: WO 0159103-A 2414 16-AUG-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
McSwiggen, James (US) ; Chowrira, Bharat M. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 462 CCGGTGTGACCCACC 478
||| ||||| ||||| |||
Db 1 CCCGTGTGACCCGCC 17

RESULT 148
AX498863/c
LOCUS AX498863 17 bp DNA linear PAT 27-SEP-2002
DEFINITION Sequence 170 from Patent EP1229046.
ACCESSION AX498863
VERSION AX498863.1 GI:23381156
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Zhan, J.
TITLE Human testis expressed patched like protein
JOURNAL Patent: EP 1229046-A 170 07-AUG-2002;
Acomica, Inc. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 295 CACTGCGGACGCTGGC 311
||||| ||||| ||||| |||
Db 17 CACTGCGGCGCGTGGC 1

RESULT 149
AX531714
LOCUS AX531714 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 1223 from Patent EPI239051.
ACCESSION AX531714
VERSION AX531714.1 GI:25255211
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1
AUTHORS Shannon, M.
TITLE Human poah-like protein 1
JOURNAL Patent: EP 1239051-A 1223 11-SEP-2002;
Acomica, Inc. (US)
FEATURES
Location/Qualifiers
source
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 557 GAGATCACCATCCCACT 573
||||| ||||| ||||| |||
Db 1 GAGATCAGACCCCACT 17

RESULT 150
AX579468
LOCUS AX579468 17 bp RNA linear PAT 10-JAN-2003
DEFINITION Sequence 1306 from Patent WO0211674.
ACCESSION AX579468
VERSION AX579468.1 GI:27648670
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

```

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.

TITLE Method and reagent for the inhibition of calcium activated chloride

channel-1 (clca-1)

JOURNAL Patent: WO 0211674-A 1306 14-FEB-2002;

RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;

Thompson, James (US)

FEATURES Location/Qualifiers

source 1..17

/organism="Homo sapiens"

/mol_type="unassigned RNA"

/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 81;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 506 GGCACACTGACCGTGA 522

Db 1 GGCACAGTGCCTGA 17

RESULT 151

LOCUS AX580066/c

DEFINITION Sequence 1904 from Patent WO0211674.

ACCESSION AX580066

VERSION AX580066.1 GI:27649268

KEYWORDS Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Eukaryota; Eutheria; Primates; Catarrhini; Hominidae; Homo.

Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.

TITLE Method and reagent for the inhibition of calcium activated chloride

channel-1 (clca-1)

JOURNAL Patent: WO 0211674-A 1304 14-FEB-2002;

RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;

Thompson, James (US)

FEATURES Location/Qualifiers

source 1..17

/organism="Homo sapiens"

/mol_type="unassigned RNA"

/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 81;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 423 ACATCTCCCGTGCTC 439

Db 17 ACATCTCCCTGTGATT 1

RESULT 152

LOCUS AX580067/c

DEFINITION Sequence 1905 from Patent WO0211674.

ACCESSION AX580067

VERSION AX580067.1 GI:27649269

KEYWORDS Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Eukaryota; Eutheria; Primates; Catarrhini; Hominidae; Homo.

Thompson,J., Mcswiggen,J., Mckenzie,T., Ayers,D., Szymkowski,D.E.
and Grupe,A.

TITLE Method and reagent for the inhibition of calcium activated chloride

JOURNAL

channel-1 (clca-1)

Patent: WO 0211674-A 1905 14-FEB-2002;

RIBOZYME PHARMACEUTICALS, INC. (US) ; Syntex (U.S.A.) LLC (US) ;

Thompson, James (US)

FEATURES Location/Qualifiers

source 1..17

/organism="Homo sapiens"

/mol_type="unassigned RNA"

/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 81;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 422 TACATCTCCCGTGCTT 438

Db 17 TACATCTCCCTGTGATT 1

RESULT 153

LOCUS AX725108/c

DEFINITION Sequence 2795 from Patent WO03025176.

ACCESSION AX725108

VERSION AX725108.1 GI:30504451

KEYWORDS Mus musculus (house mouse)

ORGANISM Mus musculus

REFERENCE 1 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

Teleman,A., Anson,R. and Tuijnder,M.

Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as

medicines

JOURNAL Patent: WO 03025176-A 2795 27-MAR-2003;

Molecular Engines Laboratories (FR)

FEATURES Location/Qualifiers

source 1..17

/organism="Mus musculus"

/mol_type="unassigned DNA"

/db_xref="taxon:10090"

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 81;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 273 GCGGGGTCTCGAGATC 289

Db 17 GCTGGGTCTCAGATC 1

RESULT 154

LOCUS AX725434

DEFINITION Sequence 3121 from Patent WO03025176.

ACCESSION AX725434

VERSION AX725434.1 GI:30504777

KEYWORDS Mus musculus (house mouse)

ORGANISM Mus musculus

REFERENCE 1 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

Teleman,A., Anson,R. and Tuijnder,M.

Sequences involved in phenomena of tumour suppression, tumour

reversion, apoptosis and/or virus resistance and their use as

medicines

JOURNAL Patent: WO 03025176-A 3121 27-MAR-2003;

Molecular Engines Laboratories (FR)

FEATURES Location/Qualifiers

source 1..17

/organism="Mus musculus"

/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
|||||
Db 1 GATCACCACCAAGTCA 17

RESULT 155
LOCUS AX735751/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1341 from Patent WO03025177.
ACCESSION AX735751
VERSION AX735751.1 GI:30515028
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 1341 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 734 TTCTCAATAAGTTC 750
|||||
Db 17 TTCTCAATAATGATC 1

RESULT 156
LOCUS AX736224 17 bp DNA linear PAT 08-MAY-2003
DEFINITION Sequence 1814 from Patent WO03025177.
ACCESSION AX736224
VERSION AX736224.1 GI:30515501
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and the use thereof as medicaments
JOURNAL Patent: WO 03025177-A 1814 27-MAR-2003;
Molecular Engines Laboratories (FR)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
|||||
Db 1 GATCACCACCAAGTCA 17

RESULT 157
LOCUS AX753978 17 bp DNA linear PAT 23-JUN-2003
DEFINITION Sequence 325 from Patent WO03037931.
ACCESSION AX753978
VERSION AX753978.1 GI:32166675
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Shannon, M. and Phan, T.
TITLE Human angiotensin-like protein 1
JOURNAL Patent: WO 03037931-A 325 08-MAY-2003;
Amersham Biosciences SV Corp. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 243 ACAGCCGCGCTCAGC 259
|||||
Db 1 ACATCCGCTCGCTCAGC 17

RESULT 158
LOCUS AX783428/c 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 1759 from Patent WO03050284.
ACCESSION AX783428
VERSION AX783428.1 GI:32951277
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1759 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 520 GGAGGCCCGCATGCCCA 536
|||||
Db 17 GGAGGCACCCAGGCCCA 1

RESULT 159
LOCUS AX783429/c 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 1760 from Patent WO03050284.
ACCESSION AX783429
VERSION AX783429.1 GI:32951278

```
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Guo, J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Amersham Biosciences (SV) Corp. (US)
FEATURES     Location/Qualifiers
              source
                1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      519 TGGAGGCCCCCATGCC 535
Db      17 TGGAGGCCACCCAGGCC 1

RESULT 160
LOCUS      CQ799952
DEFINITION Sequence 50 from Patent WO2004030660.
ACCESSION  CQ799952
VERSION     CQ799952.1 GI:46848899
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 50 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
              source
                1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.7%; Score 13; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 15e+02;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy      495 TGTCCCTCAGGGGACACTGA 515
Db      1 TGTGCCCTCAGGGGACAGGA 21

RESULT 161
LOCUS      AR110507
DEFINITION Sequence 16 from patent US 6114598.
ACCESSION  AR110507
VERSION     AR110507.1 GI:12826783
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 16)
AUTHORS     Kucherlapati, R., Jakobovits, A., Kalpholz, S., Brenner, D.G. and
            Capon, D.J.
TITLE       Generation of xenogeneic antibodies
JOURNAL     Patent: US 6114598-A 16 05-SEP-2000;
            Amersham Biosciences (SV) Corp. (US)
FEATURES    Location/Qualifiers
              source
                1..16
                /organism="Artificial Sequence".

KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Guo, J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Amersham Biosciences (SV) Corp. (US)
FEATURES     Location/Qualifiers
              source
                1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 81;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      519 TGGAGGCCCCCATGCC 535
Db      17 TGGAGGCCACCCAGGCC 1

RESULT 160
LOCUS      CQ799952
DEFINITION Sequence 50 from Patent WO2004030660.
ACCESSION  CQ799952
VERSION     CQ799952.1 GI:46848899
KEYWORDS
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
REFERENCE   1
AUTHORS     Gleave, M.E., Rocchi, P. and Signaevsky, M.
TITLE       Compositions for treatment of prostate and other cancers
JOURNAL     Patent: WO 2004030660-A 50 15-APR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
              source
                1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.7%; Score 13; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy      495 TGTCCCTCAGGGGACACTGA 515
Db      1 TGTGCCCTCAGGGGACAGGA 21

RESULT 161
LOCUS      AR110507
DEFINITION Sequence 16 from patent US 6114598.
ACCESSION  AR110507
VERSION     AR110507.1 GI:12826783
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 16)
AUTHORS     Kucherlapati, R., Jakobovits, A., Kalpholz, S., Brenner, D.G. and
            Capon, D.J.
TITLE       Generation of xenogeneic antibodies
JOURNAL     Patent: US 6114598-A 16 05-SEP-2000;
            Amersham Biosciences (SV) Corp. (US)
FEATURES    Location/Qualifiers
              source
                1..16
                /organism="Artificial Sequence".
```

```
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE     1
AUTHORS      Guo, J.
TITLE        Human prostate cancer candidate protein 1
JOURNAL      Amersham Biosciences (SV) Corp. (US)
FEATURES     Location/Qualifiers
              source
                1..17
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      68 AGCTGGGAGCCCTTCC 83
Db      1 AGCTGGGAACCCCTTGC 16

RESULT 162
LOCUS      AR137060
DEFINITION Sequence 16 from patent US 6162963.
ACCESSION  AR137060
VERSION     AR137060.1 GI:14478310
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 16)
AUTHORS     Kucherlapati, R., Jakobovits, A., Kalpholz, S., Brenner, D.G. and
            Capon, D.J.
TITLE       Generation of Xenogenetic antibodies
JOURNAL     Patent: US 6162963-A 16 19-DEC-2000;
            Amersham Biosciences (SV) Corp. (US)
FEATURES    Location/Qualifiers
              source
                1..16
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      68 AGCTGGGAGCCCTTCC 83
Db      1 AGCTGGGAACCCCTTGC 16

RESULT 163
LOCUS      BD266330/c
DEFINITION Universal arrays.
ACCESSION  BD266330
VERSION     BD266330.1 GI:33076098
KEYWORDS   JP 2002539849-A/330.
SOURCE     synthetic construct
           other sequences; artificial sequences.
REFERENCE   1 (bases 1 to 16)
AUTHORS     Fan, J.B., Hirschhorn, J.N., Huang, X., Kaplan, P., Lander, E.S.,
            Lockhart, D.J., Ryder, T. and Sklar, P.
TITLE       Universal arrays
JOURNAL     Patent: JP 2002539849-A 330 26-NOV-2002;
            WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC
COMMENT     OS Artificial Sequence
           PN JP 2002539849-A/330
           PD 26-NOV-2002
           PF 27-MAR-2000 JP 2000608794
           PR 26-MAR-1999 US 60/126473, 23-JUN-1999 US 60/140359 PT
           JIAN BING FAN, JOEL N HIRSCHHORN, XIAOHUA
           HUANG, PAUL KAPLAN, ERIC
           PI S LANDER,
           PJ DAVID J LOCKHART, THOMAS RYDER, PAMELA SKLAR
           PC C1201/68, C12M1/00, C12N15/09, C12N15/09, G01N33/53, PC
           G01N33/566,
           PC G01N37/00, C12N15/00, C12N15/00, C12N15/00
           CC Primer
           FH Key
           FT source
           /organism='Artificial Sequence'.
```

```

FEATURES
source
1..16
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 464 GGTGTGGACCCACCC 479
Db 16 GGTGAGGACCCAGCC 1

RESULT 164
CQ858645/c
LOCUS AR253867/c 16 bp DNA linear PAT 31-AUG-2004
DEFINITION Sequence 107 from Patent WO2004069991.
ACCESSION CQ858645
VERSION CQ858645.1 GI:51852612
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 Hansen,B., Thru, C.A., Petersen, K.D., Westergaard, M. and Wissenbach, M.
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Oligomeric compounds for the modulation of survivin expression
JOURNAL Patent: WO 2004069991-A 107 19-AUG-2004;
Santaris Pharma A/S (DK)
FEATURES
source
1..16
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 161 TTAGGCGGCGAGCT 176
Db 16 TTGGAGCGAGCT 1

RESULT 165
I69269/c
LOCUS I69269 16 bp DNA linear PAT 04-FEB-1998
DEFINITION Sequence 539 from patent US 5677149.
ACCESSION I69269
VERSION I69269.1 GI:2831391
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Bauer, S., Christopher., Abrams, M., Allen., Braford-Goldberg, S., Ruth., Caparon, M., Helena., Easton, A., Michael., Klein, B., Kure., McKearn, J., Patrick., Olins, P., Paik, K., Polazzi, J. and Thomas, J. Warren.
TITLE Interleukin-3 (IL-3) mutant polypeptides and their recombinant production
JOURNAL Patent: US 5677149-A 539 14-OCT-1997;
FEATURES
source
1..16
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

FEATURES
source
1..16
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 565 CATCCAGTCACCTTC 580
Db 16 CATCCAGTCACCGTC 1

RESULT 166
AR253867/c
LOCUS AR253867 16 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 539 from patent US 6479261.
ACCESSION AR253867
VERSION AR253867.1 GI:27302295
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Bauer, S.C., Abrams, M.A., Braford-Goldberg, S.R., Caparon, M.H., Easton, A.M., Klein, B.K., McKearn, J.P., Olins, P., Paik, K., Polazzi, J. and Thomas, J. W.
TITLE Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells
JOURNAL Patent: US 6479261-A 539 12-NOV-2002;
FEATURES
source
1..16
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 565 CATCCAGTCACCTTC 580
Db 16 CATCCAGTCACCGTC 1

RESULT 167
AR391398
LOCUS AR391398 16 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 10 from patent US 6613520.
ACCESSION AR391398
VERSION AR391398.1 GI:40114887
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Ashby, M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: US 6613520-A 10 02-SEP-2003;
FEATURES
source
1..16
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 525 CCCCCTGCGCCAGCT 540
Db 1 CCCCCTGCGCCAGCT 16

RESULT 168
AR391498
LOCUS AR391498 16 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 110 from patent US 6613520.
ACCESSION AR391498
VERSION AR391498.1 GI:40114996
KEYWORDS
SOURCE Unknown.

```

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Ashby,M.
TITLE Methods for the survey and genetic analysis of populations
JOURNAL Patent: US 6613520-A 110 02-SEP-2003;
FEATURES Location/Qualifiers
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 2; Indels 0; Gaps 0;

Qy 56 CTGCGGCGCCGAGCT 71
Db 1 CTGCGGTGCCGAGCT 16

RESULT 169
AR435928 AR435928 16 bp RNA linear PAT 18-DEC-2003
LOCUS
DEFINITION Sequence 187 from patent US 6656731.
ACCESSION AR435928
VERSION AR435928.1 GI:40199012
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.
TITLE Nucleic acid catalysts with endonuclease activity
JOURNAL Patent: US 6656731-A 187 02-DEC-2003;
FEATURES Location/Qualifiers
source
1..16
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 2; Indels 0; Gaps 0;

Qy 708 TCTTTTGATACATTT 723
Db 1 TCTTTTGATTAATTT 16

RESULT 170
AR451605 AR451605 16 bp DNA linear PAT 20-FEB-2004
LOCUS
DEFINITION Sequence 17 from patent US 6673986.
ACCESSION AR451605
VERSION AR451605.1 GI:42682638
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kucherlapati,R., Jakobovits,A., Klapholz,S., Brenner,D.G. and Capon,D.J.
TITLE Generation of xenogeneic antibodies
JOURNAL Patent: US 6673986-A 17 06-JAN-2004;
FEATURES Location/Qualifiers
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 2; Indels 0; Gaps 0;

Qy 68 AGCTGGGACCCCTTCC 83

Db 1 AGCTGGAACCCCTTGC 16

RESULT 171
AR451617 AR451617 16 bp DNA linear PAT 20-FEB-2004
LOCUS
DEFINITION Sequence 29 from patent US 6673986.
ACCESSION AR451617
VERSION AR451617.1 GI:42682650
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Kucherlapati,R., Jakobovits,A., Klapholz,S., Brenner,D.G. and Capon,D.J.
TITLE Generation of xenogeneic antibodies
JOURNAL Patent: US 6673986-A 29 06-JAN-2004;
FEATURES Location/Qualifiers
source
1..16
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 2; Indels 0; Gaps 0;

Qy 68 AGCTGGGACCCCTTCC 83
Db 1 AGCTGGAACCCCTTGC 16

RESULT 172
AX073744/c AX073744 16 bp DNA linear PAT 06-FEB-2001
LOCUS
DEFINITION Sequence 4 from Patent WO0104290.
ACCESSION AX073744
VERSION AX073744.1 GI:12710156
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Jin,Y.X. and Liu,J.S.
TITLE Triplex-forming oligonucleotides and their use in therapy
JOURNAL Patent: WO 0104290-A 4 18-JAN-2001;
Shanghai Institute of Biochemistry Chinese Academy of Sciences (CN)
FEATURES Location/Qualifiers
source
1..16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Single stranded TFO-p"

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1e+02; Mismatches 0; Gaps 0;
Matches 14; Conservative 0; Indels 2; Indels 0; Gaps 0;

Qy 483 TTTCCTCTCCCTGTC 498
Db 16 TTTCCTCTCCCTCTC 1

RESULT 173
AX073745/c AX073745 16 bp DNA linear PAT 06-FEB-2001
LOCUS
DEFINITION Sequence 5 from Patent WO0104290.
ACCESSION AX073745
VERSION AX073745.1 GI:12710157
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

Db 16 CATTCCAGTCAACCGTC 1

RESULT 178

LOCUS CQ799962 21 bp DNA linear PAT 28-APR-2004

DEFINITION Sequence 60 from Patent WO2004030660.

ACCESSION CQ799962

VERSION CQ799962.1 GI:46848909

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Gleave, M.E., Rocchi, P. and Signaevsky, M.

TITLE Compositions for treatment of prostate and other cancers

JOURNAL Patent: WO 2004030660-A 60 15-APR-2004;

The University of British Columbia (CA)

FEATURES

source

1..21

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

Query Match 1.6%; Score 12.6; DB 1; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 596 CTTGGGGCCCGAGCTG 614

Db 1 CTTCTGGGGCCCCCAAGCTG 19

RESULT 179

AR097225/c

LOCUS AR097225 15 bp DNA linear PAT 14-FEB-2001

DEFINITION Sequence 6 from patent US 6071695.

ACCESSION AR097225

VERSION AR097225.1 GI:12805955

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)

AUTHORS Ozkaynak, E. and Oppermann, H.

TITLE Methods and products for identification of modulators of osteogenic protein-1 gene expression

JOURNAL Patent: US 6071695-A 6 06-JUN-2000;

FEATURES

source

1..15

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 398 GAGGAGCGGAGGA 411

Db 14 GAGGAGCGGAGGA 1

RESULT 180

E05651

LOCUS E05651 15 bp DNA linear PAT 29-SEP-1997

DEFINITION PCR primer.

ACCESSION E05651

VERSION E05651.1 GI:2173838

KEYWORDS JP 1993268968-A/4.

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 15)

AUTHORS Yonemura, H., Tajima, Y., Sugawara, K. and Masuda, K.

TITLE PRODUCTION OF HUMAN COAGULATION FACTOR VIII PROTEIN COMPLEX

JOURNAL Patent: JP 1993268968-A 4 19-OCT-1993;

CHEMO SERO THERAPEUT RES INST, TEIJJIN LTD

COMMENT

OS Artificial gene

OC Artificial sequence; Genes.

PN JP 1993268968-A/4

PD 19-OCT-1993

PF 22-SEP-1992 JP 1992252688

PI 24-SEP-1991 JP 91P 243262

PL YONEMURA HIROSHI, TAJIMA YOSHITAKA, SUGAWARA KEISHIN, PI

MASUDA KENICHI

PC C12N15/12, C07K15/06, C12N5/10, C12P21/02//A61K37/465, (C12N5/10, C12R1:91),

PC C12P21/02, C12R1:91);

CC strandedness: Single;

CC topology: Linear.

FEATURES

Location/Qualifiers

source

1..15

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 594 AGCTTGGGGGCCCA 607

Db 1 AGCTTTGGGGGCCCA 14

RESULT 181

I77111

LOCUS I77111 15 bp DNA linear PAT 03-APR-1998

DEFINITION Sequence 8 from patent US 5693499.

ACCESSION I77111

VERSION I77111.1 GI:3013265

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)

AUTHORS Yonemura, H., Tajima, Y., Sugawara, K. and Masuda, K.

TITLE Process for preparing human coagulation factor VIII protein complex

JOURNAL Patent: US 5693499-A 8 02-DEC-1997;

FEATURES

Location/Qualifiers

source

1..15

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 594 AGCTTGGGGGCCCA 607

Db 1 AGCTTTGGGGGCCCA 14

RESULT 182

AR180586

LOCUS AR180586 15 bp DNA linear PAT 20-APR-2002

DEFINITION Sequence 654 from patent US 6333152.

ACCESSION AR180586

VERSION AR180586.1 GI:20222619

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 15)

AUTHORS Vogelstein, B., Kinzler, K.W., Zhang, L. and Zhou, W.

```

TITLE      Gene expression profiles in normal and cancer cells
JOURNAL    Patent: US 633152-A 654 25-DEC-2001;
FEATURES   Location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      369 ATGGCGTGGTGAG 382
Db      2 ATGGCGGGGTGGAG 15

RESULT 183
AX269347
LOCUS      AR432576 15 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 5 from patent US 6653448.
ACCESSION AR432576
VERSION    AR432576.1 GI:40195078
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS   Vernet,C., Rastelli,L. and Herrmann,J.
TITLE     Wnt-7B-like polypeptides and nucleic acids encoding same
JOURNAL   Patent: US 6653448-A 5 25-NOV-2003;
FEATURES   Location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      426 TCTCCGGGTGCTTC 439
Db      1 TCTCCGGCGCTTC 14

RESULT 184
AX269347
LOCUS      AX269347 15 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 5 from Patent WO0174856.
ACCESSION AX269347
VERSION    AX269347.1 GI:16542166
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1
AUTHORS   Vernet,C.A., Rastelli,L. and Herrmann,J.L.
TITLE     Wnt-7b-like polypeptides and nucleic acids encoding same
JOURNAL   Patent: WO 0174856-A 5 11-OCT-2001;
FEATURES   Location/Qualifiers
            1..15
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="SYNTHETIC PCR PRIMER"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      426 TCTCCGGGTGCTTC 439
Db      1 TCTCCGGCGCTTC 14

TITLE      Gene expression profiles in normal and cancer cells
JOURNAL    Patent: US 633152-A 654 25-DEC-2001;
FEATURES   Location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      369 ATGGCGTGGTGAG 382
Db      2 ATGGCGGGGTGGAG 15

RESULT 183
AX269347
LOCUS      AR432576 15 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 5 from patent US 6653448.
ACCESSION AR432576
VERSION    AR432576.1 GI:40195078
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 15)
AUTHORS   Vernet,C., Rastelli,L. and Herrmann,J.
TITLE     Wnt-7B-like polypeptides and nucleic acids encoding same
JOURNAL   Patent: US 6653448-A 5 25-NOV-2003;
FEATURES   Location/Qualifiers
            1..15
            /organism="unknown"
            /mol_type="genomic DNA"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      426 TCTCCGGGTGCTTC 439
Db      1 TCTCCGGCGCTTC 14

RESULT 184
AX269347
LOCUS      AX269347 15 bp DNA linear PAT 29-OCT-2001
DEFINITION Sequence 5 from Patent WO0174856.
ACCESSION AX269347
VERSION    AX269347.1 GI:16542166
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1
AUTHORS   Vernet,C.A., Rastelli,L. and Herrmann,J.L.
TITLE     Wnt-7b-like polypeptides and nucleic acids encoding same
JOURNAL   Patent: WO 0174856-A 5 11-OCT-2001;
FEATURES   Location/Qualifiers
            1..15
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="SYNTHETIC PCR PRIMER"

Query Match      1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      426 TCTCCGGGTGCTTC 439
Db      1 TCTCCGGCGCTTC 14

RESULT 185
AX097953/c
LOCUS      AX097953 12 bp DNA linear PAT 30-MAR-2001
DEFINITION Sequence 21 from Patent WO0118048.
ACCESSION AX097953
VERSION    AX097953.1 GI:13514648
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1
AUTHORS   van Eijs,G.J., Hateboer,G. and Havenga,M.J.
TITLE     Smooth muscle cell promoter and uses thereof
JOURNAL   Patent: WO 0118048-A 21 15-MAR-2001;
FEATURES   Location/Qualifiers
            1..12
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="variant intron-exon splice recognition sequences"

Query Match      1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      606 CAGAAGCTGCAA 617
Db      12 CAGAAGCTGCAA 1

RESULT 186
AX138529/c
LOCUS      AX138529 12 bp DNA linear PAT 30-MAY-2001
DEFINITION Sequence 21 from Patent EP1083231.
ACCESSION AX138529
VERSION    AX138529.1 GI:14274424
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct
REFERENCE  1
AUTHORS   Smooth muscle cell promoter and uses thereof
TITLE     Patent: EP 1083231-A 21 14-MAR-2001;
JOURNAL   Introgene B.V. (NL)
FEATURES   Location/Qualifiers
            1..12
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="variant intron-exon splice recognition sequences"

Query Match      1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      606 CAGAAGCTGCAA 617
Db      12 CAGAAGCTGCAA 1

RESULT 187
AX525366
LOCUS      AX525366 14 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 53 from Patent WO02066676.
ACCESSION AX525366
VERSION    AX525366.1 GI:25170255
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   synthetic construct

```

REFERENCE	1	other sequences; artificial sequences.
AUTHORS		Pugner, D., Marti, J., Manchon, L. and Piquemal, D.
TITLE		Method for qualitative and quantitative analysis of a population of nucleic acids contained in a sample
JOURNAL		Patent: WO 02066676-A 53 29-AUG-2002;
FEATURES		CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
source		1. .14 Location/Qualifiers
Query Match		1.6%; Score 12; DB 1; Length 14;
Best Local Similarity		100.0%; Pred. No. 1e+02;
Matches		12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	738	TCAAATAAAGTT 749
Db	3	TCAAATAAAGTT 14
RESULT 188		
AR180644/c		
LOCUS		AR180644 15 bp DNA linear PAT 20-APR-2002
DEFINITION		Sequence 712 from patent US 6333152.
ACCESSION		AR180644
VERSION		AR180644.1 GI:20222677
KEYWORDS		Unknown.
SOURCE		Unknown.
ORGANISM		Unknown.
REFERENCE		1 (bases 1 to 15)
AUTHORS		Vogelstein, B., Kinzler, K.W., Zhang, L. and Zhou, W.
TITLE		Gene expression profiles in normal and cancer cells
JOURNAL		Patent: US 6333152-A 712 25-DEC-2001;
FEATURES		Location/Qualifiers
source		1. .15 /organism="unknown" /mol_type="unassigned DNA"
Query Match		1.6%; Score 12; DB 1; Length 15;
Best Local Similarity		100.0%; Pred. No. 1.1e+02;
Matches		12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	500	CCTGAGGCAC 511
Db	14	CCTGAGGCAC 3
RESULT 189		
AR180645/c		
LOCUS		AR180645 15 bp DNA linear PAT 20-APR-2002
DEFINITION		Sequence 713 from patent US 6333152.
ACCESSION		AR180645
VERSION		AR180645.1 GI:20222678
KEYWORDS		Unknown.
SOURCE		Unknown.
ORGANISM		Unknown.
REFERENCE		1 (bases 1 to 15)
AUTHORS		Vogelstein, B., Kinzler, K.W., Zhang, L. and Zhou, W.
TITLE		Gene expression profiles in normal and cancer cells
JOURNAL		Patent: US 6333152-A 713 25-DEC-2001;
FEATURES		Location/Qualifiers
source		1. .15 /organism="unknown" /mol_type="unassigned DNA"
Query Match		1.6%; Score 12; DB 1; Length 15;
Best Local Similarity		100.0%; Pred. No. 1.1e+02;
Matches		12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	500	CCTGAGGCAC 511
Db	14	CCTGAGGCAC 3
other sequences; artificial sequences.		
REFERENCE		1
AUTHORS		Pugner, D., Marti, J., Manchon, L. and Piquemal, D.
TITLE		Method for qualitative and quantitative analysis of a population of nucleic acids contained in a sample
JOURNAL		Patent: WO 02066676-A 53 29-AUG-2002;
FEATURES		CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
source		1. .14 Location/Qualifiers
Query Match		1.6%; Score 12; DB 1; Length 14;
Best Local Similarity		100.0%; Pred. No. 1e+02;
Matches		12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	738	TCAAATAAAGTT 749
Db	3	TCAAATAAAGTT 14
RESULT 188		
AR180644/c		
LOCUS		AR180644 15 bp DNA linear PAT 20-APR-2002
DEFINITION		Sequence 712 from patent US 6333152.
ACCESSION		AR180644
VERSION		AR180644.1 GI:20222677
KEYWORDS		Unknown.
SOURCE		Unknown.
ORGANISM		Unknown.
REFERENCE		1 (bases 1 to 15)
AUTHORS		Vogelstein, B., Kinzler, K.W., Zhang, L. and Zhou, W.
TITLE		Gene expression profiles in normal and cancer cells
JOURNAL		Patent: US 6333152-A 712 25-DEC-2001;
FEATURES		Location/Qualifiers
source		1. .15 /organism="unknown" /mol_type="unassigned DNA"
Query Match		1.6%; Score 12; DB 1; Length 15;
Best Local Similarity		100.0%; Pred. No. 1.1e+02;
Matches		12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	500	CCTGAGGCAC 511
Db	14	CCTGAGGCAC 3
other sequences; artificial sequences.		
REFERENCE		1
AUTHORS		Pugner, D., Marti, J., Manchon, L. and Piquemal, D.
TITLE		Method for qualitative and quantitative analysis of a population of nucleic acids contained in a sample
JOURNAL		Patent: WO 02066676-A 53 29-AUG-2002;
FEATURES		CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
source		1. .14 Location/Qualifiers
Query Match		1.6%; Score 12; DB 1; Length 14;
Best Local Similarity		100.0%; Pred. No. 1e+02;
Matches		12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	738	TCAAATAAAGTT 749
Db	3	TCAAATAAAGTT 14
RESULT 188		
AR180644/c		
LOCUS		AR180644 15 bp DNA linear PAT 20-APR-2002
DEFINITION		Sequence 712 from patent US 6333152.
ACCESSION		AR180644
VERSION		AR180644.1 GI:20222677
KEYWORDS		Unknown.
SOURCE		Unknown.
ORGANISM		Unknown.
REFERENCE		1 (bases 1 to 15)
AUTHORS		Vogelstein, B., Kinzler, K.W., Zhang, L. and Zhou, W.
TITLE		Gene expression profiles in normal and cancer cells
JOURNAL		Patent: US 6333152-A 712 25-DEC-2001;
FEATURES		Location/Qualifiers
source		1. .15 /organism="unknown" /mol_type="unassigned DNA"
Query Match		1.6%; Score 12; DB 1; Length 15;
Best Local Similarity		100.0%; Pred. No. 1.1e+02;
Matches		12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	500	CCTGAGGCAC 511
Db	14	CCTGAGGCAC 3
other sequences; artificial sequences.		
REFERENCE		1
AUTHORS		

```

VERSION      CQ799930.1  GI:46848877
SOURCE       Homo sapiens (human)
ORGANISM     Homo sapiens
REFERENCE    1
AUTHORS      Gleave,M.E., Rocchi,P. and Signaevsky,M.
TITLE        Compositions for treatment of prostate and other cancers
JOURNAL      Patent: WO 2004030660-A 28 15-APR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
              source
                1..21
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.5%; Score 11.6; DB 1; Length 21;
Best Local Similarity 77.8%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 276 GGGTCTCGAGATCCGGC 293
Db 2 GGGTCTCGAGACCCCGC 19

RESULT 193
BD263080/c
LOCUS       BD263080
DEFINITION Vector.
ACCESSION  BD263080
VERSION    BD263080.1  GI:33072848
KEYWORDS   JP 2002530115-A/12.
SOURCE     Rous sarcoma virus
ORGANISM   Rous sarcoma virus
REFERENCE  1
AUTHORS    Mitrophanous,K., Uden,M., Rohll,J., Kingeman,S.M. and Kingeman,A.J.
TITLE      Vector
JOURNAL    Patent: JP 2002530115-A 12 17-SEP-2002;
              OXFORD BIOMEDICA LTD
COMMENT     OS Rous sarcoma virus
              PN JP 2002530115-A/12
              PD 17-SEP-2002
              PR 19-NOV-1999 JP 2000584089
              PR 20-NOV-1998 GB 9825524.3
              PI KYRIACOS MITROPHANOUS,MARK UDEN,JONATHAN ROHLL,SUSAN MARY PI
              KINGSMAN,
              PI ALAN JOHN KINGSMAN
              PC C12N15/09,A61K35/76,A61K48/00,A61P1/04,A61P9/00,A61P11/06, PC
              A61P17/00,
              PC A61P25/00,A61P25/28,A61P27/02,A61P29/00,A61P31/12,A61P35/00,
              PC A61P37/00,
              PC C12N5/10,C12N7/00,C12N15/00,C12N5/00
              CC Vector
              FH Key
              FT source
              1..13
              Location/Qualifiers
                /organism='Rous sarcoma virus'.
              FEATURES
                source
                  1..13
                  /organism="Rous sarcoma virus"
                  /mol_type="genomic DNA"
                  /db_xref="taxon:11886"

Query Match      1.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 483 TTTCCTCTCCCTCCCT 495
Db 13 TTTCCTCTCCCTCCCT 1

RESULT 194
BD263080/c
LOCUS       BD263080
DEFINITION Vector.
ACCESSION  BD263080
VERSION    BD263080.1  GI:33072848
KEYWORDS   JP 2002530115-A/12.
SOURCE     Rous sarcoma virus
ORGANISM   Rous sarcoma virus
REFERENCE  1
AUTHORS    Mitrophanous,K., Uden,M., Rohll,J. and Kingeman,A.J.
TITLE      Vector
JOURNAL    Patent: WO 0031280-A 12 02-JUN-2000;
              KINGSMAN SUSAN MARY (GB) ; MITROPHANOUS KYRIACOS (GB) ; UDEN MARK
              (GB) ; ROHLL JONATHAN (GB) ; KINGSMAN ALAN JOHN (GB) ; OXFORD
              BIOMEDICA LTD (GB)
FEATURES     Location/Qualifiers
              source
                1..13
                /organism="Rous sarcoma virus"
                /mol_type="unassigned DNA"
                /db_xref="taxon:11886"

Query Match      1.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 483 TTTCCTCTCCCTCCCT 495
Db 13 TTTCCTCTCCCTCCCT 1

RESULT 195
AX556272
LOCUS       AX556272
DEFINITION Sequence 17 from Patent WO0242447.
ACCESSION  AX556272
VERSION    AX556272.1  GI:25899609
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Uhler,M.D.
TITLE      Surface transection and expression procedure
JOURNAL    Patent: WO 0242447-A 17 30-MAY-2002;
              THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US)
FEATURES     Location/Qualifiers
              source
                1..13
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 CCCCCTCCCATC 214
Db 1 CCCCCTCCCATC 13

RESULT 196
A89531/c
LOCUS       A89531
DEFINITION Sequence 1679 from Patent WO9833904.
ACCESSION  A89531
VERSION    A89531.1  GI:6738101
KEYWORDS   unidentified
SOURCE     unidentified
ORGANISM   unidentified


```

```

RESULT 194
AX025026/c
LOCUS       AX025026
DEFINITION Sequence 12 from Patent WO0031280.
ACCESSION  AX025026
VERSION    AX025026.1  GI:10184946
KEYWORDS   Rous sarcoma virus
SOURCE     Rous sarcoma virus
ORGANISM   Rous sarcoma virus
REFERENCE  1
AUTHORS    Viruses; Retroid viruses; Retroviridae; Alpharetrovirus.
TITLE      Vector
JOURNAL    Kingsman,S.M., Mitrophanous,K., Uden,M., Rohll,J. and Kingeman,A.J.
              Patent: WO 0031280-A 12 02-JUN-2000;
              KINGSMAN SUSAN MARY (GB) ; MITROPHANOUS KYRIACOS (GB) ; UDEN MARK
              (GB) ; ROHLL JONATHAN (GB) ; KINGSMAN ALAN JOHN (GB) ; OXFORD
              BIOMEDICA LTD (GB)
FEATURES     Location/Qualifiers
              source
                1..13
                /organism="Rous sarcoma virus"
                /mol_type="unassigned DNA"
                /db_xref="taxon:11886"

Query Match      1.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 483 TTTCCTCTCCCTCCCT 495
Db 13 TTTCCTCTCCCTCCCT 1

RESULT 195
AX556272
LOCUS       AX556272
DEFINITION Sequence 17 from Patent WO0242447.
ACCESSION  AX556272
VERSION    AX556272.1  GI:25899609
KEYWORDS   Homo sapiens (human)
SOURCE     Homo sapiens
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS    Uhler,M.D.
TITLE      Surface transection and expression procedure
JOURNAL    Patent: WO 0242447-A 17 30-MAY-2002;
              THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US)
FEATURES     Location/Qualifiers
              source
                1..13
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      1.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 202 CCCCCTCCCATC 214
Db 1 CCCCCTCCCATC 13

RESULT 196
A89531/c
LOCUS       A89531
DEFINITION Sequence 1679 from Patent WO9833904.
ACCESSION  A89531
VERSION    A89531.1  GI:6738101
KEYWORDS   unidentified
SOURCE     unidentified
ORGANISM   unidentified


```

```

REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingsiespen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1679 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
    source      Location/Qualifiers
                1..14
                /organism="unidentified"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32644"

Query Match      1.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      20 GCCAGCATGACCG 32
Db      13 GCCAGCATGCCCG 1

RESULT 197
BD209296
LOCUS      BD209296      14 bp      RNA      linear      PAT 17-JUL-2003
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection.
ACCESSION  BD209296
VERSION     BD209296.1 GI:33019066
KEYWORDS   JP 2002512791-A/2886.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 14)
AUTHORS   Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE     Enzymatic nucleic acid treatment of diseases or conditions related
            to hepatitis C virus infection
JOURNAL   Patent: JP 2002512791-A 2887 08-MAY-2002;
            RIBOZYME PHARMACEUTICALS INC
COMMENT   OS Hepatitis virus (hepatitis C virus)
            PN JP 2002512791-A/2887
            PD 08-MAY-2002
            PF 26-APR-1999 JP 2000545991
            PR 27-APR-1998 US 60/083217,18-SEP-1998 US 60/100842 PR
            25-FEB-1999 US 09/257608,23-MAR-1999 US 09/274553 PI
            LAWRENCE BLATT,JAMES A MCSWIGGEN,ELISABETH ROBERTS,PAMELA A PI
            PAVCO, DENNIS MACEJAK
            PC C12N9/00,A61K31/7105,A61K38/21,A61K48/00,A61P31/12,C12N15/09,
            PC A61K37/66,
            PC C12N15/00
            CC Enzymatic nucleic acid treatment of diseases or conditions CC
            CC hepatitis C virus infection.
            FH Key      Location/Qualifiers
            FT source  1..14
            FT          /organism='Hepatitis virus (hepatitis C FT
                        virus)',
                        Location/Qualifiers
                        1..14
                        /organism="unidentified"
                        /mol_type="genomic RNA"
                        /db_xref="taxon:32644"

Query Match      1.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      168 GCAGCAGCTGCC 180
Db      13 GCTGCAGCTGCC 1

RESULT 199
AX025606/c
LOCUS      AX025606      14 bp      DNA      linear      PAT 16-SEP-2000
DEFINITION Sequence 6 from Patent WO0029592.
ACCESSION  AX025606
VERSION     AX025606.1 GI:10187274
KEYWORDS   Triticum aestivum (bread wheat)
SOURCE     Triticum aestivum
ORGANISM   Triticum aestivum
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Pooideae; Triticeae; Triticum.
REFERENCE  1
AUTHORS   Logemann,E., Somssich,I., Hahlbrock,K., Kirsch,C. and Rushton,P.
TITLE     Chimeric promoters capable of mediating gene expression in plants
            upon pathogen infection and uses thereof
JOURNAL   Patent: WO 0029592-A 6 25-MAY-2000;
            MAX PLANCK GESELLSCHAFT (DE); LOGEMANN ELKE (DE); SOMSSICH IMRE
            (DE); HAHLBROCK KLAUS (DE); KIRSCH CHRISTOPH (DE); RUSHTON PAUL
            (GB)
FEATURES
    source      Location/Qualifiers
                1..14
                /organism="Triticum aestivum"
                /mol_type="unassigned DNA"

```

/db_xref="taxon:4565"

Query Match 1.5%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 1.2e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 351 TGACGGTCAAGAC 363
 Db 14 TGACGGTCAAGTC 2

RESULT 200
 BD067044/c
 LOCUS 14 bp DNA linear PAT 27-AUG-2002
 DEFINITION An antisense oligonucleotide preparation method.
 ACCESSION BD067044

VERSION BD067044.1 GI:22612647
 KEYWORDS JP 2001511000-A/1679.
 SOURCE unidentified

ORGANISM
 unclassified.

REFERENCE 1 (bases 1 to 14)
 AUTHORS Schlingensiepen,K.H. and Brysch,W.
 TITLE An antisense oligonucleotide preparation method
 JOURNAL Patent: JP 2001511000-A 1679 07-AUG-2001;
 BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH

COMMENT OS Unknown

PN JP 2001511000-A/1679

PD 07-AUG-2001

PF 30-JAN-1998 JP 1998532533

PR 31-JAN-1997 EP 97101531.8

PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH

PC C12N15/11,C07H21/04,A61K31/70

CC An antisense oligonucleotide preparation method FH Key
 Location/Qualifiers

FT source 1..14
 /organism='Unknown'.
 Location/Qualifiers

FEATURES
 source
 1..14
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 1.5%; Score 11.4; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 1.2e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 20 GCCAGCATGACCG 32
 Db 13 GCCAGCATGCCCG 1

RESULT 201
 ATH523733/c
 LOCUS 14 bp DNA linear PLN 29-MAR-2003
 DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 060G05.

ACCESSION AJ523733

VERSION AJ523733.1 GI:26791969

KEYWORDS left border; T-DNA flanking sequence.

SOURCE Arabidopsis thaliana (thale cress)

ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1
 AUTHORS Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,
 Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
 Lepiniec,L., Caboche,M. and Lecharny,A.

TITLE T-DNA integration into the Arabidopsis genome depends on sequences
 of pre-insertion sites
 JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
 MEDLINE 22363535

12446565

2 (bases 1 to 14)

Balzerque,S.

Direct Submission

JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue
 Gaston Cremieux, 91057 Evry cedex, FRANCE

COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
 plants from INRA (Versailles). The DNA fragment (s) resulting from
 the PCR were directly sequenced from the left or the right border
 to determine the genomic sequence flanking the insertion. T-DNA
 derived sequences were removed. Information to order the
 corresponding mutant line and a link to a database providing a
 graphical display of the insertion site are available at
 http://dbgap.versailles.inra.fr/publiclines/. This sequence has
 been generated in the framework of the French plant genomics
 program 'Genoplante' (http://www.genoplante.com and
 http://genoplante-info.inbio.gen.fr).

FEATURES

source

1..14
 Location/Qualifiers
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultivar="Wassiliewskija"
 /db_xref="taxon:3702"
 /clone="060G05"
 /note="T-DNA insertion lines"

misc_feature

1..14
 /note="T-DNA flanking sequence
 left border"

Query Match 1.5%; Score 11.4; DB 1; Length 14;

Best Local Similarity 92.3%; Pred. No. 1.2e+02;

Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 616 AAAATCCGATCAG 628

Db 13 AAAAACCGATGAG 1

Search completed: October 18, 2005, 09:40:49

Job time : 3 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:41:56 ; Search time 1 Seconds
(without alignments)
1.623 Million cell updates/sec

Title: US-10-605-498-91-COPY
Perfect score: 764
Sequence: 1 ggcacgagcagcagtcag.....aagtcaaacgcaaccctg 764

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 62 seqs, 1062 residues

Total number of hits satisfying chosen parameters: 124

Minimum DB seq length: 0
Maximum DB seq length: 2000000000
Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 62 summaries

Database : issdb.*

Issued - Patents - NA

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	25	3.3	25	1	US-08-859-998-1170
C 2	25	3.3	25	1	US-09-225-928-1170
C 3	25	3.3	25	1	US-09-225-201B-1170
C 4	24	3.1	24	1	US-08-859-998-1169
C 5	24	3.1	24	1	US-09-225-928-1169
C 6	24	3.1	24	1	US-09-225-201B-1169
C 7	20.8	2.7	25	1	US-09-396-196G-92419
C 8	20.2	2.6	25	1	US-09-396-196G-92432
C 9	15.8	2.1	19	1	US-09-990-613A-7
C 10	15.4	2.0	17	1	US-09-866-108A-10667
C 11	15	2.0	15	1	US-09-081-646-605
C 12	14.8	1.9	18	1	US-07-977-284A-13
C 13	14.8	1.9	18	1	US-08-256-426B-13
C 14	14.8	1.9	18	1	US-09-663-834A-37
C 15	14.4	1.9	16	1	US-08-411-796-466
C 16	14.4	1.9	16	1	US-08-471-039-466
C 17	14.4	1.9	16	1	US-08-559-390-466
C 18	14.4	1.9	16	1	PCT-US93-11198-466
C 19	14.4	1.9	17	1	US-09-866-108A-10666
C 20	14.4	1.9	17	1	US-09-866-108A-10668
C 21	14.4	1.9	18	1	US-09-106-038A-27
C 22	14.4	1.9	18	1	US-08-513-974B-249
C 23	14.4	1.9	18	1	US-09-422-978-6095
C 24	14	1.8	15	1	US-08-431-048F-150
C 25	13.8	1.8	17	1	US-09-275-680-11
C 26	13.8	1.8	17	1	US-08-881-450A-6
C 27	13.8	1.8	17	1	US-09-474-432B-773
C 28	13.8	1.8	17	1	US-09-476-387-772
C 29	13.8	1.8	17	1	US-09-866-108A-2329
C 30	13.8	1.8	17	1	US-09-866-108A-2330
C 31	13.8	1.8	17	1	US-09-866-108A-2331
C 32	13.8	1.8	17	1	US-09-866-108A-10669
C 33	13.8	1.8	17	1	US-09-866-108A-10670

C 34	13.8	1.8	17	1	US-09-404-912-599	Sequence 599, App
C 35	13.6	1.8	15	1	US-08-431-048F-151	Sequence 151, App
C 36	13.4	1.8	16	1	US-08-770-235A-24	Sequence 24, App
C 37	12.8	1.7	16	1	US-08-411-796-539	Sequence 539, App
C 38	12.8	1.7	16	1	US-08-471-039-539	Sequence 539, App
C 39	12.8	1.7	16	1	US-08-464-582-16	Sequence 16, App
C 40	12.8	1.7	16	1	US-08-462-513-16	Sequence 16, App
C 41	12.8	1.7	16	1	US-08-559-390-539	Sequence 539, App
C 42	12.8	1.7	16	1	US-09-829-855-10	Sequence 10, App
C 43	12.8	1.7	16	1	US-09-829-855-110	Sequence 110, App
C 44	12.8	1.7	16	1	US-09-479-005A-187	Sequence 187, App
C 45	12.8	1.7	16	1	US-08-031-801-17	Sequence 17, App
C 46	12.8	1.7	16	1	US-08-031-801-29	Sequence 29, App
C 47	12.8	1.7	16	1	US-09-696-791-4142	Sequence 4142, App
C 48	12.8	1.7	16	1	PCT-US93-11198-539	Sequence 539, App
C 49	12.4	1.6	15	1	US-08-276-594A-8	Sequence 8, App
C 50	12.4	1.6	15	1	US-08-991-830A-9	Sequence 9, App
C 51	12.4	1.6	15	1	US-08-486-343A-6	Sequence 6, App
C 52	12.4	1.6	15	1	US-09-081-646-654	Sequence 654, App
C 53	12.4	1.6	15	1	US-09-625-634A-5	Sequence 5, App
C 54	12.4	1.6	15	1	US-09-716-320-9	Sequence 9, App
C 55	12.4	1.6	15	1	PCT-US95-07349-6	Sequence 6, App
C 56	12	1.6	13	1	US-08-390-888A-12	Sequence 12, App
C 57	12	1.6	15	1	US-09-081-646-712	Sequence 712, App
C 58	12	1.6	15	1	US-09-081-646-713	Sequence 713, App
C 59	11.4	1.5	14	1	US-08-544-381B-236	Sequence 236, App
C 60	11	1.4	12	1	US-09-614-034-75	Sequence 75, App
C 61	11	1.4	13	1	US-09-614-034-73	Sequence 73, App
C 62	11	1.4	13	1	PCT-US94-05659-22	Sequence 22, App

ALIGNMENTS

RESULT 1
US-08-859-998-1170/c
; Sequence 1170, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jekhadze, George
; APPLICANT: Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Brist E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1170:
; SEQUENCE CHARACTERISTICS:

```
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
US-08-859-998-1170

Query Match          3.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      631 TGCGCCCAAGTAAAGCCTTAGCCCG 655
Db      25 TGCGCCCAAGTAAAGCCTTAGCCCG 1

RESULT 2
US-09-225-928-1170/c
; Sequence 1170, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,2018
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1170:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 1170:
US-09-225-928-1170

Query Match          3.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      631 TGCGCCCAAGTAAAGCCTTAGCCCG 655
Db      25 TGCGCCCAAGTAAAGCCTTAGCCCG 1

RESULT 3
US-09-225-201B-1170/c
; Sequence 1170, Application US/09225201B
; Patent No. 6489455
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Chhadze, George
; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,2018
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1170:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 1170:
US-09-225-201B-1170

Query Match          3.3%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      631 TGCGCCCAAGTAAAGCCTTAGCCCG 655
Db      25 TGCGCCCAAGTAAAGCCTTAGCCCG 1

RESULT 4
US-08-859-998-1169
; Sequence 1169, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Chhadze, George
; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1169:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
;
; US-08-859-998-1169
;
; Query Match 3.1%; Score 24; DB 1; Length 24;
; Best Local Similarity 100.0%; Pred. No. 1.8;
; Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 396 ACGAGGACGGCAGCAGCAGCATG 419
; | | | | | | | | | | | | | | | | | |
; Db 1 ACGAGGACGGCAGCAGCAGCATG 24
;
; RESULT 5
; US-09-225-928-1169
; Sequence 1169, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Jukhadze, George
; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
;
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: 08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1169:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
;
; SEQUENCE DESCRIPTION: SEQ ID NO: 1169:
;
; US-09-225-928-1169
;
; Query Match 3.1%; Score 24; DB 1; Length 24;
; Best Local Similarity 100.0%; Pred. No. 1.8;
; Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 396 ACGAGGACGGCAGCAGCAGCATG 419
; | | | | | | | | | | | | | | | | | |
; Db 1 ACGAGGACGGCAGCAGCAGCATG 24
;
; RESULT 6
; US-09-225-2018-1169
; Sequence 1169, Application US/09225201B
; Patent No. 6489455
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Jukhadze, George
; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
;
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 1169:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 1169:
US-09-225-2018-1169

Query Match          3.1%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 396 ACGAGGAGCGGACGAGCAGCATG 419
Db 1 ACGAGGAGCGGACGAGCAGCATG 24

RESULT 7
US-09-396-196G-92419
; Sequence 92419, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 92419
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-92419

Query Match          2.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 5.8;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 499 CCTGTAGGCGCACACTGACCGTGGA 522
Db 2 CCTGTAGGCGCACACTTCCGTGGA 25

RESULT 8
US-09-396-196G-92432
; Sequence 92432, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 92432
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-09-396-196G-92432

Query Match          2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 7.1;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 1169:
US-09-225-2018-1169

Query Match          3.1%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 375 TGTTGGAGATCACCGGCAAGCAGCA 399
Db 1 TTGTTGAGATCACTGGCAAGCAGCA 25

RESULT 9
US-09-990-613A-7
; Sequence 7, Application US/09990613A
; Patent No. 6818446
; GENERAL INFORMATION:
; APPLICANT: Wu, Reen
; APPLICANT: Chen, Yin
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
; TITLE OF INVENTION: ANALYSIS OF MUCIN GENE EXPRESSION AND IDENTIFICATION OF
; TITLE OF INVENTION: DRUGS HAVING THE ABILITY TO INHIBIT MUCIN GENE EXPRESSION
; FILE REFERENCE: 39754-0721A
; CURRENT APPLICATION NUMBER: US/09/990,613A
; CURRENT FILING DATE: 2001-11-21
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-990-613A-7

Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 16;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 403 GCGGACGAGCAGCATGCGC 421
Db 1 GCGGACACACGAGCATGCGC 19

RESULT 10
US-09-866-108A-10667
; Sequence 10667, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10667

Query Match          2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 14;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 12 CAGAGTCAGCCAGCATG 28
    ||||| ||||| |||||
Db 1 CAGAGCCAGCCAGCATG 17

RESULT 11
US-09-081-646-605
; Sequence 605, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; EARLIER FILING DATE: 1998-05-20
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 605
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-605

Query Match          2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 529 CATGCCCAAGCTAGC 543
    ||||| ||||| |||||
Db 1 CATGCCCAAGCTAGC 15

RESULT 12
US-07-977-284A-13/C
; Sequence 13, Application US/07977284A
; Patent No. 5558988
; GENERAL INFORMATION:
; APPLICANT: Prockop, Darwin J.
; APPLICANT: Ala-Kokko, Leena
; APPLICANT: Williams, Charlene J.
; APPLICANT: Ritvaniemi, Pertti
; APPLICANT: Baldwin, Clinton
; APPLICANT: Hopkinson, Ian
; APPLICANT: Ahmad, Nilofer Nina
; TITLE OF INVENTION: METHODS OF DETECTING A GENETIC
; NUMBER OF SEQUENCES: 261
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5558988ris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 3.1
SOFTWARE: WORDPERFECT 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/256,426B
FILING DATE: 03-FEB-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10964
FILING DATE: 12-NOV-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/977,284
FILING DATE: 13-NOV-1992

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/977,284A
FILING DATE: 13-NOV-1992
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Deluca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: TJU-0697
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: NUCLEIC ACID
STRANDEDNESS: SINGLE
TOPOLOGY: LINEAR
ANTI-SENSE: NO
US-07-977-284A-13

Query Match          1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 19;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 TGCCCGGCTGCGGAGG 146
    ||||| ||||| |||||
Db 18 TGCCCTGGCTGCAGGAG 1

RESULT 13
US-08-256-426B-13/c
; Sequence 13, Application US/08256426B
; Patent No. 5948611
; GENERAL INFORMATION:
; APPLICANT: Prockop, Darwin J.
; APPLICANT: Ala-Kokko, Leena
; APPLICANT: Williams, Charlene J.
; APPLICANT: Ritvaniemi, Pertti
; APPLICANT: Baldwin, Clinton
; APPLICANT: Hopkinson, Ian
; APPLICANT: Ahmad, Nilofer Nina
; TITLE OF INVENTION: Methods of Detecting A Genetic
; NUMBER OF SEQUENCES: 293
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5948611ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 3.1
SOFTWARE: WORDPERFECT 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/256,426B
FILING DATE: 03-FEB-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/10964
FILING DATE: 12-NOV-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/977,284
FILING DATE: 13-NOV-1992
```

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Mark DeLuca
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1082
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: NUCLEIC ACID
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; ANTI-SENSE: NO
US-08-256-426B-13

```

```

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 19;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 129 TGCCCGGCTGCGGAGG 146
Db 18 TGCCCTGGCTGCAGGAGG 1

```

```

RESULT 14
US-09-663-834A-37/c
; Sequence 37, Application US/09663834A
; Patent No. 6613567
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowert
; TITLE OF INVENTION: ANTISENSE MODULATION OF HER-2 EXPRESSION
; FILE REFERENCE: RTS-0033
; CURRENT APPLICATION NUMBER: US/09/663,834A
; CURRENT FILING DATE: 2000-09-15
; NUMBER OF SEQ ID NOS: 48
; SEQ ID NO 37
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-663-834A-37

```

```

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 19;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Qy 123 TCGGGCTGCCCGGCTGC 140
Db 18 TCGGGCTGGCTGCAGGAGG 1

```

```

RESULT 15
US-08-411-796-466/c
; Sequence 466, Application US/08411796
; Patent No. 5671149
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Bauer, S. C.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Maïre H.
; APPLICANT: Easton, Alan M.
; APPLICANT: Klein, Barbara K.
; APPLICANT: McKearn, John P.
; APPLICANT: Olines, Peter O.
; APPLICANT: Paik, Kumnan
; APPLICANT: Polazzi, Joseph O.
; APPLICANT: Thomas, John W.
; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
; NUMBER OF SEQUENCES: 549
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
; STREET: P. O. Box 5110
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680

```

```

; ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
; ADDRESSEE: Corporate Patent Dept.
; STREET: P. O. Box 5110
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,796
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/981044
; FILING DATE: 24-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/111198
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Bennett, Dennis A.
; REGISTRATION NUMBER: 34,547
; REFERENCE/DOCKET NUMBER: C2713/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708)470-6501
; TELEFAX: (708)470-6881
; INFORMATION FOR SEQ ID NO: 466:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
US-08-411-796-466

```

```

Query Match 1.9%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 565 CATCCAGTCACCTTC 580
Db 16 CATCCAGTCACCTTC 1

```

```

RESULT 16
US-08-471-039-466/c
; Sequence 466, Application US/08471039
; Patent No. 6017523
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Bauer, S. C.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Maïre H.
; APPLICANT: Easton, Alan M.
; APPLICANT: Klein, Barbara K.
; APPLICANT: McKearn, John P.
; APPLICANT: Olines, Peter O.
; APPLICANT: Paik, Kumnan
; APPLICANT: Polazzi, Joseph O.
; APPLICANT: Thomas, John W.
; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
; NUMBER OF SEQUENCES: 549
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
; STREET: P. O. Box 5110
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680

```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471.039
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/981,044
; FILING DATE: 24-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/11198
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Bennett, Dennis A.
; REGISTRATION NUMBER: 34,547
; REFERENCE/DOCKET NUMBER: C2713/5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708)470-6501
; TELEFAX: (708)470-6881
; INFORMATION FOR SEQ ID NO: 466:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; US-08-471-039-466

```

```

Query Match 1.9%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 565 CATCCAGTCACCTTC 580
Db 16 CATCCAGTCACCTTC 1

```

```

RESULT 17
US-08-559-390-466/c
; Sequence 466, Application US/08559390
; Patent No. 6479261
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Bauer, S. C.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Mairé H.
; APPLICANT: Easton, Alan M.
; APPLICANT: Klein, Barbara K.
; APPLICANT: McKearn, John P.
; APPLICANT: Oline, Peter O.
; APPLICANT: Polazzi, Joseph W.
; APPLICANT: Thomas, John W.
; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
; NUMBER OF SEQUENCES: 549
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
; STREET: P. O. Box 5110
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/559,390

```

```

; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/411,796
; FILING DATE:
; APPLICATION NUMBER: US 07/981044
; FILING DATE: 24-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/11198
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Bennett, Dennis A.
; REGISTRATION NUMBER: 34,547
; REFERENCE/DOCKET NUMBER: C2713/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708)470-6501
; TELEFAX: (708)470-6881
; INFORMATION FOR SEQ ID NO: 466:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; US-08-559-390-466

```

```

Qy 565 CATCCAGTCACCTTC 580
Db 16 CATCCAGTCACCTTC 1

```

```

RESULT 18
PCT-US93-11198-466/c
; Sequence 466, Application PC/TUS9311198
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Bauer, S. C.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Mairé H.
; APPLICANT: Easton, Alan M.
; APPLICANT: Klein, Barbara K.
; APPLICANT: McKearn, John P.
; APPLICANT: Oline, Peter O.
; APPLICANT: Polazzi, Joseph W.
; APPLICANT: Thomas, John W.
; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
; NUMBER OF SEQUENCES: 549
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
; STREET: P. O. Box 5110
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/11198
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/981044
; FILING DATE: 24-NOV-1992
; ATTORNEY/AGENT INFORMATION:

```

NAME: Bennett, Dennis A.
REGISTRATION NUMBER: 34,547
REFERENCE/DOCKET NUMBER: C2713/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708)470-6501
TELEFAX: (708)470-6881
INFORMATION FOR SEQ ID NO: 466:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
PCT-US93-11198-466

Query Match 1.9%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 565 CATCCAGTCACCTTC 580
||| ||||| ||||| |||||
Db 16 CATTCCAGTCACCTTC 1

RESULT 19
US-09-866-108A-10666
; Sequence 10666, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10666
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10666

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 12 CAGAGTCAGCCAGCAT 27
||| ||||| ||||| |||||
Db 2 CAGAGCCAGCCAGCAT 17

RESULT 20
US-09-866-108A-10668
; Sequence 10668, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10668
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10668

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 19;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 AGAGTCAGCCAGCATG 28
||| ||||| ||||| |||||
Db 1 AGAGCCAGCCAGCATG 16

RESULT 21
US-09-106-038A-27
; Sequence 27, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowseert
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue

```

; CITY: Carlebad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106.038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-106-038A-27

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred.No.22;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 487 CTCCTCCCTGTCCTCCCT 502
Db 2 CTCCTCCCTGTCCTCCCT 17

RESULT 22
US-08-513-974B-249
; Sequence 249, Application US/08513974B
; Patent No. 6114139
; GENERAL INFORMATION:
; APPLICANT: Hinuma, Shuji
; APPLICANT: Hosoya, Masaki
; APPLICANT: Fujii, Ryo
; APPLICANT: Ohtaki, Tetsuya
; APPLICANT: Fukusumi, Shoji
; APPLICANT: Ohgi, Kazuhiro
; TITLE OF INVENTION: G PROTEIN COUPLED RECEPTOR PROTEIN,
; TITLE OF INVENTION: PRODUCTION, AND USE THEREOF
; NUMBER OF SEQUENCES: 380
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
; STREET: 130 Water Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/513,974B
; FILING DATE: 14-SEP-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP95/01599
; FILING DATE: 10-AUG-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 7-093989
; FILING DATE: 19-AUG-1995

; CITY: Carlebad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: JP 7-057186
; FILING DATE: 16-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 7-007177
; FILING DATE: 20-JAN-1995
; APPLICATION NUMBER: JP 6-326611
; FILING DATE: 28-DEC-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 6-270017
; FILING DATE: 02-NOV-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 6-236357
; FILING DATE: 30-SEP-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 6-236356
; FILING DATE: 30-SEP-1994
; APPLICATION NUMBER: JP 6-189274
; FILING DATE: 11-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 6-189273
; FILING DATE: 11-AUG-1945
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 6-189272
; FILING DATE: 11-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Reenick, David S.
; REGISTRATION NUMBER: 34,235
; REFERENCE/DOCKET NUMBER: 45753
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-523-3400
; TELEFAX: 617-523-6440
; INFORMATION FOR SEQ ID NO: 249:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
US-08-513-974B-249

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred.No.22;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 218 AGCCCCGCACTGGCCG 233
Db 1 AGCCTCGCACTGGCCG 16

RESULT 23
US-09-422-978-6095/c
; Sequence 6095, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6095
; LENGTH: 18

```

```
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-8894 for SEQ 2161,
US-09-422-978-6095

Query Match      1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 22;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 701 CTGTGTTCTTTTGA 716
Db 18 CTGTGTTCTTCTGA 3

RESULT 24
US-08-431-048F-150
; Sequence 150, Application US/08431048F
; Patent No. 6531586
; GENERAL INFORMATION:
; APPLICANT: ST. GEORGE-HYSLOP, PETER H
; ROMMENS, JOHANNA M
; FRASER, PAUL E
; TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
; TO ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 155
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARBY & DARBY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: N.Y.
; COUNTRY: U.S.A.
; ZIP: 10022-7513
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/431,048F
; FILING DATE: 28-Apr-1995
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: FEHLNER, PAUL F.
; REGISTRATION NUMBER: 35135
; REFERENCE/DOCKET NUMBER: 1034/0F808
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-527-7700
; TELEFAX: 212-527-6237
; INFORMATION FOR SEQ ID NO: 150:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 150:
US-08-431-048F-150

Query Match      1.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCGAGTCCA 554
Db 2 AGCCACGCGAGTCCA 15

RESULT 25
US-09-275-680-11/c
; Sequence 11, Application US/09275680
```

```
; Patent No. 6221630
; GENERAL INFORMATION:
; APPLICANT: Hopper, James E
; TITLE OF INVENTION: A High Copy Number Recombinant Expression Construct for
; TITLE OF INVENTION: Regulated High-level Production of Polypeptides in
; FILE REFERENCE: 98428
; CURRENT APPLICATION NUMBER: US/09/275,680
; CURRENT FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 11
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-275-680-11

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 290 CGGCACACTGCGGACCG 306
Db 17 CGGCACACAGTGGACCG 1

RESULT 26
US-08-881-450A-6/c
; Sequence 6, Application US/08881450A
; Patent No. 6274310
; GENERAL INFORMATION:
; APPLICANT: Habener, J.F. and Stoffers, D.A.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DETECTING
; TITLE OF INVENTION: PANCREATIC DISEASE
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Inc.
; STREET: One Financial Center
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/881,450A
; FILING DATE: June 24, 1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathleen M. Williams
; REGISTRATION NUMBER: 34,380
; REFERENCE/DOCKET NUMBER: 11275/7823
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-345-9100
; TELEFAX: 617-345-9111
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; FEATURE:
; NAME/KEY: primer S17b
US-08-881-450A-6

Query Match      1.8%; Score 13.8; DB 1; Length 17;
```

```
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 38 CGCGTCCCTCTCGCT 54
    ||| ||||| |||||
Db 17 CGCTCCCTCTCGCT 1

RESULT 27
US-09-474-432B-773
; Sequence 773, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MEH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR FILING DATE: 1999-12-19
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1998-04-29
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 773
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-773

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 23;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 123 TCGGCTGCCCGCTG 139
    :|||:|:|:|:|
Db 1 UCGGCGGCGGCGGCG 17

RESULT 28
US-09-476-387-772
; Sequence 772, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleotides
; FILE REFERENCE: MEH00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; PRIOR FILING DATE: 2001-04-04
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
```

```
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 772
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-476-387-772

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 23;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 123 TCGGCTGCCCGCTG 139
    :|||:|:|:|:|
Db 1 UCGGCGGCGGCGGCG 17

RESULT 29
US-09-866-108A-2329/c
; Sequence 2329, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2329
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2329

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 551 TCCAGCGAGATCACCAT 567
    ||||| ||||| |||||
Db 17 TCCAGCGAGATCACCAT 1
```

```
RESULT 30
US-09-866-108A-2330/c
; Sequence 2330, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2330
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2330

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      550 GTCCACGAGATCACC 566
Db      17 GTCCACGAGATCACC 1

RESULT 31
US-09-866-108A-2331/c
; Sequence 2331, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2330
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2330

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      550 GTCCACGAGATCACC 566
Db      17 GTCCACGAGATCACC 1

RESULT 32
US-09-866-108A-10669
; Sequence 10669, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEONICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2331
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2331

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      549 AGTCCACGAGATCACC 565
Db      17 AGTCCACGAGATCACC 1
```

```

DB      1  AGCCAGCCAGCATGGCC 17

RESULT 34
US-09-404-912-599/c
; Sequence 599, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; CURRENT FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 599
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-599

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 23;
Matches 15; Conservative 0; Mismatches 2; Indels 0;

QY      746  AGTTCAAGCAACACC 762
          ||| ||||| |||||
DB      17  AGTACAAAGCAACACC 1

RESULT 35
US-08-431-048F-151
; Sequence 151, Application US/08431048F
; Patent No. 6531586
; GENERAL INFORMATION:
; APPLICANT: ST. GEORGE-HYSLOP, PETER H
;              ROWMENS, JOHANNA M
;              FRASER, PAUL E
; TITLE OF INVENTION: GENETIC SEQUENCES AND PROTEINS RELATED
; NUMBER OF SEQUENCES: 155
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARBY & DARBY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: N.Y.
; COUNTRY: U.S.A.
; ZIP: 10022-7513
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/431,048F
; FILING DATE: 28-Apr-1995
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: FEHLNER, PAUL F.
; REGISTRATION NUMBER: 35135
; REFERENCE/DOCKET NUMBER: 1034/0P808
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-527-7700
; TELEFAX: 212-527-6237
; INFORMATION FOR SEQ ID NO: 151:

```

SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 151:
US-08-431-048F-151

Query Match 1.8%; Score 13.6; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 19;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCGAGTCCA 554
Db 2 AGCCACGAGTCCA 15

RESULT 36
US-08-770-235A-24/C
; Sequence 24, Application US/08770235A
; Patent No. 5939538
; GENERAL INFORMATION:
; APPLICANT: Leavitt, Markley C.
; APPLICANT: Tritz, Richard
; APPLICANT: Feng, Yu
; APPLICANT: Barber, Jack
; APPLICANT: Yu, Wang
; TITLE OF INVENTION: Methods and Compositions for Inhibiting
; TITLE OF INVENTION: HIV Infection of Cells By Cleaving HIV Co-Receptor RNA
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/770,235A
; FILING DATE: 19-DEC-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/027,875
; FILING DATE: 25-OCT-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: QUINE, Jonathan A.
; REGISTRATION NUMBER: P-41,261
; REFERENCE/DOCKET NUMBER: 016556-001610US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
US-08-770-235A-24

Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 23;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 402 AGCGGACGAGCAGC 416
Db 16 AGCGGACGAGCAGC 2

RESULT 37
US-08-411-796-539/c
; Sequence 539, Application US/08411796
; Patent No. 5677149
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Bauer, S. C.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Mairé H.
; APPLICANT: Easton, Alan M.
; APPLICANT: Klein, Barbara K.
; APPLICANT: McKearn, John P.
; APPLICANT: Oline, Peter O.
; APPLICANT: Paik, Kuman
; APPLICANT: Polazzi, Joseph O.
; APPLICANT: Thomas, John W.
; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
; NUMBER OF SEQUENCES: 549
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
; ADDRESSEE: Corporate Patent Dept.
; STREET: P. O. Box 5110
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,796
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/981044
; FILING DATE: 24-NOV-1992
; PRIOR APPLICATION DATA: PCT/US93/11198
; APPLICATION NUMBER:
; FILING DATE: 22-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Bennett, Dennis A.
; REGISTRATION NUMBER: 34,547
; REFERENCE/DOCKET NUMBER: C2713/1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (708)470-6501
; TELEFAX: (708)470-6881
; INFORMATION FOR SEQ ID NO: 539:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
US-08-411-796-539

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 565 CATCCAGTCACCTTC 580
Db 16 CATTCAGTCACCGTC 1

RESULT 38
US-08-471-039-539/c
; Sequence 539, Application US/08471039
; Patent No. 6017523
; GENERAL INFORMATION:

APPLICANT: Abrams, Mark A.
APPLICANT: Bauer, S. C.
APPLICANT: Braford-Goldberg, Sarah R.
APPLICANT: Caparon, Maïre H.
APPLICANT: Easton, Alan M.
APPLICANT: Klein, Barbara K.
APPLICANT: McKearn, John P.
APPLICANT: Olin, Peter O.
APPLICANT: Paik, Kumnan
APPLICANT: Polazzi, Joseph O.
APPLICANT: Thomas, John W.
TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
NUMBER OF SEQUENCES: 549
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
STREET: P. O. Box 5110
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60680
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,039
FILING DATE: 06-JUN-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/981,044
FILING DATE: 24-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/11198
FILING DATE: 22-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Bennett, Dennis A.
REGISTRATION NUMBER: 34,547
REFERENCE/DOCKET NUMBER: C2713/5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708)470-6501
TELEFAX: (708)470-6881
INFORMATION FOR SEQ ID NO: 539:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
US-08-471-039-539
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 565 CATCCAGTCACCTTC 580
Db 16 CATTCCAGTCACCGTC 1
RESULT 39
US-08-464-582-16
Sequence 16, Application US/08464582
Patent No. 6114598
GENERAL INFORMATION:
APPLICANT: Kuchterlapati, Raju
APPLICANT: Jakobovits, Aya
APPLICANT: Klapholz, Sue
APPLICANT: Brenner, Daniel G.
APPLICANT: Capon, Daniel J.
TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
FILE REFERENCE: CELL 4.10

CURRENT APPLICATION NUMBER: US/08/464,582
CURRENT FILING DATE: 1995-06-05
NUMBER OF SEQ ID NOS: 27
SOFTWARE: Patent in Ver. 2.1
SEQ ID NO 16
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-464-582-16
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 68 AGCTGGGACCCCTTC 83
Db 1 AGCTGGGACCCCTTC 16
RESULT 40
US-08-462-513-16
Sequence 16, Application US/08462513
Patent No. 6162963
GENERAL INFORMATION:
APPLICANT: Kuchterlapati, Raju
APPLICANT: Jakobovits, Aya
APPLICANT: Klapholz, Sue
APPLICANT: Brenner, Daniel G.
APPLICANT: Capon, Daniel J.
TITLE OF INVENTION: GENERATION OF XENOGENIC ANTIBODIES
FILE REFERENCE: CELL 4.16
CURRENT APPLICATION NUMBER: US/08/462,513
CURRENT FILING DATE: 1995-06-05
NUMBER OF SEQ ID NOS: 27
SOFTWARE: Patent in Ver. 2.1
SEQ ID NO 16
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: adapter
US-08-462-513-16
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 68 AGCTGGGACCCCTTC 83
Db 1 AGCTGGGACCCCTTC 16
RESULT 41
US-08-559-390-539/c
Sequence 539, Application US/08559390
Patent No. 6479261
GENERAL INFORMATION:
APPLICANT: Abrams, Mark A.
APPLICANT: Bauer, S. C.
APPLICANT: Braford-Goldberg, Sarah R.
APPLICANT: Caparon, Maïre H.
APPLICANT: Easton, Alan M.
APPLICANT: Klein, Barbara K.
APPLICANT: McKearn, John P.
APPLICANT: Olin, Peter O.
APPLICANT: Paik, Kumnan
APPLICANT: Polazzi, Joseph O.
APPLICANT: Thomas, John W.
TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
NUMBER OF SEQUENCES: 549
CORRESPONDENCE ADDRESS:

ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
ADDRESS: Corporate Patent Dept.
STREET: P. O. Box 5110
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60680
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/559,390
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/411,796
FILING DATE:
APPLICATION NUMBER: US 07/981044
FILING DATE: 24-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/11198
FILING DATE: 22-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Bennett, Dennis A.
REGISTRATION NUMBER: 34,547
REFERENCE/DOCKET NUMBER: C2713/1
TELECOMMUNICATION INFORMATION:
TELEPHONE: (708)470-6501
TELEFAX: (708)470-6881
INFORMATION FOR SEQ ID NO: 539:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
US-08-559-390-539

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 565 CATCCAGTCACCTTC 580
||| ||||| |||
Db 16 CATTCCAGTCACCGTC 1

RESULT 42
US-09-829-855-10
; Sequence 10, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-10

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 525 CCCCCATGCCCAAGCT 540
||| ||||| |||
Db 1 CCCCCGTGCCCAAGCT 16
RESULT 43
US-09-829-855-110
; Sequence 110, Application US/09829855
; Patent No. 6613520
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; PRIOR FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 110
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-110

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 56 CTGCGGGGGCCCCAGCT 71
||| ||||| |||
Db 1 CTGCGGTGCCGAGCT 16

RESULT 44
US-09-479-005A-187
; Sequence 187, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MBH00-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 187
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-187

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 31.2%; Pred. No. 28;
Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 708 TTCTTTTGATACATTT 723
: ||::|||:|::|
Db 1 UCCUUUGAUAUAUUU 16

RESULT 45
US-08-031-801-17
; Sequence 17, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AVA
; APPLICANT: KLAPHOLZ, SUE
; APPLICANT: BRENNER, DANIEL G.
; APPLICANT: CAPON, DANIEL J.
; TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
; FILE REFERENCE: CELL 4.4 CPA RCE
; CURRENT APPLICATION NUMBER: US/08/031,801
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 07/919,297
; PRIOR FILING DATE: 1992-07-24
; PRIOR APPLICATION NUMBER: PCT/US91/00245
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/610,515
; PRIOR FILING DATE: 1990-11-08
; PRIOR APPLICATION NUMBER: 07/466,008
; PRIOR FILING DATE: 1990-01-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-08-031-801-17

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 68 AGCTGGGACCCCTTCC 83
Db 1 AGCTGGAACCCCTTGC 16
|||||

RESULT 46
US-08-031-801-29
; Sequence 29, Application US/08031801
; Patent No. 6673986
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AVA
; APPLICANT: KLAPHOLZ, SUE
; APPLICANT: BRENNER, DANIEL G.
; APPLICANT: CAPON, DANIEL J.
; TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
; FILE REFERENCE: CELL 4.4 CPA RCE
; CURRENT APPLICATION NUMBER: US/08/031,801
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 07/919,297
; PRIOR FILING DATE: 1992-07-24
; PRIOR APPLICATION NUMBER: PCT/US91/00245
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/610,515
; PRIOR FILING DATE: 1990-11-08
; PRIOR APPLICATION NUMBER: 07/466,008
; PRIOR FILING DATE: 1990-01-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: polylinker
US-08-031-801-29

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 68 AGCTGGGACCCCTTCC 83
Db 1 AGCTGGAACCCCTTGC 16
|||||

RESULT 47
US-09-696-791-4142
; Sequence 4142, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4142
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Hairpin ribozyme recognition site for cyclin B1
US-09-696-791-4142

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 351 TGACGGTCAAGACCA 366
Db 1 TGACTGTCAAGACCA 16
|||||

RESULT 48
PCT-US93-11198-539/c
; Sequence 539, Application PC/TUS9311198
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Bauer, S. C.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Maire H.
; APPLICANT: Easton, Alan M.
; APPLICANT: Klein, Barbara K.
; APPLICANT: Mckearn, John P.
; APPLICANT: Olin, Peter O.
; APPLICANT: Paik, Kumhan
; APPLICANT: Polazzi, Joseph O.
; APPLICANT: Thomas, John W.
; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
; NUMBER OF SEQUENCES: 549
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dennis A. Bennett, G.D. Searle & Co.,
; STREET: P. O. Box 5110
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60680
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/11198
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/981044
FILING DATE: 24-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: Bennett, Dennis A.
REGISTRATION NUMBER: 34,547
REFERENCE/DOCKET NUMBER: C2713/1
TELEPHONE: (708)470-6501
TELEFAX: (708)470-6881
INFORMATION FOR SEQ ID NO: 539:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
PCT-US93-11198-539

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 28;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 565 CATCCAGTCACCTTC 580
DB 16 CATCCAGTCACCGTC 1

RESULT 49
US-08-276-594A-8
Sequence 8, Application US/08276594A
Patent No. 5693499
GENERAL INFORMATION:
APPLICANT: YONEMURA, Hiroshi
APPLICANT: TAJIMA, Yoshitaka
APPLICANT: SUGAWARA, Keishin
APPLICANT: MASUDA, Kenichi
TITLE OF INVENTION: PROCESS FOR PREPARING HUMAN COAGULATION
TITLE OF INVENTION: FACTOR VIII PROTEIN COMPLEX
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/276,594A
FILING DATE: 18-JUL-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/950,191
FILING DATE: 24-SEP-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 243262/1991
FILING DATE: 24-SEP-1991
ATTORNEY/AGENT INFORMATION:
NAME: WEGNER, Harold C.
REGISTRATION NUMBER: 25,258
REFERENCE/DOCKET NUMBER: 74129/195/AOPA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)672-5300

TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-276-594A-8

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 28;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 594 AGCTTGGGGGCCCA 607
DB 1 AGCTTGGGGGCCCA 14

RESULT 50
US-08-991-830A-9/c
Sequence 9, Application US/08991830A
Patent No. 6027892
GENERAL INFORMATION:
APPLICANT: Chang, Esther H.
APPLICANT: Pirollo, Kathleen F.
TITLE OF INVENTION: Compositions and Methods for Reducing Radiation and Drug Resis
NUMBER OF SEQUENCES: 9
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sana A. Pratt
STREET: 10821 Hillbrooke Lane
CITY: Potomac
STATE: MARYLAND
COUNTRY: USA
ZIP: 20854
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Apple Macintosh
OPERATING SYSTEM: Macintosh 7.5
SOFTWARE: Microsoft Word 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/991,830A
FILING DATE: 16 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/034,160
FILING DATE: 30 December 1996
ATTORNEY/AGENT INFORMATION:
NAME: Sana A. Pratt
REGISTRATION NUMBER: 39,441
REFERENCE/DOCKET NUMBER:
TELECOMMUNICATION INFORMATION:
TELEPHONE: (301) 294-9171
TELEFAX: (301) 294-7357
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: Nucleic acid
STRANDEDNESS: Single
TOPOLOGY: Linear
MOLECULE TYPE: DNA
US-08-991-830A-9

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 28;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 410 GACGAGCATGGCTA 423
DB 15 GACAAGCATGGCTA 2

RESULT 51

US-08-486-343A-6/c
; Sequence 6, Application US/08486343A
; Patent No. 6071695
; GENERAL INFORMATION:
; APPLICANT: OZKAYNAK, ERGIN
; APPLICANT: OPPERMAN, HERMANN
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR MODULATING
; TITLE OF INVENTION: MORPHOGENIC PROTEIN EXPRESSION
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
; ADDRESSEE: INC.
; STREET: 45 SOUTH STREET
; CITY: HOPKINTON
; STATE: MA
; COUNTRY: USA
; ZIP: 07148
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/486.343A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: PITCHER, Edmund R
; REGISTRATION NUMBER: 27,829
; REFERENCE/DOCKET NUMBER: CRP-091CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)-248-7000
; TELEFAX: (617)-248-7100
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..15
; OTHER INFORMATION: /note= "WT1/EGR MOUSE TCC BINDING"
; OTHER INFORMATION: SITE"
US-08-486-343A-6

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 28;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 398 GAGGAGCGGAGGA 411
Db 14 GAGGAGCGGAGGA 1
|||||

RESULT 52
US-09-081-646-654
; Sequence 654, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 654
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-654

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 28;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 369 ATGCGGTGGTGGAG 382
Db 2 ATGCGGTGGTGGAG 15
|||||

RESULT 53
US-09-625-634A-5
; Sequence 5, Application US/09625634A
; Patent No. 6653448
; GENERAL INFORMATION:
; APPLICANT: Vernet, Corine
; APPLICANT: Rastelli, Luca
; APPLICANT: Herrmann, John
; TITLE OF INVENTION: WNT-7B-LIKE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING
; FILE REFERENCE: Cura-244 (15966-744) US
; CURRENT APPLICATION NUMBER: US/09/625,634A
; CURRENT FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: USSN 60/194,256
; PRIOR FILING DATE: 2000-04-03
; PRIOR APPLICATION NUMBER: USSN 60/192,838
; PRIOR FILING DATE: 2000-03-29
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: SYNTHETIC PCR
; OTHER INFORMATION: PRIMER
US-09-625-634A-5

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 28;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 426 TCTCCCGGTGCTTC 439
Db 1 TCTCCCGGTGCTTC 14
|||||

RESULT 54
US-09-716-320-9/c
; Sequence 9, Application US/09716320
; Patent No. 6803360
; GENERAL INFORMATION:
; APPLICANT: Chang, Esther H
; APPLICANT: Pirolo, Kathleen F
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR REDUCING RADIATION AND DRUG RESISTAN
; FILE REFERENCE: 2444-109
; CURRENT APPLICATION NUMBER: US/09/716,320
; CURRENT FILING DATE: 2000-11-21
; PRIOR APPLICATION NUMBER: US 09/480,143
; PRIOR FILING DATE: 2000-01-10
; PRIOR APPLICATION NUMBER: US 08/991,830
; PRIOR FILING DATE: 1997-12-16
; PRIOR APPLICATION NUMBER: US 60/034,160
; PRIOR FILING DATE: 1996-12-30
; PRIOR APPLICATION NUMBER: US 09/601,444
; PRIOR FILING DATE: 2001-01-04
; PRIOR APPLICATION NUMBER: PCT/US98/24657

; PRIOR FILING DATE: 1998-11-19
; PRIOR APPLICATION NUMBER: US 60/066,188
; PRIOR FILING DATE: 1997-11-19
; PRIOR APPLICATION NUMBER: US 60/083,175
; PRIOR FILING DATE: 1998-04-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: HER-2 control oligonucleotide scrambled 2
US-09-716-320-9

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 28;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 410 GACGAGCATGGCTA 423
Db 15 GACAAGCATGGCTA 2

RESULT 55
PCT-US95-07349-6/c
; Sequence 6, Application PC/TUS9507349
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR MODULATING
; TITLE OF INVENTION: MORPHOGEN EXPRESSION
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PATENT ADMINISTRATOR, CREATIVE BIOMOLECULES
; ADDRESSES: INC.
; STREET: 45 SOUTH STREET
; CITY: HOPKINTON
; STATE: MA
; COUNTRY: USA
; ZIP: 07148
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/07349
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/938,021
; FILING DATE: 28-AUG-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: KELLEY, ROBIN D
; REGISTRATION NUMBER: 34,637
; REFERENCE/DOCKET NUMBER: CRP-091PC
; TELEPHONE: (508)-435-9001
; TELEFAX: (508)-435-0992
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..15
; OTHER INFORMATION: /note= "WT1 MOUSE TCC BINDING SITE"
PCT-US95-07349-6

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 28;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 398 GAGGAGCGGAGGA 411
Db 14 GAGGAGCGGAGGA 1

RESULT 56
US-08-390-888A-12
; Sequence 12, Application US/08390888A
; Patent No. 5916754
; GENERAL INFORMATION:
; APPLICANT: Nichol, Stuart T.
; APPLICANT: Morzunov, Sergey
; APPLICANT: Keizzek, Thomas G.
; APPLICANT: Rollin, Pierre E.
; APPLICANT: Spiropoulou, Christina F.
; TITLE OF INVENTION: THE BAYOU HANTAVIRUS AND RELATED METHODS
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NEEDLE & ROSENBERG, P.C.
; STREET: 127 Peachtree Street, N.E., Suite 1200
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30303
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,888A
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Spratt, Gwendolyn D.
; REGISTRATION NUMBER: 36,016
; REFERENCE/DOCKET NUMBER: 1414.623
; TELEPHONE: (404) 688-0770
; TELEFAX: (404) 688-9880
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 13 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA (genomic)
US-08-390-888A-12

Query Match 1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 23;
Matches 10; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
Qy 473 CCCACCCCAAGTT 484
Db 1 CCCACCCCAAGUU 12

RESULT 57
US-09-081-646-712/c
; Sequence 712, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664

; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 712
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-712

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 500 CCTGAGGGGCACA 511
Db 14 CCTGAGGGGCACA 3

RESULT 58

US-09-081-646-713/c
; Sequence 713, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 713
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-713

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 500 CCTGAGGGGCACA 511
Db 14 CCTGAGGGGCACA 3

RESULT 59

US-08-544-381B-236
; Sequence 236, Application US/08544381B
; Patent No. 6027880
; GENERAL INFORMATION:
; APPLICANT: Cronin, Maureen T.
; APPLICANT: Miyada, Charles Garrett
; APPLICANT: Hubbell, Earl A.
; APPLICANT: Chee, Mark
; APPLICANT: Fodor, Stephen P.A.
; APPLICANT: Huang, Xiaohua C.
; APPLICANT: Lipshutz, Robert J.
; APPLICANT: Lobbman, Peter E.
; APPLICANT: Morris, Macdonald S.
; APPLICANT: Sheldon, Edward L.
; TITLE OF INVENTION: Arrays of Nucleic Acid Probes for
; NUMBER OF SEQUENCES: 250
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/08/544,381B
; APPLICATION NUMBER: US/08/544,381B
; FILING DATE: 10-OCT-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/510,521
; FILING DATE: 02-AUG-1995
; PRIOR APPLICATION DATA: PCT/US94/12305
; APPLICATION NUMBER: PCT/US94/12305
; FILING DATE: 26-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/284,064
; FILING DATE: 02-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/143,312
; FILING DATE: 26-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-004130US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-576-0200
; TELEFAX: 415-576-0300
; INFORMATION FOR SEQ ID NO: 236:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
US-08-544-381B-236

Query Match 1.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 32;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 377 GTGAGATCACCG 389
Db 1 GTGAGATCAACG 13

RESULT 60

US-09-614-034-75/c
; Sequence 75, Application US/09614034
; Patent No. 6489307
; GENERAL INFORMATION:
; APPLICANT: PHILLIPS, M. IAN
; APPLICANT: ZHANG, YUAN
; TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mRNA
; FILE REFERENCE: 4300.013900
; CURRENT APPLICATION NUMBER: US/09/614,034
; CURRENT FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 09/152,717
; PRIOR FILING DATE: 1998-09-14
; PRIOR APPLICATION NUMBER: PCT/US99/21007
; PRIOR FILING DATE: 1999-09-14
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 75
; LENGTH: 12
; TYPE: DNA

```
; ORGANISM: UNKNOWN
; FEATURE:
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-614-034-75

Query Match      1.4%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      407 CAGGACGAGCA 417
Db      11 CAGGACGAGCA 1

RESULT 61
US-09-614-034-73/c
; Sequence 73, Application US/09614034
; Patent No. 6489307
; GENERAL INFORMATION:
; APPLICANT: PHILLIPS, M. IAN
; APPLICANT: ZHANG, YUAN
; TITLE OF INVENTION: ANTISENSE COMPOSITIONS TARGETED TO BETA1-ADRENOCEPTOR-SPECIFIC mRNA
; FILE REFERENCE: 4300.013900
; CURRENT APPLICATION NUMBER: US/09/614,034
; CURRENT FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 09/152,717
; PRIOR FILING DATE: 1998-09-14
; PRIOR APPLICATION NUMBER: PCT/US99/21007
; PRIOR FILING DATE: 1999-09-14
; NUMBER OF SEQ ID NOS: 204
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 73
; LENGTH: 13
; TYPE: DNA
; ORGANISM: UNKNOWN
; FEATURE:
; OTHER INFORMATION: SYNTHETIC OLIGONUCLEOTIDE
US-09-614-034-73

Query Match      1.4%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      407 CAGGACGAGCA 417
Db      12 CAGGACGAGCA 2

RESULT 62
PCT-US94-05659-22
; Sequence 22, Application PC/TUS9405659
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: TNF RESPONSIVE ELEMENT, TNF-INDUCED DNA-BINDING
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSES: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/05659
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:43:09 ; Search time 2 Seconds
(without alignments)
4.003 Million cell updates/sec

Title: US-10-605-498-91-COPY

Perfect score: 764

Sequence: 1 ggcacgaggagcagatcg.....aagttcaagcaaccactg 764

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 301 seqs, 5240 residues

Total number of hits satisfying chosen parameters: 602

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 303 summaries

Database : ngsdb.*

N. Genesey

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	25	3.3	25	1	ABK67082 Human gene specifi
C 2	24	3.1	24	1	ABK67081 Human gene specifi
C 3	21.4	2.8	23	1	ABL9424 Left PCR primer us
C 4	21	2.7	21	1	ADM94658 Human heat shock p
C 5	21	2.7	21	1	ADM94663 Human heat shock p
C 6	21	2.7	21	1	ADM94670 Human heat shock p
C 7	21	2.7	21	1	ADM94703 Human heat shock p
C 8	21	2.7	21	1	ADM94709 Human heat shock p
C 9	21	2.7	21	1	ADM94717 Human heat shock p
C 10	21	2.7	21	1	ADM94721 Human heat shock p
C 11	21	2.7	21	1	ADM94731 Human heat shock p
C 12	21	2.7	21	1	ADM94685 Human heat shock p
C 13	21	2.7	21	1	ADM94725 Human heat shock p
C 14	21	2.7	21	1	ADM94653 Human heat shock p
C 15	21	2.7	21	1	ADM94667 Human heat shock p
C 16	21	2.7	21	1	ADM94688 Human heat shock p
C 17	21	2.7	21	1	ADM94691 Human heat shock p
C 18	21	2.7	21	1	ADM94692 Human heat shock p
C 19	21	2.7	21	1	ADM94697 Human heat shock p
C 20	21	2.7	21	1	ADM94704 Human heat shock p
C 21	21	2.7	21	1	ADM94712 Human heat shock p
C 22	21	2.7	21	1	ADM94714 Human heat shock p
C 23	21	2.7	21	1	ADM94672 Human heat shock p
C 24	21	2.7	21	1	ADM94705 Human heat shock p
C 25	21	2.7	21	1	ADM94654 Human heat shock p
C 26	21	2.7	21	1	ADM94657 Human heat shock p
C 27	21	2.7	21	1	ADM94687 Human heat shock p
C 28	21	2.7	21	1	ADM94689 Human heat shock p
C 29	21	2.7	21	1	ADM94702 Human heat shock p
C 30	21	2.7	21	1	ADM94713 Human heat shock p
C 31	21	2.7	21	1	ADM94716 Human heat shock p
C 32	21	2.7	21	1	ADM94724 Human heat shock p
C 33	21	2.7	21	1	ADM94651 Human heat shock p

C 34	21	2.7	21	1	ADM94668 Human heat shock p
C 35	21	2.7	21	1	ADM94686 Human heat shock p
C 36	21	2.7	21	1	ADM94700 Human heat shock p
C 37	21	2.7	21	1	ADM94701 Human heat shock p
C 38	21	2.7	21	1	ADM94706 Human heat shock p
C 39	21	2.7	21	1	ADM94711 Human heat shock p
C 40	21	2.7	21	1	ADM94729 Human heat shock p
C 41	21	2.7	21	1	ADM94660 Human heat shock p
C 42	21	2.7	21	1	ADM94661 Human heat shock p
C 43	21	2.7	21	1	ADM94669 Human heat shock p
C 44	21	2.7	21	1	ADM94680 Human heat shock p
C 45	21	2.7	21	1	ADM94652 Human heat shock p
C 46	21	2.7	21	1	ADM94676 Human heat shock p
C 47	21	2.7	21	1	ADM94684 Human heat shock p
C 48	21	2.7	21	1	ADM94690 Human heat shock p
C 49	21	2.7	21	1	ADM94662 Human heat shock p
C 50	21	2.7	21	1	ADM94665 Human heat shock p
C 51	21	2.7	21	1	ADM94698 Human heat shock p
C 52	21	2.7	21	1	ADM94718 Human heat shock p
C 53	21	2.7	21	1	ADM94728 Human heat shock p
C 54	21	2.7	21	1	ADM94674 Human heat shock p
C 55	21	2.7	21	1	ADM94678 Human heat shock p
C 56	21	2.7	21	1	ADM94715 Human heat shock p
C 57	21	2.7	21	1	ADM94726 Human heat shock p
C 58	21	2.7	21	1	ADM94677 Human heat shock p
C 59	21	2.7	21	1	ADM94699 Human heat shock p
C 60	21	2.7	21	1	ADM94719 Human heat shock p
C 61	21	2.7	21	1	ADM94671 Human heat shock p
C 62	21	2.7	21	1	ADM94679 Human heat shock p
C 63	21	2.7	21	1	ADM94683 Human heat shock p
C 64	21	2.7	21	1	ADM94693 Human heat shock p
C 65	21	2.7	21	1	ADM94694 Human heat shock p
C 66	21	2.7	21	1	ADM94722 Human heat shock p
C 67	21	2.7	21	1	ADM94723 Human heat shock p
C 68	21	2.7	21	1	ADM94682 Human heat shock p
C 69	21	2.7	21	1	ADM94655 Human heat shock p
C 70	21	2.7	21	1	ADM94656 Human heat shock p
C 71	21	2.7	21	1	ADM94664 Human heat shock p
C 72	21	2.7	21	1	ADM94666 Human heat shock p
C 73	21	2.7	21	1	ADM94673 Human heat shock p
C 74	21	2.7	21	1	ADM94659 Human heat shock p
C 75	21	2.7	21	1	ADM94681 Human heat shock p
C 76	21	2.7	21	1	ADM94696 Human heat shock p
C 77	21	2.7	21	1	ADM94707 Human heat shock p
C 78	21	2.7	21	1	ADM94675 Human heat shock p
C 79	21	2.7	21	1	ADM94695 Human heat shock p
C 80	21	2.7	21	1	ADM94708 Human heat shock p
C 81	21	2.7	21	1	ADM94710 Human heat shock p
C 82	21	2.7	21	1	ADM94720 Human heat shock p
C 83	21	2.7	21	1	ADM94730 Human heat shock p
C 84	20	2.6	20	1	ADM94732 Human heat shock p
C 85	20	2.5	20	1	ADO55958 Probe HSP27 for de
C 86	19	2.5	19	1	ADM94740 Human heat shock p
C 87	19	2.5	19	1	ADM94737 Human heat shock p
C 88	18.4	2.4	18	1	ABA00784 HSP27 forward prim
C 89	18	2.4	18	1	ADM94727 Human heat shock p
C 90	17.8	2.3	17	1	ADM94739 Human heat shock p
C 91	17.8	2.3	17	1	ABA00785 HSP27 reverse prim
C 92	17.4	2.3	17	1	AAA66267 Dog genomic marker
C 93	17	2.2	17	1	ABT34675 Tumour suppression
C 94	17	2.2	17	1	ADB45935 Tumour suppression
C 95	17	2.2	17	1	ADBS0781 Cholesterol homeos
C 96	17	2.2	17	1	ADBS0781 Human tumour suppr
C 97	17	2.2	17	1	ACC51537 Human tumour suppr
C 98	16.4	2.1	16	1	ADR30706 Stunk cabbage S-f
C 99	15.8	2.1	15	1	ADI00879 RT-PCR 32P end-lab
C 100	15.8	2.1	15	1	ADM94733 Human heat shock p
C 101	15.8	2.1	15	1	ADM94657 Human heat shock p
C 102	15.4	2.0	15	1	ABN10675 Human GDMPL-1 17-m
C 103	15.4	2.0	15	1	ADB45924 Tumour suppression
C 104	15.4	2.0	15	1	ADI48414 Human tumour suppr
C 105	15.4	2.0	15	1	ADG71955 Human NOVX related
C 106	15.4	2.0	15	1	ADJ87293 Human G protein-co

C 253	12	1.6	12	1	ABH86717	Oligonucleotide pr
C 254	12	1.6	12	1	ABH76066	NEPHA gene transcr
C 255	12	1.6	12	1	ABH41108	Oligonucleotide SE
C 256	12	1.6	13	1	ABH41109	Oligonucleotide SE
C 257	12	1.6	13	1	ABF75056	Oligonucleotide SE
C 258	12	1.6	13	1	ABH34624	Oligonucleotide SE
C 259	12	1.6	13	1	ABF75057	Oligonucleotide SE
C 260	12	1.6	13	1	ABH34625	Oligonucleotide SE
C 261	12	1.6	14	1	ABS13442	DNA primer sequenc
C 262	12	1.6	14	1	ABS98192	Human lactoferrin
C 263	12	1.6	14	1	ADP78335	Chromosomal abnorm
C 264	12	1.6	14	1	ADH53140	Human APC (adenoma
C 265	12	1.6	14	1	ABF13746	Population analysi
C 266	12	1.6	14	1	ADR97911	Human APC DNA frag
C 267	12	1.6	14	1	ADS08595	Human APC oligonuc
C 268	12	1.6	15	1	AAK31657	Tag sequence of a
C 269	12	1.6	15	1	AAK31658	Tag sequence of a
C 270	12	1.6	15	1	AA167292	Human FKBP8 allele
C 271	12	1.6	15	1	AA167293	Human FKBP8 allele
C 272	12	1.6	15	1	AAF46723	IGFBP3 oligonucleo
C 273	12	1.6	15	1	AAF45517	IGFBP2 oligonucleo
C 274	12	1.6	15	1	AAF46724	IGFBP3 oligonucleo
C 275	12	1.6	15	1	AAF46722	IGFBP3 oligonucleo
C 276	12	1.6	15	1	AAF45480	IGFBP2 oligonucleo
C 277	12	1.6	15	1	AAF45515	IGFBP2 oligonucleo
C 278	12	1.6	15	1	AAF45478	IGFBP2 oligonucleo
C 279	12	1.6	15	1	AAF45795	IGFBP2 oligonucleo
C 280	12	1.6	15	1	AAF45169	IGFBP2 oligonucleo
C 281	12	1.6	15	1	AAF45170	IGFBP2 oligonucleo
C 282	12	1.6	15	1	AAF45481	IGFBP2 oligonucleo
C 283	12	1.6	15	1	AAF46725	IGFBP3 oligonucleo
C 284	12	1.6	15	1	AAF46287	IGFBP2 oligonucleo
C 285	12	1.6	15	1	AAF45171	IGFBP2 oligonucleo
C 286	12	1.6	15	1	AAF45172	IGFBP2 oligonucleo
C 287	12	1.6	15	1	AAF45479	IGFBP2 oligonucleo
C 288	12	1.6	15	1	AAF45799	IGFBP2 oligonucleo
C 289	12	1.6	15	1	AAF45514	IGFBP2 oligonucleo
C 290	12	1.6	15	1	AAF45516	IGFBP2 oligonucleo
C 291	12	1.6	15	1	ABK95953	Human LIPE gene po
C 292	12	1.6	15	1	ABK95954	Human LIPE gene po
C 293	12	1.6	15	1	AA144242	Human interleukin
C 294	12	1.6	15	1	ABN80605	Human P450(cytochr
C 295	12	1.6	15	1	AS1191927	ASO primer #7 to d
C 296	12	1.6	15	1	ABL91848	Human LIPI gene al
C 297	12	1.6	15	1	ABK64023	Human BF gene alle
C 298	12	1.6	15	1	ABK51277	Human Caspase-2, C
C 299	12	1.6	15	1	ABK32612	Human pancreatic c
C 300	12	1.6	15	1	ABK32611	Human pancreatic c
C 301	12	1.6	15	1	ABL36332	Human lysosomal ac
C 302	12	1.6	15	1	ACS95898	Human CALM1 gene a
C 303	12	1.6	15	1	ADG65423	UCP2allele specif

XX	05-JAN-1999;	99US-00225928.
PF		
XX	21-MAY-1997;	97US-00859998.
PR		
XX	(CLON-) CLONTECH LAB INC.	
PA		
XX	Chenchik A, Johkhadze G, Bibilashvilli R;	
PI		
XX	WPI; 2002-314699/35.	
DR		
XX	Producing sub-population of labeled nuclei	
PT	differences in RNA profiles between several	
PT	sources, using set of distinct gene specific	
XX	Example 3; SEQ ID NO 1170; 11bp; English.	
PS		

ALIGNMENTS

RESULT 2	
ABK67081	
ID	ABK67081 standard; DNA; 24 BP.
XX	
XX	
AC	ABK67081;
XX	
XX	
DT	02-JUL-2002 (first entry)
XX	
DE	Human gene specific PCR primer
XX	
XX	
KW	Primer; ss; DNA microarray; di
XX	
OS	Homo sapiens.
XX	
PN	US6352829-B1.
XX	
XX	
PD	05-MAR-2002.
XX	
XX	
PF	05-JAN-1999; 99US-00225928.
XX	
PR	21-MAY-1997; 97US-00859998.
XX	

CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

XX Sequence 21 BP; 4 A; 7 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 71 TGGGACCCCTCCGGACTGG 91

Db 21 TGGGACCCCTCCGGACTGG 1

RESULT 5

ADM94663/c
 ID ADM94663 standard; DNA; 21 BP.

XX

AC ADM94663;

XX 01-JUL-2004 (first entry)

XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:13.

XX heat shock protein 27; hsp27; cytostatic; gene therapy;

KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;

KW antisense oligonucleotide; ss.

XX Homo sapiens.

OS Synthetic.

XX WO2004030660-A2.

XX 15-APR-2004.

XX 02-OCT-2003; 2003WO-CA001588.

XX 02-OCT-2002; 2002US-0415859P.

PR 18-APR-2003; 2003US-0463952P.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave ME, Rocchi P, Signaevsky M;

XX WPI; 2004-316331/29.

XX Claim 5; SEQ ID NO 13; 38pp; English.

XX The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

XX Sequence 21 BP; 4 A; 7 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 121 CTTCCGGCTGCCCGCGCTGCC 141

Db 21 CTTCCGGCTGCCCGCGCTGCC 1

RESULT 6

ADM94670/c
 ID ADM94670 standard; DNA; 21 BP.

XX

AC ADM94670;

XX 01-JUL-2004 (first entry)

XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:20.

XX heat shock protein 27; hsp27; cytostatic; gene therapy;

KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;

KW antisense oligonucleotide; ss.

XX Homo sapiens.

OS Synthetic.

XX WO2004030660-A2.

XX 15-APR-2004.

XX 02-OCT-2003; 2003WO-CA001588.

XX 02-OCT-2002; 2002US-0415859P.

PR 18-APR-2003; 2003US-0463952P.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave ME, Rocchi P, Signaevsky M;

XX WPI; 2004-316331/29.

XX New composition comprising a therapeutic agent that reduces the amount of
 active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 useful in treating cancer, e.g., prostate cancer or a central nervous
 system malignancy.

XX Claim 5; SEQ ID NO 20; 38pp; English.

XX The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

XX Sequence 21 BP; 1 A; 4 C; 16 G; 0 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 191 CGCCCTGCTGCCCGCGCTGCC 211

Db 21 CGCCCTGCTGCCCGCGCTGCC 1

RESULT 7

ADM94703/c
 ID ADM94703 standard; DNA; 21 BP.

XX

AC ADM94703;

XX 01-JUL-2004 (first entry)

PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.
 XX
 XX Claim 5; SEQ ID NO 67; 38pp; English.
 XX
 CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.
 XX
 XX Sequence 21 BP; 3 A; 4 C; 12 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 661 CCACCCCTGCTGCCGCACTG 681
 DB 21 CCACCCCTGCTGCCGCACTG 1
 RESULT 10
 ADM94721/c
 ID ADM94721 standard; DNA; 21 BP.
 XX
 AC ADM94721;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:71.
 XX
 KW heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004030660-A2.
 XX
 PD 15-APR-2004.
 XX
 PF 02-OCT-2003; 2003WO-CA001588.
 XX
 PR 02-OCT-2002; 2002US-0415859P.
 PR 18-APR-2003; 2003US-0463952P.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX
 PI Gleave ME, Rocchi P, Signaevsky M;
 XX WPI; 2004-316331/29.
 XX
 DR New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.
 XX
 XX Claim 5; SEQ ID NO 71; 38pp; English.
 PS
 CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence

CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.
 XX
 XX Sequence 21 BP; 11 A; 4 C; 3 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 701 CTGTGCTGCTCTTTGATACAT 721
 DB 21 CTGTGCTGCTCTTTGATACAT 1
 RESULT 11
 ADM94731/c
 ID ADM94731 standard; DNA; 21 BP.
 XX
 AC ADM94731;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:81.
 XX
 KW heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004030660-A2.
 XX
 PD 15-APR-2004.
 XX
 PF 02-OCT-2003; 2003WO-CA001588.
 XX
 PR 02-OCT-2002; 2002US-0415859P.
 PR 18-APR-2003; 2003US-0463952P.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX
 PI Gleave ME, Rocchi P, Signaevsky M;
 XX WPI; 2004-316331/29.
 XX
 DR New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.
 XX
 XX Claim 5; SEQ ID NO 81; 38pp; English.
 PS
 CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.
 XX
 XX Sequence 21 BP; 2 A; 6 C; 10 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 26 ATGACCGAGCGCGCGTCCCC 46
 DB 21 ATGACCGAGCGCGCGTCCCC 1


```

XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX XX
XX DR WPI; 2004-316331/29.
XX
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 3; 38pp; English.
XX
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 1 A; 7 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 CCAGCATGACCGAGCGCGCG 41
DB 21 CCAGCATGACCGAGCGCGCG 1

RESULT 15
ADM94667/c
ID ADM94667 standard; DNA; 21 BP.
XX AC ADM94667;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:17.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX
XX PD 15-APR-2004.
XX
XX PF 02-OCT-2003; 2003WO-CA001588.
XX
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX XX
XX DR WPI; 2004-316331/29.
XX
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 17; 38pp; English.

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 CCAGCATGACCGAGCGCGCG 41
DB 21 CCAGCATGACCGAGCGCGCG 1

RESULT 16
ADM94688/c
ID ADM94688 standard; DNA; 21 BP.
XX AC ADM94688;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:38.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX
XX PD 15-APR-2004.
XX
XX PF 02-OCT-2003; 2003WO-CA001588.
XX
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX XX
XX DR WPI; 2004-316331/29.
XX
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 38; 38pp; English.

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 161 TTAGGGCGGCGAGCGCTGGCCA 181
DB 21 TTAGGGCGGCGAGCGCTGGCCA 1

RESULT 16
ADM94688/c
ID ADM94688 standard; DNA; 21 BP.
XX AC ADM94688;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:38.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX
XX PD 15-APR-2004.
XX
XX PF 02-OCT-2003; 2003WO-CA001588.
XX
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX XX
XX DR WPI; 2004-316331/29.
XX
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 38; 38pp; English.

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 161 TTAGGGCGGCGAGCGCTGGCCA 181
DB 21 TTAGGGCGGCGAGCGCTGGCCA 1

```

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 371 GCGGTGGTGGAGATCACCGGC 391
 Db 21 GCGGTGGTGGAGATCACCGGC 1

RESULT 17
 ADM94691/c
 ID ADM94691 standard; DNA; 21 BP.
 AC ADM94691;
 XX
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:41.
 XX
 KW heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.

XX Homo sapiens.
 OS Synthetic.
 XX WO2004030660-A2.
 XX
 PD 15-APR-2004.
 XX
 PF 02-OCT-2003; 2003WO-CA001588.
 XX
 PR 02-OCT-2002; 2002US-0415859P.
 PR 18-APR-2003; 2003US-0463952P.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX
 PI Gleave ME, Rocchi P, Signaevsky M;
 XX WPI; 2004-316331/29.
 DR
 XX New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.
 XX
 PS Claim 5; SEQ ID NO 41; 38pp; English.

XX The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

XX Sequence 21 BP; 1 A; 10 C; 5 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 401 GAGCGGCGAGGAGCATGGC 421
 Db 21 GAGCGGCGAGGAGCATGGC 1

RESULT 18
 ADM94692/c
 ID ADM94692 standard; DNA; 21 BP.
 XX

AC ADM94692;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:42.
 XX
 KW heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX WO2004030660-A2.
 XX
 PD 15-APR-2004.
 XX
 PF 02-OCT-2003; 2003WO-CA001588.
 XX
 PR 02-OCT-2002; 2002US-0415859P.
 PR 18-APR-2003; 2003US-0463952P.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX
 PI Gleave ME, Rocchi P, Signaevsky M;
 XX WPI; 2004-316331/29.
 DR
 XX New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.
 XX
 PS Claim 5; SEQ ID NO 42; 38pp; English.
 XX
 CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.
 XX
 PS Sequence 21 BP; 4 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 411 ACGAGCATGGCTACATCTCCC 431
 Db 21 ACGAGCATGGCTACATCTCCC 1

RESULT 19
 ADM94697/c
 ID ADM94697 standard; DNA; 21 BP.
 XX
 AC ADM94697;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:47.
 XX
 KW heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX

CC composition is useful in treating cancer, e.g., prostate, bladder, lung, breast, pancreatic, colon, skin (for example melanoma), renal or ovarian cancer or a central nervous system malignancy. The present sequence CC represents a human hsp27 antisense oligonucleotide which is used in the CC exemplification of the present invention.

XX
SQ Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 611 GCTCAAAATCGATGAGACT 631
|||||
Db 21 GCTCAAAATCGATGAGACT 1

RESULT 22
ADM94714/C
ID ADM94714 standard; DNA; 21 BP.
XX AC ADM94714;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:64.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.

XX OS Homo sapiens.
XX OS Synthetic.
XX WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.

XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent, PT useful in treating cancer, e.g., prostate cancer or a central nervous PT system malignancy.
XX
PS Claim 5; SEQ ID NO 64; 38pp; English.

XX The present invention describes a composition which comprises a CC therapeutic agent that reduces the amount of active heat shock protein 27 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The CC composition has cytostatic activity, and can be used in gene therapy. The CC composition is useful in treating cancer, e.g., prostate, bladder, lung, CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian CC cancer or a central nervous system malignancy. The present sequence CC represents a human hsp27 antisense oligonucleotide which is used in the CC exemplification of the present invention.

XX
SQ Sequence 21 BP; 4 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 TGCCGCCAAGTAAAGCCTTAG 651

Db 21 TGCCGCCAAGTAAAGCCTTAG 1
|||||

RESULT 23
ADM94672/C
ID ADM94672 standard; DNA; 21 BP.
XX AC ADM94672;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:22.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.

XX OS Homo sapiens.
XX OS Synthetic.
XX WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.

XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent, PT useful in treating cancer, e.g., prostate cancer or a central nervous PT system malignancy.

XX
PS Claim 5; SEQ ID NO 22; 38pp; English.
XX
CC The present invention describes a composition which comprises a CC therapeutic agent that reduces the amount of active heat shock protein 27 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The CC composition has cytostatic activity, and can be used in gene therapy. The CC composition is useful in treating cancer, e.g., prostate, bladder, lung, CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian CC cancer or a central nervous system malignancy. The present sequence CC represents a human hsp27 antisense oligonucleotide which is used in the CC exemplification of the present invention.

XX
SQ Sequence 21 BP; 2 A; 7 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 211 CATCGAGAGCCCGCAGTGGC 231
|||||
Db 21 CATCGAGAGCCCGCAGTGGC 1

RESULT 24
ADM94705/C
ID ADM94705 standard; DNA; 21 BP.

XX AC ADM94705;
XX
DT 01-JUL-2004 (first entry)

XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:55.

```
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX Homo sapiens.
OS Synthetic.
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
PI WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 55; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 2 A; 5 C; 7 G; 7 T; 0 U; 0 Other;
PS
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 541 AGCCACGCGAGTCCACGAGAT 561
Db 21 AGCCACGCGAGTCCACGAGAT 1
|||||
RESULT 25
ADM94654/C
ID ADM94654 standard; DNA; 21 BP.
XX
XX ADM94654;
AC
XX
XX 01-JUL-2004 (first entry)
DT
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:4.
DE
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004030660-A2.
PN
XX
XX 15-APR-2004.
PD
XX
XX 02-OCT-2003; 2003WO-CA001588.
PF
```

```
XX 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
PI WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 4; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 5 C; 11 G; 1 T; 0 U; 0 Other;
PS
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 31 CGAGCGCGCGTCCCTTC 51
Db 21 CGAGCGCGCGTCCCTTC 1
|||||
RESULT 26
ADM94657/C
ID ADM94657 standard; DNA; 21 BP.
XX
XX ADM94657;
AC
XX
XX 01-JUL-2004 (first entry)
DT
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:7.
DE
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004030660-A2.
PN
XX
XX 15-APR-2004.
PD
XX
XX 02-OCT-2003; 2003WO-CA001588.
PF
XX
XX 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
PI WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
```

```
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 7; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 61 GGGCCCCAGCTGGGACCCCTT 81
DB 21 GGGCCCCAGCTGGGACCCCTT 1

RESULT 27
ADM94687/c
ID ADM94687 standard; DNA; 21 BP.
XX
AC ADM94687;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:37.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
PF New composition comprising a therapeutic agent that reduces the amount of
PF active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PF useful in treating cancer, e.g., prostate cancer or a central nervous
PF system malignancy.
XX
PS Claim 5; SEQ ID NO 37; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
```

```
XX
SQ Sequence 21 BP; 3 A; 10 C; 3 G; 5 T; 0 U; 0 Other;

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 361 GACCAAGGATGGCGTGGTGGGA 381
DB 21 GACCAAGGATGGCGTGGTGGGA 1

RESULT 28
ADM94689/c
ID ADM94689 standard; DNA; 21 BP.
XX
AC ADM94689;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:39.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
PF New composition comprising a therapeutic agent that reduces the amount of
PF active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PF useful in treating cancer, e.g., prostate cancer or a central nervous
PF system malignancy.
XX
PS Claim 5; SEQ ID NO 39; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 7 C; 6 G; 7 T; 0 U; 0 Other;

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 381 AGATCACCGGCAAGCAGGAGG 401
DB 21 AGATCACCGGCAAGCAGGAGG 1

RESULT 29
```



```

XX Gleave ME, Rocchi P, Signaevsky M;
PI WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 66; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 3 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
SQ
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 651 GCCCGATGCCACCCCTGCT 671
DB 21 GCCCGATGCCACCCCTGCT 1
RESULT 32
ADM94724/c
ID ADM94724 standard; DNA; 21 BP.
XX
XX ADM94724;
AC
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:74.
DE
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
PR heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
PR antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
PI WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 74; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 9 A; 2 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 731 GTTTTCTCAANTAAAGTTCA 751
DB 21 GTTTTCTCAANTAAAGTTCA 1
RESULT 33
ADM94651/c
ID ADM94651 standard; DNA; 21 BP.
XX
XX ADM94651;
AC
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:1.
DE
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
PI WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 1; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 1 A; 9 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 731 GTTTTCTCAANTAAAGTTCA 751
DB 21 GTTTTCTCAANTAAAGTTCA 1

```

```
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GGCACGAGCAGCAGTGTCAGC 21
Db 21 GGCACGAGCAGCAGTGTCAGC 1

RESULT 34
ADM94686/c
ID ADM94686 standard; DNA; 21 BP.
XX AC
XX AC ADM94686;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:18.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX CC New composition comprising a therapeutic agent that reduces the amount of
XX CC active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX CC useful in treating cancer, e.g., prostate cancer or a central nervous
XX CC system malignancy.
XX PS Claim 5; SEQ ID NO 18; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 3 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 171 GCAGCTGCCAGGCTACGTGC 191
Db 21 GCAGCTGCCAGGCTACGTGC 1

RESULT 35
ADM94686/c
ID ADM94686 standard; DNA; 21 BP.
XX AC
XX AC ADM94686;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:50.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX CC New composition comprising a therapeutic agent that reduces the amount of
XX CC active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX CC useful in treating cancer, e.g., prostate cancer or a central nervous
XX CC system malignancy.
XX PS Claim 5; SEQ ID NO 18; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 3 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 171 GCAGCTGCCAGGCTACGTGC 191
Db 21 GCAGCTGCCAGGCTACGTGC 1

RESULT 35
ADM94686/c
ID ADM94686 standard; DNA; 21 BP.
XX AC
XX AC ADM94686;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:50.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX CC New composition comprising a therapeutic agent that reduces the amount of
XX CC active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX CC useful in treating cancer, e.g., prostate cancer or a central nervous
XX CC system malignancy.
XX PS Claim 5; SEQ ID NO 36; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 3 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 351 TGACGGTCAAGACCAAGGATG 371
Db 21 TGACGGTCAAGACCAAGGATG 1

RESULT 36
ADM94700/c
ID ADM94700 standard; DNA; 21 BP.
XX AC
XX AC ADM94700;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:50.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX CC New composition comprising a therapeutic agent that reduces the amount of
XX CC active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX CC useful in treating cancer, e.g., prostate cancer or a central nervous
XX CC system malignancy.
XX PS Claim 5; SEQ ID NO 36; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 3 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
```

PD 15-APR-2004.
 XX
 PF 02-OCT-2003; 2003WO-CA001588.
 XX
 PR 02-OCT-2002; 2002US-0415859P.
 PR 18-APR-2003; 2003US-0463952P.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX
 PI Gleave ME, Rocchi P, Signaevsky M;
 XX
 DR WPI; 2004-316331/29.
 XX
 XX New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.
 XX
 XX Claim 5; SEQ ID NO 50; 38pp; English.
 XX
 XX The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.
 XX
 XX Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 491 TCCCTGTCCCTGTGAGGCACA 511
 Db 21 TCCCTGTCCCTGTGAGGCACA 1
 RESULT 37
 ADM94701/c
 ID ADM94701 standard; DNA; 21 BP.
 AC ADM94701;
 XX
 XX 01-JUL-2004 (first entry)
 DT
 XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:51.
 DE
 XX heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.
 XX
 XX Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004030660-A2.
 XX
 PD 15-APR-2004 (first entry)
 DT
 XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:51.
 DE
 XX heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.
 XX
 XX Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004030660-A2.
 XX
 PD 15-APR-2004.
 DT
 XX 02-OCT-2003; 2003WO-CA001588.
 PF
 XX 02-OCT-2002; 2002US-0415859P.
 PR 18-APR-2003; 2003US-0463952P.
 XX
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA
 XX Gleave ME, Rocchi P, Signaevsky M;
 XX
 XX WPI; 2004-316331/29.
 XX

PT New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.
 XX
 XX Claim 5; SEQ ID NO 51; 38pp; English.
 XX
 XX The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.
 XX
 XX Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 501 CTGAGGGCACACTGACCGTGG 521
 Db 21 CTGAGGGCACACTGACCGTGG 1
 RESULT 38
 ADM94706/c
 ID ADM94706 standard; DNA; 21 BP.
 AC ADM94706;
 XX
 XX 01-JUL-2004 (first entry)
 DT
 XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:56.
 DE
 XX heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.
 XX
 XX Homo sapiens.
 OS Synthetic.
 XX
 PN WO2004030660-A2.
 XX
 PD 15-APR-2004.
 DT
 XX 02-OCT-2003; 2003WO-CA001588.
 PF
 XX 02-OCT-2002; 2002US-0415859P.
 PR 18-APR-2003; 2003US-0463952P.
 XX
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA
 XX Gleave ME, Rocchi P, Signaevsky M;
 PI
 XX WPI; 2004-316331/29.
 DR
 XX New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.
 XX
 XX Claim 5; SEQ ID NO 56; 38pp; English.
 XX
 XX The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.
 XX

CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

SQ Sequence 21 BP; 3 A; 2 C; 9 G; 7 T; 0 U; 0 Other;
 Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 TCCACGAGATCACCATCCCA 571
 |||||
 Db 21 TCCACGAGATCACCATCCCA 1

RESULT 39

ADM94711/C
 ID ADM94711 standard; DNA; 21 BP.

AC AC
 XX XX
 XX XX

DT 01-JUL-2004 (first entry)

DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:61.

XX heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.
 OS Synthetic.

XX WO2004030660-A2.

XX 15-APR-2004.

PF 02-OCT-2003; 2003WO-CA001588.

PR 02-OCT-2002; 2002US-0415859P.

PR 18-APR-2003; 2003US-0463952P.

XX (UYBR-) UNIV BRITISH COLUMBIA.

PI Gleave ME, Rocchi P, Signaevsky M;

XX WPI; 2004-316331/29.

XX New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.

XX Claim 5; SEQ ID NO 61; 38pp; English.

CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

SQ Sequence 21 BP; 2 A; 6 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 601 GGGCCCAAGAGTCAAAATC 621
 |||||

Db 21 GGGCCCAAGAGTCAAAATC 1

RESULT 40

ADM94729/C
 ID ADM94729 standard; DNA; 21 BP.

AC AC
 XX XX
 XX XX

DT 01-JUL-2004 (first entry)

DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:79.

XX heat shock protein 27; hsp27; cytostatic; gene therapy;
 KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
 KW antisense oligonucleotide; ss.

OS Homo sapiens.
 OS Synthetic.

XX WO2004030660-A2.

XX 15-APR-2004.

PF 02-OCT-2003; 2003WO-CA001588.

PR 02-OCT-2002; 2002US-0415859P.

PR 18-APR-2003; 2003US-0463952P.

XX (UYBR-) UNIV BRITISH COLUMBIA.

PI Gleave ME, Rocchi P, Signaevsky M;

XX WPI; 2004-316331/29.

XX New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.

XX Claim 5; SEQ ID NO 79; 38pp; English.

CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

SQ Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 265 ACTCAGCAGCGGGGTCTCGGA 285
 |||||

Db 21 ACTCAGCAGCGGGGTCTCGGA 1

RESULT 41

ADM94660/C
 ID ADM94660 standard; DNA; 21 BP.

AC AC
 XX XX
 XX XX

DT 01-JUL-2004 (first entry)

DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:10.

XX heat shock protein 27; hsp27; cytostatic; gene therapy;

```
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
OS Homo sapiens.
OS Synthetic.
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
XX 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
XX active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX useful in treating cancer, e.g., prostate cancer or a central nervous
XX system malignancy.
XX
XX Claim 5; SEQ ID NO 10; 38pp; English.
XX
XX The present invention describes a composition which comprises a
XX therapeutic agent that reduces the amount of active heat shock protein 27
XX (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX composition has cytostatic activity, and can be used in gene therapy. The
XX composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX cancer or a central nervous system malignancy. The present sequence
XX represents a human hsp27 antisense oligonucleotide which is used in the
XX exemplification of the present invention.
XX
XX Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 91 GTACCGCATAGCCGCTCTT 111
XX |||||
XX Db 21 GTACCGCATAGCCGCTCTT 1
XX
XX RESULT 42
XX ADM94661/c
XX ID ADM94661 standard; DNA; 21 BP.
XX
XX AC ADM94661;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:11.
XX
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX PN WO2004030660-A2.
XX
XX PD 15-APR-2004.
XX
XX PF 02-OCT-2003; 2003WO-CA001588.
XX
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX useful in treating cancer, e.g., prostate cancer or a central nervous
XX system malignancy.
XX
XX Claim 5; SEQ ID NO 10; 38pp; English.
XX
XX The present invention describes a composition which comprises a
XX therapeutic agent that reduces the amount of active heat shock protein 27
XX (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX composition has cytostatic activity, and can be used in gene therapy. The
XX composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX cancer or a central nervous system malignancy. The present sequence
XX represents a human hsp27 antisense oligonucleotide which is used in the
XX exemplification of the present invention.
XX
XX Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 91 GTACCGCATAGCCGCTCTT 111
XX |||||
XX Db 21 GTACCGCATAGCCGCTCTT 1
XX
XX RESULT 43
XX ADM94669/c
XX ID ADM94669 standard; DNA; 21 BP.
XX
XX AC ADM94669;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:19.
XX
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX PN WO2004030660-A2.
XX
XX PD 15-APR-2004.
XX
XX PF 02-OCT-2003; 2003WO-CA001588.
XX
XX PR 02-OCT-2002; 2002US-0415859P.
XX 18-APR-2003; 2003US-0463952P.
XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
XX active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX useful in treating cancer, e.g., prostate cancer or a central nervous
XX system malignancy.
XX
XX Claim 5; SEQ ID NO 11; 38pp; English.
XX
XX The present invention describes a composition which comprises a
XX therapeutic agent that reduces the amount of active heat shock protein 27
XX (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX composition has cytostatic activity, and can be used in gene therapy. The
XX composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX cancer or a central nervous system malignancy. The present sequence
XX represents a human hsp27 antisense oligonucleotide which is used in the
XX exemplification of the present invention.
XX
XX Sequence 21 BP; 3 A; 5 C; 10 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 101 AGCCGCTCTTCGACGAGGCC 121
XX |||||
XX Db 21 AGCCGCTCTTCGACGAGGCC 1
XX
XX RESULT 43
XX ADM94669/c
XX ID ADM94669 standard; DNA; 21 BP.
XX
XX AC ADM94669;
XX
XX DT 01-JUL-2004 (first entry)
XX
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:19.
XX
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX PN WO2004030660-A2.
XX
XX PD 15-APR-2004.
XX
XX PF 02-OCT-2003; 2003WO-CA001588.
XX
XX PR 02-OCT-2002; 2002US-0415859P.
XX 18-APR-2003; 2003US-0463952P.
XX
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
XX active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX useful in treating cancer, e.g., prostate cancer or a central nervous
XX system malignancy.
XX
```

```

PS Claim 5; SEQ ID NO 19; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 6 C; 10 G; 2 T; 0 U; 0 Other;

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 AGGCTACGTGGCGCCCGCTGCC 201
DB 21 AGGCTACGTGGCGCCCGCTGCC 1

RESULT 44
ADM94680/c
ID ADM94680 standard; DNA; 21 BP.
XX
AC ADM94680;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:30.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
DR New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 30; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 8 C; 8 G; 3 T; 0 U; 0 Other;

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 AGGCTACGTGGCGCCCGCTGCC 201
DB 21 AGGCTACGTGGCGCCCGCTGCC 1

RESULT 45
ADM94652/c
ID ADM94652 standard; DNA; 21 BP.
XX
AC ADM94652;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:2.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
DR New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 2; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 GCAGAGTCAGCCAGCATGACC 31
DB 21 GCAGAGTCAGCCAGCATGACC 1

RESULT 46
ADM94676/c
ID ADM94676 standard; DNA; 21 BP.

```

```
XX AC ADM94676;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:26.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX DR WPI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 26; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 2 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 251 GCGCTCAGCCGCAACTCAGC 271
XX Db |||||
XX
XX RESULT 47
XX ADM94684/c
XX ID ADM94684 standard; DNA; 21 BP.
XX AC ADM94684;
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX DR WPI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 26; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 2 A; 6 C; 9 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 251 GCGCTCAGCCGCAACTCAGC 271
XX Db |||||
XX
XX RESULT 47
XX ADM94684/c
XX ID ADM94684 standard; DNA; 21 BP.
XX AC ADM94684;
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX DR WPI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 34; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 3 A; 5 C; 10 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 331 CCACCTTCGCCCCGACGAGCT 351
XX Db |||||
XX
XX RESULT 48
XX ADM94690/c
XX ID ADM94690 standard; DNA; 21 BP.
XX AC ADM94690;
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
```

```

XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 40; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 0 A; 9 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      391 CAAGCAGGAGGAGCGGACGGA 411
DB      21 CAAGCAGGAGGAGCGGACGGA 1
|||||
RESULT 49
ADM94662/c
ID ADM94662 standard; DNA; 21 BP.
XX
XX AC ADM94662;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:12.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
XX heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
XX heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
XX 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 12; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 0 A; 9 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      391 CAAGCAGGAGGAGCGGACGGA 411
DB      21 CAAGCAGGAGGAGCGGACGGA 1
|||||

```

```

CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 7 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      111 TCGACACGAGCGCTTCGGGCTGC 131
DB      21 TCGACACGAGCGCTTCGGGCTGC 1
|||||
RESULT 50
ADM94665/c
ID ADM94665 standard; DNA; 21 BP.
XX
XX AC ADM94665;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:15.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
XX heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
XX 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 15; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 11 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 141 CGGAGGAGTGGTCGAGTGGT 161
Db 21 CGGAGGAGTGGTCGAGTGGT 1

RESULT 51
ADM94698/c
ID ADM94698 standard; DNA; 21 BP.
XX
AC ADM94698;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:48.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 48; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 5 A; 1 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 471 ACCCCACCCCAAGTTTCCTCT 491
Db 21 ACCCCACCCCAAGTTTCCTCT 1

RESULT 52
ADM94718/c
ID ADM94718 standard; DNA; 21 BP.
XX
AC ADM94718;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:78.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 671 TGCGCCGACCTGGCTGTGCCTC 691
Db 21 TGCGCCGACCTGGCTGTGCCTC 1

RESULT 53
ADM94728/c
ID ADM94728 standard; DNA; 21 BP.
XX
AC ADM94728;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:78.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX

```

```

PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 78; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 365 AAGGATGGCGTGGTGGAGATC 385
Db 21 AAGGATGGCGTGGTGGAGATC 1
|||||
RESULT 54
ADM94674/c
ID ADM94674 standard; DNA; 21 BP.
XX
AC ADM94674;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:24.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 78; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 4 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 365 AAGGATGGCGTGGTGGAGATC 385
Db 21 AAGGATGGCGTGGTGGAGATC 1
|||||
RESULT 54
ADM94674/c
ID ADM94674 standard; DNA; 21 BP.
XX
AC ADM94674;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:28.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 28; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 6 C; 12 G; 2 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 231 CCGGCGCCGCTACAGCCGCG 251
Db 21 CCGGCGCCGCTACAGCCGCG 1
|||||
RESULT 55
ADM94678/c
ID ADM94678 standard; DNA; 21 BP.
XX
AC ADM94678;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:28.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 28; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 6 C; 12 G; 2 T; 0 U; 0 Other;

```

CC	exemplification of the present invention.
XX	
SQ	Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
	Query Match 2.7%; Score 21; DB 1; Length 21;
	Best Local Similarity 100.0%; Pred. No. 7.5;
	Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	271 CAGCGGGTCTCGGATCCG 291
DB	21 CAGCGGGTCTCGGATCCG 1
RESULT 56	
ID	ADM94715 standard; DNA; 21 BP.
AC	ADM94715;
XX	
DT	01-JUL-2004 (first entry)
DE	Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:65.
XX	
KW	heat shock protein 27; hsp27; cytostatic; gene therapy;
KW	heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW	antisense oligonucleotide; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PX	WO2004030660-A2.
XX	
DT	01-JUL-2004 (first entry)
DE	Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:65.
XX	
KW	heat shock protein 27; hsp27; cytostatic; gene therapy;
KW	heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW	antisense oligonucleotide; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PX	WO2004030660-A2.
XX	
PD	15-APR-2004.
PF	02-OCT-2003; 2003WO-CA001588.
XX	
KW	heat shock protein 27; hsp27; cytostatic; gene therapy;
KW	heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW	antisense oligonucleotide; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PX	WO2004030660-A2.
XX	
PD	15-APR-2004.
PF	02-OCT-2003; 2003WO-CA001588.
XX	
PR	02-OCT-2002; 2002US-0415859P.
PR	18-APR-2003; 2003US-0463952P.
XX	
PA	(UYBR-) UNIV BRITISH COLUMBIA.
PI	Gleave ME, Rocchi P, Signaevsky M;
DR	WPI; 2004-316331/29.
XX	
PT	New composition comprising a therapeutic agent that reduces the amount of active hsp27 in hsp27 expressing cells exposed to the therapeutic agent, useful in treating cancer, e.g., prostate cancer or a central nervous system malignancy.
PS	Claim 5; SEQ ID NO 65; 38pp; English.
XX	
CC	The present invention describes a composition which comprises a therapeutic agent that reduces the amount of active heat shock protein 27 (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The composition has cytostatic activity, and can be used in gene therapy. The composition is useful in treating cancer, e.g., prostate, bladder, lung, breast, pancreatic, colon, skin (for example melanoma), renal or ovarian cancer or a central nervous system malignancy. The present sequence represents a human hsp27 antisense oligonucleotide which is used in the exemplification of the present invention.
XX	
QY	641 TAAAGCCTTAGCCCGATGCC 661
DB	21 TAAAGCCTTAGCCCGATGCC 1
RESULT 57	
ID	ADM94726 standard; DNA; 21 BP.
AC	ADM94726;
XX	
DT	01-JUL-2004 (first entry)
DE	Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:76.
XX	
KW	heat shock protein 27; hsp27; cytostatic; gene therapy;
KW	heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW	antisense oligonucleotide; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PX	WO2004030660-A2.
XX	
DT	15-APR-2004.
PF	02-OCT-2003; 2003WO-CA001588.
XX	
PR	02-OCT-2002; 2002US-0415859P.
PR	18-APR-2003; 2003US-0463952P.
XX	
PA	(UYBR-) UNIV BRITISH COLUMBIA.
PI	Gleave ME, Rocchi P, Signaevsky M;
DR	WPI; 2004-316331/29.
XX	
PT	New composition comprising a therapeutic agent that reduces the amount of active hsp27 in hsp27 expressing cells exposed to the therapeutic agent, useful in treating cancer, e.g., prostate cancer or a central nervous system malignancy.
PS	Claim 5; SEQ ID NO 76; 38pp; English.
XX	
CC	The present invention describes a composition which comprises a therapeutic agent that reduces the amount of active heat shock protein 27 (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The composition has cytostatic activity, and can be used in gene therapy. The composition is useful in treating cancer, e.g., prostate, bladder, lung, breast, pancreatic, colon, skin (for example melanoma), renal or ovarian cancer or a central nervous system malignancy. The present sequence represents a human hsp27 antisense oligonucleotide which is used in the exemplification of the present invention.
XX	
QY	744 AAAGTTCAAAGCACCATCTG 764
DB	21 AAAGTTCAAAGCACCATCTG 1
RESULT 58	
ID	ADM94677 standard; DNA; 21 BP.
AC	ADM94677;
XX	
DT	01-JUL-2004 (first entry)
DE	Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:27.
XX	
KW	heat shock protein 27; hsp27; cytostatic; gene therapy;
KW	heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW	antisense oligonucleotide; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PX	WO2004030660-A2.
XX	
DT	15-APR-2004.
PF	02-OCT-2003; 2003WO-CA001588.
XX	
PR	02-OCT-2002; 2002US-0415859P.
PR	18-APR-2003; 2003US-0463952P.
XX	
PA	(UYBR-) UNIV BRITISH COLUMBIA.
PI	Gleave ME, Rocchi P, Signaevsky M;
DR	WPI; 2004-316331/29.
XX	
PT	New composition comprising a therapeutic agent that reduces the amount of active hsp27 in hsp27 expressing cells exposed to the therapeutic agent, useful in treating cancer, e.g., prostate cancer or a central nervous system malignancy.
PS	Claim 5; SEQ ID NO 65; 38pp; English.
XX	
CC	The present invention describes a composition which comprises a therapeutic agent that reduces the amount of active heat shock protein 27 (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The composition has cytostatic activity, and can be used in gene therapy. The composition is useful in treating cancer, e.g., prostate, bladder, lung, breast, pancreatic, colon, skin (for example melanoma), renal or ovarian cancer or a central nervous system malignancy. The present sequence represents a human hsp27 antisense oligonucleotide which is used in the exemplification of the present invention.
XX	
QY	641 TAAAGCCTTAGCCCGATGCC 661
DB	21 TAAAGCCTTAGCCCGATGCC 1
RESULT 59	
ID	ADM94677 standard; DNA; 21 BP.
AC	ADM94677;
XX	
DT	01-JUL-2004 (first entry)
DE	Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:27.
XX	
KW	heat shock protein 27; hsp27; cytostatic; gene therapy;
KW	heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW	antisense oligonucleotide; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PX	WO2004030660-A2.
XX	
DT	15-APR-2004.
PF	02-OCT-2003; 2003WO-CA001588.
XX	

```

XX OS Homo sapiens.
XX PI Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 27; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 261 GGCAACTCAGCAGCGGGTCT 281
Db 21 GGCAACTCAGCAGCGGGTCT 1
|||||
RESULT 59
ADM94699/c
ID ADM94699 standard; DNA; 21 BP.
XX AC ADM94699;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:49.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 27; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

```

```

PA (UYBR-) UNIV BRITISH COLUMBIA.
XX Gleave ME, Rocchi P, Signaevsky M;
XX WI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 49; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 7 A; 2 C; 11 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 481 AGTTTCCTCTCTCCCTGTCCCC 501
Db 21 AGTTTCCTCTCTCCCTGTCCCC 1
|||||
RESULT 60
ADM94719/c
ID ADM94719 standard; DNA; 21 BP.
XX AC ADM94719;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:69.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 69; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent,
XX CC useful in treating cancer, e.g., prostate cancer or a central nervous
XX CC system malignancy.
XX SQ Sequence 21 BP; 7 A; 2 C; 11 G; 1 T; 0 U; 0 Other;

```

CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

SQ Sequence 21 BP; 3 A; 5 C; 12 G; 1 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 681 GGCTGTGCTCCCGCCACC 701
 Db 21 GGCTGTGCTCCCGCCACC 1

RESULT 61

ADM94671/c
 ID ADM94671 standard; DNA; 21 BP.

AC ADM94671;

XX 01-JUL-2004 (first entry)

XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:21.

XX heat shock protein 27; hsp27; cytostatic; gene therapy;

KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;

KW antisense oligonucleotide; ss.

XX Homo sapiens.

OS Synthetic.

XX WO2004030660-A2.

XX 15-APR-2004.

XX 02-OCT-2003; 2003WO-CA001588.

XX 02-OCT-2002; 2002US-0415859P.

PR 18-APR-2003; 2003US-0463952P.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave ME, Rocchi P, Signaevsky M;

XX WPI; 2004-316331/29.

XX New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.

PS Claim 5; SEQ ID NO 21; 38pp; English.

XX The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

SQ Sequence 21 BP; 1 A; 5 C; 12 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 201 CCCCCCGCGCATCGAGGCC 221

Db 21 CCCCCCGCGCATCGAGGCC 1

RESULT 62

ADM94679/c
 ID ADM94679 standard; DNA; 21 BP.

XX ADM94679;

XX 01-JUL-2004 (first entry)

XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:29.

XX heat shock protein 27; hsp27; cytostatic; gene therapy;

KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;

KW antisense oligonucleotide; ss.

XX Homo sapiens.

OS Synthetic.

XX WO2004030660-A2.

XX 15-APR-2004.

XX 02-OCT-2003; 2003WO-CA001588.

XX 02-OCT-2002; 2002US-0415859P.

PR 18-APR-2003; 2003US-0463952P.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave ME, Rocchi P, Signaevsky M;

XX WPI; 2004-316331/29.

XX New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.

PS Claim 5; SEQ ID NO 29; 38pp; English.

XX The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

SQ Sequence 21 BP; 3 A; 7 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 7.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 281 TCGGAGATCCGGCACACTGCG 301

Db 21 TCGGAGATCCGGCACACTGCG 1

RESULT 63

ADM94683/c

ID ADM94683 standard; DNA; 21 BP.

XX AC ADM94683;

```
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:33.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX DR WPI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 33; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 321 TGGATGTCACACCACTTCGCC 341
Db 21 TGGATGTCACACCACTTCGCC 1

RESULT 64
ADM94693/C
ID ADM94693 standard; DNA; 21 BP.
XX AC ADM94693;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:43.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX DR WPI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 33; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
```

```
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX DR WPI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 43; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 6 A; 3 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 421 CTACATCTCCCGGTGCTTCAC 441
Db 21 CTACATCTCCCGGTGCTTCAC 1

RESULT 65
ADM94694/C
ID ADM94694 standard; DNA; 21 BP.
XX AC ADM94694;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:44.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX DR WPI; 2004-316331/29.
```

```

XX PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX PS Claim 5; SEQ ID NO 44; 38pp; English.
XX CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX SQ Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 431 CGGTGCTTCACGCGGAATAC 451
Db 21 CGGTGCTTCACGCGGAATAC 1
RESULT 66
ADM94722/c
ID ADM94722 standard; DNA; 21 BP.
XX AC ADM94722;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:72.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX PS Claim 5; SEQ ID NO 72; 38pp; English.
XX CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX SQ Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 431 CGGTGCTTCACGCGGAATAC 451
Db 21 CGGTGCTTCACGCGGAATAC 1

```

```

CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX SQ Sequence 21 BP; 12 A; 2 C; 3 G; 4 T; 0 U; 0 Other;
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 711 TTTTGATACATTTTATCTCTCG 731
Db 21 TTTTGATACATTTTATCTCTCG 1
RESULT 67
ADM94723/c
ID ADM94723 standard; DNA; 21 BP.
XX AC ADM94723;
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:73.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX PS Claim 5; SEQ ID NO 73; 38pp; English.
XX CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX SQ Sequence 21 BP; 13 A; 1 C; 4 G; 3 T; 0 U; 0 Other;
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 721 TTTTATCTCTGTTTTTCTCAA 741

```


PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
DR
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 6; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 7 C; 10 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 51 CGCTCTCGGGGCCCCAGCT 71
Db 21 CGCTCTCGGGGCCCCAGCT 1
XX
RESULT 71
ADM94664/c
ID ADM94664 standard; DNA; 21 BP.
XX
AC ADM94664;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:14.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
XX Gleave ME, Rocchi P, Signaevsky M;
PI
XX WPI; 2004-316331/29.
DR
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.

XX Claim 5; SEQ ID NO 14; 38pp; English.
PS
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 2 A; 10 C; 7 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 131 CCCCGGCTGCGGAGGAGTGG 151
Db 21 CCCCGGCTGCGGAGGAGTGG 1
XX
RESULT 72
ADM94666/c
ID ADM94666 standard; DNA; 21 BP.
XX
AC ADM94666;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:16.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
XX Gleave ME, Rocchi P, Signaevsky M;
PI
XX WPI; 2004-316331/29.
DR
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 16; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX

```

SQ Sequence 21 BP; 4 A; 10 C; 4 G; 3 T; 0 U; 0 Other;
  Query Match      2.7%; Score 21; DB 1; Length 21;
  Best Local Similarity 100.0%; Pred. No. 7.5;
  Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 151 CTCGCAGTGGTTAGCGCGCAG 171
  |||||
Db 21 CTCGCAGTGGTTAGCGCGCAG 1

RESULT 73
ADM94673/c
ID ADM94673 standard; DNA; 21 BP.
XX
AC ADM94673;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:23.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
XX
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
PI WPI; 2004-316331/29.
XX
DR New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 23; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 1 A; 7 C; 12 G; 1 T; 0 U; 0 Other;
  Query Match      2.7%; Score 21; DB 1; Length 21;
  Best Local Similarity 100.0%; Pred. No. 7.5;
  Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 221 CCCGCAGTGGCGCGCGCGCC 241
  |||||
Db 21 CCCGCAGTGGCGCGCGCGCC 1

RESULT 74
ADM94659/c
ID ADM94659 standard; DNA; 21 BP.
XX
AC ADM94659;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:31.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.

```

OS Synthetic.
XX WO2004030660-A2.
XX
XX PD 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
XX
XX PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 31; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 8 C; 8 G; 1 T; 0 U; 0 Other;
PS
PS Claim 5; SEQ ID NO 31; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 8 C; 8 G; 1 T; 0 U; 0 Other;
SQ
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 301 GGACCGCTGGCGCGTGCTCT 321
DB 21 GGACCGCTGGCGCGTGCTCT 1
RESULT 76
ADM94696/c
ID ADM94696 standard; DNA; 21 BP.
XX
XX ADM94696;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:46.
DE
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
XX
XX PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 31; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 8 C; 8 G; 1 T; 0 U; 0 Other;
SQ

PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 46; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;
SQ
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 451 CACGCTGCCCCCGGTGTGGA 471
DB 21 CACGCTGCCCCCGGTGTGGA 1
RESULT 77
ADM94707/c
ID ADM94707 standard; DNA; 21 BP.
XX
XX ADM94707;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:57.
DE
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS
OS Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
XX
XX PR 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 57; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27

CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

XX SQ Sequence 21 BP; 5 A; 2 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 2.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 7.5; Indels 0; Gaps 0;
 Matches 21; Conservative 0; Mismatches 0;

Qy 561 TCACCATCCCGAGTCACCTTCG 581

Db 21 TCACCATCCCGAGTCACCTTCG 1

RESULT 78

ADM94675/c

ID ADM94675 standard; DNA; 21 BP.

XX AC ADM94675;

XX DT 01-JUL-2004 (first entry)

XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:25.

XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;

XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;

XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX OS Synthetic.

XX FN WO2004030660-A2.

XX PD 15-APR-2004.

XX PF 02-OCT-2003; 2003WO-CA001588.

XX PR 02-OCT-2002; 2002US-0415859P.

XX PR 18-APR-2003; 2003US-0463952P.

XX PA (UYBR-) UNIV BRITISH COLUMBIA.

XX PI Gleave ME, Rocchi P, Signaevsky M;

XX DR WPI; 2004-316331/29.

XX PT New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.

XX PS Claim 5; SEQ ID NO 25; 38pp; English.

XX CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

XX SQ Sequence 21 BP; 2 A; 6 C; 10 G; 3 T; 0 U; 0 Other;

Query Match

Best Local Similarity 2.7%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 241 CTACAGCCGCGCGCTCAGCCG 261

Db 21 CTACAGCCGCGCGCTCAGCCG 1

RESULT 79

ADM94695/c

ID ADM94695 standard; DNA; 21 BP.

XX AC ADM94695;

XX DT 01-JUL-2004 (first entry)

XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:45.

XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;

XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;

XX KW antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX OS Synthetic.

XX FN WO2004030660-A2.

XX PD 15-APR-2004.

XX PF 02-OCT-2003; 2003WO-CA001588.

XX PR 02-OCT-2002; 2002US-0415859P.

XX PR 18-APR-2003; 2003US-0463952P.

XX PA (UYBR-) UNIV BRITISH COLUMBIA.

XX PI Gleave ME, Rocchi P, Signaevsky M;

XX DR WPI; 2004-316331/29.

XX PT New composition comprising a therapeutic agent that reduces the amount of
 PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
 PT useful in treating cancer, e.g., prostate cancer or a central nervous
 PT system malignancy.

XX PS Claim 5; SEQ ID NO 45; 38pp; English.

XX CC The present invention describes a composition which comprises a
 CC therapeutic agent that reduces the amount of active heat shock protein 27
 CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
 CC composition has cytostatic activity, and can be used in gene therapy. The
 CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
 CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
 CC cancer or a central nervous system malignancy. The present sequence
 CC represents a human hsp27 antisense oligonucleotide which is used in the
 CC exemplification of the present invention.

XX SQ Sequence 21 BP; 2 A; 5 C; 9 G; 5 T; 0 U; 0 Other;

Query Match

Best Local Similarity 2.7%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 441 CGCGGAATAACAGCTGCCCC 461

Db 21 CGCGGAATAACAGCTGCCCC 1

RESULT 80

ADM94708/c

ID ADM94708 standard; DNA; 21 BP.

XX AC ADM94708;

XX DT 01-JUL-2004 (first entry)

```

XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:58.
XX PF
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD
XX PD 15-APR-2004.
XX PF
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PR
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX XX
XX XX New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 58; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 4 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 571 AGTCACCTTCGAGTCGCGGC 591
XX Db |||||||||||||||||||
XX |||||||||||||||||||
XX RESULT 81
XX ADM94710/c
XX ID ADM94710 standard; DNA; 21 BP.
XX AC ADM94710;
XX XX
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:60.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.

```

```

XX PF 02-OCT-2003; 2003WO-CA001588.
XX PF
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX XX
XX XX New composition comprising a therapeutic agent that reduces the amount of
XX PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX PT useful in treating cancer, e.g., prostate cancer or a central nervous
XX PT system malignancy.
XX PS Claim 5; SEQ ID NO 60; 38pp; English.
XX CC The present invention describes a composition which comprises a
XX CC therapeutic agent that reduces the amount of active heat shock protein 27
XX CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX CC composition has cytostatic activity, and can be used in gene therapy. The
XX CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX CC cancer or a central nervous system malignancy. The present sequence
XX CC represents a human hsp27 antisense oligonucleotide which is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 2 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 2.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 591 CCCAGCTTGGGGGCCCAAG 611
XX Db |||||||||||||||||||
XX |||||||||||||||||||
XX RESULT 82
XX ADM94720/c
XX ID ADM94720 standard; DNA; 21 BP.
XX AC ADM94720;
XX XX
XX DT 01-JUL-2004 (first entry)
XX DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:70.
XX KW heat shock protein 27; hsp27; cytostatic; gene therapy;
XX KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX KW antisense oligonucleotide; ss.
XX OS
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO2004030660-A2.
XX PD 15-APR-2004.
XX DE
XX PF 02-OCT-2003; 2003WO-CA001588.
XX PF
XX PR 02-OCT-2002; 2002US-0415859P.
XX PR 18-APR-2003; 2003US-0463952P.
XX PA (UYBR-) UNIV BRITISH COLUMBIA.
XX PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX XX
XX XX New composition comprising a therapeutic agent that reduces the amount of

```

PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 70; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 6 A; 4 C; 10 G; 1 T; 0 U; 0 Other;
XX
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 691 CCCCCGCCACCTGTGTCT 711
Db 21 CCCCCGCCACCTGTGTCT 1
XX
RESULT 83
ADM94730/c
ID ADM94730 standard; DNA; 21 BP.
XX
AC ADM94730;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:80.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 5; SEQ ID NO 80; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.

CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;
XX
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 264 AACTCAGCAGCGGGTCTCGG 284
Db 21 AACTCAGCAGCGGGTCTCGG 1
XX
RESULT 84
ADM94732/c
ID ADM94732 standard; DNA; 20 BP.
XX
AC ADM94732;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:82.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 6; SEQ ID NO 82; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
XX
Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 26 ATGACCGAGCGCGGTCCC 45
Db 20 ATGACCGAGCGCGGTCCC 1

```

RESULT 85
ADO55958
ID ADO55958 standard; DNA; 20 BP.
AC ADO55958;
XX
DT 26-AUG-2004 (first entry)
DE Probe HSP27 for detecting gene expression in metastatic melanoma cells.
XX
KW ss; probe; detection; metastatic melanoma; GainACT; PAX3.
XX
OS Homo sapiens.
XX
PN WO2004045521-A2.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-US036493.
XX
PR 14-NOV-2002; 2002US-0426216P.
XX
PA (WAYN-) WAYNE CANCER INST JOHN.
XX
PI Hoon DSB, Takeuchi H;
XX
DR WPI; 2004-420519/39.
XX
PT Detecting metastatic melanoma cells in a patient by isolating nucleic
PT acid from a biological sample obtained from the patient, amplifying
PT nucleic acid targets, if present, from a panel of marker genes.
XX
PS Example 4; SEQ ID NO 13; 43pp; English.
XX
CC The invention relates to a method of detecting metastatic melanoma cells
CC in a patient by: (a) isolating nucleic acid from a biological sample
CC obtained from the patient; (b) amplifying nucleic acid targets, if
CC present, from a panel of marker genes, where the panel comprises GainACT
CC and/or PAX3; and (c) detecting the presence or absence of the nucleic
CC acid targets. The method is useful in detecting metastatic melanoma
CC cells. This sequence corresponds to a probe used in the method of the
CC invention.
XX
SQ Sequence 20 BP; 6 A; 4 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 2.6%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 399 AGGAGCGGCGGAGCAGCAT 418
Db 1 AGGAGCGGCGGAGCAGCAT 20
|||||

RESULT 86
ADM94740
ID ADM94740 standard; DNA; 19 BP.
XX
AC ADM94740;
XX
DT 01-JUL-2004 (first entry)
DE Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:90.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.

RESULT 87
ADM94737
ID ADM94737 standard; DNA; 19 BP.
XX
AC ADM94737;
XX
DT 01-JUL-2004 (first entry)
DE Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:87.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
DR WPI; 2004-316331/29.

Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 14;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 26 ATGACCGGCGCGCGTCC 44
Db 1 AUGACCGGCGCGCGGUCC 19
|||||

The present invention describes a composition which comprises a
therapeutic agent that reduces the amount of active heat shock protein 27
(hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
composition has cytostatic activity, and can be used in gene therapy. The
composition is useful in treating cancer, e.g., prostate, bladder, lung,
breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
cancer or a central nervous system malignancy. The present sequence
represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
which is used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 3 A; 8 C; 6 G; 0 T; 2 U; 0 Other;

New composition comprising a therapeutic agent that reduces the amount of
active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
useful in treating cancer, e.g., prostate cancer or a central nervous
system malignancy.
XX
Claim 10; SEQ ID NO 90; 38pp; English.
XX
The present invention describes a composition which comprises a
therapeutic agent that reduces the amount of active heat shock protein 27
(hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
composition has cytostatic activity, and can be used in gene therapy. The
composition is useful in treating cancer, e.g., prostate, bladder, lung,
breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
cancer or a central nervous system malignancy. The present sequence
represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
which is used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 3 A; 8 C; 6 G; 0 T; 2 U; 0 Other;

```

XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX Claim 10; SEQ ID NO 87; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC which is used in the exemplification of the present invention.
XX
XX Sequence 19 BP; 5 A; 8 C; 3 G; 0 T; 3 U; 0 Other;
SQ
Query Match 2.5%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 14;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 556 CGAGATCACCATCCAGTC 574
Db 1 CGAGAUCAACCAUCCAGUC 19
|||||:|||||:|||||:

RESULT 88
ABA00784
ID ABA00784 standard; DNA; 21 BP.
AC ABA00784;
XX
XX
DT 01-APR-2003 (first entry)
XX
XX HSP27 forward primer.
XX
XX Primer; PCR; amplify; heat shock protein; HSP; HSP27; inducer;
KW digestive system; nephropathy; inflammation; arthritis;
KW chronic rheumatism; arthritis deformans; asthma; allergy;
KW arteriosclerosis; diabetic complication; diabetic neuropathy;
KW chronic obstructive pulmonary disease; systemic lupus erythematosus;
KW autoimmune haemolytic anaemia; psoriasis; neurodegeneration;
KW Parkinson's disease; AIDS related dementia; CNS; cerebral haemorrhage;
KW cerebral ischaemia; toxemia; cachexia; cancer; Addison's disease;
KW viral infection; pain; chronic inflammation; toothache; angina; ss.
XX
XX Synthetic.
XX
XX WO200278705-A1.
XX
XX 10-OCT-2002.
XX
XX 27-MAR-2002; 2002WO-JP002946.
XX
XX 28-MAR-2001; 2001JP-00092704.
XX
XX (TAKE) TAKEDA CHEM IND LTD.
XX
XX Terashita Z, Naruo K, Uchikawa O, Nakanishi A;
XX WPI; 2003-111786/10.
XX
XX Heat shock protein (HSP) inducer comprises a fused bicyclic or tricyclic
PT compound.
XX
XX Example 4; Page 46; 66pp; Japanese.
XX
XX The sequences given in ABA00784-86 are primers and a probe which were
CC used in the amplification and isolation of the heat shock protein (HSP)
CC 27 coding sequence. These sequences may be used to monitor the

CC effectiveness of the heat shock protein inducer of the invention. The HSP
CC inducer of the invention may be used for treating and preventing
CC digestive system disorders, nephropathies, inflammatory diseases,
CC arthritis, chronic rheumatism and arthritis deformans. The inducer may
CC also be useful for treating and preventing asthma, allergic diseases,
CC arteriosclerosis, diabetic complications (e.g. diabetic neuropathy),
CC chronic obstructive pulmonary disease, systemic lupus erythematosus,
CC autoimmune haemolytic anaemia, psoriasis, neuro- degenerative disorders
CC (e.g. Parkinson's disease or AIDS related dementia), CNS disorders (e.g.
CC cerebral haemorrhage or cerebral ischaemia), toxemia, cachexia, cancer,
CC Addison's disease, viral infections or pain (e.g. due to chronic
CC inflammatory diseases, toothache or angina)
XX
SQ Sequence 21 BP; 7 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 2.4%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 22;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 359 AAGACCAAGGATGCGTGGT 378
Db 2 AAGACCAAGGAGCGTGGT 21
|||||:|||||:|||||:

RESULT 89
ADM94727/c
ID ADM94727 standard; DNA; 18 BP.
AC ADM94727;
XX
XX
DT 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:77.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
XX
XX 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 77; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX

```
SQ Sequence 18 BP; 2 A; 6 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 2.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 226 AGTGGCCGCGCCGCGCTA 243
Db 18 AGTGGCCGCGCCGCGCTA 1

RESULT 90
ADM94739
ID ADM94739 standard; DNA; 21 BP.
XX
AC ADM94739;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:89.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
DR
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 10; SEQ ID NO 89; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC which is used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 0 A; 9 C; 7 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 29;
Matches 16; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 576 CCTTCAGTCTCGGGGCCGAGC 596
Db 1 CCUUCGUGUCGGGGCCGCGC 21

RESULT 91
ABA00785/c
SQ Sequence 18 BP; 2 A; 6 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 2.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 226 AGTGGCCGCGCCGCGCTA 243
Db 18 AGTGGCCGCGCCGCGCTA 1

RESULT 90
ADM94739
ID ADM94739 standard; DNA; 21 BP.
XX
AC ADM94739;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:89.
XX
KW heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW short interfering RNA; siRNA; RNA interference; RNAi; ds.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX WPI; 2004-316331/29.
XX
DR
PT New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 10; SEQ ID NO 89; 38pp; English.
XX
CC The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC which is used in the exemplification of the present invention.
XX
SQ Sequence 21 BP; 0 A; 9 C; 7 G; 0 T; 5 U; 0 Other;
Query Match 2.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 29;
Matches 16; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 576 CCTTCAGTCTCGGGGCCGAGC 596
Db 1 CCUUCGUGUCGGGGCCGCGC 21

RESULT 91
ABA00785/c
SQ Sequence 18 BP; 2 A; 6 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 2.3%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 413 GAGCATGGCTACATCTCCCGG 433
Db 21 GAACATGGCTACATCTCTCGG 1

RESULT 92
AAA66267
ID AAA66267 standard; DNA; 20 BP.
XX
AC AAA66267;
XX
DT 09-OCT-2000 (first entry)
```

XX DE Dog genomic marker oligonucleotide sequence SEQ ID NO:129.
 XX KW Dog; genome; genomic marker; radiation hybrid map; identification;
 KW KW Chromosome location; gene marker; polymorphic microsatellite marker;
 KW KW phenotype; behaviour; pedigree; sb.
 XX OS Canis familiaris.
 XX PN WO200029615-A2.
 XX XX 25-MAY-2000.
 XX PD 15-NOV-1999; 99WO-IB001907.
 XX PF 13-NOV-1998; 98US-0108193P.
 XX PR (CNRS) CNRS CENT NAT RECH SCI.
 XX PA Galibert F, Andre C;
 XX PI WPI; 2000-387821/33.
 XX DR New radiation hybrid map of the dog, Canine familiaris, genome, useful
 XX PT for e.g. identifying genes implicated in phenotypic and behavioral traits
 XX PT or in genetic diseases and for studying dog pedigrees.
 XX PS Claim 1; Page 58; 87pp; English.
 XX CC The present invention describes a radiation hybrid map of the dog (Canine
 CC familiaris) genome comprising the genome location of a marker selected
 CC from AAA66139 to AAA66942. The radiation hybrid map is useful for
 CC identifying and localising dog genes, since it covers approximately 80 %
 CC of the dog genome and provides a dense map integrating different types
 CC (i.e. Type I and Type II) of markers. The map and the dog genome markers
 CC (or complementary sequences) are especially useful to identify genes
 CC responsible for phenotypic and behavioural traits in dogs, to identify
 CC morbid genes, to analyse diseases and identify implicated genes in such
 CC diseases and their alleles, and to study dog pedigrees. They may also be
 CC useful for isolating corresponding human gene sequences e.g. genes
 CC involved in genetic diseases
 XX SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 2.3%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 31;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 495 TGTCCCTGAGGGCACT 513
 Db 1 TGTCCCTGAGGGCACTCT 19
 RESULT 93
 ABT34675
 ID ABT34675 standard; DNA; 17 BP.
 XX AC ABT34675;
 XX DT 12-JUN-2003 (first entry)
 XX DE Tumour suppression related human fukutin oligo SEQ ID No 312.
 XX KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX OS Homo sapiens.
 XX PN WO2003025175-A2.
 XX PD 27-MAR-2003.

XX 17-SEP-2002; 2002WO-IB004208.
 XX PR 17-SEP-2001; 2001FR-00011978.
 XX PA (MOLE-) MOLECULAR ENGINES LAB.
 XX PT Telerman A, Amson R, Tuijnder M;
 XX PI WPI; 2003-313353/30.
 XX DR New isolated nucleic acid, useful for treating viral diseases associated
 XX PT with tumors and cell degeneration, also related polypeptides, antibodies
 XX PT and transfected cells.
 XX PS Disclosure; Page 70; 720pp; French.
 XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15 consecutive
 CC nucleotides from the 17 mer sequence, a sequence with, after optimal
 CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
 CC hybridizes to them under highly stringent conditions, or the complement
 CC of any of them, or the corresponding RNA. The novel isolated nucleic
 CC acids of the invention are useful as probes and primers for detecting,
 CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
 CC component of a gene chip, in vitro as (anti)sense reagents, and for
 CC production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the nucleic acids, cells containing the
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention
 XX SQ Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 2.2%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 26;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 559 GATCACCATCCAGTCA 575
 Db 1 GATCACCATCCAGTCA 17
 RESULT 94
 ADB45935
 ID ADB45935 standard; DNA; 17 BP.
 XX AC ADB45935;
 XX DT 18-DEC-2003 (first entry)
 XX DE Tumour suppression/reversion associated nucleotide #6258.
 XX KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 XX OS Homo sapiens.
 XX PN WO2003040369-A2.
 XX PD 15-MAY-2003.
 XX PF 17-SEP-2002; 2002WO-IB004219.

```

XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI
XX XX Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-441574/41.
XX XX
XX PT New nucleic acid encoding human prostate membrane-specific antigen,
XX PT useful e.g. for treatment of tumors and viral infection, also related
XX PT polypeptide and antibodies.
XX PS Disclosure; Page 763; 771pp; French.
XX XX
XX CC The invention relates to the isolation of 6327 nucleotide sequences,
XX CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX CC sequence having at least 80% identity, after optimal alignment, with the
XX CC nucleotides, a sequence that hybridizes under stringent conditions with
XX CC the nucleotides, or the complement, or corresponding RNA, of the
XX CC nucleotides. The nucleotides are used as probes or primers for detecting,
XX CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX CC sense and antisense sequences, of nucleotides involved in tumour
XX CC suppression or reversion, apoptosis and or viral resistance, to produce
XX CC recombinant polypeptides, and to prepare transgenic animals, as
XX CC experimental models. The nucleotides (also vectors containing them and
XX CC cells containing the vectors), the encoded polypeptides and antibodies
XX CC (Ab) against the polypeptide are useful for prevention and/or treatment
XX CC of viral infections or diseases characterized by development of tumours
XX CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX CC Analysis of the expression of the nucleotides can be used for diagnosis
XX CC and/or prognosis of these diseases. The nucleotides and polypeptides can
XX CC also be used to screen for their specific interactive molecules,
XX CC potentially useful for treating diseases associated with abnormal
XX CC expression of the nucleotides.
XX SQ Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 559 GATCACCATCCCGATCA 575
Db 1 GATCACCATCCCGATCA 17

RESULT 95
ADE30781
ID ADE30781 standard; DNA; 17 BP.
XX AC ADE30781;
XX XX
XX DT 29-JAN-2004 (first entry)
XX DE Cholesterol homeostasis/adipogenesis related DNA seq id 168.
XX XX
XX KW expression vector; anorectic; antiarteriosclerotic; cardiant;
XX KW antidiabetic; elevated cholesterol; elevated lipid; adipogenesis;
XX KW obesity; atherosclerosis; diabetes mellitus;
XX KW coronary artery heart disease; cholesterol homeostasis; ss;
XX KW differential expression.
XX OS Homo sapiens.
XX XX
XX PN US2003180764-A1.
XX XX
XX PD 25-SEP-2003.
XX XX
XX PF 08-JAN-2003; 2003US-00339793.
XX XX
XX PR 09-JAN-2002; 2002US-0347286P.
XX XX

(LYNX-) LYNX THERAPEUTICS INC.
XX XX Shang J, Bowen B;
XX DR WPI; 2003-830986/77.
XX XX
XX PT Polynucleotides differentially regulated in response to cholesterol and
XX PT adipogenesis are useful to detect and treat associated conditions such as
XX PT obesity, atherosclerosis, diabetes mellitus and coronary artery heart
XX PT disease.
XX XX
XX PS Claim 8; SEQ ID NO 168; 59pp; English.
XX XX
XX CC The invention describes a composition comprising at least one expression
XX CC vector comprising a polynucleotide of the invention. The composition has
XX CC anorectic, antiarteriosclerotic, cardiant and antidiabetic properties.
XX CC The invention is used to detect and treat conditions associated with
XX CC elevated cholesterol and lipid or during adipogenesis, particularly
XX CC obesity, atherosclerosis, diabetes mellitus or coronary artery heart
XX CC disease. This sequence represents a polynucleotide differentially
XX CC expressed during cholesterol homeostasis and adipogenesis.
XX SQ Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 26;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 559 GATCACCATCCCGATCA 575
Db 1 GATCACCATCCCGATCA 17

RESULT 96
ADI52044
ID ADI52044 standard; DNA; 17 BP.
XX AC ADI52044;
XX XX
XX DT 15-APR-2004 (first entry)
XX DE Human tumour suppression/reversion-related DNA sequence SeqID4547.
XX XX
XX KW tumour suppression; tumour reversion; apoptosis; virus resistance;
XX KW cytosatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
XX KW primer; PCR; gene chip; antisense; viral disease; tumour;
XX KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX OS Homo sapiens.
XX XX
XX PN WO2003025177-A2.
XX XX
XX PD 27-MAR-2003.
XX XX
XX PF 17-SEP-2002; 2002WO-IB004523.
XX XX
XX PR 17-SEP-2001; 2001FR-00011980.
XX XX
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-313354/30.
XX XX
XX PT New isolated nucleic acid, useful for treating viral diseases associated
XX PT with tumors and cell degeneration, also related polypeptides, antibodies
XX PT and transfected cells.
XX PS Disclosure; SEQ ID NO 4547; 30pp; French.
XX XX
XX CC This invention relates to novel isolated nucleic acid sequences involved
XX CC in the phenomena of tumour suppression, tumour reversion, apoptosis
XX CC and/or resistance to viruses. The invention may be useful for the

```

development of compounds with a cytostatic, virucide, neuroprotective, nontropic or neuroleptic activity. The DNA sequences may be useful as probes and primers for detecting, identifying, quantifying and/or amplifying nucleic acid, for example as one component of a gene chip, in viro as antisense reagents and for production of recombinant polypeptides. The invention may therefore be useful for preparation of pharmaceuticals for prevention and/or treatment of viral diseases that are characterised by development of tumours or cell degeneration, specifically cancer but also Alzheimer's disease and schizophrenia. The present sequence is that of a nucleic acid sequence of the invention. Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/publishedpct_sequences

Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 26;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 559 GATCACCATCCCAAGTCA 575
 Db 1 GATCACCATCCCAAGTCA 17

RESULT 97
 ACC51537
 ID ACC51537 standard; DNA; 17 BP.

XX AC51537;
 XX 27-JUN-2003 (first entry)
 XX Human tumour suppressor sequence #304.

ss; tumour suppressor; antitumour; cytostatic; tumour suppression;
 tumour regression; apoptosis; virus resistance; diagnosis;
 cellular degeneration.

Homo sapiens.
 FR2826373-A1.
 27-DEC-2002.

20-JUN-2001; 2001FR-00008139.

20-JUN-2001; 2001FR-00008139.

(MOLE-) MOLECULAR ENGINES LAB SA.

Tuijnder M, Telerman A, Amson R;

WPI; 2003-250498/25.

New nucleic acid sequences associated with tumor suppression, regression, apoptosis or virus resistance are useful to diagnose and treat viral disease, development of tumor cells and cell degeneration.

Claim 1; Page 110; 798pp; French.

This sequence represents an isolated nucleic acid sequence associated with tumour suppression or regression, apoptosis or virus resistance. The invention relates to these sequences or sequences having at least 80% identity to them, and polypeptides encoded by the sequences or polypeptides having 80% identity to the polypeptide sequences. The invention is used to diagnose or treat viral disease or disease characterized by development of tumour cells or cellular degeneration

Sequence 17 BP; 5 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 2.2%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 26;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 559 GATCACCATCCCAAGTCA 575
 Db 1 GATCACCATCCCAAGTCA 17

RESULT 98
 ADR30706/C
 ID ADR30706 standard; DNA; 18 BP.

XX ADR30706;
 XX 18-NOV-2004 (first entry)

Skunk cabbage S. foetidus alternative oxidase gene primer, RACE-R2-4.

skunk cabbage; Symplocarpus foetidus alternative oxidase; Sfaox;
 skunk cabbage origin cyanogen resistant respiratory enzyme; Sfpre-AOX;
 mitochondria transfer signal peptide; Sfmt1; low temperature; heat;
 plant; homeothermism; environmental purification; genetic engineering;
 crop breeding; diabetes; obesity; primer; ss.

Unidentified.

JP2004242643-A.

02-SEP-2004.

17-FEB-2003; 2003JP-00038874.

17-FEB-2003; 2003JP-00038874.

(IWAT-) UNIV IWATE.

WPI; 2004-629613/61.

Novel skunk cabbage Symplocarpus foetidus alternative oxidase gene encoding skunk cabbage origin cyanogen resistant respiratory enzyme Sfpre-AOX, useful in development of crops capable of growing at low temperature.

Example 1; SEQ ID NO 7; 26pp; Japanese.

The invention relates to a novel skunk cabbage Symplocarpus foetidus alternative oxidase (Sfaox) gene encoding a skunk cabbage origin cyanogen resistant respiratory enzyme, Sfpre-AOX, having a fully defined sequence of 349 amino acids as given in the specification. The invention further comprises: a polynucleotide purified from the genomic DNA, mRNA and cDNA or complementary sequence of the Sfaox gene; an oligonucleotide probe hybridising under stringent conditions with the purified polynucleotide from above; an oligonucleotide primer set carrying out PCR amplification of the purified polynucleotide; a recombinant vector containing the purified polynucleotide; transforming a somatic cell using the vector; an expression product of the Sfaox gene, comprising a skunk cabbage origin cyanogen resistant respiratory enzyme Sfpre-AOX having the 349 amino acid protein; a mitochondria transfer signal peptide Sfmt1, which is a portion of enzyme Sfpre-AOX; a protein Sfaox having a fully defined sequence of 328 amino acids as given in the specification, and capable of being transferred to a mitochondrial inner membrane and functioning as a cyanogen resistant respiratory enzyme, where the protein is a portion of enzyme Sfpre-AOX; and a polynucleotide encoding the Sfaox protein. The Sfaox gene is useful in the development of crops capable of growing at low temperature, as the cyanogen resistant respiratory enzyme encoded by the Sfaox gene is useful for generating heat in a plant, and for maintaining homeothermism. The Sfaox gene is useful in developing microorganisms involved in environmental purification. The expression product of the Sfaox gene is useful in genetic engineering for crop breeding and in the medicinal field for the development of drugs related to diabetes or obesity. This polynucleotide sequence represents a primer of the skunk cabbage Symplocarpus foetidus alternative oxidase (Sfaox) gene of the invention.

```
XX SQ Sequence 18 BP; 4 A; 3 C; 8 G; 3 T; 0 U; 0 Other;
Query Match      2.1%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 37;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 326 GTCACCACTTCGCCCG 343
Db 18 GTCACCACTTCGCCCTCG 1

RESULT 99
ADI00879
ID ADI00879 standard; DNA; 19 BP.
XX
AC ADI00879;
XX
DT 22-APR-2004 (first entry)
XX
DE RT-PCR 32P end-labelled Pell primer used to amplify human MUC5B RNA.
XX
KW MUC5B-b1; MUC5B-b2; mucin; MUC5B promoter; ss; PCR; primer; human;
KW RT-PCR; Pell.
XX
OS Homo sapiens.
XX
PN US2003096219-A1.
XX
PD 22-MAY-2003.
XX
PF 21-NOV-2001; 2001US-00990613.
XX
PR 21-NOV-2001; 2001US-00990613.
XX
PA (WURR/) WU R.
PA (CHEN/) CHEN Y.
XX
PI Wu R, Chen Y;
XX
WPI; 2004-088749/09.
XX
Novel MUC5B gene useful for identifying a compound capable of modulating
PT MUC5B gene promoter activity.
XX
PS Example 5; SEQ ID NO 7; 52pp; English.
XX
The invention relates to a novel isolated nucleic acid molecule
CC comprising a nucleotide sequence chosen from a fully defined sequence of
CC MUC5B-b1 and MUC5B-b2. The method of the invention may be useful for
CC identifying a compound capable of modulating mucin MUC5B gene promoter
CC activity. The current sequence is that of the RT-PCR 32P end-labelled
CC Pell primer of the invention which was used to amplify human MUC5B RNA.
XX
SQ Sequence 19 BP; 4 A; 7 C; 7 G; 1 T; 0 U; 0 Other;
Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 53;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 403 GCGGACGACGAGCATGCG 421
Db 1 GCGGACGACGAGCATGCG 19

RESULT 100
ADM94733
ID ADM94733 standard; DNA; 19 BP.
XX
AC ADM94733;
XX
DT 01-JUL-2004 (first entry)
XX
```

```
DE Human heat shock protein 27 siRNA oligonucleotide SEQ ID NO:83.
XX
KW heat shock protein 27; hsp27; cytosstatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX short interfering RNA; siRNA; RNA interference; RNAi; ds.
OS Homo sapiens.
XX
XX Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
PF 02-OCT-2003; 2003WO-CA001588.
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave ME, Rocchi P, Signaevsky M;
XX
WPI; 2004-316331/29.
XX
New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
PS Claim 10; SEQ ID NO 83; 38pp; English.
XX
The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytosstatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 short interfering RNA (siRNA) oligonucleotide
CC which is used in the exemplification of the present invention.
XX
SQ Sequence 19 BP; 0 A; 6 C; 8 G; 0 T; 5 U; 0 Other;
Query Match      2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 53;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 266 CTCAGCAGCGGGGTCGCG 284
Db 1 CUCUGCUGCGGGGUCUGCG 19

RESULT 101
ADM94657
ID ADM94657 standard; DNA; 21 BP.
XX
AC ADM94657;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:7.
XX
KW heat shock protein 27; hsp27; cytosstatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX Synthetic.
XX
PN WO2004030660-A2.
XX
PD 15-APR-2004.
XX
```

```

PF 02-OCT-2003; 2003WO-CA001588.
XX
XX
PR 02-OCT-2002; 2002US-0415859P.
PR 18-APR-2003; 2003US-0463952P.
XX
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
XX
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 7; 38pp; English.
XX
XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
XX
XX Sequence 21 BP; 3 A; 7 C; 9 G; 2 T; 0 U; 0 Other;
SQ
Query Match 2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 65;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 60 GGGGCCCCAGCTGGGACCC 78
Db 3 GGGGTCCAGCTGGGGCCC 21
RESULT 102
ABN10675
ID ABN10675 standard; DNA; 17 BP.
XX
XX
XX ABN10675;
XX
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10667.
XX
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX
XX 06-DEC-2001.
XX
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
XX
XX 05-FEB-2001; 2001US-0266860P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
PT or as specific biomolecule capture probes for surface-enhanced laser
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX
XX Disclosure; SEQ ID NO 10667; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
CC nucleic acids can be used as probes to detect, characterise and quantify
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
CC provide initial substrates for the recombinant engineering of hGDMPLP-1
CC protein variants having desired phenotypic improvements, and for
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
CC -1 proteins, as standards in assays used to determine the concentration
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
CC capture probes for surface-enhanced laser desorption/ionisation, as
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
CC production, and in vaccines or for replacement therapy. The
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
CC disorder associated with the expression of hGDMPLP-1, in particular heart
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
CC The present sequence represents an oligomer used in the screening of the
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX
XX Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 U; 0 Other;
SQ
Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 12 CAGAGTCAGCCAGCATG 28
Db 1 CAGAGCCAGCCAGCATG 17
RESULT 103
ADB45924
ID ADB45924 standard; DNA; 17 BP.
XX
XX ADB45924;
XX
XX
XX 18-DEC-2003 (first entry)
XX
XX Tumour suppression/reversion associated nucleotide #6247.
XX
XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
XX Homo sapiens.
XX
XX WO2003040369-A2.
XX
XX
XX 15-MAY-2003.
XX
XX 17-SEP-2002; 2002WO-IB004219.
XX
XX

```

```

PR 17-SEP-2001; 2001FR-00011981.
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX
PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-441574/41.
XX
XX New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
XX Disclosure; Page 762; 771pp; French.
XX
XX The invention relates to the isolation of 6327 nucleotide sequences,
XX fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX sequence having at least 80% identity, after optimal alignment, with the
XX nucleotides, a sequence that hybridizes under stringent conditions with
XX the nucleotides, or the complement, or corresponding RNA, of the
XX nucleotides. The nucleotides are used as probes or primers for detecting,
XX identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX sense and antisense sequences of nucleotides involved in tumour
XX suppression or reversion, apoptosis and or viral resistance, to produce
XX recombinant polypeptides, and to prepare transgenic animals, as
XX experimental models. The nucleotides (also vectors containing them and
XX cells containing the vectors), the encoded polypeptides and antibodies
XX (Ab) against the polypeptide are useful for prevention and/or treatment
XX of viral infections or diseases characterized by development of tumours
XX or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX Analysis of the expression of the nucleotides can be used for diagnosis
XX and/or prognosis of these diseases. The nucleotides and polypeptides can
XX also be used to screen for their specific interactive molecules,
XX potentially useful for treating diseases associated with abnormal
XX expression of the nucleotides.
XX
XX Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;
SQ

```

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 559 GATCACCATCCCGTCA 575
Db 1 GATCACCATCCCGCCA 17

```

RESULT 104
AD148414
ID AD148414 standard; DNA; 17 BP.
XX
AC AD148414;
XX
XX 15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID917.
DE
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
XX Homo sapiens.
OS
XX
XX WO2003025177-A2.
PN
XX
XX 27-MAR-2003.
PD
XX
XX 17-SEP-2002; 2002WO-IB004523.
PF
XX
XX 17-SEP-2001; 2001FR-00011980.
PR
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
PA
XX

```

PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313354/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
PT with tumors and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
XX Disclosure; SEQ ID NO 917; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX nontropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
XX Sequence 17 BP; 5 A; 8 C; 2 G; 2 T; 0 U; 0 Other;
SQ

```

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 559 GATCACCATCCCGTCA 575
Db 1 GATCACCATCCCGCCA 17

```

RESULT 105
ADG71955/c
ID ADG71955 standard; DNA; 17 BP.
XX
XX ADG71955;
AC
XX
XX 11-MAR-2004 (first entry)
DT
XX
XX Human NOVX related primer #3.
DE
XX
XX human; NOVX-associated disorder; NOVX; cancer; infectious disease;
KW anorexia; Alzheimer's disease; Parkinson's disease; immune disorder;
KW haematopoietic disorder; dyslipidaemia; diabetes; obesity;
KW metabolic syndrome X; tissue typing; vaccine; ss; primer.
XX
XX Homo sapiens.
OS
XX
XX US2003232347-A1.
PN
XX
XX 18-DEC-2003.
PD
XX
XX 01-AUG-2002; 2002US-00211689.
PF
XX
XX 08-AUG-2001; 2001US-0310795P.
PR 08-AUG-2001; 2001US-0310802P.
PR 09-AUG-2001; 2001US-0311292P.
PR 10-AUG-2001; 2001US-0311571P.
PR 10-AUG-2001; 2001US-0311594P.
PR 10-AUG-2001; 2001US-0311751P.
PR 13-AUG-2001; 2001US-0311979P.
PR 16-AUG-2001; 2001US-0312892P.
PR 17-AUG-2001; 2001US-0313201P.
PR 21-AUG-2001; 2001US-0314031P.
PR 29-AUG-2001; 2001US-0315853P.
PR 17-SEP-2001; 2001US-0322716P.

```

PR 21-SEP-2001; 2001US-0323944P.
PR 21-FEB-2002; 2002US-0359294P.
PR 28-FEB-2002; 2002US-0360890P.
PR 28-FEB-2002; 2002US-0361159P.
PR 16-APR-2002; 2002US-0372998P.
PR 16-APR-2002; 2002US-0373050P.
PR 15-MAY-2002; 2002US-0380970P.
PR 15-MAY-2002; 2002US-0380971P.
PR 16-MAY-2002; 2002US-0381030P.
XX
PA (ANDE/) ANDERSON D W.
PA (ALSO/) ALSOBROOK J P.
PA (BOLD/) BOLDOG F L.
PA (BURG/) BURGESS C E.
PA (CASM/) CASMAN S J.
PA (EDIN/) EDINGER S R.
PA (GANG/) GANGOLLI E A.
PA (GORM/) GORMAN L.
PA (GUOX/) GUO X S.
PA (KHRA/) KHRAMTSOV N V.
PA (LEPL/) LEPLEY D M.
PA (MACD/) MACDOUGALL J R.
PA (PENA/) PENA C E A.
PA (PEYM/) PEYMAN J A.
PA (PATT/) PATTURAJAN M.
PA (RIEG/) RIEGER D K.
PA (SHIM/) SHIMKETS R A.
PA (SMIT/) SMITHSON G.
PA (SPYT/) SPYTEK K A.
PA (VERN/) VERNET C A M.
PA (VOSS/) VOSS E Z.
PA (ZHON/) ZHONG M.
XX
PI Anderson DW, Alsbrook JP, Burgees CE, Casman SJ;
PI Edinger SR, Gangolli EA, Gorman L, Guo XS, Khrantsov NV, Lepley DM;
PI MacDougall JR, Pena CE, Peyman JA, Patturajan M, Rieger DK;
PI Shinkets RA, Smithson G, Spytek KA, Vernet CAM, Voss EZ, Zhong M;
XX
DR WPI; 2004-061271/06.
XX
XX New NOVX polypeptides and nucleic acids, useful for diagnosing,
PT preventing or treating NOVX-associated disorders, e.g. cancer, diabetes
PT or immune diseases, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
XX Example; SEQ ID NO 82; 115pp; English.
XX
XX The invention relates to a new isolated polypeptide. The polypeptide is
CC useful in the manufacture of a medicament for treating a syndrome
CC associated with a human disease selected from a pathology associated with
CC the polypeptide. These are used in diagnosing, treating or preventing
CC NOVX-associated disorders such as cancer, infectious diseases, anorexia,
CC Alzheimer's disease, Parkinson's disease, immune disorders,
CC haematopoietic disorders, dyslipidaemias, diabetes, obesity or metabolic
CC syndrome X. The nucleic acids are further used as hybridisation probes,
CC in chromosome mapping, tissue typing, preventive medicine, and
CC pharmacogenomics. The polypeptides are also useful as vaccines. The
CC present sequence is used in the exemplification of the invention.
XX
XX Sequence 17 BP; 0 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
SQ
Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 399 AGGAGCGGACGACGAG 415
Db 17 AGGAGCGGACGACGAG 1
RESULT 106
ADJ87293/c
ID ADJ87293 standard; DNA; 17 BP.

```

```

XX ADJ87293;
XX
XX 06-MAY-2004 (first entry)
XX
XX Human G protein-coupled receptor NOV4 forward PCR primer SEQ ID NO:82.
XX
XX human; NOVX; G protein-coupled receptor; GPCR; antiarteriosclerotic;
XX hypotensive; dermatological; anorectic; cytostatic; antidiabetic;
XX haemostatic; immunosuppressive; anti-HIV; antiasthmatic;
XX antiinflammatory; neuroprotective; antimicrobial; anabolic;
XX eating disorder; immunomodulator; nootropic; antiparkinsonian;
XX antilipemic; gene therapy; vaccine; cardiomyopathy; atherosclerosis;
XX hypertension; scleroderma; obesity; cancer; diabetes; haemophilia;
XX graft-versus-host disease; AIDS; asthma; Crohn's disease;
XX multiple sclerosis; infection; anorexia; cancer-associated cachexia;
XX neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
XX haematopoietic disorder; dyslipidaemia; wasting disorder;
XX chromosome mapping; tissue typing; preventive medicine; pharmacogenomic;
XX PCR; primer; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX W02004015060-A2.
XX
XX 19-FEB-2004.
XX
XX 02-AUG-2002; 2002WO-US024492.
XX
XX 08-AUG-2001; 2001US-0310795P.
XX 08-AUG-2001; 2001US-0310802P.
XX 09-AUG-2001; 2001US-0311292P.
XX 10-AUG-2001; 2001US-0311571P.
XX 10-AUG-2001; 2001US-0311594P.
XX 10-AUG-2001; 2001US-0311751P.
XX 13-AUG-2001; 2001US-0311979P.
XX 16-AUG-2001; 2001US-0312892P.
XX 17-AUG-2001; 2001US-0313201P.
XX 21-AUG-2001; 2001US-0314031P.
XX 29-AUG-2001; 2001US-0315853P.
XX 17-SEP-2001; 2001US-0322716P.
XX 21-SEP-2001; 2001US-0323944P.
XX 21-FEB-2002; 2002US-0359294P.
XX 28-FEB-2002; 2002US-0360890P.
XX 16-APR-2002; 2002US-0372998P.
XX 16-APR-2002; 2002US-0373050P.
XX 15-MAY-2002; 2002US-0380970P.
XX 15-MAY-2002; 2002US-0380971P.
XX 16-MAY-2002; 2002US-0381030P.
XX 01-AUG-2002; 2002US-00211689.
XX (CURA-) CURAGEN CORP.
XX
XX Anderson DW, Boldog FL, Casman SJ, Edinger SR, Gangolli EA;
XX Gerlach VL, Gorman JA, Khrantsov NV, Li L, MacDougall JR;
XX Pena CE, Peyman JA, Patturajan M, Shinkets RA, Smithson G;
XX Spytek KA, Vernet CAM, Voss EZ, Zhong M;
XX
XX WPI; 2004-191740/18.
XX
XX New NOVX polypeptides and nucleic acids, useful for preventing or
PT treating NOVX-associated disorders, e.g. cancer, diabetes,
PT atherosclerosis, asthma, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
XX Example C; SEQ ID NO 82; 210pp; English.
XX
XX The present sequence represents a PCR primer for a human NOVX polypeptide
CC (1), which is a G protein-coupled receptor (GPCR). Also described: (1) a
CC composition comprising (1) and a carrier; (2) a kit comprising, in one or
CC more containers, the composition of (1); (3) determining the presence or

```

amount of the above polypeptide (I) in a sample; (4) determining the presence of or predisposition to a disease associated with altered levels of expression of (I) in a first mammalian subject; (5) identifying an agent that binds to the polypeptide (I); (6) identifying a potential therapeutic agent for use in the treatment of a pathology, where the pathology is related to aberrant expression or aberrant physiological interactions of polypeptide (I); (7) screening for a modulator of activity of or of latency or predisposition to a pathology associated with the polypeptide (I); (8) modulating the activity of the polypeptide (I); (9) treating or preventing a pathology associated with polypeptide (I), or treating a pathological state in a mammal; (10) an isolated nucleic acid molecule (II) encoding (I); (11) a vector (III) comprising (II); (12) a cell (IV) comprising (III); (13) an antibody that immunospecifically binds to (I); (14) determining the presence of or amount of (II) in a sample; (15) determining the presence of or predisposition to a disease associated with altered levels of expression of the nucleic acid molecule (II) in a first mammalian subject; and (16) producing the above polypeptide (I). (I) has antiarteriosclerotic, hypotensive, dermatological, anorectic, cytostatic, antidiabetic, haemostatic, immunosuppressive, anti-HIV, antiasthmatic, antiinflammatory, neuroprotective, antimicrobial, anabolic, eating disorder, immunomodulator, nootropic, antiparkinsonian and antilipaeamic activities, and can be used in gene therapy, and in vaccines. The NOVX polypeptide (I) is useful in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide. (I) may also be used in diagnosing, treating or preventing NOVX-associated disorders such as cardiomyopathy, atherosclerosis, hypertension, scleroderma, obesity, cancer, diabetes, haemophilia, graft-versus-host disease, AIDS, asthma, Crohn's disease, multiple sclerosis, infections, anorexia, cancer-associated cachexia, neurodegenerative disorders (e.g. Alzheimer's disease or Parkinson's disease), haematopoietic disorders, dyslipidaemias and other wasting disorders associated with chronic diseases. The nucleic acids (II) are also used as hybridisation probes, in chromosome mapping, tissue typing, preventive medicine, and pharmacogenomics.

Sequence 17 BP; 0 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 50;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 399 AGGAGCGGCGAGCAG 415
 ||||| ||||| |||||
 Db 17 AGGAGCAGCAGCAGCAG 1

RESULT 107
 ACN73765
 ID ACN73765 standard; DNA; 17 BP.
 XX ACN73765;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:10667.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist1; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.

PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIYV/) JI Y.
 PA (PENW/) PENN S G.
 PA (HANK/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 WPI; 2004-533378/51.

Novel myosin-like protein-1, useful for treating or preventing disorder associated with decreased expression or activity of human genome-derived myosin-like protein-1 such as disorder of heart and/or skeletal muscle function.

Disclosure; SEQ ID NO 10667; Opp; English.

The invention relates to a novel polypeptide (I) comprising a sequence (SI) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully defined in the specification, a fragment of at least 8 amino acids of (SI), 95% deviation from (SI) which are conservative substitutions, and 65% identity to (SI). A polypeptide of the invention acts as an agonist or antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A pharmaceutical composition of the invention is useful for treating or preventing a disorder associated with decreased expression or activity of hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function. The present sequence represents a 17-mer nucleotide, used in the invention for scanning the sequence represented in ACN63103

Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 2.0%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 50;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 12 CAGAGTCAGCCAGCATG 28
 ||||| ||||| |||||
 Db 1 CAGAGCCAGCCAGCATG 17

RESULT 108

ADE29797
 ID ADE29797 standard; RNA; 19 BP.
 XX
 AC ADE29797;
 XX
 DT 29-JAN-2004 (first entry)

DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:419.
 XX
 KW short interfering nucleic acid; siNA; downregulation; inhibition;
 KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
 KW cytosolic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;
 KW immunosuppressive; antibacterial; antirheumatic; antitumor;
 KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
 KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
 KW psoriasis; inflammatory bowel disease; drug screening;
 KW genetic engineering; pharmacogenomic; gene mapping; ss.

```

XX OS Synthetic.
XX PN WO2003072590-A1.
XX PD 04-SEP-2003.
XX PF 28-JAN-2003; 2003WO-US002510.
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PA (STRN-) SIRNA THERAPEUTICS INC.
XX PI Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;
XX DR WPI; 2003-689980/65.
XX PT New short interfering nucleic acid, useful e.g. for treatment and
XX PT diagnosis of cancer, downregulates expression of mitogen-activated
XX PT protein kinase genes.
XX PS Example 3; SEQ ID NO 419; 164pp; English.
XX CC The present invention describes a short interfering nucleic acid (siNA)
XX CC that downregulates expression of a mitogen-activated protein kinase
XX CC (MAPK) genes by RNA interference. Also described: (1) a method for
XX CC modulating expression of MAPK genes in cells, tissue explants or
XX CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
XX CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
XX CC vectors that express siNA and cells containing these vectors. MAPK siNAs
XX CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
XX CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
XX CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
XX CC siNAs can be used to modulate the expression of MAPK genes, in cells,
XX CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
XX CC and II; a wide range of tumours, and inflammatory diseases (asthma,
XX CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
XX CC disease). They can also be used for drug screening; diagnosis; target
XX CC identification and validation; genetic engineering; pharmacogenomics;
XX CC studying gene function and gene mapping (e.g. of single-nucleotide
XX CC polymorphisms). The present sequence represents a MAPK siNA which is used
XX CC in the exemplification of the present invention.
XX SQ Sequence 19 BP; 3 A; 10 C; 1 G; 0 T; 5 U; 0 Other;
Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 76.5%; Pred. No. 62;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 471 ACCCCACCCCAAGTTTCC 487
DB 1 ACCCCACCCCAAGTTTCC 17
RESULT 109
ADE29902/c
ID ADE29902 standard; RNA; 19 BP.
XX AC ADE29902;
XX XX
XX DT 29-JAN-2004 (first entry)
XX DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:524.
XX KW short interfering nucleic acid; siNA; downregulation; inhibition;
XX KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
XX KW cytostatic; anorectic; antidiabetic; antiinflammatory; antiasthmatic;

```

```

KW KW immunosuppressive; antibacterial; antirheumatic; antiarthritic;
KW KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
KW KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
KW KW psoriasis; inflammatory bowel disease; drug screening;
KW KW genetic engineering; pharmacogenomic; gene mapping; ss.
XX OS Synthetic.
XX PN WO2003072590-A1.
XX PD 04-SEP-2003.
XX PF 28-JAN-2003; 2003WO-US002510.
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PA (STRN-) SIRNA THERAPEUTICS INC.
XX PI Mcswiggen J, Beigelman L, Usman N, Haerberli P, Chowrira B;
XX DR WPI; 2003-689980/65.
XX PT New short interfering nucleic acid, useful e.g. for treatment and
XX PT diagnosis of cancer, downregulates expression of mitogen-activated
XX PT protein kinase genes.
XX PS Example 3; SEQ ID NO 524; 164pp; English.
XX CC The present invention describes a short interfering nucleic acid (siNA)
XX CC that downregulates expression of a mitogen-activated protein kinase
XX CC (MAPK) genes by RNA interference. Also described: (1) a method for
XX CC modulating expression of MAPK genes in cells, tissue explants or
XX CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
XX CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
XX CC vectors that express siNA and cells containing these vectors. MAPK siNAs
XX CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
XX CC antiasthmatic, immunosuppressive, antibacterial, antirheumatic,
XX CC antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
XX CC siNAs can be used to modulate the expression of MAPK genes, in cells,
XX CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
XX CC and II; a wide range of tumours, and inflammatory diseases (asthma,
XX CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
XX CC disease). They can also be used for drug screening; diagnosis; target
XX CC identification and validation; genetic engineering; pharmacogenomics;
XX CC studying gene function and gene mapping (e.g. of single-nucleotide
XX CC polymorphisms). The present sequence represents a MAPK siNA which is used
XX CC in the exemplification of the present invention.
XX SQ Sequence 19 BP; 5 A; 1 C; 10 G; 0 T; 3 U; 0 Other;
Query Match 2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 62;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 471 ACCCCACCCCAAGTTTCC 487
DB 19 ACCCCACCCCAAGTTTCC 3
RESULT 110
ADOI4933.
ID ADO14933 standard; RNA; 19 BP.
XX AC ADO14933;
XX XX
XX DT 01-JUL-2004 (first entry)
XX

```


CC targeted double-stranded siNA, which is identical to the PDGFR transcript
 CC target sequence.

SQ Sequence 19 BP; 4 A; 1 C; 11 G; 0 T; 3 U; 0 Other;
 Query Match 2.0%; Score 15.4; DB 1; Length 19;
 Best Local Similarity 94.1%; Pred. No. 62;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 485 TCCTCTCCCTGTCC 501

Db 17 TCCACTCTCTGTCC 1

RESULT 112

AAAX31550

ID AAX31550 standard; DNA; 15 BP.

XX AAX31550;

AC AAX31550;

DT 21-MAY-1999 (first entry)

DE Tag sequence of a transcript increased in pancreatic cancer.

KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;

KW diagnosis; prognosis; treatment; ss.

XX Homo sapiens.

OS WO9853319-A2.

PN 26-NOV-1998.

XX 20-MAY-1998; 98WO-US010277.

XX 21-MAY-1997; 97US-0047352P.

XX (UYJO) UNIV JOHNS HOPKINS.

PA Vogelstein B, Kinzler KW;

PI WPI; 1999-070161/06.

DR Use of isolated gene transcripts - useful for developing products for the

XX diagnosis, prognosis and treatment of cancers, particularly colon and

XX pancreatic cancer.

XX Claim 13; Page 60; 120pp; English.

PS AAX30947-31815 represent tag sequences of transcripts that are

XX differentially expressed in colorectal cancer, in pancreatic cancer, or

XX in both. The tag sequences can be used to identify genes by matching the

XX tag to a gen data base member, or by using the tag sequences as probes to

XX isolate unidentified genes from cDNA libraries. The tag sequences can

XX also be used in a method for diagnosing colon or pancreatic cancer in a

XX sample suspected of being neoplastic. The method comprises comparing the

XX level of at least one transcript in a first sample of a tissue to a

XX second sample, where the first sample is a colonic tissue suspected of

XX being neoplastic and the second sample is a normal human colonic tissue.

XX The transcript is identified by a tag selected from AAX30947-31815. The

XX methods of the invention can be used in the diagnosis, prognosis and

XX treatment of cancer

XX SQ Sequence 15 BP; 4 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 46;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 529 CATGCCCAAGCTAGC 543

Db 1 CATGCCCAAGCTAGC 15

RESULT 113

AAF46290

ID AAF46290 standard; DNA; 15 BP.

XX AAF46290;

AC AAF46290;

DT 30-MAR-2001 (first entry)

XX IGFBP2 oligonucleotide #1129.

DE Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;

XX cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;

KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;

KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;

KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;

KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;

KW hyperneovascular condition; hyperplasia; kidney disease;

KW neovascular condition of the retina; ss.

XX Homo sapiens.

OS WO200078341-A1.

PN 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

PA Wraight CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering

XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that

XX inhibits or reduces growth factor mediated cell proliferation and/or

XX inflammation.

XX Example 6; Page 41; 201pp; English.

PS The present invention relates to a method for ameliorating the effects of

XX skin disorders. The method comprises contacting the skin with an

XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1

XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of

XX inhibiting or reducing growth factor mediated cell proliferation,

XX inflammation and/or other disorders. The present sequence is an

XX oligonucleotide which can be used to design the antisense

XX oligonucleotides of the present invention (see AAF45151 and AAF45153-

XX F45161). The method is useful for ameliorating the effects of psoriasis,

XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,

XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a

XX hyperneovascular condition such as a neovascular condition of the retina,

XX brain or skin, growth factor-mediated malignancies, other sclerotic

XX disease, kidney disease, hyperproliferation of the inside of blood

XX vessels or any other hyperplasia

XX SQ Sequence 15 BP; 0 A; 12 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 46;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 194 CCCTGCCCCCGCC 208

Db 1 CCCTGCCCCCGCC 15

RESULT 114

ABK32504

ID ABK32504 standard; DNA; 15 BP.

```

XX AC ABK32504;
XX
XX DT 23-APR-2002 (first entry)
XX
XX DE Human pancreatic cancer SAGE tag #56.
XX
XX KW Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;
XX KW serial analysis of gene expression; diagnostic; prognostic; probe;
XX KW cancer marker; sb.
XX
XX OS Homo sapiens.
XX
XX PN US6333152-B1.
XX
XX PD 25-DEC-2001.
XX
XX PF 20-MAY-1998; 98US-00081646.
XX
XX PR 20-MAY-1998; 98US-00081646.
XX
XX PA (UYJO ) UNIV JOHNS HOPKINS.
XX
XX PI Vogelstein B, Kinzler KW, Zhang L, Zhou W;
XX
XX DR WPI; 2002-153821/20.
XX
XX PT New human nucleic acid containing specific SAGE tags, useful as
XX PT diagnostic markers for cancer, also derived probes.
XX
XX PS Disclosure; Col 69; 161pp; English.
XX
XX CC The invention relates to an isolated, purified human nucleic acid (I)
XX CC that has the same sequence as a mRNA found in humans and is a SAGE
XX CC (serial analysis of gene expression) tag comprising a single stranded
XX CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
XX CC diagnostic and prognostic markers of cancer, especially of the colon and
XX CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
XX CC SAGE tags of the invention
XX
XX SQ Sequence 15 BP; 4 A; 6 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 2.0%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 529 CATGCCCAAGCTAGC 543
Db 1 CATGCCCAAGCTAGC 15

RESULT 115
AAQ65740/c
ID AAQ65740 standard; DNA; 18 BP.
XX
XX AC AAQ65740;
XX
XX DT 25-MAR-2003 (revised)
XX DT 19-DEC-1994 (first entry)
XX
XX DE Type II procollagen sequencing primer CW-14.
XX
XX KW Type II procollagen; COL2A1; amplification; primer;
XX KW polymerase chain reaction; PCR; osteoarthritis; cartilage; ss.
XX
XX OS Synthetic.
XX
XX PN WO9411532-A1.
XX
XX PD 26-MAY-1994.
XX
XX PF 12-NOV-1993; 93WO-US010964.
XX

```

```

PR 13-NOV-1992; 92US-00977284.
XX
XX PA (UYJE-) UNIV JEFFERSON THOMAS.
XX
XX PI Prockop DJ, Ala-Kokko L, Williams CJ, Ritvaniemi P, Baldwin C;
XX PI Hopkinson I, Ahmad NN;
XX
XX DR WPI; 1994-183530/22.
XX
XX PT Detecting genetic pre-disposition to osteoarthritis - and other diseases
XX PT involving mutation in cartilage protein genes, by amplification and
XX PT analysis of DNA and comparison with standards.
XX
XX PS Claim 18; Page 20; 112pp; English.
XX
XX CC Claim 18 claims primers for use in detecting mutations in a mammalian
XX CC gene for a structural protein of cartilage comprising a sequence
XX CC identified in Table I (Page 18-31). Table I includes 179 primer sequences
XX CC (see AAQ65728-Q65906). The following details are given for primer CW-14:
XX CC Region/exon: 11 Direction: sense Primer position: 1640 (Updated on 25-MAR
XX CC -2003 to correct PN field.)
XX
XX SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 71;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 129 TGCCCCGGCTGCCGAGG 146
Db 18 TGCCCTGGCTGCAGGAGG 1

RESULT 116
AAF77820
ID AAF77820 standard; DNA; 18 BP.
XX
XX AC AAF77820;
XX
XX DT 29-MAY-2001 (first entry)
XX
XX DE PCR primer BAR2.
XX
XX KW PCR primer; gene amplification; ss.
XX
XX OS Unidentified.
XX
XX PN JP2001008680-A.
XX
XX PD 16-JAN-2001.
XX
XX PF 30-JUN-1999; 99JP-00185279.
XX
XX PR 30-JUN-1999; 99JP-00185279.
XX
XX PA (SHMA ) SHIMADZU CORP.
XX
XX DR WPI; 2001-248255/26.
XX
XX PT Amplification of viral, bacterial or fungal nucleic acids, by adding
XX PT biological sample of a host infected with a microbe directly to
XX PT amplification solution containing polyamine, sulfated polysaccharide,
XX PT dithiothreitol.
XX
XX PS Example 3; Page 5; 7pp; Japanese.
XX
XX CC The present invention relates to a method for gene amplification. The
XX CC method is useful for direct nucleic acid amplification of bacterial,
XX CC fungal, protozoal genes, viral genes including DNA, RNA or retrovirus
XX CC genes or a cell containing a malignant neoplasm without pre-processing.
XX CC Nucleic acid amplification is carried out quickly and sensitively.
XX CC Nucleic acid synthesis is not inhibited by the presence of impurities.
XX CC The present sequence is a PCR primer used in the method of the present

```

```
CC invention
XX SQ Sequence 18 BP; 5 A; 1 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 71;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 366 AGGATGGCGTGTGGAGA 383
Db 1 AGGATGGCGTGGAGA 18
RESULT 117
AAD38938/c
ID AAD38938 standard; DNA; 18 BP.
AC AAD38938;
XX 23-SEP-2002 (first entry)
XX Human Her-2 antisense oligonucleotide, ISIS #27965.
XX Human; Her-2; epidermal growth factor receptor 2; infection; cancer;
KW hyperproliferative disorder; prophylaxis; inflammation; antisense;
KW tumour; gene therapy; phosphorothioate backbone; ss.
XX Homo sapiens.
OS Synthetic.
XX Location/Qualifiers
FH modified_base 1..18
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
FT modified_base 1..4
FT /tag= b
FT /mod_base= OTHER
FT modified_base 2
FT /note= "2'methoxyethyl nucleotides"
FT /tag= d
FT /mod_base= m5c
FT modified_base 5
FT /tag= e
FT /mod_base= m5c
FT modified_base 6
FT /tag= f
FT /mod_base= m5c
FT modified_base 10
FT /tag= g
FT /mod_base= m5c
FT modified_base 11
FT /tag= h
FT /mod_base= m5c
FT modified_base 14
FT /tag= i
FT /mod_base= m5c
FT modified_base 15..18
FT /tag= c
FT /mod_base= OTHER
FT modified_base 15
FT /note= "2'methoxyethyl nucleotides"
FT /tag= j
FT /mod_base= m5c
FT modified_base 16
FT /tag= k
FT /mod_base= m5c
XX WO200222636-A1.
XX 21-MAR-2002.
XX 12-SEP-2001; 2001WO-US028572.
```

```
XX 15-SEP-2000; 2000US-00663834.
XX (ISIS-) ISIS PHARM INC.
XX Bennett CF, Cowser LM;
XX WPI; 2002-471192/50.
XX Novel antisense oligonucleotide which modulates the expression of Human
XX Epidermal Growth Factor receptor, Her2, is useful for treating tumors
XX inflammation or to prevent infection in humans.
XX Claim 1; Page 89; 116pp; English.
XX The invention relates to antisense compounds targetted to a nucleic acid
XX molecule encoding Her2 (human Epidermal Growth Factor receptor 2) that
XX specifically hybridise with and inhibits the expression of Her2.
XX Antisense compounds of the invention are used for treating diseases or
XX conditions associated with Her2 such as hyperproliferative disorders e.g.
XX lung, breast, gastric, oesophageal, colon, bladder, salivary, neural or
XX cardiac cancer. They are also useful prophylactically e.g. to prevent or
XX delay infection, inflammation and tumour formation. The invention is also
XX used in gene therapy. The present sequence is an antisense
XX oligonucleotide targetted to human Her-2
XX Sequence 18 BP; 4 A; 8 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 71;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 123 TCGGGCTGCCCGCTGC 140
Db 18 TCGGGCTGGCTCGCTGC 1
RESULT 118
ABK98126
ID ABK98126 standard; DNA; 18 BP.
XX AC ABK98126;
XX 07-OCT-2002 (first entry)
XX Triple helix forming associated oligonucleotide #15.
XX Triple-helix formation; purine-rich target sequence; double-helix DNA;
XX gene expression; regulatory sequence; pathogenic double-stranded DNA;
XX pathogenic bacteria; virus; replication; virulence; cancer;
XX oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX Synthetic.
XX US6403302-B1.
XX 11-JUN-2002.
XX 16-DEC-1993; 93US-00168920.
XX 17-SEP-1992; 92US-00946976.
XX (CALY ) CALIFORNIA INST OF TECHNOLOGY.
XX Dervan PB, Beal PA;
XX WPI; 2002-536030/57.
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
XX oligonucleotide which binds in parallel and antiparallel orientation,
XX respectively, for targetting sequences on alternate strands of DHNA to
XX control gene expression.
```

PS Example 7; Col 41; 108pp; English.

XX The present invention relates to methods and oligonucleotides for forming

CC a triple-helix comprising a double helical nucleic acid comprising first

CC and second substantially complementary strands, and an oligonucleotide

CC bound to a purine-rich target sequence within the double helical nucleic

CC acid, where the oligonucleotide binds in a parallel and antiparallel

CC orientation, respectively, to target sequences on alternate strands of

CC the double helical nucleic acid. The method has therapeutic applications,

CC where gene expression is controlled by selective triple-helix formation

CC within expression regulatory sequences of a target gene. The

CC oligonucleotides can be used to form triple-helices, and are useful to

CC detect the presence or absence of specific sequences within genomic DNA

CC for diagnostic and therapeutic purposes. The oligonucleotides can be

CC selected to specifically bind to pathogenic double-stranded DNA including

CC specific sequences required by pathogenic bacteria or viruses for

CC replication or virulence, reducing their pathogenicity. Alternatively,

CC the oligonucleotide can be chosen to target a unique sequence of the

CC pathogen which is not found in the genome of pathogen's host. The

CC oligonucleotides can be used in cancer treatment by way of triple-helix

CC suppression of specific oncogenes including those of endogenous or viral

CC origin. Such therapeutic oligonucleotides are capable of forming triple-

CC helices with such sequences in cancerous cells containing the activated

CC oncogene, so preferentially killing or repressing the cancer causing

CC cell. The present sequence represents an oligonucleotide used in the

CC methods of the present invention

XX

SQ Sequence 18 BP; 0 A; 2 C; 0 G; 14 T; 0 U; 2 Other;

Query Match 1.9%; Score 14.8; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 71;

Matches 15; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 721 TTTATCTCTCTGTTTTCT 738

DB 1 TTTDTTTTCTDTTTTCT 18

RESULT 119

ABS66626/c

ID ABS66626 standard; DNA; 18 BP.

AC ABS66626;

XX 29-NOV-2002 (first entry)

DT

DE TN-Kpni-fo PCR primer.

XX Scaffold protein; C-type lectin-like domain; CTLD; alpha-helix;

KW beta-strand; connecting segment; 14loop region; tetranectin;

KW ligand-binding specificity; human; PCR; primer; ss.

XX

OS Homo sapiens.

OS Synthetic.

XX

PN WO200248189-A2.

XX

PD 20-JUN-2002.

XX

PF 13-DEC-2001; 2001WO-DK000825.

XX

XX 13-DEC-2000; 2000DK-00001872.

PR 28-FEB-2001; 2001US-0272098P.

XX

PA (BORE-) BOREAN PHARMA AS.

XX

XX Etzerodt M, Holtet TL, Gravarsen NJH, Thogersen HC;

XX

XX WPI; 2002-643278/69.

XX

PT Protein comprising a variant of model C-type lectin-like domains (CTLD),

PT in which alpha helices, beta-strands, connecting segments are conserved

PT to maintain CTLD scaffold structure, while the loop region is altered.

XX Example 5; Page 157; 168pp; English.

XX The present invention relates to a new protein with scaffold structure of

CC C-type lectin-like domains (CTLD). The invention comprises a variant of a

CC model CTLD where alpha-helices and beta-strands and connecting segments

CC are conserved such that scaffold structure of C-type lectin-like domains

CC (CTLD) is substantially maintained, while the 14loop region is altered by

CC amino acid substitution, deletion, insertion or their combination. The

CC invention is useful for preparing a library of nucleotide sequences

CC encoding related proteins by randomising part or all of the nucleic acid

CC sequence encoding the loop region of its CTLD. The artificial CTLD

CC protein products are preferable to antibody derivatives as each binding

CC site is a single structurally autonomous protein domain. When used as

CC components of compositions to be used for in vivo diagnostic or

CC therapeutic purposes, artificial CTLD protein products constructed on the

CC basis of human CTLDs are virtually identical to the corresponding natural

CC CTLD protein already present in the body and are therefore less

CC immunogenic to the patient. They also have a smaller size, and thus

CC provide tissue penetration and distribution, as well as shorter half life

CC in circulation. Since murine and human tetranectin are identical in

CC structure, straightforward swapping of polypeptide segments defining

CC ligand-binding specificity between murine and human tetranectin

CC derivatives may be achieved. The present nucleic acid sequence represents

CC an oligonucleotide used in the methods of the invention

XX

SQ Sequence 18 BP; 2 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 71;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 86 GACTGCTACCCGCATAGC 103

DB 18 GACCGGTACCCGCATCGC 1

RESULT 120

ABZ98168

ID ABZ98168 standard; DNA; 18 BP.

XX

AC ABZ98168;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human CD23 + A1261 oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

OS

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

XX WPI; 2003-229219/22.

DR

XX Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 PS Disclosure; SEQ ID NO 13410; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
 Query Match 1.9%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 71;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3 CACGAGGAGCAGAGTCAG 20
 DB 1 CAGGAGAGCAGAGTCAG 18
 |||||
 RESULT 121
 ABD31199
 ID ABD31199 standard; DNA; 18 BP.
 XX
 AC ABD31199;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human CD23-derived oligonucleotide SEQ ID 13410.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiasthmatic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX

PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13410; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiasthmatic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 18 BP; 7 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
 Query Match 1.9%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 71;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3 CACGAGGAGCAGAGTCAG 20
 DB 1 CAGGAGAGCAGAGTCAG 18
 |||||
 RESULT 122
 ADJ60033
 ID ADJ60033 standard; DNA; 18 BP.
 XX
 AC ADJ60033;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to CD23-X04772 #27.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX

KW systemic lupus erythematosus; leukaemia; myelodysplastic syndrome;
KW myelofibrosis; interleukin 3; IL-3; mutagenesis; ss.
XX Homo sapiens.
OS Synthetic.
XX US2004018618-A1.
XX PN 29-JAN-2004.
XX PD 19-JUN-2002; 2002US-00179940.
XX PF 24-NOV-1992; 92US-00981044.
XX PR 22-NOV-1993; 93WO-US011198.
XX PR 06-APR-1995; 95US-00411796.
XX PR 15-NOV-1995; 95US-00559390.
XX (BAUE/) BAUER S C.
XX (ABRA/) ABRAMS M A.
XX (BRAP/) BRAFORD-GOLDBERG S R.
XX (CAPA/) CAPARON M H.
XX (EAST/) EASTON A M.
XX (KLEI/) KLEIN B K.
XX (MCKE/) MCKEARN J P.
XX (OLIN/) OLINS P.
XX (PAIK/) PAIK K.
XX (POLA/) POLAZZI J.
XX (THOM/) THOMAS J W.
XX BAUER SC, Abrams MA, Braford-Goldberg SR, Caparon MH, Easton AM;
XX Klein BK, Mckearn JP, Ollins P, Paik K, Polazzi J, Thomas JW;
XX WPI; 2004-122043/12.
XX Culturing stem cells using a recombinant human interleukin-3 mutant
XX polypeptide, useful for treating aplastic anemia, neutropenia, Chediak-
XX Higashi syndrome, systemic lupus erythematosus, leukemia and
XX myelodysplastic syndrome.
XX Example 65; SEQ ID NO 466; 328pp; English.
XX The invention describes cultured stem cells obtained by a method for
XX selective ex-vivo expansion of stem cells comprising separating stem
XX cells from other cells, culturing the separated stem cells with a
XX selected media which comprises a human interleukin-3 mutant polypeptide
XX comprising defined amino acid sequences SEQ ID NO 15 or 19 given in the
XX specification, and harvesting the cultured cells. The methods and
XX compositions of the present invention are useful for treating aplastic
XX anaemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi
XX syndrome, systemic lupus erythematosus, leukaemia, myelodysplastic
XX syndrome and myelofibrosis. This sequence represents a DNA used in the
XX construction of human interleukin 3 (IL-3) mutants.
XX Sequence 16 BP; 5 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
SQ Query Match 1.9%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 67;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 565 CATCCAGTCACCTTC 580
Db 16 CATTCAGTCACCTTC 1
RESULT 127
ID AAV92679
XX AAV92679 standard; RNA; 17 BP.
XX AC AAV92679;
XX 18-FEB-1999 (first entry)
XX DT
XX DE Human A-Raf substrate position 2408.

XX Human; c-raf, A-raf, B-raf; hammerhead ribozyme; hairpin ribozyme;
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
KW screening; identification; synthesis; deprotection; Raf gene; cancer;
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
KW restenosis; rheumatoid arthritis; ss.
XX Homo sapiens.
XX WO9850530-A2.
XX PN 12-NOV-1998.
XX PD 05-MAY-1998; 98WO-US009249.
XX PF 09-MAY-1997; 97US-0046059P.
XX PR 03-JUN-1997; 97US-0049002P.
XX PR 03-JUL-1997; 97US-0051718P.
XX PR 22-AUG-1997; 97US-0056808P.
XX PR 02-OCT-1997; 97US-0061321P.
XX PR 02-OCT-1997; 97US-0061324P.
XX PR 05-NOV-1997; 97US-0064866P.
XX PR 19-DEC-1997; 97US-0068212P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
XX Parry T, Bergelman L, Mcswiggen JA, Karpeisky A, Burgin A;
XX Thompson J, Workman CT, Beaudry A, Sweedler D;
XX WPI; 1999-009494/01.
XX Identifying new catalytic nucleic acid that modulates selected processes
XX - especially ribozymes that cleave Raf RNA for treating cancer,
XX restenosis, and also new ribozymes and modified nucleoside triphosphates
XX used as antiviral agents and synthons.
XX Claim 177; Page 162; 259pp; English.
XX A method has been developed for the identification of a nucleic acid
XX capable of modulating a process in a biological system. The method
XX comprises: (a) introducing into the system a random library of nucleic
XX acid catalysts (NAC) having a substrate binding domain (SBD), comprising
XX a random sequence, and a catalytic domain (CD); and (b) identifying NAC
XX in systems where modulation has occurred and/or determining the sequence
XX of at least part of the SBDs in such systems. Nucleic acid molecules with
XX endonuclease activity and catalytic activity, from the present invention,
XX are used to modulate gene expression in plant and mammalian cells and to
XX cleave target nucleic acid, particularly for treating systemic diseases
XX caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
XX mutations in diseased cells and to determine c-raf RNA. Specifically NACs
XX with RNA-cleaving activity that modulate expression of the Raf gene, are
XX used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
XX generally any condition associated with the level of c-raf. Introduction
XX of sugar/phosphate modifications increases stability against nuclease and
XX activity. AAV90922 to AAV93877 represent NACs that can be used in the
XX method, specifically for modulating the expression of a Raf gene
XX Sequence 17 BP; 1 A; 8 C; 3 G; 0 T; 5 U; 0 Other;
SQ Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 75;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
OY 684 TGTGCTCTCCCGCCCA 699
Db 2 UGUGUCUCCCGCCCA 17
RESULT 128
ID AEN10674
XX AEN10674 standard; DNA; 17 BP.

CC disorder associated with the expression of hGDMPLP-1, in particular heart
 CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
 CC The present sequence represents an oligomer used in the screening of the
 CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence

SQ Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 75;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 AGAGTCAGCCAGCATG 28
 Db 1 AGAGCCAGCCAGCATG 16
 ||||| ||||| ||||| |||||

RESULT 130
 ABZ61415/C
 ID ABZ61415 standard; RNA; 17 BP.

XX AC ABZ61415;

XX DT 21-MAR-2003 (first entry)

XX DE Human H-Ras DNAzyme target #206.

XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.

XX OS Homo sapiens.

XX PN WO200297114-A2.

XX PD 05-DEC-2002.

XX PF 29-MAY-2002; 2002WO-US016840.

XX PR 29-MAY-2001; 2001US-0294140P.

XX PR 06-JUN-2001; 2001US-0296249P.

XX PR 10-SEP-2001; 2001US-0318471P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Mcswiggen J;

XX DR WPI; 2003-140484/13.

XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding

XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

XX PS Claim 58; Page 115; 185pp; English.

XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
 CC rheumatic activity. The nucleic acid molecules are useful for reducing
 CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
 CC also useful for treating breast, ovarian, colorectal, lung, prostate,
 CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
 CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
 CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
 CC ribozymes of the invention

SQ Sequence 17 BP; 2 A; 7 C; 8 G; 0 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 75;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 227 GTGCGCGCGCCGCGCT 242
 Db 16 GTGCGCGCGCGCGCT 1
 ||||| ||||| ||||| |||||

RESULT 131

ID ADF64299 standard; DNA; 17 BP.

XX AC ADF64299;

XX DT 12-FEB-2004 (first entry)

XX DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2203.

XX KW chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.

XX OS Homo sapiens.

XX PN WO2003050284-A1.

XX PD 19-JUN-2003.

XX PF 22-NOV-2002; 2002WO-US037506.

XX PR 10-DEC-2001; 2001US-0339764P.

XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX PI Guo J;

XX DR WPI; 2003-532916/50.

XX PT New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.

XX PS Example 2; SEQ ID NO 2203; 164pp; English.

XX CC The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the Wipoweb
 CC database.

SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 75;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 56 CTGCGGGGCCCCAGCT 71
 Db 2 CTGAGGGGGCCCCAGCT 17
 ||||| ||||| ||||| |||||

RESULT 132

ID ADF64300 standard; DNA; 17 BP.

XX AC ADF64300;

DT 12-FEB-2004 (first entry)
 DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 2204.
 KW Chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.
 XX Homo sapiens.
 OS
 XX WO2003050284-A1.
 PN
 XX 19-JUN-2003.
 PD
 XX 22-NOV-2002; 2002WO-US037506.
 PF
 XX 10-DEC-2001; 2001US-0339764P.
 XX (AMSH) AMERSHAM BIOSCIENCES SV CORP.
 PA
 XX Guo J;
 PI
 XX WPI; 2003-532916/50.
 DR
 XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.
 XX Example 2; SEQ ID NO 2204; 164pp; English.
 PS
 XX The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the Wipoweb
 CC database.
 XX
 XX Sequence 17 BP; 2 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 75;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 56 CTGCGGGGCCCCAGCT 71
 ||| |||||
 Db 1 CTGAGGGGGCCCCAGCT 16

RESULT 133
 ADL47964
 ID ADL47964 standard; RNA; 17 BP.
 XX
 AC ADL47964;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX Human IKK-gamma substrate sequence #474.
 DE
 XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
 KW substrate; ds.

XX Unidentified.
 OS
 XX WO200281628-A2.
 PN
 XX 17-OCT-2002.
 PD
 XX 03-APR-2002; 2002WO-US010512.
 PF
 XX 05-APR-2001; 2001US-00827395.
 PR
 XX 29-MAY-2001; 2001US-0294412P.
 PR
 XX 28-AUG-2001; 2001US-0315315P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fornaugh K;
 PI
 XX WPI; 2003-058513/05.
 DR
 XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 XX Claim 59; SEQ ID NO 1497; 317pp; English.
 PS
 XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection,
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human IKK-
 CC gamma substrate sequence.
 XX
 XX Sequence 17 BP; 0 A; 13 C; 2 G; 0 T; 2 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 75;
 Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 193 CCCCCTGCCCCCGCC 208
 ||||| : |||||
 Db 1 CCCCCTGCCCCCGCC 16

RESULT 134
 ACN73764
 ID ACN73764 standard; DNA; 17 BP.
 XX
 AC ACN73764;
 XX
 XX 02-DEC-2004 (first entry)
 DT
 XX Human GDMPLP-1 probe SEQ ID NO:10566.
 DE
 XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 XX Homo sapiens.
 OS
 XX US2004137589-A1.
 PN
 XX 15-JUL-2004.
 PD
 XX

```

PF 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 10666; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 5 A; 7 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 75;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 12 CAGAGTCAGCCAGCAT 27
DB ||||| ||||| |||||

RESULT 135
ACN73766
ID ACN73766 standard; DNA; 17 BP.
XX
AC ACN73766;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMPLP-1 probe SEQ ID NO:10668.
XX
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;

```

```

KW skeletal muscle function.
XX
OS Homo sapiens.
XX
PN US2004137589-A1.
XX
PD 15-JUL-2004.
XX
PP 26-NOV-2003; 2003US-00723361.
XX
PR 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
PS Disclosure; SEQ ID NO 10668; Opp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 5 A; 5 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 75;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 13 AGAGTCAGCCAGCATG 28
DB ||||| ||||| |||||
  1 AGAGCCAGCCAGCATG 16

RESULT 136
AAZ48501
ID AAZ48501 standard; DNA; 18 BP.
XX

```

AC AAZ48501;
 XX 31-MAR-2000 (first entry)
 XX Human TNFR1 mRNA inhibiting antisense oligo ISIS# 18894.
 DE Tumour necrosis factor receptor type 1; TNFR1; antisense; infection;
 XX inflammation; tumour formation; TNFR1; anticancer; ss.
 KW Synthetic.
 XX Homo sapiens.
 OS US6007995-A.
 XX 28-DEC-1999.
 PD 26-JUN-1998; 98US-00106038.
 XX 26-JUN-1998; 98US-00106038.
 PF (ISIS-) ISIS PHARM INC.
 XX Baker BP, Cowsert LM;
 PI WPI; 2000-105333/09.
 XX Antisense inhibition of tumor necrosis factor type 1 expression for
 PT diagnosis, treatment and prevention of disease, particularly tumors.
 PT Example 10; Col 24; 34pp; English.
 PS The invention provides antisense compounds targeted to human tumour
 CC necrosis factor receptor type 1 (TNFR1) RNA. These antisense compounds
 CC can be used in a method of inhibiting the expression of TNFR1 human cells
 CC or tissues. The antisense compounds specifically hybridize with one or
 CC more nucleic acids encoding TNFR1 modulating the function of nucleic acid
 CC molecules encoding TNFR1, ultimately modulating the amount of TNFR1
 CC produced. The antisense compounds and method are useful as research
 CC reagents and diagnostics, and in the treatment and prophylaxis of
 CC infection, inflammation or tumour formation. Sequences AAZ48482-565
 CC represent antisense oligos used for inhibition of the human TNFR1 mRNA
 XX Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 84;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 487 CTCCTCCCTGTCCTCCCT 502
 DB 2 CTTCTCCTGTCCTCCCT 17
 RESULT 137
 ID AAZ71739/c
 XX AAZ71739 standard; DNA; 18 BP.
 AC AAZ71739;
 XX 10-SEP-2001 (first entry)
 DT Human biallelic marker upstream amplification primer SEQ ID NO:6095.
 DE Human genome; biallelic marker; high density disequilibrium map;
 XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX Homo sapiens.
 OS WO9954500-A2.
 XX Bunch RT, Curtis SW, Rodi CP, Morris DL;
 PN WPI; 2000-505977/45.
 DR

PD 28-OCT-1999.
 XX 21-APR-1999; 99WO-IB000822.
 XX 21-APR-1998; 98US-0082614P.
 PR 23-NOV-1998; 98US-0109732P.
 XX (GEST) GENSET.
 PA Cohen D, Blumenfeld M, Chumakov I;
 PI WPI; 2000-013267/01.
 XX Novel biallelic markers used to construct a high density disequilibrium
 DR map of the human genome.
 PT Claim 8; Page 1530; 2745pp; English.
 PS AAZ65654 to AAZ69578 represent human biallelic markers from the present
 XX invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention
 XX Sequence 18 BP; 9 A; 4 C; 4 G; 1 T; 0 U; 0 Other;
 SQ Query Match 1.9%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 84;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 701 CTGTGTCTCTCTTGA 716
 DB 18 CTGTGTCTCTCTCTGA 3
 RESULT 138
 ID AAA87651
 XX AAA87651 standard; DNA; 18 BP.
 AC AAA87651;
 XX 08-JAN-2001 (first entry)
 DT Rat hepatocyte carcinogenesis biomarker nucleic acid SEQ ID NO:575.
 XX Rat; phenobarbital; carcinogenesis marker; carcinogenesis; detection;
 XX identification; carcinogenic; probe; primer; ds.
 KW Rattus norvegicus.
 OS WO200044902-A2.
 XX 03-AUG-2000.
 PD 28-JAN-2000; 2000WO-US000503.
 XX 29-JAN-1999; 99US-0118078P.
 XX (SEAR) SEARLE & CO G D.
 PA Bunch RT, Curtis SW, Rodi CP, Morris DL;
 PI WPI; 2000-505977/45.
 DR

XX PT New nucleic acid encoding a carcinogenic biomarker, induced by
PT phenobarbital treatment of rat hepatocytes, useful for identifying
PT carcinogenic compounds.
XX PS Claim 1; Page 239; 240pp; English.
XX CC AAA87080 to AAA87656 represent nucleic acid sequences (NI) encoding a
CC carcinogenesis biomarkers. The carcinogenesis biomarkers are induced by
CC treating rat hepatocytes with phenobarbital. The nucleic acids are useful
CC for identifying carcinogenic compounds. The nucleic acid molecules can be
CC used to derive probes and/or primers for detecting or inducing
CC carcinogenesis, respectively
XX SQ Sequence 18 BP; 7 A; 5 C; 6 G; 0 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 84;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 388 CGGCAAGCAGCAGGAG 403
Db 3 CGGCAAGCAGCAGGAG 18
RESULT 139
ABT04997
ID ABT04997 standard; DNA; 18 BP.
XX AC ABT04997;
XX 11-OCT-2002 (first entry)
XX TNFR1 expression modulation related antisense oligo SEQ ID No 27.
XX Antisense compound; tumour necrosis factor receptor 1; liver disease;
KW TNFR1; hepatitis; liver injury; hyperproliferative disorder; cancer;
KW human; ds.
XX Homo sapiens.
XX WO200248168-A1.
XX 20-JUN-2002.
XX 22-OCT-2001; 2001WO-US051224.
XX 24-OCT-2000; 2000US-00695451.
XX (ISIS-) ISIS PHARM INC.
XX Baker BP, Cowseert LM, Zhang H, Dean NW;
XX WPI; 2002-583481/62.
XX Novel antisense compound targeted to nucleic acid molecule encoding tumor
PT necrosis factor receptor 1 (TNFR1), useful for treating humans having
PT disease associated with TNFR1 e.g. hepatitis, liver injury, liver cancer.
XX Example 10; Page 44; 121pp; English.
XX The invention relates to an antisense compound 8 to 30 nucleotides in
CC length targeted to nucleic acid molecule encoding tumour necrosis factor
CC receptor 1 (TNFR1), where the antisense compound inhibits expression of
CC TNFR1. The antisense compound is useful for inhibiting the expression of
CC TNFR1 in cells or tissues. The antisense compound is also useful for
CC treating an animal (preferably human) having a disease or condition
CC associated with TNFR1, e.g. a liver disease (such as hepatitis, or liver
CC injury) or a hyperproliferative disorder such as cancer, by inhibiting
CC the expression of TNFR1. The antisense compound is useful for
CC diagnostics, therapeutics, prophylaxis and as research reagents and kits.
CC This polynucleotide sequence represents a human oligonucleotide relating
CC to the TNFR1 of the invention

XX SQ Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 84;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 487 CTCCTCCCTGTCCCT 502
Db 2 CTCCTCCCTGTCCCT 17
RESULT 140
ADR06029
ID ADR06029 standard; DNA; 18 BP.
XX AC ADR06029;
XX 21-OCT-2004 (first entry)
XX Human TNFR1 antisense oligonucleotide seqid 27.
XX cytostatic; gene therapy; apoptosis inhibitor;
KW radiation-induced apoptosis; tumour necrosis factor receptor 1; TNFR1;
KW human; antisense oligonucleotide; antisense technology; ss.
XX Homo sapiens.
XX Key Location/Qualifiers
FT modified_base 1..18 /*tag= b
FT /*mod_base= OTHER
FT /*note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..4 /*tag= a
FT /*mod_base= OTHER
FT /*note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE)
FT modified_base 15..18 /*tag= c
FT /*mod_base= OTHER
FT /*note= "OTHER= Optionally 2'-O-Methoxyethyl (2'-MOE)
FT nucleotides"
XX US2004147471-A1.
XX 29-JUL-2004.
XX 06-NOV-2003; 2003US-00702817.
XX 26-JUN-1998; 98US-00106038.
XX 17-JUN-1999; 99WO-US013763.
XX 24-OCT-2000; 2000US-00695451.
XX (ZHAN/) ZHANG H.
XX Zhang H;
XX WPI; 2004-561407/54.
XX Inhibiting radiation-induced apoptosis in a cell or tissue comprises
PT administering to the cell or tissue an antisense oligonucleotide targeted
PT to a nucleic acid molecule encoding tumor necrosis factor receptor 1.
XX Example 10; SEQ ID NO 27; 24pp; English.
XX The invention describes a method of inhibiting radiation-induced
CC apoptosis in a cell or tissue comprising administering to the cell or
CC tissue an antisense oligonucleotide of 8-30 nucleotides in length
CC targeted to a nucleic acid molecule encoding tumour necrosis factor
CC receptor 1 (TNFR1). The method and antisense oligonucleotides are useful
CC for inhibiting radiation-induced apoptosis in a cell or tissue, and for
CC treating diseases associated with the expression of TNFR1. This sequence

CC represents a human tumour necrosis factor receptor 1 (TNFR1) antisense oligonucleotide.

SQ Sequence 18 BP; 1 A; 9 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 84;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 487 CTCCTCCCTGTCCTCCT 502
DB 2 CTCCTCCCTGTCCTCCT 17

RESULT 141
AAF46289

ID AAF46289 standard; DNA; 15 BP.

XX AC AAF46289;

XX 30-MAR-2001 (first entry)

XX IGFBP2 oligonucleotide #1128.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid; skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease;

KW neovascular condition of the retina; ss.

XX OS Homo sapiens.

XX PN WO200078341-A1.

XX PD 28-DEC-2000.

XX PF 21-JUN-2000; 2000WO-AU000693.

XX PR 21-JUN-1999; 99US-0140345P.

XX PA (MURD-) MURDOCH CHILDRENS RES INST.

XX PI Wraight CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

XX Example 6; Page 41; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAF45151 and AAF45153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

SQ Sequence 15 BP; 0 A; 11 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 194 CCCCTGCCCCCGC 207
DB 2 CCCCTGCCCCCGC 15

RESULT 142

AAF46291

ID AAF46291 standard; DNA; 15 BP.

XX AC AAF46291;

XX 30-MAR-2001 (first entry)

XX IGFBP2 oligonucleotide #1130.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid; skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease;

KW neovascular condition of the retina; ss.

XX OS Homo sapiens.

XX PN WO200078341-A1.

XX PD 28-DEC-2000.

XX PF 21-JUN-2000; 2000WO-AU000693.

XX PR 21-JUN-1999; 99US-0140345P.

XX PA (MURD-) MURDOCH CHILDRENS RES INST.

XX PI Wraight CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

XX Example 6; Page 41; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotides of the present invention (see AAF45151 and AAF45153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

SQ Sequence 15 BP; 0 A; 12 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 195 CCTGCCCCCGCC 208
DB 1 CCTGCCCCCGCC 14

RESULT 143
ID ADF32131/c
AC ADF32131;
XX
XX 12-FEB-2004 (first entry)
DE
XX Probe #55 used to illustrate chip detection techniques.
XX
XX Chip detection; probe; Single Nucleotide Polymorphism; SNP; detection;
KW ss.
XX
XX Unidentified.
OS
XX CN1381590-A.
XX
XX 27-NOV-2002.
XX
XX 13-APR-2001; 2001CN-00105980.
XX
XX 13-APR-2001; 2001CN-00105980.
XX
XX (MIAO/) MIAO J.
XX
XX Miao J;
XX
XX WPI; 2003-249035/25.
XX
XX Simple and fast technique for detecting single nucleotide polymorphism
PT (SNP) by high-temp hybridized chip.
XX
XX Example 1; Page 14; 19pp; Chinese.
XX
XX The present invention related to an improvement to existing chip
CC detection techniques. The invention uses DNA oligonucleotide probes
CC (ADF32077-ADF32266) to detect Single Nucleotide Polymorphisms (SNP) in
CC genomic DNA. Its advantages are simple process and short time (within 2
XX hr).
XX
XX Sequence 15 BP; 1 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 14; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 69;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 AGCCACGCGAGTCCA 554
DB 14 AGCCACGCGAGTCCA 1

RESULT 144
ID ADF32131/c
AC ADF32131;
XX
XX 12-FEB-2004 (first entry)
DE
XX Humicola grisea glucoamylase hybridization probe.
XX
XX Glucoamylase; DNA probe; gene cloning; protein secretion; ss.
XX
XX Synthetic.
XX
XX EP625577-A1.

XX
XX 23-NOV-1994.
XX
XX 27-AUG-1986; 94EP-00201751.
XX
XX 29-AUG-1985; 85US-00771374.
XX 07-JUL-1986; 86US-00882224.
PR 27-AUG-1986; 86EP-00306624.
XX
XX (GEMV ) GENENCOR INT INC.
XX
XX Berka RM, Cullen D, Gray GL, Hayenga KJ, Lawlis VB;
XX WPI; 1994-359750/45.
XX
XX Vectors and DNA for expressing polypeptide(s) in filamentous fungi -
PT include secretory signal sequences that are native or foreign to
PT heterologous polypeptide(s), such as chymosin or glucoamylase.
XX
XX Example 9A3; Page 22; 50pp; English.
XX
XX The DNA probe and corresponding probes covering the degenerate sites
CC (AAQ78885-Q78891) correspond to amino acids 17-22 of the H. grisea
CC glucoamylase peptide GA1 (AAK62933), and are used as hybridization probes
CC to detect and isolate H. grisea glucoamylase DNA in a Southern blot.
CC Resulting genomic DNA fragments are excised and cloned in plasmid pRS1.
CC This illustrates the main claims of the patent, i.e. a vector containing
CC (i) DNA encoding a heterologous polypeptide (chymosin, prochymosin,
CC preprochymosin, Aspergillus niger glucoamylase, H. grisea glucoamylase,
CC or Mucor miehei carboxyl protease) and (ii) a secretory signal peptide,
CC and a filamentous fungus (Aspergillus, Trichoderma, Neurospora,
CC Podosporea, Endothia, Mucor, Cochliobolus or Pyricularia, especially A.
CC nidulans, A. awamori or T. reesei) transformed with the vector for
CC recombinant protein (enzyme) production. (Updated on 25-MAR-2003 to
CC correct PF field.) (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 17 BP; 10 A; 2 C; 0 G; 4 T; 0 U; 1 Other;

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 88;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 713 TTGATACATTATCTT 728
DB 17 TTGATATATTATTTWT 2

RESULT 145
ID ADF32131/c
AC ADF32131;
XX
XX 12-MAR-2002 (first entry)
XX
XX Human NOGO Zinzyne #113.
XX
XX Human; ss; antiseize therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberyne; zinzyne; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX

```

PN WO200159103-A2.
 XX 16-AUG-2001.
 XX 09-FEB-2001; 2001WO-US004273.
 XX 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 DR
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 97; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving a NYN motif) pr
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a zinzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 1.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 88;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 164 GCGCGCAGCGTGT 177
 |||||
 DB 2 GCGCGCAGCGTGT 15
 RESULT 146
 ABK00765
 ID ABK00765 standard; RNA; 17 BP.
 XX

AC ABK00765;
 XX 12-MAR-2002 (first entry)
 DT
 XX Human NOGO Inozyme #35.
 DE
 XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
 KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
 KW DNzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX Homo sapiens.
 OS
 OS Synthetic.
 XX
 XX WO200159103-A2.
 PN
 XX 16-AUG-2001.
 PD
 XX 09-FEB-2001; 2001WO-US004273.
 XX
 PF 11-FEB-2000; 2000US-0181797P.
 XX
 PR 28-FEB-2000; 2000US-0185516P.
 PR
 XX 06-MAR-2000; 2000US-0187128P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 XX WPI; 2001-607195/69.
 DR
 XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 88; Page 78; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNzyme) an Inozyme (an endolytic nucleic acid cleaving a NYN motif) pr
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
 CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOGO expression. The present
 CC sequence is a zinzyme molecule of the invention
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 7 G; 0 T; 1 U; 0 Other;
 Query Match 1.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 88;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 164 GCGCGCAGCGTGT 177
 |||||
 DB 2 GCGCGCAGCGTGT 15

CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NQO expression. The present
 CC sequence is an inozyme of the invention
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 8 G; 0 T; 1 U; 0 Other;
 Query Match 1.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 92.9%; Pred. No. 88;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 164 GCGGCGAGCAGCTG 177
 DB 3 GCGGCGAGCAGCUG 16
 RESULT 147
 ABA81385
 ID ABA81385 standard; DNA; 17 BP.
 XX
 AC ABA81385;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4231.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antiscikling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PP 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 XX
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 272; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 1.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 541 AGCCACGCGAGTCCA 554
 DB 3 AGCCACGCGAGTCCA 16
 RESULT 148
 ABA81384/C
 ID ABA81384 standard; DNA; 17 BP.
 XX
 AC ABA81384;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4230.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytosolic; antiscikling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PP 27-MAR-2001; 2001WO-US009761.
 XX
 PR 27-MAR-2000; 2000US-0192176P.
 XX
 PR 27-MAR-2000; 2000US-0192179P.
 PR 01-JUN-2000; 2000US-0208538P.
 PR 30-OCT-2000; 2000US-0244989P.
 XX
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 PI WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification.
 XX
 XX Claim 7; Page 271; 294pp; English.
 PS
 XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention
 XX
 SQ Sequence 17 BP; 3 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 541 AGCCACGAGTCCA 554
 DB 15 AGCCACGAGTCCA 2
 |||||

RESULT 149
 ADF92264
 ID ADF92264 standard; DNA; 17 BP.
 XX
 AC ADF92264;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Human cytokeratin 19-derived F2 DNA - SEQ ID 352.
 XX
 KW human; cytokeratin; CK; LAMP; loop mediated isothermal amplification;
 KW tumour metastasis; prostate cancer; lymphoma; human; CK19; ss; primer;
 KW PCR; probe; F2.
 XX
 OS Homo sapiens.
 XX
 FN WO2003097878-A1.
 XX
 PD 27-NOV-2003.
 XX
 XX 20-MAY-2003; 2003WO-JP006256.
 XX
 XX 21-MAY-2002; 2002JP-00145689.
 PR 17-JUN-2002; 2002JP-00175271.
 PR 09-JUL-2002; 2002JP-00199759.
 XX
 XX (SYSM-) SYSMEX CORP.
 PA
 PI Tada S, Akai Y, Imura Y, Abe S, Minekawa H;
 XX
 DR WPI; 2004-012543/01.
 XX
 PT LAMP nucleic acid amplification primers for detection of cytokeratin
 PT expression as indicator in diagnosis of tumour metastasis.
 XX
 PS Claim 19; SEQ ID NO 352; 266bp; Japanese.
 XX
 CC The invention relates to novel nucleic acid amplification primers for the
 CC detection of human cytokeratin (CK) 18, 19 or 20 expression by the LAMP
 CC (loop mediated isothermal amplification) method. The primers of the
 CC invention may be useful for the detecting cytokeratin 18-20 expression as
 CC an indicator for the diagnosis of tumour metastasis, particularly
 CC prostate cancer and lymphoma. The amplification using the primers is
 CC highly efficient and allows very sensitive detection of tumour
 CC metastasis. The current sequence is that of the human CK19-derived DNA of
 CC the invention.
 XX
 SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 88;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 81 TCCGCGACTGGTAC 94
 DB 4 TCCGCGACTGGTAC 17
 |||||

RESULT 150
 AAA17447
 ID AAA17447 standard; RNA; 17 BP.
 XX
 AC AAA17447;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Aryl hydrocarbon nuclear transport substrate sequence SEQ ID NO:673.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 XX 24-MAR-1999; 99WO-US006507.
 PR
 XX 27-MAR-1998; 98US-0079678P.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 PI Pavco PA, Roberts E, Jarvis T, Coeshott C, Mcswiggen JA;
 XX
 DR WPI; 1999-591315/50.
 XX
 PT Novel ribozymes for modulating the synthesis, expression and/or stability
 PT of an mRNA encoding an angiogenic factors.
 XX
 PS Claim 53; Page 80; 305pp; English.
 XX
 CC The present invention describes enzymatic nucleic acid molecules with RNA
 CC cleaving activity, which specifically cleave RNA encoded by an aryl
 CC hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 CC gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 CC AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 CC and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 CC corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 CC AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 CC and AAA19155 to AAA19222 represent their corresponding target sequences;
 CC AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 CC sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 CC AAA21596 to AAA21688 represent their corresponding target sequences;
 CC AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequence
 CC for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 CC AAA23422 represent their corresponding target sequences. The ribozymes of
 CC the invention are used for modulating the synthesis, expression and/or
 CC stability of an mRNA encoding angiogenic factor, especially ARNT,
 CC integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 CC especially used to treat cancer, diabetic retinopathy, age related
 CC macular degeneration (ARMD), inflammation, and arthritis, as well as
 CC neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 CC angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 CC syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 CC and other syndromes and diseases related to the levels of ARNT, Tie-2,
 CC integrin subunit alpha-6, or integrin subunit beta-3
 XX
 SQ Sequence 17 BP; 3 A; 9 C; 2 G; 0 T; 3 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 95;
 Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY 64 CCCACGCTGGGACCCCT 80
 DB 1 CCCCAACUUGGACCCCU 17

RESULT 151
 ID AAV93490 standard; RNA; 17 BP.
 AC AAV93490;
 XX
 DT 18-FEB-1999 (first entry)
 DE Human B-raf substrate nucleotide position 1221.
 XX
 KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
 KW screening; identification; synthesis; deprotection; purification; cancer;
 KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
 KW restenosis; rheumatoid arthritis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9850530-A2.
 XX
 PD 12-NOV-1998.
 XX
 PF 05-MAY-1998; 98WO-US009249.
 XX
 PR 09-MAY-1997; 97US-0046059P.
 PR 09-JUN-1997; 97US-0049002P.
 PR 03-JUL-1997; 97US-0051718P.
 PR 22-AUG-1997; 97US-0056808P.
 PR 02-OCT-1997; 97US-0061321P.
 PR 02-OCT-1997; 97US-0061324P.
 PR 05-NOV-1997; 97US-0064866P.
 PR 19-DEC-1997; 97US-0068212P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
 PI Parry T, Beigelman L, Mcswiggen JA, Karpisky A, Burgin A;
 PI Thompson J, Workman CT, Beaudry A, Sweedler D;
 XX
 WPI; 1999-009494/01.
 XX
 PT Identifying new catalytic nucleic acid that modulates selected processes
 PT - especially ribozymes that cleave Raf RNA for treating cancer,
 PT restenosis, and also new ribozymes and modified nucleoside triphosphates
 PT used as antiviral agents and synthons.
 XX
 PS Claim 177; Page 168; 259pp; English.
 XX
 CC A method has been developed for the identification of a nucleic acid
 CC capable of modulating a process in a biological system. The method
 CC comprises: (a) introducing into the system a random library of nucleic
 CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules with
 CC endonuclease activity and catalytic activity, from the present invention,
 CC are used to modulate gene expression in plant and mammalian cells and to
 CC cleave target nucleic acid, particularly for treating systemic diseases
 CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
 CC ascites and infection. They may also be used to detect genetic drift and
 CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
 CC with RNA-cleaving activity that modulate expression of the Raf gene, are
 CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or

CC generally any condition associated with the level of c-raf. Introduction
 CC of sugar/phosphate modifications increases stability against nuclease and
 CC activity. AAV90922 to AAV93877 represent NACs that can be used in the
 CC method, specifically for modulating the expression of a Raf gene
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 6 G; 0 T; 5 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 95;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 363 CCAAGATGGCGGTG 379
 DB 1 CCAAGAUUUGUGUG 17

RESULT 152
 ID AAX01065 standard; DNA; 17 BP.
 XX
 AC AAX01065;
 XX
 DT 06-APR-1999 (first entry)
 XX
 DE IPF1 gene exon 1 amplifying primer S17b.
 XX
 KW Mature onset diabetes of the young; MODY; insulin promoter factor 1;
 KW IPF1; mutation; MODY4; pancreatic disorder; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9859078-A1.
 XX
 PD 30-DEC-1998.
 XX
 PF 24-JUN-1998; 98WO-US013467.
 XX
 PR 24-JUN-1997; 97US-00881450.
 XX
 PA (GEO) GEN HOSPITAL CORP.
 XX
 PI Habener JF, Stoffers DA;
 XX
 WPI; 1999-105636/09.
 XX
 PT Detecting heterozygosity for insulin promoter factor 1 - useful to detect
 PT the presence of, or predisposition for, mature onset diabetes of the
 PT young.
 XX
 PS Example 1; Page 9; 46pp; English.
 XX
 CC The invention relates to a new method to screen for mature onset diabetes
 CC of the young (MODY). The method comprises detecting a mutation in the
 CC gene encoding insulin promoter factor 1 (IPF1), wherein heterozygosity
 CC for the mutation is indicative of MODY. The method may be used to
 CC determine if a patient with MODY symptoms has MODY4, to assess patients
 CC risk of developing MODY4, to assess the risk of a couple's progeny of
 CC inheriting MODY, and to assist in determining the genetic basis for other
 CC pancreatic disorders that might result from IPF-1 deficiency. Sequences
 CC AAX01063-66 represent primers used for amplifying the exon 1 of the IPF1
 CC gene using a nested PCR priming scheme
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 38 CGCGTCCCTCTCGCT 54
 DB 17 CGCTCCCTCGCTCGCT 1

RESULT 153
 AAA36540/c
 ID AAA36540 standard; DNA; 17 BP.
 XX
 XX AAA36540;
 AC AAA36540;
 XX
 DT 26-JUL-2000 (first entry)
 XX
 DE Human genomic SNP allele specific oligonucleotide SEQ ID NO:605.
 XX
 XX Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
 KW allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
 KW genomic classification; identification; DNA fingerprinting;
 KW tumour characterisation; hybridisation; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200018960-A2.
 FN
 XX PD 06-APR-2000.
 XX
 XX PF 24-SEP-1999; 99WO-US022283.
 XX
 XX PR 25-SEP-1998; 98US-0101757P.
 XX
 XX PA (MASI) MASSACHUSETTS INST TECHNOLOGY.
 XX
 XX PI Landers JB, Jordan B, Housman DE, Charest A;
 XX
 XX WPI; 2000-293181/25.
 DR
 XX
 XX PT Detection of single nucleotide polymorphisms in genomes by preparation
 PT and analysis of reduced complexity genomes, useful for genotyping,
 PT fingerprinting and determining allele frequency of SNPs.
 XX
 XX PS Disclosure; Page 71; 11pp; English.
 XX
 CC A method has been developed for detecting the presence or absence of a
 CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
 CC method comprises preparing a reduced complexity genome (RCG) from the
 CC genomic sample and analysing the RCG for the presence or absence of a SNP
 CC allele. The method can be used to characterise a tumour, to generate a
 CC genomic pattern for an individual genome or to generate a genomic
 CC classification code for a genome. The method can be used to assess
 CC whether a subject is at risk for developing a disease or to identify a
 CC set of SNP alleles associated with a disease. The method can also be used
 CC to perform linkage analysis. AAA35944 to AAA35947 represent sequences
 CC used in the exemplification of the present invention. AAA35948 to
 CC AAA36632 represent nucleotide sequences containing SNPs
 XX
 SQ Sequence 17 BP; 1 A; 2 C; 5 G; 9 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. NO. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 746 AGTTCACAGCACACC 762
 DB 17 AGTACAAAGCAACACC 1
 RESULT 154
 ABK02414
 ID ABK02414 standard; RNA; 17 BP.
 XX
 AC ABK02414;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human NIGO Amberzyme #86.
 XX
 XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;

KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KW muscular; CD20; neurite growth inhibitor gene; NIGO; hammerhead ribozyme;
 KW DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia;
 KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
 KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
 KW inflammatory arthropathy; central nervous system injury;
 KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KW Parkinson's disease; ataxia; Huntington's disease;
 KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 XX Homo sapiens.
 OS
 XX Synthetic.
 XX
 XX WO200159103-A2.
 FN
 XX PD 16-AUG-2001.
 XX
 XX PF 09-FEB-2001; 2001WO-US004273.
 XX
 XX PR 11-FEB-2000; 2000US-0181797P.
 XX
 XX PR 28-FEB-2000; 2000US-0185516P.
 XX
 XX PR 06-MAR-2000; 2000US-0187128P.
 XX
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX PA (BLAT/) BLATT L.
 XX
 XX PA (MCSW/) MCSWIGGEN J.
 XX
 XX PA (CHOW/) CHOWRIRA B M.
 XX
 XX PI Blatt L, Mcswiggen J, Chowrira BM;
 XX
 XX WPI; 2001-607195/69.
 DR
 XX
 XX PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 XX PS Claim 88; Page 132; 200pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NIGO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopaenia, and inflammatory arthropathy. The NIGO-
 CC targeting nucleic acid is used to cleave RNA of the NIGO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NIGO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NIGO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NIGO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NIGO expression. The present
 CC sequence is an amberzyme molecule of the invention
 XX

SQ Sequence 17 BP; 1 A; 9 C; 5 G; 0 T; 2 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 76.5%; Pred. No. 95;
 Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 QY 462 CCGGTGTGGACCCACCC 478
 |||:|||||||
 Db 1 CCCGUGGACCCGCC 17
 RESULT 155
 AAH24028/c
 ID AAH24028 standard; DNA; 17 BP.
 XX AC AAH24028;
 XX DT 29-AUG-2001 (first entry)
 XX DE Yeast GAL3 gene upstream UASgal site, SEQ ID NO:11.
 XX KW UASgal site; cis-acting transcription control element; Gal4; Gal3; Gal80;
 KW stoichiometrically balanced expression; yeast;
 KW galactose-inducible expression; expression construct; promoter; ds.
 XX OS Saccharomyces cerevisiae.
 XX PN US6221630-B1.
 XX PD 24-APR-2001.
 XX PF 24-MAR-1999; 99US-00275680.
 XX PR 24-MAR-1999; 99US-00275680.
 XX PA (PENN-) PENN STATE RES FOUND.
 XX PI Hopper JE;
 XX DR WPI; 2001-307557/32.
 XX PT Expression construct for inducing and sustaining high level recombinant
 PT polypeptide production in yeast, comprises nucleic acids encoding a trans-
 PT -acting transcription factor, selectable marker and yeast origin of
 PT replication.
 XX PS Disclosure; Col 15; 22pp; English.
 CC The invention relates to high copy number expression constructs for high
 CC level polypeptide expression in yeast. The yeast expression constructs
 CC comprise a nucleic acid sequence encoding a set of trans-acting
 CC transcription factors, a nucleic acid encoding a yeast selectable marker
 CC providing an inefficiently or inefficiently selected phenotype, a nucleic
 CC acid encoding a yeast or bacterial origin of replication (ori), and a
 CC unique restriction site downstream of a promoter containing a cis-acting
 CC transcription control element that is regulated by the transcription
 CC factors which are encoded by the expression construct. In a specific
 CC embodiment of the invention, the expression construct provides for
 CC galactose-inducible protein expression. Such constructs contain DNA
 CC encoding the transcription factors Gal3, Gal4 and Gal80, and a UASgal cis-
 CC -acting control element within the promoter which drives expression of
 CC the inserted gene of interest. The vector-encoded transcription factors
 CC are expressed in stoichiometrically-balanced amounts, which is
 CC particularly important for a galactose-inducible system, as Gal4, when
 CC not balanced by stoichiometric levels of Gal3 and Gal80, becomes a
 CC constitutive transcription factor, and can become toxic to the cell. The
 CC constructs of the invention express the transcription factors at levels
 CC higher than those found in native yeast cells, thereby ensuring
 CC expression of the gene of interest. The expression constructs provide
 CC robust, high level expression of a gene of interest (which can encode an
 CC endogenous or heterologous polypeptide) in yeast. Sequences AAH24019-
 CC AAH24035 represent actual UASgal sites found within the promoters of
 CC various yeast galactose-inducible genes which may be used as the cis-

CC acting control element in a galactose-inducible expression construct of
 CC the invention
 XX Sequence 17 BP; 1 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 290 CGGCACACTGGGACCG 306
 |||||:|||||
 Db 17 CGGCACACAGTGGACCG 1
 RESULT 156
 ABN02338/c
 ID ABN02338 standard; DNA; 17 BP.
 XX AC ABN02338;
 XX DT 29-MAY-2002 (first entry)
 XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2330.
 XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX OS Homo sapiens.
 XX PN WO200192524-A2.
 XX PD 06-DEC-2001.
 XX PF 25-MAY-2001; 2001WO-US016981.
 XX PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000861.
 PR 30-JAN-2001; 2001WO-US000862.
 PR 30-JAN-2001; 2001WO-US000863.
 PR 30-JAN-2001; 2001WO-US000864.
 PR 30-JAN-2001; 2001WO-US000865.
 PR 30-JAN-2001; 2001WO-US000866.
 PR 30-JAN-2001; 2001WO-US000867.
 PR 30-JAN-2001; 2001WO-US000868.
 PR 30-JAN-2001; 2001WO-US000869.
 PR 30-JAN-2001; 2001WO-US000870.
 PR 05-FEB-2001; 2001US-0266860P.
 XX PA (AEOM-) AEOMICA INC.
 XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
 XX PS Disclosure; SEQ ID NO 2330; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
 CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
 CC nucleic acids can be used as probes to detect, characterize and quantify
 CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
 CC provide initial substrates for the recombinant engineering of hGDMPLP-1
 CC protein variants having desired phenotypic improvements, and for
 CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
 CC used as immunogens to raise antibodies that specifically recognise hGDMPLP

-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence

Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 550 GTCCACGAGATCACC 566
 Db 17 GTCCACGAGATCACC 1

RESULT 157
 ABN02339/c
 ID ABN02339 standard; DNA; 17 BP.

AC ABN02339;
 XX
 DT 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2331.
 DE
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.
 XX 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.
 XX
 PA (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX
 DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
 PT or as specific biomolecule capture probes for surface-enhanced laser
 PT desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
 XX

PS Disclosure; SEQ ID NO 2331; 214pp; English.

XX The present invention describes a human genome-derived myosin-like protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption/ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequence

Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 549 AGTCCACGAGATCACC 565
 Db 17 AGTCCACGAGATCACC 1

RESULT 158
 ABN02337/c
 ID ABN02337 standard; DNA; 17 BP.
 AC ABN02337;
 XX
 DT 29-MAY-2002 (first entry)
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2329.
 DE
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 30-JAN-2001; 2001WO-US000670.
 PR 05-FEB-2001; 2001US-0266860P.

```

XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX FI WPI; 2002-179446/23.
XX DR
XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX PS Disclosure; SEQ ID NO 2329; 214pp; English.
XX PA
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption/ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 551 TCCACGAGATCACCAT 567
Db 17 TCCACGAGATCACCAT 1

RESULT 159
ABN10677
ID ABN10677 standard; DNA; 17 BP.
XX AC ABN10677;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10669.
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.

```

```

PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
XX PA
XX CC (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX DR or as specific biomolecule capture probes for surface-enhanced laser
XX DR desorption ionization, comprises human myosin-like protein hGDMPLP-1.
XX PT Disclosure; SEQ ID NO 10669; 214pp; English.
XX PS
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMPLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption/ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMPLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 14 GAGTCAGCCAGCATGAC 30
Db 1 GAGCCAGCCAGCATGGC 17

RESULT 160
ABN10678
ID ABN10678 standard; DNA; 17 BP.
XX AC ABN10678;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10670.
XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.

```

```

XX FN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024283.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 30-JAN-2001; 2001WO-US000670.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (ABOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX DR
XX PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,
XX or as specific biomolecule capture probes for surface-enhanced laser
XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.
XX PS Disclosure; SEQ ID NO 10670; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1
XX nucleic acids can be used as probes to detect, characterize and quantify
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to
XX provide initial substrates for the recombinant engineering of hGDMPLP-1
XX protein variants having desired phenotypic improvements, and for
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP
XX -1 proteins, as standards in assays used to determine the concentration
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule
XX capture probes for surface-enhanced laser desorption/ionisation, as
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1
XX production, and in vaccines or for replacement therapy. The
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a
XX disorder associated with the expression of hGDMPLP-1, in particular heart
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.
XX The present sequence represents an oligomer used in the screening of the
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.
XX The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;
    Query Match 1.8%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 95;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 15 AGTCAGCCAGCATGACC 31
    |||||
Db 1 AGCCAGCCAGCATGACC 17
    |||||

RESULT 161
ABV78924/c
ID ABV78924 standard; DNA; 17 BP.
XX

```

```

AC ABV78924;
XX 03-JAN-2003 (first entry)
XX DE Human HTPL scanning oligonucleotide SEQ ID 170.
XX KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX KW human testis expressed Patched like protein; testis; adrenal; liver;
XX KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX OS Homo sapiens.
XX FN EPI229046-A2.
XX PD 07-AUG-2002.
XX PF 28-JAN-2002; 2002EP-00001167.
XX PR 30-JAN-2001; 2001WO-US0000563.
XX PR 30-JAN-2001; 2001WO-US0000564.
XX PR 30-JAN-2001; 2001WO-US0000565.
XX PR 30-JAN-2001; 2001WO-US0000567.
XX PR 30-JAN-2001; 2001WO-US0000568.
XX PR 30-JAN-2001; 2001WO-US0000569.
XX PR 23-MAY-2001; 2001US-00864761.
XX PR 09-OCT-2001; 2001US-0327898P.
XX PA (ABOM-) AEOMICA INC.
XX PI Zhan J;
XX WPI; 2002-676582/73.
XX PT Novel isolated human testis expressed Patched like protein (HTPL), useful
XX for identifying agonist and antagonist and specific binding partners, and
XX for treating subjects having defects in HTPL.
XX PS Example 2; Page 86; 718pp; English.
XX CC The present invention relates to human testis expressed Patched like
XX protein (HTPL, see ABV78759 to ABV78762 and ABV98519 to ABV98520). HTPL
XX has two isoforms, with a few single base pair differences between the
XX two. One of the single base pair changes introduces a premature stop
XX codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX shares an overall structure organisation with the Patched protein. The
XX shared structural features strongly imply that HTPL plays a role similar
XX to that of Patched, and is a potential tumour suppressor. HTPL is
XX important in regulating male germ cell development, and the HTPL gene was
XX mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX useful for diagnosing a disorder caused by mutation in HTPL, and in
XX therapy and manufacture of a medicament for treatment or prevention of
XX such disorder associated with decreased expression or activity of human
XX HTPL. Such disorders include disorders of testis, or adrenal, adult and
XX foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
XX skeletal muscle or colon function. HTPL proteins and nucleic acids are
XX clinically useful diagnostic markers and potential therapeutic agents for
XX male infertility and cancer. The present oligonucleotide was used in an
XX example from the invention
XX SQ Sequence 17 BP; 2 A; 7 C; 7 G; 1 T; 0 U; 0 Other;
    Query Match 1.8%; Score 13.8; DB 1; Length 17;
    Best Local Similarity 88.2%; Pred. No. 95;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 295 CACTGCGGACCGCTGGC 311
    |||||
Db 17 CACTGCGGCGCGTGGC 1

RESULT 162
ABV90510

```

```

ID ABV90510 standard; DNA; 17 BP.
XX
AC ABV90510;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1223.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
XX
XX 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
XX
PR 30-JAN-2001; 2001WO-US000664.
XX
PR 30-JAN-2001; 2001WO-US000665.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 30-JAN-2001; 2001WO-US000667.
XX
PR 30-JAN-2001; 2001WO-US000668.
XX
PR 30-JAN-2001; 2001WO-US000669.
XX
PR 30-JAN-2001; 2001WO-US000670.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
XX
XX WPI; 2002-684061/74.
XX
DR
XX
PT Novel human SH3 domain (POSH)-like signaling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS
XX Example 2; SEQ ID NO 1223; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 U; 0 Other;
XX
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 557 GAGATCACCATCCCACT 573
|||||
Db 1 GAGATCAGCACCACCACT 17

RESULT 163
ABKS6935
ID ABKS6935 standard; RNA; 17 BP.
XX
AC ABKS6935;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #1306.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX
PN WO200211674-A2.
XX
PD 14-FEB-2002.
XX
XX
XX 09-AUG-2001; 2001WO-US024970.
XX
XX 09-AUG-2000; 2000US-0224383P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (SYNT) SYNTEX USA LLC.
XX
XX (THOM) THOMPSON J.
XX
XX Thompson J, Mcswiggen J, Mckenzie T, Ayers D, Szymkowski DE;
XX Grupe A;
XX
XX WPI; 2002-217145/27.
XX
DR
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX
XX Claim 4; Page 87; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibiotics, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 0 T; 3 U; 0 Other;
XX
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 95;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 506 GGCACACTGACCGTGA 522
|||||
Db 1 GGCACAGUGAUCGUGGA 17

RESULT 164
ABKS7534/c
```

```

ID XX ABK57534 standard; RNA; 17 BP.
AC XX ABK57534;
XX DT
XX DE
XX DT 02-JUL-2002 (first entry)
XX DE Human CLCA1 gene enzymatic nucleic acid #1905.
XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
XX KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
XX KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
XX KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
XX KW acetylcysteine.
XX OS
XX OS Homo sapiens.
XX PN WO200211674-A2.
XX PN 14-FEB-2002.
XX PD
XX PF 09-AUG-2001; 2001WO-US024970.
XX PF 09-AUG-2000; 2000US-0224383P.
XX PR
XX PR (RIBO-) RIBOZYME PHARM INC.
XX PA (SYNT ) SYNTEX USA LLC.
XX PA (THOM/) THOMPSON J.
XX PI
XX PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE,
XX PI Grupe A;
XX PI WPI; 2002-217145/27.
XX DR
XX DR Enzymatic polynucleotide that down regulates expression of chloride
XX PT channel calcium activated gene, useful for treating Chronic obstructive
XX PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX PS
XX PS Claim 4; Page 128; 152pp; English.
XX CC The invention relates to enzymatic nucleic acid molecules that down
XX CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
XX CC by cleaving RNA derived from the genes. The nucleic acid sequences are
XX CC useful as pharmaceutical agents for treating conditions such as chronic
XX CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
XX CC that are related to or will respond to the levels of CLCA1 in a cell or
XX CC tissue. The sequences are useful for reducing CLCA1 activity in a cell or
XX CC hence, are useful for treatment of a patient having a condition
XX CC associated with the level of CLCA1, where the invention further comprises
XX CC the use of one or more therapies under conditions suitable for the
XX CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
XX CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
XX CC nucleic acids of the invention are also used as diagnostic tools to
XX CC examine genetic drift and mutations within diseased cells or to detect
XX CC the presence of CLCA1 RNA in a cell. This sequence represents an
XX CC enzymatic nucleic acid molecule of the invention
XX SQ Sequence 17 BP; 7 A; 2 C; 5 G; 0 T; 3 U; 0 Other;
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 95;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 422 TACATCTCCCGTGCTT 438
DB 17 TACATCTCCCGTGATT 1
RESULT 165
ABK57533/c
ID ABK57533 standard; RNA; 17 BP.
XX ABK57533;
AC

```

```

XX DT 02-JUL-2002 (first entry)
XX DE Human CLCA1 gene enzymatic nucleic acid #1904.
XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
XX KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
XX KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
XX KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
XX KW acetylcysteine.
XX OS
XX OS Homo sapiens.
XX PN WO200211674-A2.
XX PN 14-FEB-2002.
XX PD
XX PF 09-AUG-2001; 2001WO-US024970.
XX PF 09-AUG-2000; 2000US-0224383P.
XX PR
XX PR (RIBO-) RIBOZYME PHARM INC.
XX PA (SYNT ) SYNTEX USA LLC.
XX PA (THOM/) THOMPSON J.
XX PI
XX PI Thompson J, Mcswiggen J, McKenzie T, Ayers D, Szymkowski DE,
XX PI Grupe A;
XX PI WPI; 2002-217145/27.
XX DR
XX DR Enzymatic polynucleotide that down regulates expression of chloride
XX PT channel calcium activated gene, useful for treating Chronic obstructive
XX PT pulmonary disease (COPD), chronic bronchitis and asthma.
XX PS
XX PS Claim 4; Page 128; 152pp; English.
XX CC The invention relates to enzymatic nucleic acid molecules that down
XX CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
XX CC by cleaving RNA derived from the genes. The nucleic acid sequences are
XX CC useful as pharmaceutical agents for treating conditions such as chronic
XX CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
XX CC that are related to or will respond to the levels of CLCA1 in a cell or
XX CC tissue. The sequences are useful for reducing CLCA1 activity in a cell or
XX CC hence, are useful for treatment of a patient having a condition
XX CC associated with the level of CLCA1, where the invention further comprises
XX CC the use of one or more therapies under conditions suitable for the
XX CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
XX CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
XX CC nucleic acids of the invention are also used as diagnostic tools to
XX CC examine genetic drift and mutations within diseased cells or to detect
XX CC the presence of CLCA1 RNA in a cell. This sequence represents an
XX CC enzymatic nucleic acid molecule of the invention
XX SQ Sequence 17 BP; 6 A; 2 C; 6 G; 0 T; 3 U; 0 Other;
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 95;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 423 ACATCTCCCGTGCTTC 439
DB 17 ACATCTCCCGTGATT 1
RESULT 166
ACN00114/c
ID ACN00114 standard; RNA; 17 BP.
XX ACN00114;
AC
XX 22-APR-2004 (first entry)
DT
XX

```

```

DE WNV Hammerhead Ribozyme substrate SEQ ID NO 104.
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX
XX 19-OCT-2001; 2001WO-US048350.
PF
XX
XX 20-OCT-2000; 2000US-0242411P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 104; 495pp; English.
PS
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;
SQ
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 728 TCTGTTTCTCAATA 744
Db ||||| |||||
17 TCTGTTTCTCAATA 1

RESULT 167
ACN09334
ID ACN09334 standard; RNA; 17 BP.
XX
XX ACN09334;
AC
XX 22-APR-2004 (first entry)
DT
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9337.
DE
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.

```

```

XX West Nile Virus.
OS
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX
XX 19-OCT-2001; 2001WO-US048350.
PF
XX
XX 20-OCT-2000; 2000US-0242411P.
PR
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
PI
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 9337; 495pp; English.
PS
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 4 A; 3 C; 1 G; 0 T; 9 U; 0 Other;
SQ
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 35.3%; Pred. No. 95;
Matches 6; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

QY 727 TTCGTTTTCTCAAT 743
Db ::||::: ||||
1 UUCUGUUUUACCAAU 17

RESULT 168
ACN09335
ID ACN09335 standard; RNA; 17 BP.
XX
XX ACN09335;
AC
XX 22-APR-2004 (first entry)
DT
XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 9338.
DE
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
OS
XX WO200268637-A2.
PN
XX 06-SEP-2002.
PD
XX

```

```

PF 19-OCT-2001; 2001WO-US048350.
XX
PR 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLATT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.
DR
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
PT (WNV), useful for treating a condition related to WNV infection e.g.
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 9338; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC treating a condition related to WNV infection e.g. pancreatitis,
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC molecule is selected from the group of ribozymes consisting of
CC Hammerhead, inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
CC nucleic acid molecules further comprise at least five ribose residues, at
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC least three of the 5' terminal nucleotides and a 3' end modification of a
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC in the specification. The present sequence is that of a nucleic acid
CC molecule of the invention
XX
SQ Sequence 17 BP; 5 A; 3 C; 1 G; 0 T; 8 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 41.2%; Pred. No. 95;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

Qy 728 TCTGTTTTCACAAATA 744
Db 1 UCUGUUUUUACCAAU 17

RESULT 169
ACAO7606/c
ID ACAO7606 standard; RNA; 17 BP.
XX
XX ACAO7606;
XX
XX 03-JUN-2003 (first entry)
XX
XX NFkB sub-unit modulating zinzyme substrate #5.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection; ss.
XX
XX Homo sapiens.
XX
XX US2002177568-A1.
PN
XX 28-NOV-2002.
PD

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 62 GGCCCCAGCTGGGACCC 78
Db 17 GGCCCCAGCTGGGACCC 1

RESULT 170
ABZ65193
ID ABZ65193 standard; RNA; 17 BP.
XX
XX ABZ65193;
XX
XX 21-MAR-2003 (first entry)
XX
XX Human HER2 DNAzyme substrate #650.
XX
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cyostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX
XX Homo sapiens.
OS

```

```

XX 23-MAY-2001; 2001US-00864785.
XX
XX 07-DEC-1992; 92US-00987132.
PR 18-MAY-1994; 94US-00245466.
PR 15-AUG-1994; 94US-00291932.
PR 23-DEC-1996; 96US-00777916.
XX
XX (STIN/) STINCHCOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
XX Stinchcomb DT, Mcswiggen J, Draper KG;
XX WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression of
PT a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases.
XX
XX Claim 3; Page 37; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg2+. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel enzymatic
CC nucleic acid molecule
XX
XX Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;

```

```

XX WO200297114-A2.
XX
XX PD 05-DEC-2002.
XX
XX PF 29-MAY-2002; 2002WO-US016840.
XX
XX PR 29-MAY-2001; 2001US-0294140P.
XX
XX PR 06-JUN-2001; 2001US-0296249P.
XX
XX PR 10-SEP-2001; 2001US-0318471P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX PA Mcswiggen J;
XX
XX PI WPI; 2003-140484/13.
XX
XX DR Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX PS Claim 4; Page 145; 185pp; English.
XX
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
XX SQ Sequence 17 BP; 0 A; 5 C; 8 G; 0 T; 4 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 70.6%; Pred. No. 95;
XX Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
XX
QY 123 TCGGGCTGCCCGGCTG 139
DB :||||:||||:
1 UCGGGCUGCGCUGGUG 17

RESULT 171
ABZ60372
ID ABZ60372 standard; RNA; 17 BP.
XX
XX AC ABZ60372;
XX
XX DT 21-MAR-2003 (first entry)
XX
XX DE Human K-Ras DNzyme substrate #484.
XX
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX anti-rheumatic; cancer; AIDS; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200297114-A2.
XX
XX PD 05-DEC-2002.
XX
XX PF 29-MAY-2002; 2002WO-US016840.
XX
XX PR 29-MAY-2001; 2001US-0294140P.
XX
XX PR 06-JUN-2001; 2001US-0296249P.
XX
XX PR 10-SEP-2001; 2001US-0318471P.
XX

```

```

PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Mcswiggen J;
XX
XX DR WPI; 2003-140484/13.
XX
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX PS Claim 58; Page 94; 185pp; English.
XX
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
XX SQ Sequence 17 BP; 5 A; 2 C; 1 G; 0 T; 9 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 35.3%; Pred. No. 95;
XX Matches 6; Conservative 9; Mismatches 2; Indels 0; Gaps 0;
XX
QY 708 TTCCTTTTGATACATTTA 724
DB :||||:||||:
1 UCCUUUGAUAUUUA 17

RESULT 172
ACD65526
ID ACD65526 standard; RNA; 17 BP.
XX
XX AC ACD65526;
XX
XX DT 30-SEP-2003 (first entry)
XX
XX DE HCV minus strand DNzyme substrate sequence #2101.
XX
XX KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
XX RNA stability; RNA expression; RNA synthesis; antisense;
XX enzymatic nucleic acid; hammerhead ribozyme; DNzyme; zinzyme;
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;
XX HBV reverse transcriptase; Enhancer 1 region; viral replication;
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
XX virucide; antiinflammatory; substrate; ss.
XX
XX OS Hepatitis C virus.
XX
XX PN WO200281494-A1.
XX
XX PD 17-OCT-2002.
XX
XX PF 26-MAR-2002; 2002WO-US009187.
XX
XX PR 26-MAR-2001; 2001US-00817879.
XX
XX PR 08-JUN-2001; 2001US-00877478.
XX
XX PR 08-JUN-2001; 2001US-0296876P.
XX
XX PR 24-OCT-2001; 2001US-0335059P.
XX
XX PR 05-DEC-2001; 2001US-0337055P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX PA (BLAT/) BLATT L.
XX
XX PA (MACE/) MACEJAK D.
XX
XX (MCSW/) MCSWIGGEN J.

```


CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro aa (anti)sense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 273 GCGGGGTCTCGGAGATC 289

Db 17 GCTGGGTCTCAGAGATC 1

RESULT 175

ADC37976

ID ADC37976 standard; DNA; 17 BP.

XX AC ADC37976;

XX DT 18-DEC-2003 (first entry)

XX Human AMLP1a scanning 17-mer oligonucleotide SEQ ID NO:325.

XX human; angiominotin-like protein 1; AMLP1; cytostatic; gene therapy;
 KW AMLP1a; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO2003037931-A2.

XX PD 08-MAY-2003.

XX PF 01-NOV-2002; 2002WO-US035129.

XX PR 01-NOV-2001; 2001US-0334773P.

XX PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX PI Shannon M, Phan T;

XX DR WPI; 2003-430501/40.

XX New isolated nucleic acid molecule encoding a human angiominotin-like
 PT protein, useful for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of AMLP1.

XX Example 2; SEQ ID NO 325; 172pp; English.

XX The present invention describes the human angiominotin-like protein 1
 CC (AMLP1). human AMLP1 has cytostatic activity, and can be used in gene
 CC therapy. The AMLP1 protein, nucleic acid molecules, antibodies, and
 CC compositions of the present invention can be used for treating or
 CC preventing a disorder associated with decreased or increased expression
 CC or activity of AMLP1. The present sequence represents a scanning
 CC oligonucleotide for human AMLP1a, which is used in an example from the
 CC present invention.

XX Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 243 ACAGCGCGGCTCAGC 259

Db 1 ACATCCGCTCGCTCAGC 17

RESULT 176

ADC24273/C

ID ADC24273 standard; DNA; 17 BP.

XX AC ADC24273;

XX DT 18-DEC-2003 (first entry)

XX Human NOV9 forward PCR primer SEQ ID NO:80.

XX human; NOVX; cardiant; antiarteriosclerotic; hypotensive; vasotrophic;
 KW dermatological; anorectic; immunosuppressive; cytostatic;
 KW antiinfertility; haemostatic; anti-HIV; antiasthmatic; antiinflammatory;
 KW neuroprotective; anabolic; nootropic; antiparkinsonian; gene therapy;
 KW cardiomyopathy; atherosclerosis; hypertension; congenital heart defect;
 KW pulmonary stenosis; scleroderma; obesity; metabolic disturbance; obesity;
 KW transplantation; adrenoleukodystrophy; congenital adrenal hyperplasia;
 KW prostate cancer; diabetes; metabolic disorder; neoplasm; adenocarcinoma;
 KW fertility; haemophilia; graft versus host disease; AIDS;
 KW bronchial asthma; Crohn's disease; multiple sclerosis;
 KW infectious disease; anorexia; neurodegenerative disorder;
 KW Alzheimer's disease; Parkinson's disease; immune disorder;
 KW haematopoietic disorder; dyslipidaemia; wasting disorder; PCR primer; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO2003076584-A2.

XX PD 18-SEP-2003.

XX PF 06-MAR-2003; 2003WO-US006951.

XX PR 06-MAR-2002; 2002US-0361974P.

XX PR 19-MAR-2002; 2002US-0365477P.

XX PR 22-MAR-2002; 2002US-0366928P.

XX PR 06-AUG-2002; 2002US-0401661P.

XX PR 05-MAR-2003; 2003US-00401661.

XX PA (CURA-) CURAGEN CORP.

XX Alsobrook JP, Burgess CE, Edinger SR, Gerlach VL, Ji W, Kekuda R;
 PI Li L, Macdougall JR, Miller CE, Millet I, Patturajan M, Pena CEA;
 PI Rieser DK, Sciore P, Shenoy SG, Smithson G, Spytek KA, Stone DJ;
 PI Voss EZ, Zhong M;

XX WPI; 2003-722330/68.

XX New NOVX polypeptides and nucleic acids, useful for diagnosing or
 PT treating e.g. cardiomyopathy, atherosclerosis, hypertension, scleroderma,
 PT obesity, prostate cancer, AIDS, bronchial asthma, Crohn's disease, or
 PT multiple sclerosis.

XX Example C; SEQ ID NO 80; 229pp; English.

XX The present invention describes novel human proteins, designated NOVX
 CC proteins. The NOVX sequences have cardiant, antiarteriosclerotic,
 CC hypotensive, vasotrophic, dermatological, anorectic, immunosuppressive,
 CC cytostatic, antiinfertility, haemostatic, anti-HIV, antiasthmatic,
 CC antiinflammatory, neuroprotective, anabolic, nootropic and
 CC antiparkinsonian activities, and can be used in gene therapy. The NOVX
 CC sequences can be used as a therapeutic in the manufacture of a medicament
 CC for treating a syndrome associated with a human disease, such as a
 CC pathology associated with NOVX. The NOVX proteins and nucleic acids
 CC encoding them are useful for diagnosing or treating pathologies, diseases
 CC or conditions associated with NOVX sequences, including cardiomyopathy,
 CC atherosclerosis, hypertension, congenital heart defects, pulmonary
 CC stenosis, scleroderma, obesity, metabolic disturbances associated with
 CC obesity, transplantation, adrenoleukodystrophy, congenital adrenal
 CC hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm,
 CC adenocarcinoma, fertility, haemophilia, graft versus host disease, AIDS,

CC bronchial asthma, Crohn's disease, multiple sclerosis, infectious
 CC disease, anorexia, neurodegenerative disorders (e.g. Alzheimer's disease,
 CC or Parkinson's disease), immune disorders, haematopoietic disorders,
 CC dyslipidaemias, and wasting disorders associated with chronic diseases,
 CC The proteins can also be used as immunogens to produce antibodies and as
 CC vaccines. The sequences may further be used in chromosome mapping,
 CC identifying individual from minute biological samples (tissue typing),
 CC and in forensic identification of a biological sample. The present
 CC sequence represents a PCR primer for a human NOVX sequence, which is used
 CC in an example from the present invention.

XX Sequence 17 BP; 4 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 664 CCCCTGCTGCCGCACT 680
 Db 17 CCCCTTCTGCAGCCACT 1

RESULT 177

ADP63855/c
 ID ADF63855 standard; DNA; 17 BP.

AC ADF63855;

XX 12-FEB-2004 (first entry)

DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1759.

XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.

XX Homo sapiens.

XX WO2003050284-A1.

XX 19-JUN-2003.

XX 22-NOV-2002; 2002WO-US037506.

XX 10-DEC-2001; 2001US-0339764P.

PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX Guo J;

XX WPI; 2003-532916/50.

XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.

XX Example 2; SEQ ID NO 1759; 164pp; English.

XX The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the Wipoweb
 CC database.

XX Sequence 17 BP; 0 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 520 GGAGGCCCCCATGCCCA 536
 Db 17 GGAGGCCCCCAGGCCCA 1

RESULT 178

ADP63856/c
 ID ADF63856 standard; DNA; 17 BP.

AC ADF63856;

XX 12-FEB-2004 (first entry)

DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1760.

XX chromatin organisation modifier; CHROMO domain; cytostatic; PCCP1;
 KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
 KW human; ss; probe.

XX Homo sapiens.

XX WO2003050284-A1.

XX 19-JUN-2003.

XX 22-NOV-2002; 2002WO-US037506.

XX 10-DEC-2001; 2001US-0339764P.

PA (AMSH) AMERSHAM BIOSCIENCES SV CORP.

XX Guo J;

XX WPI; 2003-532916/50.

XX New prostate cancer candidate protein 1 (PCCP1), useful for preparing a
 PT composition for treating or preventing a disorder associated with
 PT decreased or increased expression or activity of PCCP1 e.g., tumor.

XX Example 2; SEQ ID NO 1760; 164pp; English.

XX The invention relates to a novel isolated nucleic acid that encodes a
 CC protein with a chromatin organisation modifier (CHROMO) domain. The
 CC polynucleotide of the invention demonstrates cytostatic activity and may
 CC be useful for preparing a composition for treating or preventing a
 CC disorder associated with decreased or increased expression or activity of
 CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as
 CC during gene therapy and vaccine production procedures. The current
 CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-
 CC directed probe of the invention. Note: The current sequence is not shown
 CC within the specification per se but was retrieved from the Wipoweb
 CC database.

XX Sequence 17 BP; 1 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 519 TGGAGGCCCCCATGCCCC 535
 Db 17 TGGAGGCCCCCAGGCCCC 1

RESULT 179

ADI49311
 ID ADI49311 standard; DNA; 17 BP.

XX ADI49311;

XX

```

DT 15-APR-2004 (first entry)
XX Human tumour suppression/reversion-related DNA sequence SeqID1814.
XX
DE
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
XX 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; SEQ ID NO 1814; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX nootropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
XX Sequence 17 BP; 7 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 559 GATCACCACCCAGTCA 575
DB 1 GATCACCACCCAGTCA 17

RESULT 180
ADI48838/c
ID ADI48838 standard; DNA; 17 BP.
XX
XX ADI48838;
XX
XX 15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID1341.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
KW

15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID1814.
XX
XX
DE
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
XX 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; SEQ ID NO 1814; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX nootropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
XX Sequence 17 BP; 7 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 559 GATCACCACCCAGTCA 575
DB 1 GATCACCACCCAGTCA 17

RESULT 180
ADI48838/c
ID ADI48838 standard; DNA; 17 BP.
XX
XX ADI48838;
XX
XX 15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID1341.
XX
XX tumour suppression; tumour reversion; apoptosis; virus resistance;
XX cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
KW

15-APR-2004 (first entry)
XX
XX Human tumour suppression/reversion-related DNA sequence SeqID1814.
XX
XX
DE
XX
KW tumour suppression; tumour reversion; apoptosis; virus resistance;
KW cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;
KW primer; PCR; gene chip; antisense; viral disease; tumour;
KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
XX
OS Homo sapiens.
XX
XX WO2003025177-A2.
XX
XX 27-MAR-2003.
XX
XX 17-SEP-2002; 2002WO-IB004523.
XX
XX 17-SEP-2001; 2001FR-00011980.
XX
XX (MOLE-) MOLECULAR ENGINES LAB.
XX
XX Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-313354/30.
XX
XX New isolated nucleic acid, useful for treating viral diseases associated
XX with tumors and cell degeneration, also related polypeptides, antibodies
XX and transfected cells.
XX
XX Disclosure; SEQ ID NO 1341; 30pp; French.
XX
XX This invention relates to novel isolated nucleic acid sequences involved
XX in the phenomena of tumour suppression, tumour reversion, apoptosis
XX and/or resistance to viruses. The invention may be useful for the
XX development of compounds with a cytostatic, virucide, neuroprotective,
XX nootropic or neuroleptic activity. The DNA sequences may be useful as
XX probes and primers for detecting, identifying, quantifying and/or
XX amplifying nucleic acid, for example as one component of a gene chip, in
XX vitro as antisense reagents and for production of recombinant
XX polypeptides. The invention may therefore be useful for preparation of
XX pharmaceuticals for prevention and/or treatment of viral diseases that
XX are characterised by development of tumours or cell degeneration,
XX specifically cancer but also Alzheimer's disease and schizophrenia. The
XX present sequence is that of a nucleic acid sequence of the invention.
XX Note: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/publishedpct_sequences
XX
XX Sequence 17 BP; 7 A; 1 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 734 TTTCTCAAAATAAGTTC 750
DB 17 TTTCTCAAAATAAGTTC 1

RESULT 181
ABZ76956/c
ID ABZ76956 standard; DNA; 17 BP.
XX
XX ABZ76956;
XX
XX 07-MAY-2003 (first entry)
XX
XX Bovine DGAT BAC-DNA sequencing primer #29.
XX
XX Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14; bovine;
KW milk; meat marbling; low fat; polymorphic; SNP;
KW single nucleotide polymorphism; PCR primer; ss.
XX
XX Bos taurus.
XX
XX Synthetic.
XX
XX WO2003004630-A2.
XX
XX 16-JAN-2003.
XX
XX 05-JUL-2002; 2002WO-EP007520.
XX

```

```

XX 06-JUL-2001; 2001EP-00116412.
PR 13-MAY-2002; 2002US-0379412P.
XX (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
XX Fries H, Winter A;
PI WPI; 2003-239205/23.
XX
XX New nucleic acid molecule comprising a sequence of an allele of a
PT polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
PT testing a mammal for its predisposition for fat content of milk and for
PT meat marbling.
XX
XX Example 1; Page 35; 91pp; English.
XX
XX The present invention describes a nucleic acid molecule (NA) (I) encoding
CC a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
CC indicative for low fat content of milk and to low meat marbling
CC (intramuscular fat content). Human DGAT is located to chromosome 8, and
CC bovine DGAT is located to chromosome 14. (I) is useful for testing a
CC mammal for its predisposition for fat content of milk and/or its
CC predisposition for meat marbling. The method comprises analysing the gene
CC encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
CC polymorphisms (SNPs)) which are connected with the predisposition. The
CC nucleotide polymorphisms are located in the coding region of the DGAT
CC gene and result in substitution, deletion and/or addition of an amino
CC acid sequence of the polypeptide which is encoded by the gene. The
CC nucleic acid molecule has at the position 10433 and 10434 of the DGAT
CC gene a guanine and a cytosine residue, at position 3343 a cytosine or
CC guanine, 11030 a guanine, 11048 a cytosine or thymine and 11093 a
CC thymine, which correlate with a predisposition for low fat content of
CC milk and low meat marbling. The nucleic acid molecule has at the position
CC corresponding to position 10433 and 10434 of the DGAT gene two adenine
CC residues which correlate with a predisposition for high content of milk
CC and high meat marbling. The nucleotide polymorphisms are located in a
CC region which is responsible for the regulation of the expression of the
CC product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
CC ABP96046 represent sequences used in the exemplification of the present
CC invention
XX
XX Sequence 17 BP; 3 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 467 GTGGACCCACCCCAAGT 483
Db 17 GTGGACCCCAATCCAGGT 1

```

```

XX Unidentified.
OS WO200281628-A2.
PN 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
XX
XX 29-MAY-2001; 2001US-0294412P.
PR
XX 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Blatt L, Chowrira B, Haerberli P, Mcawiggen J, Foenbaugh K;
PI WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
XX Claim 59; SEQ ID NO 1498; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
XX Sequence 17 BP; 0 A; 13 C; 2 G; 0 T; 2 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 95;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Oy 194 CCCCTGCCCGCCCGCCG 210
Db 1 CCCUUGCCCCCGCCCG 17

```

RESULT 183

```

ADL47965
ID ADL47965 standard; RNA; 17 BP.
XX
XX ADL47965;
AC
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Human IKK-gamma substrate sequence #475.
DE
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.

```

RESULT 183

```

ADL47965
ID ADL47965 standard; RNA; 17 BP.
XX
XX ADL47965;
AC
XX
XX 03-JUN-2004 (first entry)
DT
XX
XX HCV DNzyme substrate sequence #4378.
DE
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNzyme.
XX
XX Hepatitis C virus.
XX
XX US2003125270-A1.
PN
XX
XX 03-JUL-2003.
PD
XX
XX 18-DEC-2000; 2000US-00740332.
PF

```

```

XX 18-DEC-2000; 2000US-00740332.
XX (BLATT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (ROBE/) ROBERTS E.
XX (PAVC/) PAVCO P A.
XX (MACE/) MACEJACK D.
XX
PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
XX
XX WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,
XX especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 4378; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which
XX the binding arms of the enzymatic nucleic acid molecule comprises
XX sequences complementary to any of the defined substrate sequences given
XX in the specification. The nucleic acid molecule may be administered for
XX the treatment of HCV infections, especially in combination with type I
XX interferons. The present sequence represents a HCV DNzyme substrate
XX sequence.
XX
XX Sequence 17 BP; 1 A; 9 C; 4 G; 0 T; 3 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 70.6%; Pred. No. 95;
XX Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
XX
QY 677 CACTGCGTGTGCTCC 693
DB 1 CCCGCGAGGCGCC 17
XX
XX RESULT 184
XX ACN65429/c
XX ID ACN65429 standard; DNA; 17 BP.
XX
XX ACN65429;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:2331.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.

```

```

PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIYY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 2331; 0pp; English.
XX
XX The invention relates to a novel polypeptide (1) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 95;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 549 AGTCCACGAGATCACC 565
DB 17 AGTCGAGCGACATCACC 1
XX
XX RESULT 185
XX ACN73767
XX ID ACN73767 standard; DNA; 17 BP.
XX
XX ACN73767;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:10669.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.

```

```

PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 10669; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
SQ Sequence 17 BP; 4 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 14 GAGTCAGCCAGCATGAC 30
DB |||||
1 GAGCCAGCCAGCATGCC 17
RESULT 186
ACN65427/c
ID ACN65427 standard; DNA; 17 BP.
XX
AC ACN65427;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:2329.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
KW skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX

```

```

PD 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 2329; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SQ Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 95;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 551 TCCACGAGATCACCAT 567
DB |||||
17 TCCAGCGACATCACCAT 1
RESULT 187
ACN73768
ID ACN73768 standard; DNA; 17 BP.
XX
AC ACN73768;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:10670.
XX

```

KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX
 DR WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 10670; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63103
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 15 AGTCAGCCAGCATGACC 31
 |||||
 Db 1 AGCCAGCCAGCATGGCC 17

RESULT 188
 ACN65428/c

ID ACN65428 standard; DNA; 17 BP.
 XX
 AC ACN65428;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human GDMPLP-1 probe SEQ ID NO:2330.
 XX
 KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
 KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
 KW skeletal muscle function.
 XX
 OS Homo sapiens.
 XX
 PN US2004137589-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 26-NOV-2003; 2003US-00723361.
 XX
 PR 26-MAY-2000; 2000US-0207456P.
 PR 21-SEP-2000; 2000US-0234687P.
 PR 27-SEP-2000; 2000US-0236359P.
 PR 04-OCT-2000; 2000GB-00024263.
 PR 30-JAN-2001; 2001WO-US000661.
 PR 30-JAN-2001; 2001WO-US000662.
 PR 30-JAN-2001; 2001WO-US000663.
 PR 30-JAN-2001; 2001WO-US000664.
 PR 30-JAN-2001; 2001WO-US000665.
 PR 30-JAN-2001; 2001WO-US000666.
 PR 30-JAN-2001; 2001WO-US000667.
 PR 30-JAN-2001; 2001WO-US000668.
 PR 30-JAN-2001; 2001WO-US000669.
 PR 05-FEB-2001; 2001WO-US000670.
 PR 25-MAY-2001; 2001US-00866108.
 XX
 PA (GUY/) GU Y.
 PA (JIY/) JI Y.
 PA (PENN/) PENN S G.
 PA (HANZ/) HANZEL D K.
 PA (RANK/) RANK D.
 PA (CHEN/) CHEN W.
 PA (SHAN/) SHANNON M E.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
 XX
 DR WPI; 2004-533378/51.
 XX
 PT Novel myosin-like protein-1, useful for treating or preventing disorder
 PT associated with decreased expression or activity of human genome-derived
 PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
 PT function.
 XX
 PS Disclosure; SEQ ID NO 2330; Opp; English.
 XX
 CC The invention relates to a novel polypeptide (I) comprising a sequence
 CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
 CC defined in the specification, a fragment of at least 8 amino acids of
 CC (S1), 95% deviation from (S1) which are conservative substitutions, and
 CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
 CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
 CC pharmaceutical composition of the invention is useful for treating or
 CC preventing a disorder associated with decreased expression or activity of
 CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
 CC The present sequence represents a 17-mer nucleotide, used in the
 CC invention for scanning the sequence represented in ACN63102
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 1.8%; Score 13.8; DB 1; Length 17;
 Best Local Similarity 88.2%; Pred. No. 95;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 550 GTCCAACGAGATCACCA 566
ID 17 GTCCAGCCGACATCACCA 1
Db

RESULT 189
AAF46292
ID AAF46292 standard; DNA; 15 BP.
XX
AC AAF46292;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #1131.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wraight CJ, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 41; 20lpp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 0 A; 12 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 1.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 88;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 196 CTGCCCCCCCCCGCC 210
Db 1 CCTGCCCCCCCCCGCC 15

RESULT 191
AAF46288
ID AAF46288 standard; DNA; 15 BP.
XX
QY 402 AGCGGACGAGCAGC 416
Db 16 AGCGGACGAGCAGC 2
Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

RESULT 191
AAF46288
ID AAF46288 standard; DNA; 15 BP.
XX

```

RESULT 190
AAV43464/C
ID AAV43464 standard; RNA; 16 BP.
XX
AC AAV43464;
XX

17-OCT-2003 (revised)
14-SEP-1998 (first entry)
XX

HIV-1 beta-chemokine receptor (CCR)-5 target sequence 11.
XX

Endo-ribonuclease; ribozyme; cleave; co-receptor RNA; HIV infection;
KW chemokine receptor; CCR; fusin; ss.
XX

Human immunodeficiency virus 1.
XX

WO9817308-A1.
XX

30-APR-1998.
XX

24-OCT-1997; 97WO-US019923.
XX

25-OCT-1996; 96US-0027875P.
XX

19-DEC-1996; 96US-00770235.
XX

(IMMU-) IMMUSOL INC.
XX

Leavitt MC, Tritz R, Feng Y, Barber J, Yu M;
XX

WPI; 1998-261188/23.
XX

Endo-ribonuclease nucleic acids - which encode ribozymes which cleave co-
receptor RNA expressed in cells, used particularly for inhibiting HIV
infection of cells.
XX

Claim 3; Page 27; 83pp; English.
XX

This represents a target sequence of HIV-1 co-receptor beta-chemokine
receptor (CCR)-5. The invention provides endo-ribonuclease nucleic acid
that encodes a ribozyme which cleaves a co-receptor RNA expressed in a
cell. The co-receptor RNA is a member of the seven trans-membrane protein
receptor family. This can be used in a method of inhibiting HIV infection
of a cell which comprises cleaving a co-receptor mRNA expressed in the
cell. The co-receptor mRNA encodes an HIV co-receptor protein selected
from fusin, beta-chemokine receptor-5 (CCR-5), CCR-3 and CCR-2b. The
cleavage of the co-receptor mRNA inhibits the production of the selected
co-receptor protein, thereby inhibiting HIV infection of the cell. The
endo-ribonucleases can be used to specifically cleave RNAs. The method
can be used for inhibiting HIV infection of cells by inhibiting
expression of HIV co-receptor on the surface of cells. Because the level
of co-receptor on the surface of the cell is reduced, HIV entry into the
cells is inhibited. Cleavage of HIV co-receptor mRNA using targeted
ribozymes is not cytotoxic to cells expressing the co-receptor and the
cells retain normal immune function. (Updated on 17-OCT-2003 to
standardise OS field)
XX

Sequence 16 BP; 0 A; 6 C; 6 G; 0 T; 4 U; 0 Other;
XX

Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 402 AGCGGACGAGCAGC 416

Db 16 AGCGGACGAGCAGC 2

RESULT 191

AAF46288

ID AAF46288 standard; DNA; 15 BP.

XX

AC AAF46288;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP2 oligonucleotide #1127.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 6; Page 41; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 0 A; 11 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 194 CCCCTGCCCGCCG 206
 DB 3 CCCCTGCCCGCCG 15
 RESULT 192
 AAF45796/c
 ID AAF45796 standard; DNA; 15 BP.
 XX
 AC AAF45796;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;

DE IGFBP2 oligonucleotide #635.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 6; Page 38; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 2 A; 2 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 1.7%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 686 TGCCTCCCGCCG 698
 DB 15 TGCCTCCCGCCG 3
 RESULT 193
 AAF45798/c
 ID AAF45798 standard; DNA; 15 BP.
 XX
 AC AAF45798;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP2 oligonucleotide #637.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;

KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pterygia; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease; hyperneovascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.

XX Homo sapiens.

OS WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 200WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

XX Example 6; Page 38; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotide of the present invention (see AAF45151 and AAF45153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, pterygia, ruba, pilaris, serborrhea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

XX Sequence 15 BP; 2 A; 2 C; 10 G; 1 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 TGCTCTCCCGCC 698
DB 13 TGCTCTCCCGCC 1

RESULT 194
AAF45797/c
ID AAF45797 standard; DNA; 15 BP.

XX AAF45797;

XX 30-MAR-2001 (first entry)

XX IGFBP2 oligonucleotide #636.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic; cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid; skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pterygia; IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris; growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba; keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;

KW hyperneovascular condition; hyperplasia; kidney disease; neovascular condition of the retina; ss.

XX Homo sapiens.

PN WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 200WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering UV (ultra-violet) treatment (optional) and an antisense nucleic acid that inhibits or reduces growth factor mediated cell proliferation and/or inflammation.

XX Example 6; Page 38; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of skin disorders. The method comprises contacting the skin with an antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1 receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of inhibiting or reducing growth factor mediated cell proliferation, inflammation and/or other disorders. The present sequence is an oligonucleotide which can be used to design the antisense oligonucleotide of the present invention (see AAF45151 and AAF45153-F45161). The method is useful for ameliorating the effects of psoriasis, ichthyosis, pterygia, ruba, pilaris, serborrhea, keloids, keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the skin, a hyperneovascular condition such as a neovascular condition of the retina, brain or skin, growth factor-mediated malignancies, other sclerotic disease, kidney disease, hyperproliferation of the inside of blood vessels or any other hyperplasia

XX Sequence 15 BP; 2 A; 2 C; 11 G; 0 T; 0 U; 0 Other;

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 TGCTCTCCCGCC 698
DB 14 TGCTCTCCCGCC 2

RESULT 195
ADD15802/c
ID ADD15802 standard; RNA; 15 BP.

XX ADD15802;

XX 15-JAN-2004 (first entry)

XX K-ras targeting zinzyme substrate sequence #11.

XX Zinzyme; ss; K-ras; human; gene therapy; cytostatic; catalytic RNA; gene expression; cancer; HER-2.

XX Synthetic.

XX Homo sapiens.

XX US2003105308-A1.

XX 05-JUN-2003.

```

PF 31-JUL-2001; 2001US-00918728.
XX
XX 05-NOV-1997; 97US-0064866P.
XX 29-APR-1998; 98US-0083727P.
PR 04-NOV-1998; 98US-0018667S.
PR 28-APR-1999; 99US-00301511.
PR 29-DEC-1999; 99US-00474432.
PR 30-DEC-1999; 99US-00476387.
PR 23-MAY-2000; 2000US-00578223.
PR 04-APR-2001; 2001US-00825805.
XX
PA (BEIG/) BEIGELMAN L.
PA (ZINN/) ZINNEN S.
XX
XX Beigelman L, Zinnen S;
XX
XX WPI; 2003-801249/75.
XX
XX New nucleoside triphosphate compound for use in inhibiting gene
XX expression and in human therapy, such as, for the treatment of cancer.
XX
XX Example 3; SEQ ID NO 11; 100pp; English.
XX
XX The invention relates to a catalytic RNA compound (termed a Zinzyme)
XX which is a nucleoside triphosphate, where the structure (A) is given in
XX the specification, and has a sequence of ADD15811, comprising a core
XX zincyme sequence(ADD15811) flanked by sequences homologous to the target
XX molecule and incorporating a 5' linker. The zinzyme is used to inhibit
XX gene expression, in human therapy of e.g. cancer), in diagnosing gene
XX expression, in pharmaceutical, agricultural, research and diagnostic
XX applications. Examples were given showing the optimisation of zinzymes
XX targeting human K-ras and HER2 mRNA. The present sequence is a zinzyme
XX target/substrate sequence.
XX
XX Sequence 15 BP; 2 A; 4 C; 9 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 1e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 685 GTGCCTCCCGCGC 697
DB 15 GTGCCTCCCGCGC 3
XX
RESULT 196
ADM94700
ID ADM94700 standard; DNA; 21 BP.
XX
XX ADM94700;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:50.
XX
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
XX heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
XX antisense oligonucleotide; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO2004030660-A2.
XX
XX 15-APR-2004.
XX
XX
XX 02-OCT-2003; 2003WO-CA001588.
XX
XX 02-OCT-2002; 2002US-0415859P.
XX 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX

```

```

PI Gleave ME, Rocchi P, Signaevsky M;
XX
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
XX active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
XX useful in treating cancer, e.g., prostate cancer or a central nervous
XX system malignancy.
XX
XX Claim 5; SEQ ID NO 50; 38pp; English.
XX
XX The present invention describes a composition which comprises a
XX therapeutic agent that reduces the amount of active heat shock protein 27
XX (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
XX composition has cytostatic activity, and can be used in gene therapy. The
XX composition is useful in treating cancer, e.g., prostate, bladder, lung,
XX breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
XX cancer or a central nervous system malignancy. The present sequence
XX represents a human hsp27 antisense oligonucleotide which is used in the
XX exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 13; DB 1; Length 21;
XX Best Local Similarity 76.2%; Pred. No. 1.8e+02;
XX Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
XX
QY 495 TGTCCCTCGAGGGCAGCACTCA 515
DB 1 TGTCCCTCGAGGGCAGCGGA 21
XX
RESULT 197
AAA86552
ID AAA86552 standard; DNA; 16 BP.
XX
XX AAA86552;
XX
XX 04-DEC-2000 (first entry)
XX
XX Cyclin B1 hairpin ribozyme recognition site #12.
XX
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic; restenosis; ss.
XX Mammalia.
XX
XX WO200032765-A2.
XX
XX 08-JUN-2000.
XX
XX 06-DEC-1999; 99WO-US028772.
XX
XX 04-DEC-1998; 98US-0110954P.
XX (IMMU-) IMMUSOL INC.
XX
XX Tritz R, Welch PJ, Barber JR, Robbins JM;
XX
XX WPI; 2000-412314/35.
XX
XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX PCNA and Cyclin B1.
XX
XX Example 1; Page 16; 109pp; English.
XX
XX The present invention relates to a hairpin or hammerhead ribozyme,
XX designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX Representative examples of ribozyme recognition sites are given in
XX AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX inhibiting restenosis by introduction of the ribozyme into cells. The
XX ribozyme is resistant to endonuclease activity and hence is efficient in
XX

```

```

CC restenosis treatment
XX
SQ Sequence 16 BP; 7 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

  Query Match      1.7%; Score 12.8; DB 1; Length 16;
  Best Local Similarity 87.5%; Pred. NO. 1.2e+02;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 351 TGACGGTCAAGACCAA 366
Db 1 TGACTGTCAAGACCAA 16

RESULT 198
AAC73182/c
XX AAC73182 standard; DNA; 16 BP.
XX
AC AAC73182;
XX
DT 02-FEB-2001 (first entry)
XX
DE Reverse primer #28 used in multiplexing PCR/SBE assay.
XX
KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX
OS Unidentified.
XX
PN WO200058516-A2.
XX
PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
XX 23-JUN-1999; 99US-0140359P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
DR WPI; 2000-656171/63.
XX
PT Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
XX using single base extension reactions.
XX
PS Example 7; Page 50; 70pp; English.
XX
CC The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present sequence is one of the primers used in
CC the method of the present invention to amplify a polymorphic sample. The
CC amplified nucleic acid product is then used as a template in a SBE
CC reaction with an extension primer. The SBE reaction products are used to
CC form the oligonucleotide array
XX
SQ Sequence 16 BP; 1 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

  Query Match      1.7%; Score 12.8; DB 1; Length 16;
  Best Local Similarity 87.5%; Pred. NO. 1.2e+02;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 464 GGTGTGGACCCACCC 479
Db 16 GGTGAGGACCCAGCC 1

```

```

RESULT 199
AAF25893/c
XX AAF25893 standard; DNA; 16 BP.
XX
AC AAF25893;
XX
DT 19-APR-2001 (first entry)
XX
DB Human c-sis/PDGF-B proto-oncogene promoter primer TPO-1.
XX
KW PDGF-B; platelet derived growth factor; c-sis; promoter; cytostatic;
KW antiarteriosclerotic; antiinflammatory; TPO; tumor; drug; primer;
KW triplex forming oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO200104290-A1.
XX
PD 18-JAN-2001.
XX
PF 10-JUL-2000; 2000WO-GB002645.
XX
PR 09-JUL-1999; 99CN-00113864.
XX
PA (SHAN-) SHANGHAI BIO-CHEM INST.
PA (GENE-) GENEMEDIX PLC.
XX
PI Jin Y, Liu J;
XX
DR WPI; 2001-138343/14.
XX
PT Novel triplex forming oligonucleotides useful for treating tumor,
PT atherosclerosis and inflammation, binds to double-stranded promoter
PT region of the c-sis/platelet-derived growth factor proto-oncogene.
XX
PS Claim 3; Page 21; 27pp; English.
XX
CC This invention describes a novel polynucleotide (I) capable of
CC selectively binding to the double-stranded promoter region of the c-
CC sis/platelet-derived growth factor B (PDGF-B) proto-oncogene to form a
CC triplex, which inhibits the function of the promoter and affects have
CC expression of the proto-oncogene. The products of the invention have
CC antiarteriosclerotic, cytostatic and antiinflammatory activity. The
CC effect of triplex formation on c-sis/PDGF-B transcription was studied. A
CC reporter plasmid pGL3 promoter carrying a firefly luciferase gene driven
CC by the 255 base pair (bp) c-sis/PDGF-B promoter was constructed to
CC measure the in vivo effects of triplex forming oligonucleotide (TFO) 1,
CC 2, 6 and 8, which have sequences of 86, 85, 85 and 85 bp, respectively
CC defined in the specification, on c-sis/PDGF-B transcription. Triplex was
CC formed in vitro by incubating supercoil pGL3 promoter plasmid with TFOs,
CC and then the entire DNA complex was transfected into K562 cells.
CC Incubation of TFO1 resulted in a 56.2% decrease in luciferase activity while TFO6
CC caused 85.3% and TFO8 caused 76.3% decrease in luciferase activity. As a
CC non-triplex forming control, TFO2 had little effect on the expression of
CC the firefly luciferase. (I) is useful as a therapeutic agent for treating
CC a condition associated with the expression of c-sis/PDGF-B, including
CC tumors, atherosclerosis or inflammation. (I) binds to the promoter region
CC of c-sis/PDGF-B proto-oncogene preventing nuclear factors binding to the
CC promoter and initiating transcription. (I) is useful for preparing drugs
CC which are specific and stable. The triplex oligonucleotides have
CC generally one to two targets per cell as compared with the 100-1000s of
CC mRNA target for antisense oligonucleotide thus offering the potential for
CC low dose long-acting therapeutics
XX
SQ Sequence 16 BP; 8 A; 0 C; 8 G; 0 T; 0 U; 0 Other;

  Query Match      1.7%; Score 12.8; DB 1; Length 16;
  Best Local Similarity 87.5%; Pred. NO. 1.2e+02;
  Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 483 TTTCCTCTCCCTGTC 498
Db 16 TTTCCTCTCCCTGTC 1

```

RESULT 200	Db				16	TTTCCTCTCCCTCTC 1
AAF25892/c	RESULT 201					
ID AAF25892 standard; DNA; 16 BP.	AAH61718					
AC AAF25892;	XX AAH61718 standard; DNA; 16 BP.					
XX	XX AAH61718;					
DT 19-APR-2001 (first entry)	AC AAH61718;					
XX	XX 10-SEP-2001 (first entry)					
DE Human c-sis/PDGF-B proto-oncogene promoter primer TFO-p.	XX Cyclin B1 hairpin/hammerhead ribozyme recognition site SEQ ID NO:4142.					
XX PDGF-B; platelet derived growth factor; c-sis; promoter; cytostatic;	XX Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;					
KW antiarteriosclerotic; antiinflammatory; TFO; tumor; drug; primer;	KW recognition site; target; ribozyme binding site; eye disease; vulnery;					
KW triplex forming oligonucleotide; ss.	KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;					
XX	KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;					
OS Homo sapiens.	KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;					
XX WO200104290-A1.	KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;					
XX 18-JAN-2001.	KW antipsoriatic; dermatological; antiseborrheic; antidiabetic; virucide;					
XX 10-JUL-2000; 2000WO-GB002645.	KW antisickling; ophthalmological; keratolytic; gene therapy; viral wart;					
XX 09-JUL-1999; 99CN-00113864.	KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;					
XX (SHAN-) SHANGHAI BIO-CHEM INST.	KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;					
XX (GENE-) GENEMEDIX PLC.	KW sickle cell retinopathy; ss.					
XX Jin Y, Liu J;	OS Homo sapiens.					
XX WPI; 2001-138343/14.	OS Synthetic.					
XX Novel triplex forming oligonucleotides useful for treating tumor,	XX WO200130362-A2.					
PT atherosclerosis and inflammation, binds to double-stranded promoter-	XX 03-MAY-2001.					
PT region of the c-sis/platelet-derived growth factor proto-oncogene.	XX 26-OCT-2000; 2000WO-US029500.					
XX Disclosure; Page 21; 27pp; English.	XX 26-OCT-1999; 99US-0161532P.					
XX This invention describes a novel polynucleotide (I) capable of	XX (IMMU-) IMMUSOL INC.					
CC selectively binding to the double-stranded promoter region of the c-	XX Robbins JM, Tritz R;					
CC sis/platelet-derived growth factor B (PDGF-B) proto-oncogene to form a	XX WPI; 2001-300427/31.					
CC triplex, which inhibits the function of the promoter and affects	XX Treating proliferative skin or eye diseases and scarring, using ribozymes					
CC expression of the proto-oncogene. The products of the invention have	PT that cleave RNA encoding cytokines involved in inflammation, matrix					
CC antiarteriosclerotic, cytostatic and antiinflammatory activity. The	PT metalloproteinases, growth factors and cell-cycle dependent kinases.					
CC effect of triplex formation on c-sis/PDGF-B transcription was studied. A	XX Example 1; Page 19; 408pp; English.					
CC reporter plasmid pGL3 promoter carrying a firefly luciferase gene driven	PS The present invention describes a method for treating a proliferative					
CC by the 255 base pair (bp) c-sis/PDGF-B promoter was constructed to	CC skin or eye disease and scarring. The method involves administering a					
CC measure the in vivo effects of triplex forming oligonucleotide (TFO) 1,	CC ribozyme (I) which cleaves RNA encoding a cytokine involved in					
CC 2, 6 and 8, which have sequences of 86, 85, 85 and 85 bp, respectively	CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle					
CC defined in the specification, on c-sis/PDGF-B transcription. Triplex was	CC dependent kinase, growth factor or a reductase, or administering a					
CC formed in vitro by incubating supercoil pGL3 promoter plasmid with TFOs,	CC nucleic acid molecule (II) comprising a promoter operably linked to a					
CC and then the entire DNA complex was transfected into K562 cells.	CC nucleic acid segment encoding (I). (I) can have antipsoriatic,					
CC Incubation of TFO1 resulted in a 56.2% luciferase activity while TFO6	CC dermatological, cytostatic, antiseborrheic, antidiabetic, antisickling,					
CC caused 85.3% and TFO8 caused 76.3% decrease in luciferase activity. As a	CC ophthalmological, vulnery, keratolytic and virucide activities, and					
CC non-triplex forming control. TFO2 had little effect on the expression of	CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used					
CC the firefly luciferase. (I) is useful as a therapeutic agent for treating	CC in gene therapy. (I) and (II) are useful for treating proliferative skin					
CC a condition associated with the expression of c-sis/PDGF-B, including	CC diseases such as psoriasis, atopic dermatitis, actinic keratosis,					
CC tumors, atherosclerosis or inflammation. (I) binds to the promoter region	CC squamous or basal cell carcinoma and viral or seborrheic wart. They can					
CC of c-sis/PDGF-B proto-oncogene preventing nuclear factors binding to the	CC also be used for treating proliferative eye diseases such as diabetic					
CC promoter and initiating transcription. (I) is useful for preparing drugs	CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of					
CC which are specific and stable. The triplex oligonucleotides have	CC prematurity and retinal detachment, and for treating and preventing					
CC generally one to two targets per cell as compared with the 100-1000s of	CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn					
CC mRNA target for antisense oligonucleotide thus offering the potential for	CC scar. AAH57577 to AAH62099 represent sequences used in the					
CC low dose long-acting therapeutics	CC exemplification of the present invention					
XX	XX					
SQ Sequence 16 BP; 8 A; 0 C; 8 G; 0 T; 0 U; 0 Other;	SQ Sequence 16 BP; 7 A; 3 C; 3 G; 3 T; 0 U; 0 Other;					
Query Match	Query Match					
Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;	Best Local Similarity 1.7%; Score 12.8; DB 1; Length 16;					
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;					
QY 483 TTTCCTCTCCCTCTC 498						

```

Qy 351 TGACGGTCAAGACCAA 366
Db 1 TGACTGTCAAGACCAA 16

RESULT 202
AAS15504
ID AAS15504 standard; DNA; 16 BP.
XX AC AAS15504;
XX DT 16-JAN-2002 (first entry)
XX DE N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #1.
XX KW N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
XX KW single nucleotide polymorphism; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT variation replace(8,G)
XX FT FT /*tag= a
XX FT FT /standard_name= "Single nucleotide polymorphism"
XX FT FT /*tag= b
XX FT FT /standard_name= "Single nucleotide polymorphism"
XX PN WO200166804-A2.
XX PD 13-SEP-2001.
XX PF 09-MAR-2001; 2001WO-US007775.
XX PR 09-MAR-2000; 2000US-00521983.
XX PR 10-JUL-2000; 2000US-00613517.
XX PA (PROT-) PROTOGENE LAB INC.
XX PI Cronin MT, Frueh F, Brennan TM;
XX DR WPI; 2001-616243/71.
XX PT Determining sequence variation in, or monitoring expression of genes in
XX PT target nucleic acid for high-throughput genotyping of (un)known
XX PT polymorphisms/mutations, comprises hybridization pattern differences
XX PT between target and probe sequences.
XX PS Example 5; Page 34; 60pp; English.
XX CC The invention relates to a method of simultaneously determining the
XX CC presence of 2 or more sequence variations in target nucleic acids, or
XX CC simultaneously monitoring expression of 2 or more genes. The method
XX CC comprises determining differences in hybridisation between the target
XX CC nucleic acid and immobilised probes, where differences in hybridisation
XX CC between indicates sequence variations or transcription levels. The method
XX CC is used for simultaneously determining the presence or absence of two or
XX CC more sequence variations in target nucleic acids or simultaneously
XX CC monitoring expression of two or more genes in target nucleic acids. The
XX CC methods are applicable to high-throughput genotyping of known and unknown
XX CC polymorphisms and mutations. The method maximises the information yield
XX CC of hybridisation-based array applications by increasing the number of
XX CC informative array-immobilised polynucleotide probes. The present sequence
XX CC represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
XX CC polymorphism (SNP) hybridisation probe #1
XX SQ Sequence 16 BP; 2 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. NO. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 473 CCCACCCAGTTTCCT 488
Db 1 CCCACCCAGTTTCCT 16

RESULT 203
AAS15520
ID AAS15520 standard; DNA; 16 BP.
XX AC AAS15520;
XX DT 16-JAN-2002 (first entry)
XX DE N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #17.
XX KW N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
XX KW single nucleotide polymorphism; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT variation replace(8,G)
XX FT FT /*tag= a
XX FT FT /standard_name= "Single nucleotide polymorphism"
XX FT FT /*tag= b
XX FT FT /standard_name= "Single nucleotide polymorphism"
XX PN WO200166804-A2.
XX PD 13-SEP-2001.
XX PF 09-MAR-2001; 2001WO-US007775.
XX PR 09-MAR-2000; 2000US-00521983.
XX PR 10-JUL-2000; 2000US-00613517.
XX PA (PROT-) PROTOGENE LAB INC.
XX PI Cronin MT, Frueh F, Brennan TM;
XX DR WPI; 2001-616243/71.
XX PT Determining sequence variation in, or monitoring expression of genes in
XX PT target nucleic acid for high-throughput genotyping of (un)known
XX PT polymorphisms/mutations, comprises hybridization pattern differences
XX PT between target and probe sequences.
XX PS Example 5; Page 35; 60pp; English.
XX CC The invention relates to a method of simultaneously determining the
XX CC presence of 2 or more sequence variations in target nucleic acids, or
XX CC simultaneously monitoring expression of 2 or more genes. The method
XX CC comprises determining differences in hybridisation between the target
XX CC nucleic acid and immobilised probes, where differences in hybridisation
XX CC between indicates sequence variations or transcription levels. The method
XX CC is used for simultaneously determining the presence or absence of two or
XX CC more sequence variations in target nucleic acids or simultaneously
XX CC monitoring expression of two or more genes in target nucleic acids. The
XX CC methods are applicable to high-throughput genotyping of known and unknown
XX CC polymorphisms and mutations. The method maximises the information yield
XX CC of hybridisation-based array applications by increasing the number of
XX CC informative array-immobilised polynucleotide probes. The present sequence
XX CC represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
XX CC polymorphism (SNP) hybridisation probe #20
XX SQ Sequence 16 BP; 2 A; 8 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. NO. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 473 CCCACCCAGTTTCCT 488
Db 1 CCCACCCAGTTTCCT 16

```

```

RESULT 204
AAS15516
ID AAS15516 standard; DNA; 16 BP.
XX
AC AAS15516;
XX
DT 16-JAN-2002 (first entry)
XX
DE N-acetyltransferase 2 (NAT2) G191A SNP hybridisation probe #13.
XX
KW N-acetyltransferase 2; NAT2; human; genotyping; SNP; G191A; probe;
KW single nucleotide polymorphism; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FH variation replace(8,G)
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism"
FT variation replace(9,G)
FT /*tag= b
FT /standard_name= "Single nucleotide polymorphism"
XX
PN WO200166804-A2.
XX
PD 13-SEP-2001.
XX
PF 09-MAR-2001; 2001WO-US007775.
XX
PR 09-MAR-2000; 2000US-00521983.
PR 10-JUL-2000; 2000US-00613517.
XX
PA (PROT-) PROTOGENE LAB INC.
XX
PI Cronin MT, Frueh F, Brennan TM;
XX
WPI; 2001-616243/71.
XX
PT Determining sequence variation in, or monitoring expression of genes in
PT target nucleic acid for high-throughput genotyping of (un)known
PT polymorphisms/mutations, comprises hybridization pattern differences
PT between target and probe sequences.
XX
PS Example 5; Page 35; 60pp; English.
XX
CC The invention relates to a method of simultaneously determining the
CC presence of 2 or more sequence variations in target nucleic acids, or
CC simultaneously monitoring expression of 2 or more genes. The method
CC comprises determining differences in hybridisation between the target
CC nucleic acid and immobilised probes, where differences in hybridisation
CC between indicates sequence variations or transcription levels. The method
CC is used for simultaneously determining the presence or absence of two or
CC more sequence variations in target nucleic acids or simultaneously
CC monitoring expression of two or more genes in target nucleic acids. The
CC methods are applicable to high-throughput genotyping of known and unknown
CC polymorphisms and mutations. The method maximises the information yield
CC of hybridisation-based array applications by increasing the number of
CC informative array-immobilised polynucleotide probes. The present sequence
CC represents N-acetyltransferase 2 (NAT2) G191A single nucleotide
CC polymorphism (SNP) hybridisation probe #13
XX
SQ Sequence 16 BP; 2 A; 7 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 473 CCCACCCCAAGTTTCTT 488
||||| |||||
DB 1 CCCACCCTAGTTTCTT 16

```

```

RESULT 205
ABA89669
ID ABA89669 standard; DNA; 16 BP.
XX
AC ABA89669;
XX
DT 12-FEB-2002 (first entry)
XX
DE Serial analysis of ribosomal DNA tag #28.
XX
KW Serial analysis of ribosomal DNA; SARD; Genetic diversity;
KW geochemical exploration; agriculture; bioremediation; forensic science;
KW environmental analysis; parasite detection; virus detection; ss.
XX
OS Unidentified.
XX
PN WO200177392-A2.
XX
PD 18-OCT-2001.
XX
PF 10-APR-2001; 2001WO-US011609.
XX
PR 10-APR-2000; 2000US-0196063P.
PR 11-APR-2000; 2000US-0196258P.
XX
PA (ASHB/) ASHBY M.
XX
PI Ashby M;
XX
WPI; 2002-010926/01.
XX
PT Determining genetic diversity of population by analyzing a specific
PT polymorphic region characteristic of particular genome in population of
PT interest, useful for locating mineral deposits or petroleum reserves.
XX
PS Example 3; Fig 15; 83pp; English.
XX
CC The present invention relates to a method of determining the genetic
CC diversity of a population, involving amplifying a genome subregion with a
CC polymorphic site, cleaving amplified fragment close to the polymorphic
CC site, immobilising the amplified fragment, spitting into two pools,
CC adding a linker to each pool, digesting the immobilised product to form
CC tags that are ligated to form ditags, and amplifying, cleaving and
CC ligating to form concatemers and sequencing. The method is known as
CC serial analysis of ribosomal DNA (SARD). This can be used to determine the
CC genetic diversity of a population including microbial, viral or immune
CC cell populations. The microbial population whose genetic diversity can be
CC determined is from a sample associated with a site for petroleum or
CC natural gas exploration, i.e., at a site of oil or gas reserves,
CC associated with a site of mineral exploration, associated with a
CC agricultural field, of patient sample suspected to have bacterial or
CC fungal infection, associated with bioremediation site, or of an insect or
CC parasite. The methods have application in fields of geochemical
CC exploration, agriculture, bioremediation, environmental analysis,
CC clinical microbiology, forensic science and medicine. The present
CC sequence is an oligonucleotide described in the exemplification of the
CC invention
XX
SQ Sequence 16 BP; 2 A; 8 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 525 CCCCCATGCCCAAGCT 540
||||| |||||
DB 1 CCCCCGTGCCCAAGCT 16

```

```

RESULT 206
ABA89738
ID ABA89738 standard; DNA; 16 BP.
XX

```

AC ABA89738;
 XX
 DT 12-FEB-2002 (first entry)
 XX
 DE Serial analysis of ribosomal DNA tag #97.
 XX
 KW Serial analysis of ribosomal DNA; SARD; genetic diversity;
 KW geochemical exploration; agriculture; bioremediation; forensic science;
 KW environmental analysis; parasite detection; virus detection; ss.
 XX
 OS Unidentified.
 XX
 PN WO200177392-A2.
 XX
 PD 18-OCT-2001.
 XX
 PP 10-APR-2001; 2001WO-US011609.
 XX
 PR 10-APR-2000; 2000US-0196063P.
 PR 11-APR-2000; 2000US-0196258P.
 XX
 PA (ASHB/) ASHBY M.
 XX
 XX Ashby M;
 XX
 XX WPI; 2002-010926/01.
 DR
 XX
 XX Determining genetic diversity of population by analyzing a specific
 PT polymorphic region characteristic of particular genome in population of
 PT interest, useful for locating mineral deposits or petroleum reserves.
 XX
 PS Example 3; Fig 16; 83pp; English.
 XX
 XX The present invention relates to a method of determining the genetic
 CC diversity of a population, involving amplifying a genome subregion with a
 CC polymorphic site, cleaving amplified fragment close to the polymorphic
 CC site, immobilising the amplified fragment, splitting into two pools,
 CC adding a linker to each pool, digesting the immobilised product to form
 CC tags that are ligated to form ditags, and amplifying, cleaving and
 CC ligating to form concatamers and sequencing. The method is known as
 CC serial analysis of ribosomal DNA (SARD). This can be used to determine the
 CC genetic diversity of a population including microbial, viral or immune
 CC cell populations. The microbial population whose genetic diversity can be
 CC determined is from a sample associated with a site for petroleum or
 CC natural gas exploration, i.e., at a site of oil or gas reserves,
 CC associated with a site of mineral exploration, associated with a
 CC agricultural field, of patient sample suspected to have bacterial or
 CC fungal infection, associated with bioremediation site, or of an insect or
 CC parasite. The methods have application in fields of geochemical
 CC exploration, agriculture, bioremediation, environmental analysis,
 CC clinical microbiology, forensic science and medicine. The present
 CC sequence is an oligonucleotide described in the exemplification of the
 CC invention
 XX
 SQ Sequence 16 BP; 1 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 56 CTGCGGGGCCCCAGCT 71
 DB 1 CTGCGGTGCGCAGCT 16
 |||||
 RESULT 207
 ID ADC03079/c
 XX ADC03079 standard; DNA; 16 BP.
 AC ADC03079;
 XX
 XX 18-DEC-2003 (first entry)
 DT
 XX

DE Ex vivo stem-cell expansion related polynucleotide #514.
 XX
 XX cytostatic; antianaemic; immunomodulator; immunostimulant;
 KW immunosuppressive; antiinflammatory; interleukin agonist 3;
 KW interleukin antagonist 3; gene therapy; ex vivo expansion of stem cell;
 KW modified human interleukin-3; cell proliferation;
 KW acute myelogenous leukaemia cell proliferation; TP-1 cell proliferation;
 KW methylcellulose assay; haematopoietic disorder; cancer;
 KW acute myelogenous leukaemia; B lymphoid cancer; leukopenia; neutropenia;
 KW aplastic anaemia; Chediak-Higashi's syndrome;
 KW systemic lupus erythematosus; myelodysplastic syndrome; myelofibrosis;
 KW bone marrow; blood cell activation; blood cell growth; ds.
 XX
 OS Synthetic.
 XX
 XX US6479261-B1.
 PN
 PD 12-NOV-2002.
 XX
 PP 15-NOV-1995; 95US-00559390.
 XX
 PR 24-NOV-1992; 92US-00981044.
 PR 22-NOV-1993; 93WO-US011198.
 PR 06-APR-1995; 95US-00411796.
 XX
 XX (PHAA) PHARMACIA CORP.
 PA
 XX
 XX Bauer SC, Abrams MA, Bradford-Goldberg SR, Caparon MH, Easton AM;
 PI Klein BK, McKearn JP, Olins P, Paik K, Polazzi J, Thomas JW;
 XX
 DR WPI; 2003-655574/62.
 XX
 XX Selective ex vivo expansion of stem cells, useful for treating a patient
 PT having hematopoietic disorder, e.g. leukemia, neutropenia or aplastic
 PT anemia, comprises using recombinant human interleukin-3 variant or mutant
 PT proteins.
 XX
 PS Example 66; SEQ ID NO 539; 288pp; English.
 XX
 XX The invention describes selective ex vivo expansion of stem cells
 CC comprising separating stem cells from other cells, culturing the cells
 CC with modified human interleukin-3 polypeptide with at least 3 times
 CC greater cell proliferative activity than native human interleukin-3 in at
 CC least one assay selected from the group of acute myelogenous leukaemia
 CC cell proliferation, TP-1 cell proliferation, and methylcellulose assay,
 CC and harvesting the cultured cells. The method is useful for selective ex
 CC vivo expansion of stem cells. The recombinant human interleukin-3 variant
 CC or mutant proteins are useful for treating a patient having a
 CC haematopoietic disorder, such as cancer (e.g. acute myelogenous leukaemia
 CC or certain types of B lymphoid cancers), leukopenia, neutropenia,
 CC aplastic anaemia, Chediak-Higashi's syndrome, systemic lupus
 CC erythematosus, myelodysplastic syndrome, or myelofibrosis. The
 CC interleukin-3 mutants are also useful as antagonists for producing
 CC antibodies used in immunoassay and immunotherapy protocols, or for
 CC stimulating bone marrow and blood cell activation and growth before
 CC infusion into patients. This sequence represents an ex vivo stem cell
 CC expansion method associated polynucleotide.
 XX
 SQ Sequence 16 BP; 4 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.2e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 565 CATCCAGTCACCTTC 580
 DB 16 CATCCAGTCACCTTC 1
 |||||
 RESULT 208
 ID ADF28804
 XX ADF28804 standard; DNA; 16 BP.
 DT
 XX

```

AC ADF28804;
XX
XX
XX 12-FEB-2004 (first entry)
XX
XX Sense primer flanking T-vector insertion site.
XX
XX Dendritic cell; T cell immunity; ss; DC; primer; PCR.
XX
XX Synthetic.
XX
XX WO2003082891-A1.
XX
XX 09-OCT-2003.
XX
XX 28-MAR-2003; 2003WO-KR000631.
XX
XX 29-MAR-2002; 2002KR-00017470.
XX
XX (CREA-) CREAGENE INC.
XX
XX (LEES/) LEE S.
XX
XX Ahn J, Lee Y, Jeon C, Lee B, Choi K, Bae Y;
XX
XX WPI; 2003-804020/75.
XX
XX New dendritic cell-specific polynucleotide comprising e.g. a myosin
XX PT phosphatase target subunit 1, a CD20-like precursor, a Ig superfamily
XX PT protein or a 5-lipoxygenase activating protein gene, useful in modulating
XX PT T cell immunity.
XX
XX Example; Page 27; 70pp; English.
XX
XX The invention relates to dendritic cell-specific polynucleotides. The
XX CC dendritic cell-specific nucleotide sequence comprises myosin phosphatase
XX CC target subunit 1 gene, CD20-like precursor gene, Ig superfamily protein
XX CC gene, glycoprotein mb gene, 5-lipoxygenase activating protein gene,
XX CC dihydropyrimidinase related protein-2 gene, cystatin A gene,
XX CC immunoglobulin transcription factor 2 gene, transforming growth factor
XX CC beta-induced 68k gene, myeloid DAP12-associating lectin gene, B cell
XX CC linker protein gene, activated RNA polymerase II transcription cofactor 4
XX CC gene, enolase 1 alpha gene, 90 kDa heat shock protein gene, accessory
XX CC proteins BAP31/BAP29 gene, isocitrate dehydrogenase 3 (NAD+) alpha gene,
XX CC microsomal glutathione S-transferase 2 gene, GABA(A) receptor-associated
XX CC protein gene, nicastrin gene, purinergic receptor (family A group 5)
XX CC gene, Rho GDP dissociation inhibitor beta gene, MAD homolog 2 gene, MLN51
XX CC gene, interferon regulatory factor 4 gene, the fragments of these genes,
XX CC or a polynucleotide selected from
XX CC ADF28789ADF28790ADF28791ADF28792ADF28793ADF28794. The dendritic cell-
XX CC specific polynucleotide is useful in modulating T cell immunity. Methods
XX CC for detecting a dendritic cell; for identifying a lymphoid CD11c-
XX CC dendritic cell; for identifying a myeloid monocyte-derived dendritic cell
XX CC ; for identifying a myeloid CD140plus; dendritic cell; for identifying a
XX CC myeloid CD140plus dendritic cell; for identifying a maturation stage of
XX CC a lymphoid CD140minus; dendritic cell; for identifying a maturation
XX CC stage of a myeloid monocyte-derived dendritic cell are all provided. The
XX CC dendritic cell-specific polynucleotide is useful in modulating T cell
XX CC immunity. The present sequence represents a primer flanking T-vector
XX CC insertion site, used in back hybridization to screen out redundant clones.
XX
XX Sequence 16 BP; 1 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 16;
XX Best Local Similarity 87.5%; Pred. No. 1.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 198 TGCCCCCGCGCGCCAT 213
DB 1 TGCTCCCGCGCGCCAT 16
RESULT 209
ADM18315/c
ID ADM18315 standard; DNA; 16 BP.

```

```

XX
XX ADM18315;
XX
XX 20-MAY-2004 (first entry)
XX
XX Sequence added to 5' end of Chlamydia sense primers.
XX
XX anti-bacterial; antilipemic; antiarteriosclerotic; antiasthmatic;
XX KW antiinflammatory; antiarthritic; neuroprotective; nootropic;
XX KW ophthalmological; antigen; pneumonia; cardiovascular disease;
XX KW atherosclerosis; bronchitis; pharyngitis; laryngitis; sinusitis;
XX KW obstructive lung disease; asthma; chronic pulmonary disease;
XX KW reactive arthritis; otis media; abdominal aortic aneurysm;
XX KW erythema nodosum; Reiter syndrome; sarcoidosis; Alzheimer's disease;
XX KW multiple sclerosis; lymphogranuloma venereum; ocular trachoma;
XX KW pelvic inflammatory disease; inclusion conjunctivitis; genital trachoma;
XX KW infant pneumonitis; incipient trachoma; keratitis; papillary hyper trophy;
XX KW corneal infiltration; vulvovaginitis; mucopurulent rhinitis; salpingitis;
XX KW cervicitis; cervical follicle; prostatitis; proctitis; urethritis;
XX KW lymphogranule inguinale; climatic bubo; tropical bubo; esthiomene;
XX KW primer; ss.
XX
XX Synthetic.
XX
XX WO2003068811-A2.
XX
XX 21-AUG-2003.
XX
XX 13-FEB-2003; 2003WO-IB001161.
XX
XX 13-FEB-2002; 2002GB-00003403.
XX
XX (CHIR ) CHIRON SRL.
XX
XX Bensi G, Grandi G;
XX
XX WPI; 2003-646479/61.
XX
XX Peptides derived from Chlamydia pneumoniae and C. trachomatis bind to
XX PT human class I MHC molecules and are useful to diagnose, treat and
XX PT immunize against Chlamydia infections.
XX
XX Disclosure; SEQ ID NO 182; 61pp; English.
XX
XX The invention relates to a polypeptide (P1) derived from Chlamydia
XX CC pneumoniae for use as an antigen, or a sequence with at least 50%
XX CC identity; or a sequence comprising a fragment of at least 7 amino acids
XX CC of (P1). The invention is used to treat or prevent disease or infection
XX CC caused by Chlamydia, particularly preferably pneumonia, a cardiovascular
XX CC disease, atherosclerosis, bronchitis, pharyngitis, laryngitis, sinusitis,
XX CC an obstructive lung disease, asthma, chronic pulmonary disease, reactive
XX CC arthritis, otis media, abdominal aortic aneurysm, erythema nodosum,
XX CC Reiter syndrome, sarcoidosis, Alzheimer's disease, multiple sclerosis,
XX CC lymphogranuloma venereum, ocular trachoma, pelvic inflammatory disease,
XX CC inclusion conjunctivitis, genital trachoma, infant pneumonitis, incipient
XX CC trachoma, keratitis, papillary hypertrophy, corneal infiltration,
XX CC vulvovaginitis, mucopurulent rhinitis, salpingitis, cervicitis, cervical
XX CC follicles, prostatitis, proctitis, urethritis, lymphogranule inguinale,
XX CC climatic bubo, tropical bubo and/or esthiomene. The invention is also
XX CC used to diagnose Chlamydia infection. This sequence represents a fragment
XX CC added to the 5' end of a PCR primer used to amplify the DNA sequence
XX CC encoding the peptide of the invention.
XX
XX Sequence 16 BP; 3 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.7%; Score 12.8; DB 1; Length 16;
XX Best Local Similarity 87.5%; Pred. No. 1.2e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 538 GCTAGCCACGCGAGTCC 553
DB 16 GCTAGCCATGCGATGC 1

```

```

RESULT 210
ADI58754/c
ID ADI58754 standard; DNA; 16 BP.
XX
XX
AC ADI58754;
XX
XX
DT 22-APR-2004 (first entry)
XX
DE Human interleukin 3 expressing vector related DNA seq id 539.
XX
XX immunostimulant; antianemic; immunomodulator; antiinflammatory;
KW dermatological; immunosuppressive; cytostatic; neuroprotective;
KW gene therapy; interleukin-agonist-3; cultured stem cell;
KW ex-vivo cell expansion; interleukin-3 mutant; aplastic anaemia;
KW cyclic neutropenia; idiopathic neutropenia; Chediak-Higashi syndrome;
KW systemic lupus erythematosus; leukaemia; myelodysplastic syndrome;
KW myelofibrosis; interleukin 3; IL-3; mutagenesis; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX US2004018618-A1.
PN
XX
XX 29-JAN-2004.
PD
XX
XX 19-JUN-2002; 2002US-00179940.
XX
XX 24-NOV-1992; 92US-00981044.
PR
XX 22-NOV-1993; 93WO-US011198.
PR
XX 06-APR-1995; 95US-00411796.
PR
XX 15-NOV-1995; 95US-00559390.
XX
XX (BAUE/) BAUER S C.
PA
XX (ABRA/) ABRAMS M A.
PA
XX (BRAP/) BRAFORD-GOLDBERG S R.
PA
XX (CAPA/) CAPARON M H.
PA
XX (EAST/) EASTON A M.
PA
XX (KLEI/) KLEIN B K.
PA
XX (MCKE/) MCKEARN J P.
PA
XX (OLIN/) OLINS P.
PA
XX (PAIK/) PAIK K.
PA
XX (POLA/) POLAZZI J.
PA
XX (THOM/) THOMAS J W.
XX
XX Bauer SC, Abrams MA, Braford-Goldberg SR, Caparon MH, Easton AM;
PI Klein BK, Mckearn JP, Olins P, Paik K, Polazzi J, Thomas JW;
PI
XX WPI; 2004-122043/12.
XX
XX Culturing stem cells using a recombinant human interleukin-3 mutant
PT polypeptide, useful for treating aplastic anemia, neutropenia, Chediak-
PT Higashi syndrome, systemic lupus erythematosus, leukemia and
PT myelodysplastic syndrome.
XX
XX Example 65; SEQ ID NO 539; 328pp; English.
PS
XX
XX The invention describes cultured stem cells obtained by a method for
CC selective ex-vivo expansion of stem cells comprising separating stem
CC cells from other cells, culturing the separated stem cells with a
CC selected media which comprises a human interleukin-3 mutant polypeptide
CC comprising defined amino acid sequences SEQ ID NO 15 or 19 given in the
CC specification, and harvesting the cultured cells. The methods and
CC compositions of the present invention are useful for treating aplastic
CC anaemia, cyclic neutropenia, idiopathic neutropenia, Chediak-Higashi
CC syndrome, systemic lupus erythematosus, leukaemia, myelodysplastic
CC syndrome and myelofibrosis. This sequence represents a DNA used in the
CC construction of human interleukin 3 (IL-3) mutants.
XX
XX Sequence 16 BP; 4 A; 2 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. NO. 1.2e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Oy 565 CATCCAGTCACCTTC 580
Db 16 CATCCAGTCACCGTC 1

RESULT 211
ADR70038/c
ID ADR70038 standard; DNA; 16 BP.
XX
XX ADR70038;
AC
XX
XX 04-NOV-2004 (first entry)
DT
XX Human survivin gene modulatory oligonucleotide #106.
DE
XX
XX ss; antiangiogenic; cytostatic; antiarteriosclerotic; antipsoriatic;
KW antidiabetic; ophthalmological; antiarthritic; antirheumatic;
KW antidiabetic; antiallergic; antiinflammatory; dermatological; anti-HIV;
KW virucide; survivin antagonist; apoptosis inhibitor;
KW cellular proliferation inhibitor; survivin; gene expression;
KW abnormal angiogenesis; chemotherapeutic agent; busulfan; myleran;
KW carboplatin; parapiatin; Taxol; doxorubicin; adriamycin; atherosclerosis;
KW psoriasis; diabetic retinopathy; rheumatoid arthritis; asthma; warts;
KW allergic dermatitis; cancer; tumour; sarcoma; glioma; carcinoma;
KW melanoma; osteosarcoma; Ewing's sarcoma; chondrosarcoma;
KW malignant fibrous histiocytoma; fibrosarcoma; Kaposi's sarcoma;
KW Paclitaxel; Docetaxel.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..16
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER = phosphorothioate internucleotide
FT linkages, all locked nucleic acid (LNA) residues are 5'-
FT methyl cytosine residues"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER = beta-D-oxy-locked nucleic acid but
FT optionally DNA nucleotides, optionally phosphate
FT internucleotide linkages"
FT modified_base 13..16
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER = beta-D-oxy-locked nucleic acid but
FT optionally DNA nucleotides, optionally phosphate
FT internucleotide linkages"
XX
XX WO2004069991-A2.
PN
XX
XX 19-AUG-2004.
PD
XX
XX 10-FEB-2004; 2004WO-DK000096.
XX
XX 10-FEB-2003; 2003DK-00000183.
PR
XX 18-NOV-2003; 2003DK-00001708.
XX
XX (SANT-) SANTARIS PHARMA AS.
XX
XX Hansen B, Thru CA, Petersen KD, Westergaard M, Wissenbach M;
PI WPI; 2004-625494/60.
XX
XX New locked nucleic acid containing oligomeric compound capable of
PT modulating survivin expression, useful for treating cancer such as breast
PT carcinoma, lung carcinoma, etc.
XX
XX Claim 1; SEQ ID NO 107; 122pp; English.
PS

```

XX The invention relates to an oligomeric compound (I) capable of modulating
CC survivin expression, having 8-50 nucleotides and/or nucleotide analogues,
CC where the compound comprises a subsequence of at least 8 nucleotides or
CC nucleotide analogues, where the subsequence is located within a sequence
CC chosen from one of 143 sequences given in the specification. (I) is
CC useful for treating a mammal suffering from or susceptible from a disease
CC caused by abnormal angiogenesis, by administering (I) containing one or
CC more DNA units that are targeted to survivin. (I) is useful as a
CC medicament and for the manufacture of a medicament for the treatment of
CC cancer, in combination with chemotherapeutic agent such as busulfan
CC (myleran), carboplatin (paraplatin), Taxol, doxorubicin (adriamycin),
CC etc. (I) or a conjugate (II) containing (I) is useful in the preparation
CC of a medicament for the treatment of atherosclerosis, psoriasis, diabetic
CC retinopathy, rheumatoid arthritis, asthma, warts and allergic dermatitis.
CC (I), (II) or a pharmaceutical (III) containing (I) is useful for treating
CC cancer in the form of a solid tumour, sarcoma, glioma or carcinoma chosen
CC from malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast
CC carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder
CC carcinoma, recurrent superficial bladder cancer, stomach carcinoma,
CC prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical
CC carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma,
CC colorectal carcinoma and carcinoma tumours. The malignant melanoma is
CC chosen from superficial spreading melanoma, nodular melanoma, lentigo
CC maligna melanoma, acral melanoma, amelanotic melanoma, and desmoplastic
CC melanoma. The sarcoma is chosen from osteosarcoma, Ewing's sarcoma,
CC chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's
CC sarcoma. The treatment further involves administration of a
CC chemotherapeutic agent such as taxanes, preferably Taxol, Paclitaxel or
CC Docetaxel. (I), (II) or (III) is also useful for preventing or limiting
CC apoptosis or for preventing cellular proliferation. This sequence
CC corresponds to an antisense oligonucleotide targeted to the human
CC survivin gene.
XX
XX Sequence 16 BP; 4 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
SQ

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 161 TTATGGCGGAGCAGCT 176
||| |||||
DB 16 TTTGGAGGCGAGCAGCT 1

RESULT 212
ABA93324
ID ABA93324 standard; DNA; 15 BP.
XX ABA93324;
AC
XX 22-APR-2002 (first entry)
DT
XX Human ACAA1 gene polymorphism detection ASO primer SEQ ID NO:39.
DE
XX Human; acetyl-Coenzyme A acyltransferase; ACAA1; chromosome 3p23-p22;
KW peroxisomal 3-oxoacyl-Coenzyme A thiolase; SNP; genotype; haplotype;
KW single nucleotide polymorphism; polymorphic variant; enzyme; probe;
KW primer; allele specific oligonucleotide; ss.
XX
XX Homo sapiens.
OS
XX WO200187903-A2.
PN
XX 22-NOV-2001.
PD
XX 03-MAY-2001; 2001WO-US014330.
PF
XX 18-MAY-2000; 2000US-0205022P.
PR
XX (GENA-) GENAISSANCE PHARM INC.
PA (DUDA/) DUDA A E.
XX

PI Chew A, Koshy B;
XX WPI; 2002-164134/21.
XX Isolated polymorphic variant, comprising a polymorphic variant of the acetyl-
PT Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-Coenzyme A thiolase)
PT gene useful for providing haplotype information and in therapy for
PT treating related disorders.
XX
XX Claim 15; Page 13; 93pp; English.
PS
XX The present invention describes a polypeptide (I) which is a polymorphic
CC variant (PV) of the acetyl-Coenzyme A acyltransferase (peroxisomal 3-
CC oxoacyl-Coenzyme A thiolase) ACAA1 protein (ABB05516). ACAA1 is located
CC on chromosome 3p23-p22. (I) can be encoded by ABA93286 (or ABA93288)
CC where the sequence comprises one of the haplotypes shown in Table 4 or
CC one of the haplotype pairs shown in Table 3, where Tables 3 and 4 are
CC given in the specification. The polynucleotide encoding ACAA1 can be used
CC for providing haplotype and genotype information of an individual.
CC Furthermore, the polynucleotide is useful for the treatment of disorders
CC related to its abnormal expression or function. ABA93289 to ABA93383
CC represent allele specific oligonucleotides (ASOs) which are used in the
CC detection of polymorphisms in the human ACAA1 gene
XX
XX Sequence 15 BP; 3 A; 4 C; 6 G; 1 T; 0 U; 1 Other;
SQ

Query Match 1.6%; Score 12.6; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.2e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 171 GCAGCTGGCCAGG 183
|||||||
DB 3 GCAGCTGGCCAGG 15

RESULT 213
ADM94710
ID ADM94710 standard; DNA; 21 BP.
XX ADM94710;
AC
XX 01-JUL-2004 (first entry)
DT
XX Human heat shock protein 27 antisense oligonucleotide SEQ ID NO:60.
DE
XX heat shock protein 27; hsp27; cytostatic; gene therapy;
KW heat shock protein 27 inhibitor; hsp27 inhibitor; cancer; human;
KW antisense oligonucleotide; ss.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX WO2004030660-A2.
PN
XX 15-APR-2004.
PD
XX 02-OCT-2003; 2003WO-CA001588.
PF
XX 02-OCT-2002; 2002US-0415859P.
PR
XX 18-APR-2003; 2003US-0463952P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
XX Gleave ME, Rocchi P, Signaevsky M;
PI
XX WPI; 2004-316331/29.
XX
XX New composition comprising a therapeutic agent that reduces the amount of
PT active hsp27 in hsp27 expressing cells exposed to the therapeutic agent,
PT useful in treating cancer, e.g., prostate cancer or a central nervous
PT system malignancy.
XX
XX Claim 5; SEQ ID NO 60; 38pp; English.
PS

XX The present invention describes a composition which comprises a
CC therapeutic agent that reduces the amount of active heat shock protein 27
CC (hsp27) in hsp27 expressing cells exposed to the therapeutic agent. The
CC composition has cytostatic activity, and can be used in gene therapy. The
CC composition is useful in treating cancer, e.g., prostate, bladder, lung,
CC breast, pancreatic, colon, skin (for example melanoma), renal or ovarian
CC cancer or a central nervous system malignancy. The present sequence
CC represents a human hsp27 antisense oligonucleotide which is used in the
CC exemplification of the present invention.
SQ Sequence 21 BP; 2 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 1.6%; Score 12.6; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 2.1e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
Qy 596 CTTGGGGGCCAGAGCTG 614
Db 1 CTTGGGGGCCAGAGCTG 19
RESULT 214
AAQ39025
ID AAQ39025 standard; DNA; 15 BP.
XX
AC AAQ39025;
XX
DT 25-MAR-2003 (revised)
DT 19-JUL-1993 (first entry)
XX
DE Mutagenic PCR primer 4 to make mutant Factor VIII.
XX
KW FVIII; amplification; heavy; light; chain; expression; ss.
XX
OS Synthetic.
XX
FN EPS34383-A2.
XX
PD 31-MAR-1993.
XX
PF 23-SEP-1992; 92EP-00116246.
XX
PR 24-SEP-1991; 91JP-00243262.
XX
PA (KAGA) CEMO SERO THERAPEUTIC RES INS.
PA (TEIJ) TEIJIN LTD.
XX
PI Yonemura H, Tajima Y, Sugawara K, Maeuda K;
XX
WPI; 1993-102540/13.
XX
PT Plasmids for expression of human factor VIII H and L chains - comprises
PT promoter active in animal cell, DNA encoding signal peptide and including
PT initiation codon, DNA encoding A1-A2 domain and aminoacid(s) at N-
PT terminus of B-domain of factor 8, etc.
XX
PS Example 6; Page 10; 34pp; English.
XX
CC Using PCR utilising the expression plasmid 8.1 contg. the full length of
CC Factor VIII (FVIII) cDNA as a template, the FVIII signal sequence was
CC linked to the upstream of Glu 1649 at the N-terminus of the light chain.
CC Two synthetic oligomers (primers 3 and -4) were used as PCR primers for
CC the amplification of the N-terminal portion of the L-chain. The mutant
CC thus has most of the B domains deleted and is expressed in a separate
CC cistron so that each chain is obtd. in large amts. Recombinant prodn.
CC removes risk of infection from e.g. hepatitis virus, present when Factor
CC VIII is prepd. from human plasma. See also AAQ39022-27. (Updated on 25-
CC MAR-2003 to correct FN field.)
XX
SQ Sequence 15 BP; 2 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 594 AGCTTGGGGCCCCA 607
Db 1 AGCTTGGGGCCCCA 14
RESULT 215
AAT42858
ID AAT42858 standard; DNA; 15 BP.
XX
AC AAT42858;
XX
DT 16-JUN-1997 (first entry)
XX
DB Primer #2 for the phospholipase D protein coding sequence.
XX
KW Phospholipase D; rice; promoter; PLD; probe; primer; amplify; PCR;
KW polymerase chain reaction; ss.
XX
OS Synthetic.
XX
FN WO9630510-A1.
XX
PD 03-OCT-1996.
XX
PF 28-MAR-1996; 96WO-JP000812.
XX
PR 29-MAR-1995; 95JP-00096126.
XX
PA (NISR) JAPAN TOBACCO INC.
XX
PI Morioka S, Ueki J;
XX
WPI; 1996-455357/45.
XX
PT Promoter DNA sequence derived from rice - used to increase expression of
PT foreign genes in transformed hosts.
XX
PS Example 9; Page 13; 29pp; Japanese.
XX
CC AAT42857 and AAT42858 represent amplification primers for the promoter of
CC the rice phospholipase D gene (PLD). The PLD gene sequence (see AAT42853)
CC was identified using the probes shown in AAT42855 and AAT42856. The
CC promoters (see AAT42851 and AAT42852) are efficient promoters for greatly
CC increasing the expression of foreign genes in transformant rice and other
CC plants
XX
SQ Sequence 15 BP; 1 A; 10 C; 2 G; 2 T; 0 U; 0 Other;
Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 184 CTACGTCGCCCCC 197
Db 2 CTACGTCGCCCCC 15
RESULT 216
AA331599
ID AA331599 standard; DNA; 15 BP.
XX
AC AA331599;
XX
DT 21-MAY-1999 (first entry)
XX
DB Tag sequence of a transcript increased in pancreatic cancer.
XX
KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
KW diagnosis; prognosis; treatment; ss.
XX

```

OS Homo sapiens.
XX WO9853319-A2.
PN
XX
XX 26-NOV-1998.
PD
XX
XX 20-MAY-1998; 98WO-US010277.
PF
XX
XX 21-MAY-1997; 97US-0047352P.
PR
XX
XX (UYJO ) UNIV JOHNS HOPKINS.
PA
XX
XX
XX Vogelstein B, Kinzler KW;
PI
XX
XX WPI; 1999-070161/06.
DR
XX
XX Use of isolated gene transcripts - useful for developing products for the
PT diagnosis, prognosis and treatment of cancers, particularly colon and
PT pancreatic cancer.
PT
XX
XX Claim 13; Page 63; 120pp; English.
PS
XX
XX AAX30947-31815 represent tag sequences of transcripts that are
CC differentially expressed in colorectal cancer, in pancreatic cancer, or
CC in both. The tag sequences can be used to identify genes by matching the
CC tag to a gen data base member, or by using the tag sequences as probes to
CC isolate unidentified genes from cDNA libraries. The tag sequences can
CC also be used in a method for diagnosing colon or pancreatic cancer in a
CC sample suspected of being neoplastic. The method comprises comparing the
CC level of at least one transcript in a first sample of a tissue to a
CC second sample, where the first sample is a colonic tissue suspected of
CC being neoplastic and the second sample is a normal human colonic tissue.
CC The transcript is identified by a tag selected from AAX30947-31815. The
CC methods of the invention can be used in the diagnosis, prognosis and
CC treatment of cancer
XX
XX
SQ Sequence 15 BP; 2 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 369 ATGGCGTGTGGAG 382
DB 2 ATGGCGGTGGAG 15

RESULT 217
AAX59902/c
ID AAX59902 standard; DNA; 15 BP.
XX
XX
XX AAX59902;
AC
XX
XX 16-OCT-2000 (first entry)
DT
XX
XX Murine Op-1 Wt-1/Egr-1 binding site.
DE
XX
XX Osteogenic protein-1; OP-1; morphogenic protein; mouse; osteoporosis;
KW morphogen concentration; bone metabolism disease; ss.
XX
XX Mus sp.
OS
XX
XX US6071695-A.
PN
XX
XX 06-JUN-2000.
PD
XX
XX 07-JUN-1995; 95US-00486343.
PF
XX
XX 21-FEB-1992; 92US-00841646.
PR
XX
XX 01-NOV-1993; 93US-00147023.
PR
XX
XX 07-JUN-1994; 94US-00255250.
PR
XX
XX 23-MAY-1995; 95US-00449700.
PR
XX
XX 24-MAY-1995; 95US-00449699.
PR

(CREA-) CREATIVE BIOMOLECULES INC.
XX
PA
XX
XX Oppermann H, Ozkaynak E;
PI
XX
XX WPI; 2000-422077/36.
DR
XX
XX Screening for compounds able to modulate osteogenic protein-1 (OP-1)
PT expression by incubating a candidate compound with a nucleic acid with a
PT reporter gene operatively associated with an OP-1 non-coding nucleic acid
PT fragment.
XX
XX
XX Disclosure; Col 47; 33pp; English.
PS
XX
XX A method for screening a candidate compound for its ability to modulate
CC the expression of osteogenic protein-1 (OP-1) uses a cell transfected
CC with a nucleic acid sequence comprising a reporter gene and an upstream
CC non-coding sequence from OP-1. OP-1 is a tissue morphogenic protein. The
CC method is useful for screening compounds capable of stimulating or
CC inhibiting transcription and/or translation of the OP-1 gene, as well as
CC compounds which may be used as therapeutics for in vivo and ex vivo
CC mammalian applications, e.g. morphogen expression inducing compounds for
CC correcting and alleviating a diseased condition or to regenerate lost or
CC damaged tissue. The compounds may also be used to maintain viability of
CC the differentiated phenotype of cells in culture. Morphogen expression
CC inhibiting compounds identified by the new method can be used to modulate
CC the degree and/or timing of morphogen concentration. Compounds which up-
CC regulate levels of circulating OP-1 in vivo can be used to correct bone
CC metabolism diseases such as osteoporosis. This sequence represents the
CC TCC binding sequence or Wt-1/Egr-1 binding site sequence contained in the
CC upstream region of the osteogenic protein-1 (OP-1) gene. The DNA binding
CC proteins Wt-1 and Egr-1 bind to and control transcription of DNA
XX sequences at these sites
XX
XX
SQ Sequence 15 BP; 0 A; 10 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 398 GAGGAGCGGCGGGA 411
DB 14 GAGGAGCGGCGGGA 1

RESULT 218
AAX90403/c
ID AAX90409 standard; DNA; 15 BP.
XX
XX
XX AAX90409;
AC
XX
XX 30-MAY-2000 (first entry)
DT
XX
XX Scrambled control oligomer 2 for HER-2 gene.
DE
XX
XX Radiation; drug resistance; HER-2; raf-1; radioresistant; tumour; cancer;
KW restenosis; osteoarthritis; neurological; pre-eclampsia;
KW intestinal abnormality; antisense; ss.
XX
XX Homo sapiens.
OS
XX
XX US6027892-A.
PN
XX
XX 22-FEB-2000.
PD
XX
XX 16-DEC-1997; 97US-00991830.
PF
XX
XX 30-DEC-1996; 96US-0034160P.
PR
XX
XX (CHAN/) CHANG E H.
PA (PIRO/) PIROLLO K F.
XX
XX Chang EH, Pirollo KF;
PI

```

XX WPI; 2000-194828/17.
 DR Reducing radiation or drug resistance in a cell comprises introduction of
 PT antisense nucleic acid for treating or diagnosing cancer, restenosis,
 PT osteoarthritis, neurological and intestinal abnormalities and pre-
 XX eclampsia.
 PS Disclosure; Col 10; 18pp; English.
 CC The invention provides a method for reducing radiation or drug resistance
 CC of a cell, in vitro, which does not overexpress HER-2 or raf-1 genes. The
 CC method comprises introducing to the cell an antisense nucleic acid
 CC comprising a segment complementary to HER-2 or raf-1. The method is
 CC useful for increasing drug and radiation sensitivity in a cell,
 CC particularly in the treatment of radioresistant tumours. The antisense
 CC nucleic acids are useful for treating or diagnosing cancer, restenosis,
 CC osteoarthritis, neurological and intestinal abnormalities and pre-
 CC eclampsia. The present sequence represents a scrambled control oligomer
 CC for HER-2 gene
 XX
 SQ Sequence 15 BP; 2 A; 5 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. NO. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 410 GACGAGCATGGCTA 423
 DB |||||
 15 GACAGCATGGCTA 2
 RESULT 219
 AAA95134
 ID AAA95134 standard; DNA; 15 BP.
 AC AAA95134;
 XX
 DT 12-JAN-2001 (first entry)
 DE Allele specific primer #5 for detection of TNFR1 gene polymorphism.
 XX
 KW TNFR1; tumour necrosis factor receptor; polymorphism; human; tumour;
 KW cancer; apoptosis; bacterial infection; primer;
 KW allele specific oligonucleotide; ASO; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200050436-A1.
 XX
 PD 31-AUG-2000.
 XX
 PF 23-FEB-2000; 2000WO-US004606.
 XX
 PR 23-FEB-1999; 99US-0121314P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 PA (NAND/) NANDABALAN K.
 PA (SCHU/) SCHULZ V P.
 PA (STEP/) STEPHENS J C.
 PA (CHEW/) CHEW A.
 XX
 PI Nandabalan K, Schulz VP, Stephens JC, Chew A;
 XX
 DR WPI; 2000-543909/49.
 XX
 PT Polynucleotides comprising polymorphic variants of a reference sequence
 PT for tumor necrosis factor receptor 1 (TNFR1), useful for studying the
 PT biological function of TNFR1 and identifying drugs targeting the protein
 PT for treating disorders.
 XX
 PS Claim 14; Page 20; 79pp; English.

CC The present invention relates to polymorphic variants of the tumour
 CC necrosis factor receptor 1 (TNFR1) gene. The sequence of the gene is
 CC given in AAA95102, AAA95103 and AAA95104. The polymorphisms were
 CC identified by amplifying and sequencing regions of the gene. Twelve
 CC polymorphic loci were discovered. Of these twelve polymorphisms, four can
 CC cause a change in the TNFR1 protein. The present sequence is an allele
 CC specific oligonucleotide (ASO) primer that may be used to detect a TNFR1
 CC gene polymorphism. The TNFR1 polymorphisms may be useful for studying the
 CC biological function of TNFR1 as well as for identifying drugs targeting
 CC the protein for treatment of disorders related to its abnormal expression
 CC or function such as tumours, apoptosis related disorders and bacterial
 CC infection
 XX
 SQ Sequence 15 BP; 2 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. NO. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 666 CCTGCTGCCGCCAC 679
 DB |||||
 2 CCTGCTGCCGCCAC 15
 RESULT 220
 AAA95135/c
 ID AAA95135 standard; DNA; 15 BP.
 XX
 AC AAA95135;
 XX
 DT 12-JAN-2001 (first entry)
 DE Allele specific primer #6 for detection of TNFR1 gene polymorphism.
 XX
 KW TNFR1; tumour necrosis factor receptor; polymorphism; human; tumour;
 KW cancer; apoptosis; bacterial infection; primer;
 KW allele specific oligonucleotide; ASO; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200050436-A1.
 XX
 PD 31-AUG-2000.
 XX
 PF 23-FEB-2000; 2000WO-US004606.
 XX
 PR 23-FEB-1999; 99US-0121314P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 PA (NAND/) NANDABALAN K.
 PA (SCHU/) SCHULZ V P.
 PA (STEP/) STEPHENS J C.
 PA (CHEW/) CHEW A.
 XX
 PI Nandabalan K, Schulz VP, Stephens JC, Chew A;
 XX
 DR WPI; 2000-543909/49.
 XX
 PT Polynucleotides comprising polymorphic variants of a reference sequence
 PT for tumor necrosis factor receptor 1 (TNFR1), useful for studying the
 PT biological function of TNFR1 and identifying drugs targeting the protein
 PT for treating disorders.
 XX
 PS Claim 14; Page 20; 79pp; English.
 XX
 CC The present invention relates to polymorphic variants of the tumour
 CC necrosis factor receptor 1 (TNFR1) gene. The sequence of the gene is
 CC given in AAA95102, AAA95103 and AAA95104. The polymorphisms were
 CC identified by amplifying and sequencing regions of the gene. Twelve
 CC polymorphic loci were discovered. Of these twelve polymorphisms, four can
 CC cause a change in the TNFR1 protein. The present sequence is an allele
 CC specific oligonucleotide (ASO) primer that may be used to detect a TNFR1
 CC gene polymorphism. The TNFR1 polymorphisms may be useful for studying the

CC biological function of TNFR1 as well as for identifying drugs targeting
 CC the protein for treatment of disorders related to its abnormal expression
 CC or function such as tumours, apoptosis related disorders and bacterial
 CC infection

XX SQ Sequence 15 BP; 1 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 165 GCGGCAGCAGCTGG 178
 Db 15 GCGGCAGCAGCAGG 2

RESULT 221

AAS02947
 ID AAS02947 standard; DNA; 15 BP.

XX AAS02947;

XX 29-AUG-2001 (first entry)

XX Human CHMR1 allele specific oligonucleotide probe #7.

XX Human; m1 acetylcholine receptor; CHRM1; immunogen; antibody;

KW Alzheimer's disease; dementia with Lewy bodies; DLB;

KW allele specific oligonucleotide probe; ss.

XX Homo sapiens.

XX WO200127312-A2.

XX 19-APR-2001.

XX 12-OCT-2000; 2000WO-US028211.

PR 13-OCT-1999; 99US-0159269P.

XX (GENA-) GENAISANCE PHARM INC.

PI Choi JY, Denton RR, Nandabalan K, Stephens JC;
 WPI; 2001-282046/29.

XX New variants of the m1 muscarinic acetylcholine receptor gene, useful to
 PT find treatment for Alzheimer's and dementia, have single nucleotide
 PT variations at one or more of five polymorphic sites.

XX Claim 15; Page 18; 52pp; English.

XX The sequence represents an allele specific oligonucleotide probe for
 CC genotyping individuals using the Human gene encoding the m1 muscarinic
 CC acetylcholine receptor, CHMR1. CHMR1 is one subtype of a family of 5
 CC genetically distinct muscarinic acetylcholine receptors, mAChR, that play
 CC important roles in higher brain function such as learning and memory. The
 CC protein is a possible drug target for treatments for Alzheimer's disease
 CC and dementia with Lewy bodies (DLB). The gene, polypeptide, haplotypes
 CC and antibodies raised against the protein are useful for diagnosing and
 CC developing treatments for diseases associated with the abnormal
 CC expression of the gene or activity of the protein, e.g. Alzheimer's
 CC disease and dementia with Lewy bodies

XX Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 168 GCAGCAGCTGGCCA 181
 Db 2 GCAGCAGCTGGCCA 15

RESULT 222

AAF48536/C
 ID AAF48536 standard; DNA; 15 BP.

XX AAF48536;

XX 30-MAR-2001 (first entry)

XX IGFBP3 oligonucleotide #1956.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wraight CJ, Werther GA, Edmondson SR;
 WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX Example 7; Page 56; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 8 A; 1 C; 6 G; 0 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 484 TTCCTCCTCCTGT 497
 Db 15 TTCCTCCTCCTGT 2

RESULT 223

AAF46293

```

ID AAF46293 standard; DNA; 15 BP.
XX AC
XX AAF46293;
XX DT
XX 30-MAR-2001 (first entry)
XX DE
XX IGFBP2 oligonucleotide #1132.
XX KW
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX OS
XX Homo sapiens.
XX PN WO200078341-A1.
XX PD
XX 28-DEC-2000.
XX PF
XX 21-JUN-2000; 200WO-AU000693.
XX PD
XX 28-DEC-2000.
XX PF
XX 21-JUN-2000; 200WO-AU000693.
XX PR
XX 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX DR
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX PS
XX Example 6; Page 41; 201pp; English.
XX CC
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX SQ Sequence 15 BP; 0 A; 11 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 197 CTGCCCCCGCGCGC 210
Db 1 CTGCCCCCGCGCCC 14

RESULT 224
AAF48537/c
ID AAF48537 standard; DNA; 15 BP.
XX AC
XX AAF48537;
XX DT
XX 30-MAR-2001 (first entry)
XX DE
XX IGFBP3 oligonucleotide #1957.
XX KW
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX OS
XX Homo sapiens.
XX PN WO200078341-A1.
XX PD
XX 28-DEC-2000.
XX PF
XX 21-JUN-2000; 200WO-AU000693.
XX PR
XX 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX DR
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX PS
XX Example 7; Page 56; 201pp; English.
XX CC
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX SQ Sequence 15 BP; 7 A; 1 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 484 TTCTCTCTCTCTGT 497
Db 14 TTCTCTCTCTCTGT 1

RESULT 225
AAF49788/c
ID AAF49788 standard; DNA; 15 BP.
XX AC
XX AAF49788;
XX DT
XX 30-MAR-2001 (first entry)
XX DE
XX IGF-I oligonucleotide #748.
XX

```

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 8; Page 65; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 171 GCAGCTGCCAGGC 184
 |||||
 DB 15 GCAGCTGCCAGGC 2
 RESULT 226
 AAF45880/c
 ID AAF45880 standard; DNA; 15 BP.
 XX
 AC AAF45880;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP2 oligonucleotide #719.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;

KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 OS
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 6; Page 38; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 4 A; 4 C; 6 G; 1 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 424 CATCTCCCGTGCT 437
 |||||
 DB 14 CATCTGCCGTGCT 1
 RESULT 227
 AAF49789/c
 ID AAF49789 standard; DNA; 15 BP.
 XX
 AC AAF49789;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGF-I oligonucleotide #749.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

```

XX OS Homo sapiens.
XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX PT WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 8; Page 65; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAP45151 and AAP45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 2 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 171 GCAGCTGCCAGGC 184
Db ||||| |||||
14 GCAGCTGCCAGGC 1

RESULT 228
AAF45998/c
ID AAF45998 standard; DNA; 15 BP.
XX AC AAF45998;
XX DT 30-MAR-2001 (first entry)
XX XX IGFBP2 oligonucleotide #837.
XX DE
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN WO200078341-A1.

```

```

XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX PT WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PT inflammation.
XX PS Example 6; Page 39; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAP45151 and AAP45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 372 GCGTGGTGGAGATC 385
Db ||||| |||||
14 GCATGGTGGAGATC 1

RESULT 229
AAF45879/c
ID AAF45879 standard; DNA; 15 BP.
XX AC AAF45879;
XX DT 30-MAR-2001 (first entry)
XX XX IGFBP2 oligonucleotide #718.
XX DE
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX PN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.

```

```

XX 21-JUN-1999; 99US-0140345P.
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 6; Page 38; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 5 C; 5 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 1.3e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 424 CATCTCCCGTGCT 437
XX Db 15 CATCTCCCGTGCT 2
XX
XX RESULT 230
XX AAF45997/c
XX ID AAF45997 standard; DNA; 15 BP.
XX
XX AC AAF45997;
XX
XX DT 30-MAR-2001 (first entry)
XX
XX DE IGFBP2 oligonucleotide #836.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX PN WO200078341-A1.
XX
XX PD 28-DEC-2000.
XX
XX PF 21-JUN-2000; 2000WO-AU000693.
XX
XX PR 21-JUN-1999; 99US-0140345P.
XX
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 6; Page 39; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 6 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 12.4; DB 1; Length 15;
XX Best Local Similarity 92.9%; Pred. No. 1.3e+02;
XX Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 372 GCGTGGTGGAGATC 385
XX Db 15 GCATGGTGGAGATC 2
XX
XX RESULT 231
XX AAD20988
XX ID AAD20988 standard; DNA; 15 BP.
XX
XX AC AAD20988;
XX
XX DT 28-JAN-2002 (first entry)
XX
XX DE Human Wnt-7B-like DNA clone 29518614 expressing reverse RT-PCR primer.
XX
XX Human; Wnt-7B-like protein; gene therapy; hypotensive; neoplasia; cancer;
XX tranquilizer; inflammatory disorder; arthritis; haematopoiesis; allergy;
XX immune disorder; autoimmune disease; thyroiditis; restenosis; thrombosis;
XX neurological disease; Alzheimer's disease; cardiovascular disorder; burn;
XX diabetes mellitus; periodontal disease; haemorrhage; multiple sclerosis;
XX rheumatoid arthritis; thrombocytopaenia; skin disorder; atherosclerosis;
XX lung fibrosis; skeletal disorder; platelet disorder; cell proliferation;
XX transplant rejection; acquired immune deficiency syndrome; AIDS; wound;
XX connective tissue disease; drug screening; ulcer; liver fibrosis;
XX RT-PCR primer; ss.
XX
XX Homo sapiens.
XX
XX PN WO200174856-A2.
XX
XX PD 11-OCT-2001.
XX
XX PF 03-APR-2001; 2001WO-US010679.
XX
XX PR 03-APR-2000; 2000US-0194256P.
XX
XX PR 26-JUL-2000; 2000US-00625634.
XX
XX PA (CURA-) CURAGEN CORP.
XX

```

```

PI Vernet CAM, Rastelli L, Herrmann JL;
XX WPI; 2001-626382/72.
XX
XX New Wnt-7B-like polypeptides and polynucleotides for diagnosing, as
XX preventing and treating broad range of pathological states such as
XX cancer, hematopoietic, inflammatory, skin, skeletal disorders and
XX atherosclerosis.
XX
XX Example 1; Page 100; 115pp; English.
XX
XX The invention relates to human Wnt-7B-like protein and its cDNA molecule.
XX Human Wnt-7B-like proteins and their nucleic acids are useful for
XX treating and preventing Wnt-7B-like-associated disorders such as
XX neoplasia, cancer, e.g., colorectal carcinoma, prostate cancer, immune
XX disorder, autoimmune diseases, such as connective tissue disease,
XX multiple sclerosis, rheumatoid arthritis, autoimmune thyroiditis,
XX acquired immune deficiency syndrome (AIDS), transplant rejection,
XX allergy, infection, inflammatory disorder, arthritis, hematopoietic
XX disorder, skin disorder (keloid), restenosis, neurological disease,
XX Alzheimer's disease, trauma, wound, spinal cord injury, skeletal disorder
XX and cardiovascular disorders such as diabetes mellitus, atherosclerosis,
XX cerebral thrombosis or haemorrhage, and other diseases, including
XX hypertension, hypothyroidism, myeloid or lymphoid cell deficiencies and
XX various platelet disorders such as thrombocytopaenia. Wnt-7B-like protein
XX is also useful for cell proliferation, tissue repair and in the treatment
XX of burns, incisions and ulcers, periodontal disease and treatment of lung
XX or liver fibrosis. Wnt-7B-like protein plays an important role in
XX autocrine stimulation of tumour growth, chemoresistance, radiotherapy
XX resistance and also for screening drugs. Wnt-7B-like nucleic acids are
XX useful in gene therapy. The present DNA sequence is reverse RT (reverse
XX transcriptase)-PCR primer Ag 316, which is used for expressing human Wnt-
XX 7B-like DNA clone 29518614
XX
XX Sequence 15 BP; 0 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 426 TCTCCCGGTGCTTC 439
Db 1 TCTCCCGGTGCTTC 14

RESULT 232
AAF70359
ID AAF70359 standard; DNA; 15 BP.
AC AAF70359;
XX
XX 20-APR-2001 (first entry)
XX
XX Human DRD2 allele specific oligonucleotide primer SEQ ID NO:102.
DE
XX Human; dopamine receptor D2; DRD2; polymorphism; allele specific;
XX drug target isogene; detection; single nucleotide polymorphism; SNP;
XX genotype; schizophrenia; Parkinson's disease; myoclonus dystonia; MD;
XX probe; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX WO200105832-A1.
XX
XX 25-JAN-2001.
XX
XX 19-JUL-2000; 2000WO-US019644.
XX
XX 19-JUL-1999; 99US-0144493P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Chew A, Denton RR, Duda A, Nandabalan K, Stephens JC;
PI

```

```

XX WPI; 2001-091967/10.
XX
XX Polynucleotides comprising single nucleotide polymorphisms in the human
XX dopamine receptor D2, useful for detecting mutations associated with,
XX e.g. schizophrenia, Parkinson's and myoclonus dystonia.
XX
XX Claim 15; Page 23; 135pp; English.
XX
XX The present invention describes polynucleotides comprising single
XX nucleotide polymorphisms (SNPs) in the human dopamine receptor D2 (DRD2).
XX The polynucleotides may be used in assays to detect and characterise
XX polymorphisms in DRD2 that affect its expression and activity and are
XX involved in disorders such as schizophrenia, Parkinson's and myoclonus
XX dystonia (MD). This information would be useful for studying the
XX biological function of DRD2 as well as in identifying drugs targeting
XX this protein for the treatment of disorders related to its abnormal
XX expression or function. Polymorphisms in the DRD2 gene affect the
XX expression of active and functional polypeptides. Therefore it is
XX advantageous to detect polymorphisms in the DRD2 gene and how those
XX polymorphisms are combined in different copies of the gene. AAF70261 to
XX AAF70308 represent human DRD2 allele specific oligonucleotide probes, and
XX AAF70309 to AAF70404 represent human DRD2 allele specific oligonucleotide
XX primers which are used in the detection of DRD2 polymorphisms. AAF70405
XX to AAF70452 represent oligonucleotide primers for the detection of human
XX DRD2 polymorphisms which are given in the exemplification of the present
XX invention. AAF70453 to AAF70538 represent PCR primers for the human DRD2
XX gene which are used in examples from the present invention
XX
XX Sequence 15 BP; 3 A; 6 C; 2 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.6%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 528 CCATGCCCAAGCTA 541
Db 1 CCATGCCCAAGCTA 14

RESULT 233
AAF83156
ID AAF83156 standard; DNA; 15 BP.
XX
XX AAF83156;
XX
XX 09-JUL-2001 (first entry)
XX
XX NAT2 gene G191A polymorphism determining probe 191C_A.
DE
XX
XX Immobilisation; chemical; biological; polynucleotide amplification;
XX nucleic acid detection; probe; hybridisation; PCR primer; NAT2 gene; ss.
XX
XX Synthetic.
OS
XX WO200127327-A2.
XX
XX 19-APR-2001.
XX
XX 06-OCT-2000; 2000WO-US027872.
XX
XX 08-OCT-1999; 99US-0158315P.
XX
XX (PROT-) PROTOGENE LAB INC.
XX
XX Brennan TM, Chatelain F, Berninger M;
XX
XX WPI; 2001-290733/30.
XX
XX Apparatus and method for performing a large number of chemical and
XX biological reactions by bringing two arrays into close apposition and
XX allowing reactants on the surfaces of the two arrays to come into
XX contact.
XX

```

XX Example 9; Fig 13; 112pp; English.

XX The invention provides a novel system for performing reactions, that

CC comprises a first solid support with a reactant of each reaction

CC immobilized on to it, and a second solid support either providing a

CC second reactant confined to a specific area on the surface, or a chemical

CC /mechanical separation of the reactions, where the first and second solid

CC supports are assembled to provide an environment for performing the

CC reactions in parallel. The methods and apparatus are useful for

CC performing a large number of chemical and biological reactions,

CC especially polynucleotide amplification reactions and the detection of

CC sequence variations, expression levels and their functions. The method is

CC capable of generating large amounts of data or products per unit time by

CC carrying out large numbers of reactions in parallel. The process is also

CC amenable to full automation. Sequences AAF83154-161 represent primers and

CC probes used for determining G91A polymorphic site of the NAT2 gene

XX

SQ Sequence 15 BP; 3 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.3e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 473 CCCACCCAGTTTC 486

Db 2 CCCACCCAGTTTC 15

RESULT 234

AAD44441/C

ID AAD44441 standard; DNA; 15 BP.

XX

AC AAD44441;

XX

XX 13-DEC-2002 (first entry)

XX Human F2RL1 gene polymorphisms detecting ASO probe #3.

XX

XX Human; haplotype; coagulation factor II receptor like 1; F2RL1; asthma;

KW polymorphism; chronic pulmonary disease; inflammatory disorder;

KW gene therapy; probe; ss.

XX

XX Homo sapiens.

XX

XX WO200255534-A2.

XX

XX 18-JUL-2002.

XX

XX 13-NOV-2001; 2001WO-US046475.

XX

XX 10-NOV-2000; 2000US-0247516P.

XX

XX (GENA-) GENAISSANCE PHARM INC.

XX

XX Bieglecki KM, Sanchis A, Shah N;

XX

XX WPI; 2002-566728/60.

XX

XX New genetic variants having polymorphisms in the coagulation factor II

PT (thrombin) receptor like 1 (F2RL1) gene, useful for studying the function

PT of F2RL1 and treating disorders associated with abnormal expression or

PT function of F2RL1.

XX

XX Claim 14; Page 13; 65pp; English.

XX

XX The invention relates to an isolated polynucleotide comprising genes and

CC haplotypes of the coagulation factor II (thrombin) receptor like 1

CC (F2RL1) gene. Polymorphic variants of the F2RL1 gene are useful in

CC studying the expression and biological function of F2RL1, and in

CC identifying drugs targeting F2RL1 protein for treating disorders

CC associated with abnormal expression or function of F2RL1, e.g. asthma,

CC chronic pulmonary disease, and inflammatory disorders. Polynucleotides

CC comprising a polymorphic gene variant or fragment may be used for

CC therapeutic purposes, where a patient could benefit from expression or

CC increased expression of a particular F2RL1 protein isoform, or an

CC expression vector encoding the isoform may be administered to the

CC patient. Haplotype information is useful in improving the efficiency and

CC output of several steps in drug discovery and development process,

CC including target validation, identifying lead compounds, and early phase

CC clinical trials. Information on polymorphisms may be applied in studying

CC biological functions of F2RL1 as well as in identifying drugs targeting

CC this protein for the treatment of disorders related to its abnormal

CC expression or function. The invention is useful in gene therapy. The

CC present sequence is human F2RL1 gene polymorphism detecting ASO (allele

CC specific oligonucleotide) probe

XX

SQ Sequence 15 BP; 1 A; 2 C; 11 G; 0 T; 0 U; 1 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.3e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 191 CGCCCCCTGCCCC 204

Db 15 CGCCCCCTGCCCC 2

RESULT 235

ABK32553

ID ABK32553 standard; DNA; 15 BP.

XX

AC ABK32553;

XX

XX 23-APR-2002 (first entry)

XX Human pancreatic cancer SAGE tag #105.

XX

XX Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;

KW serial analysis of gene expression; diagnostic; prognostic; probe;

KW cancer marker; ss.

XX

XX Homo sapiens.

XX

XX US6333152-B1.

XX

XX 25-DEC-2001.

XX

XX 20-MAY-1998; 98US-00081646.

XX

XX 20-MAY-1998; 98US-00081646.

XX

XX (UWJO) UNIV JOHNS HOPKINS.

XX

XX Vogelstein B, Kinzler KW, Zhang L, Zhou W;

XX

XX WPI; 2002-153821/20.

XX

XX New human nucleic acid containing specific SAGE tags, useful as

PT diagnostic markers for cancer, also derived probes.

XX

XX Disclosure; Col 75; 161pp; English.

XX

XX The invention relates to an isolated, purified human nucleic acid (I)

CC that has the same sequence as a mRNA found in humans and is a SAGE

CC (serial analysis of gene expression) tag comprising a single stranded

CC probe containing at least 10 consecutive nucleotides. SAGE tags, are

CC diagnostic and prognostic markers of cancer, especially of the colon and

CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer

CC SAGE tags of the invention

XX

SQ Sequence 15 BP; 2 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.3e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 369 ATGGCGTGGTGAG 382
 DB 2 ATGGCGGTTGAG 15

RESULT 236
 ACD66331
 ID ACD66331 standard; RNA; 15 BP.
 AC ACD66331;
 XX
 DT 23-SEP-2003 (first entry)
 DE
 DE Anti-HCV nucleic acid molecule target sequence #214.

Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 RNA stability; RNA expression; RNA synthesis; antisense;
 enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 HBV reverse transcriptase; Enhancer I region; anti-HCV;
 viral replication; degenerative; disease state; HBV infection;
 HCV infection; cirrhosis; liver failure; hepatocellular carcinoma;
 hepatotropic; cytostatic; virucide; antiinflammatory; target; ss.

OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX WPI; 2003-229207/22.
 XX
 XX Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PT
 XX Claim 1; Page 322; 387pp; English.

The present invention relates to nucleic acid molecules which modulate
 the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
 inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
 are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 transcriptase and/or HBV reverse transcriptase primer sequences, as well
 as oligonucleotides that specifically bind the Enhancer I region of HBV
 DNA. The nucleic acids may be used to modulate the expression of HBV
 genes and HBV viral replication. Also disclosed is a method for screening
 compounds and/or potential therapies directed against HBV, and compounds
 that modulate the expression and/or replication of HCV. The compounds and
 methods of the invention are useful for the treatment of degenerative and

CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a target for one of the anti-
 CC HCV nucleic acid molecules disclosed in the present invention
 XX
 SQ Sequence 15 BP; 0 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 71.4%; Pred. No. 1.3e+02;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 35 CGCGCGTCCCTT 48
 DB 2 CGCGCGTCCCTT 15

RESULT 237
 ACD66430
 ID ACD66430 standard; RNA; 15 BP.
 XX
 AC ACD66430;
 XX
 DT 23-SEP-2003 (first entry)
 XX
 DE Anti-HCV enzymatic nucleic acid substrate sequence #16.

Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
 RNA stability; RNA expression; RNA synthesis; antisense;
 enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;
 amberyne; G-cleaver ribozyme; decoy molecule; aptamer;
 HBV reverse transcriptase; Enhancer I region; anti-HCV;
 viral replication; degenerative; disease state; HBV infection;
 HCV infection; cirrhosis; liver failure; hepatocellular carcinoma;
 hepatotropic; cytostatic; virucide; antiinflammatory; substrate; ss.

OS Hepatitis C virus.
 XX
 PN WO200281494-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 26-MAR-2002; 2002WO-US009187.
 XX
 PR 26-MAR-2001; 2001US-00817879.
 PR 08-JUN-2001; 2001US-00877478.
 PR 08-JUN-2001; 2001US-0296876P.
 PR 24-OCT-2001; 2001US-0335059P.
 PR 05-DEC-2001; 2001US-0337055P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MACE/) MACEJAK D.
 PA (MCSW/) MCSWIGGEN J.
 PA (MORR/) MORRISSEY D.
 PA (PAVC/) PAVCO P.
 PA (LEEP/) LEE P.
 PA (DRAP/) DRAPER K.
 PA (ROBE/) ROBERTS E.
 XX
 PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
 PI Draper K, Roberts E;
 XX WPI; 2003-229207/22.
 XX
 XX Novel compound useful for treating cirrhosis, liver failure,
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus
 PT infection.
 PT
 XX Claim 1; Page 326; 387pp; English.

The present invention relates to nucleic acid molecules which modulate
 the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
 Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
 and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes,
 inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed
 are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 transcriptase and/or HBV reverse transcriptase primer sequences, as well
 as oligonucleotides that specifically bind the Enhancer I region of HBV
 DNA. The nucleic acids may be used to modulate the expression of HBV
 genes and HBV viral replication. Also disclosed is a method for screening
 compounds and/or potential therapies directed against HBV, and compounds
 that modulate the expression and/or replication of HCV. The compounds and
 methods of the invention are useful for the treatment of degenerative and

CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
 CC inozymes, zinzymes, amberyases, and G-cleaver ribozymes. Also disclosed
 CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
 CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
 CC as oligonucleotides that specifically bind the Enhancer I region of HBV
 CC DNA. The nucleic acids may be used to modulate the expression of HBV
 CC genes and HBV viral replication. Also disclosed is a method for screening
 CC compounds and/or potential therapies directed against HBV, and compounds
 CC that modulate the expression and/or replication of HCV. The compounds and
 CC methods of the invention are useful for the treatment of degenerative and
 CC disease states related to HBV and HCV infection, replication and gene
 CC expression such as cirrhosis, liver failure, and hepatocellular
 CC carcinoma. The present sequence represents a substrate for one of the
 CC anti-HCV enzymatic nucleic acid sequences disclosed in the present
 CC invention
 XX
 XX Sequence 15 BP; 0 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 SQ
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 71.4%; Pred. No. 1.3e+02;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 35 CGCCGCGGCCCTT 48
 DB 2 CGCCGCGGCCCTT 15
 |||||:|:|:
 RESULT 238
 ADA27240
 ID ADA27240 standard; DNA; 15 BP.
 XX
 AC ADA27240;
 XX
 XX 20-NOV-2003 (first entry)
 XX
 DE Human NOV5 reverse PCR primer SEQ ID NO:14.
 XX
 XX human; NOV5; antidiabetic; anorectic; virucide; antibacterial; fungicide;
 KW antiarteriosclerotic; anorectic; virucide; antibacterial; fungicide;
 KW protozoacide; nootropic; neuroprotective; antiparkinsonian;
 KW anticonvulsant; antipathic; antiarthritic; antiinflammatory;
 KW dermatological; antiasthmatic; antilipemic; gene therapy;
 KW metabolic disorder; diabetes; obesity; infectious disease; anorexia;
 KW cancer; cardiovascular disease; hypertension; atherosclerosis;
 KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
 KW epilepsy; immune disorder; osteoarthritis; haematopoietic disorder;
 KW inflammatory skin disorder; asthma; dyslipidaemia; neurogenesis;
 KW cell differentiation; cell proliferation; haematopoiesis; wound healing;
 KW angiogenesis; PCR primer; ss.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX
 XX WO2003068921-A2.
 XX
 XX 21-AUG-2003.
 XX
 XX 12-FEB-2003; 2003WO-US004188.
 XX
 XX 12-FEB-2002; 2002US-0356375P.
 PR 07-JUN-2002; 2002US-0387082P.
 XX
 XX (CURA-) CURAGEN CORP.
 PA
 XX Rastelli L, Zhong H, Boldog FL, Gangolli EA, Guo X, Malyankar UM;
 PI Patturajan M, Pena CEA, Shimkets RA, Spytek KA, Vernet CAM;
 PI Rieger DK, Edinger SR, Burgess CE;
 XX
 XX WPI; 2003-679626/64.
 XX
 XX Isolated NOVX polypeptides and polynucleotides, useful for preventing,
 PT diagnosing or treating NOVX-associated disorders, e.g. osteoarthritis,
 PT obesity, atherosclerosis, cancer, Parkinson's disease, asthma, or

PT infections.
 XX
 XX Example C; Page 129; 167pp; English.
 XX
 CC The present invention describes novel human proteins designated NOVX,
 CC where X can be 5a, 5b, 5c, or 5d. The NOVX proteins have antidiabetic,
 CC anorectic, cardiant, hypotensive, antiarteriosclerotic, anorectic,
 CC virucide, antibacterial, fungicide, protozoacide, nootropic,
 CC neuroprotective, antiparkinsonian, anticonvulsant, osteopathic,
 CC antiarthritic, antiinflammatory, dermatological, antiasthmatic and
 CC antilipemic activities, and can be used in gene therapy. The NOVX
 CC polypeptides, nucleic acid molecules and antibodies can be used in the
 CC manufacture of a medicament for treating a syndrome associated with a
 CC human disease, preferably a NOVX-associated disorder. The nucleic acid
 CC molecules, polypeptides and antibodies are useful for treating,
 CC preventing or diagnosing diseases such as metabolic disorders, diabetes,
 CC obesity, infectious diseases (viral, bacterial, fungal, helminthic, and
 CC protozoal), anorexia, cancer, cardiovascular diseases (hypertension,
 CC atherosclerosis), neurodegenerative disorders, Alzheimer's disease,
 CC Parkinson's disease, epilepsy, immune disorders (osteoarthritis),
 CC haematopoietic disorders, inflammatory skin disorders, asthma, and
 CC various dyslipidaemias. The nucleic acids and polypeptides may also be
 CC used as targets for the identification of small molecules that modulate
 CC or inhibit e.g. neurogenesis, cell differentiation, cell proliferation,
 CC haematopoiesis, wound healing and angiogenesis, in gene therapy, in
 CC generation of antibodies that bind immunospecifically to NOVX substances
 CC for use in therapeutic or diagnostic methods. The nucleic acids are
 CC further useful as hybridisation probes, in chromosome mapping, tissue
 CC typing, preventive medicine, and pharmacogenomics. The present sequence
 CC represents a PCR primer for a human NOV5 gene, which is used in an
 CC example from the present invention.
 XX
 XX Sequence 15 BP; 0 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 426 TCTCCCGCGCTTC 439
 DB 1 TCTCCCGCGCTTC 14
 |||||:|:|:
 RESULT 239
 ADA27237
 ID ADA27237 standard; DNA; 15 BP.
 XX
 AC ADA27237;
 XX
 XX 20-NOV-2003 (first entry)
 XX
 XX Human NOV5 reverse PCR primer SEQ ID NO:11.
 XX
 XX human; NOV5; antidiabetic; anorectic; cardiant; hypotensive;
 KW antiarteriosclerotic; anorectic; virucide; antibacterial; fungicide;
 KW protozoacide; nootropic; neuroprotective; antiparkinsonian;
 KW anticonvulsant; osteopathic; antiarthritic; antiinflammatory;
 KW dermatological; antiasthmatic; antilipemic; gene therapy;
 KW metabolic disorder; diabetes; obesity; infectious disease; anorexia;
 KW cancer; cardiovascular disease; hypertension; atherosclerosis;
 KW neurodegenerative disorder; Alzheimer's disease; Parkinson's disease;
 KW epilepsy; immune disorder; osteoarthritis; haematopoietic disorder;
 KW inflammatory skin disorder; asthma; dyslipidaemia; neurogenesis;
 KW cell differentiation; cell proliferation; haematopoiesis; wound healing;
 KW angiogenesis; PCR primer; ss.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX
 XX WO2003068921-A2.
 XX
 XX 21-AUG-2003.
 XX

PF 12-FEB-2003; 2003WO-US004188.
 XX 12-FEB-2002; 2002US-0356375P.
 PR 07-JUN-2002; 2002US-0387082P.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Rastelli L, Zhong H, Boldog FL, Gangolli EA, Guo X, Malyankar UM;
 PI Patturajan M, Pena CEA, Shinkets RA, Spytek KA, Vernet CAM,
 PI Rieger DK, Edinger SR, Burgess CE;
 XX
 DR WPI; 2003-679626/64.
 XX
 XX Isolated NOVX polypeptides and polynucleotides, useful for preventing,
 PT diagnosing or treating NOVX-associated disorders, e.g. osteoarthritis,
 PT obesity, atherosclerosis, cancer, Parkinson's disease, asthma, or
 PT infections.
 XX
 PS Example C; Page 129; 167pp; English.
 XX
 CC The present invention describes novel human proteins designated NOVX,
 CC where X can be 5a, 5b, 5c, or 5d. The NOVX proteins have antidiabetic,
 CC anorectic, cardiant, hypotensive, antiarteriosclerotic, anorectic,
 CC virucide, antibacterial, fungicide, protozoacide, nootropic,
 CC neuroprotective, antiparkinsonian, anticonvulsant, osteopathic,
 CC antiarthritic, antiinflammatory, dermatological, antiasthmatic and
 CC antilipemic activities, and can be used in gene therapy. The NOVX
 CC polypeptides, nucleic acid molecules and antibodies can be used in the
 CC manufacture of a medicament for treating a syndrome associated with a
 CC human disease, preferably a NOVX-associated disorder. The nucleic acid
 CC molecules, polypeptides and antibodies are useful for treating,
 CC preventing or diagnosing diseases such as metabolic disorders, diabetes,
 CC obesity, infectious diseases (viral, bacterial, fungal, helminthic, and
 CC protozoal), anorexia, cancer, cardiovascular diseases (hypertension,
 CC atherosclerosis), neurodegenerative disorders, Alzheimer's disease,
 CC Parkinson's disease, epilepsy, immune disorders (osteoarthritis),
 CC haematopoietic disorders, inflammatory skin disorders, asthma, and
 CC various dyslipidaemias. The nucleic acids and polypeptides may also be
 CC used as targets for the identification of small molecules that modulate
 CC or inhibit e.g. neurogenesis, cell differentiation, cell proliferation,
 CC haematopoiesis, wound healing and angiogenesis, in gene therapy, in
 CC generation of antibodies that bind immunospecifically to NOVX substances
 CC for use in therapeutic or diagnostic methods. The nucleic acids are
 CC further useful as hybridisation probes, in chromosome mapping, tissue
 CC typing, preventive medicine, and pharmacogenomics. The present sequence
 CC represents a PCR primer for a human NOV5 gene, which is used in an
 CC example from the present invention.
 XX
 SQ Sequence 15 BP; 0 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 426 TCTCCCGTGCTTC 439
 Db 1 TCTCCCGCGCTTC 14
 RESULT 240
 ADF32169/c
 ID ADF32169 standard; DNA; 15 BP.
 XX
 AC ADF32169;
 XX
 DT 12-FEB-2004 (first entry)
 DE
 XX Probe #93 used to illustrate chip detection techniques.
 XX
 KW Chip detection; probe; Single Nucleotide Polymorphism; SNP; detection;
 KW ss.
 XX Unidentified.

XX CN1381590-A.
 XX 27-NOV-2002.
 PD
 XX 13-APR-2001; 2001CN-00105980.
 PF
 XX 13-APR-2001; 2001CN-00105980.
 PR
 XX (MIAO/) MIAO J.
 PA
 XX Miao J;
 FI
 XX WPI; 2003-249035/25.
 XX
 DR Simple and fast technique for detecting single nucleotide polymorphism
 PT (SNP) by high-temp hybridized chip.
 PT
 XX Example 1; Page 14; 19pp; Chinese.
 PS
 XX The present invention related to an improvement to existing chip
 CC detection techniques. The invention uses DNA oligonucleotide probes
 CC (ADF32077-ADF32266) to detect Single Nucleotide Polymorphisms (SNP) in
 CC genomic DNA. Its advantages are simple process and short time (within 2
 CC hr).
 CC
 SQ Sequence 15 BP; 2 A; 3 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 541 AGCCACTCAGTCCA 554
 Db 14 AGCCACTCAGTCCA 1
 RESULT 241
 ADH69864/c
 ID ADH69864 standard; DNA; 15 BP.
 XX
 AC ADH69864;
 XX
 DT 25-MAR-2004 (first entry)
 DE
 XX Human Vbeta genes intron 1 3' splice site #4.
 XX
 KW human; T-cell associated disease; Vbeta; autoimmune disease;
 KW degenerative nervous system disease; graft versus host disease;
 KW hypersensitivity disease; infectious disease; neoplastic disease;
 KW Addison's disease; atrophic gastritis;
 KW degenerative nervous system disease; multiple sclerosis;
 KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
 KW allergy; type II hypersensitivity; Goodpasture's syndrome;
 KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
 KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
 KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
 KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
 KW breast cancer; ds.
 XX
 OS Homo sapiens.
 XX
 XX US2002150891-A1.
 XX
 PD 17-OCT-2002.
 XX
 XX 05-MAR-1999; 99US-00263959.
 PF
 XX 19-SEP-1994; 94US-00309335.
 PR
 XX 19-SEP-1995; 95US-00531241.
 PR
 XX (HOOD/) HOOD L B.
 PA (ROWE/) ROWEN L.

XX Hood LE, Rowen L;
 XX WPI; 2004-059052/06.
 XX
 XX Kit for diagnosing and treating T-cell associated diseases e.g.
 PT autoimmune, degenerative nervous system and infectious disease, comprises
 PT nucleic acid primers specifically priming and allowing amplification of a
 PT Vbeta gene.
 XX
 XX Disclosure; SEQ ID NO 58; 164pp; English.
 XX
 XX The invention relates to a kit for diagnosing and treating T-cell
 CC associated diseases which comprises a panel of nucleic acid primers
 CC specifically priming and allowing amplification of each Vbeta gene.
 CC VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
 CC rejection and diagnosing and treating T-cell associated diseases
 CC including autoimmune diseases, degenerative nervous system diseases,
 CC graft versus host disease, hypersensitivity diseases, infectious diseases
 CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
 CC atrophic gastritis. Degenerative nervous system diseases include multiple
 CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
 CC I hypersensitivities such as contact with allergens that lead to
 CC allergies, Type II hypersensitivities such as those present in
 CC Goodpasture's syndrome and Type IV hypersensitivities such as those
 CC manifested in leprosy. Infectious diseases include viral infections
 CC caused by viruses such as HIV, fungal infections such as those caused by
 CC the yeast genus Candida, parasitic infections such as those caused by
 CC schistosomes, filaria and bacterial infections such as those caused by
 CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
 CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
 CC breast. The present sequence represents a Vbeta gene intron splice site.
 XX
 XX Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 698 CACCTGTGTGTCCT 711
 DB 14 CACCTGTGTGTCCT 1
 RESULT 242
 ADI87750
 ID ADI87750 standard; RNA; 15 BP.
 XX
 XX ADI87750;
 XX
 XX 03-JUN-2004 (first entry)
 XX
 XX Anti-HCV molecule target sequence #239.
 XX
 XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
 KW HCV infection; type I interferon; DNazyme.
 XX
 XX Hepatitis C virus.
 XX
 XX US2003125270-A1.
 XX
 XX 03-JUL-2003.
 XX
 XX 18-DEC-2000; 2000US-00740332.
 XX
 XX 18-DEC-2000; 2000US-00740332.
 XX
 XX (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGEN J.
 PA (ROBE/) ROBERTS E.
 PA (PAVC/) PAVCO P A.
 PA (MACE/) MACEJACK D.
 XX

PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
 DR WPI; 2004-031273/03.
 XX
 XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
 PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
 PT especially in combination with type I interferon therapy.
 XX
 XX Claim 1; SEQ ID NO 4793; 198pp; English.
 XX
 XX The invention relates to an enzymatic nucleic acid molecule which
 CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
 CC the binding arms of the enzymatic nucleic acid molecule comprises
 CC sequences complementary to any of the defined substrate sequences given
 CC in the specification. The nucleic acid molecule may be administered for
 CC the treatment of HCV infections, especially in combination with type I
 CC interferons. The present sequence represents an anti-HCV molecule target
 CC sequence.
 XX
 XX Sequence 15 BP; 0 A; 7 C; 3 G; 0 T; 5 U; 0 Other;
 SQ
 Query Match 1.6%; Score 12.4; DB 1; Length 15;
 Best Local Similarity 71.4%; Pred. No. 1.3e+02;
 Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
 QY 35 CGCGCGTCGTCCTT 48
 DB 2 CGCGCGTCGTCCTT 15
 RESULT 243
 ADO50238/C
 ID ADO50238 standard; DNA; 15 BP.
 XX
 XX ADO50238;
 XX
 XX 29-JUL-2004 (first entry)
 XX
 XX H. pylori strain J99 genome fragment SEQ ID NO:861.
 XX
 XX ds; stroke; phosphodiesterase 4D; PDE4D.
 XX
 XX Helicobacter pylori.
 XX
 XX US2004091865-A1.
 XX
 XX 13-MAY-2004.
 XX
 XX 25-SEP-2002; 2002US-00255120.
 XX
 XX 19-MAR-2001; 2001US-00811352.
 XX
 XX 04-FEB-2002; 2002US-00067514.
 XX
 XX (DECO-) DECODE GENETICS EHP.
 XX
 XX Gretaredottir S, Jonsdottir S, Reynisdottir ST, Thorleifsson G;
 PI WPI; 2004-374932/35.
 XX
 XX Diagnosing susceptibility to a stroke in an individual comprising
 PT screening for an at-risk haplotype in the phosphodiesterase 4D gene.
 XX
 XX Disclosure; SEQ ID NO 861; 574pp; English.
 XX
 XX The invention relates to a method of diagnosing susceptibility to a
 CC stroke in an individual comprising screening for an at-risk haplotype in
 CC the phosphodiesterase 4D (PDE4D) gene that is more frequently present
 CC in an individual susceptible to stroke (affected) compared to a healthy
 CC individual (control), where the at-risk haplotype increases risk of
 CC stroke significantly. The composition, methods and kit are useful for
 CC diagnosing, predicting of clinical course and treating stroke using
 CC polymorphisms in the PDE4D gene. These may also be used in identifying
 CC agents that enhance or inhibit PDE4D polypeptide expression or activity.

CC The present sequence represents a fragment of H. pylori strain J99 genome
 CC which is not referred to at all in the main body of the specification.

SQ Sequence 15 BP; 8 A; 1 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 730 TGTTCCTCAAT 743

Db 15 TGTTCCTCAAT 2

RESULT 244

ADO49955/c
 ID ADO49955 standard; DNA; 15 BP.

XX ADO49955;

AC ADO49955;

DT 29-JUL-2004 (first entry)

DE H. pylori strain J99 genome fragment SEQ ID NO:578.

KW ds; stroke; phosphodiesterase 4D; PDE4D.

OS Helicobacter pylori.

FN US2004091865-A1.

XX 13-MAY-2004.

XX 25-SEP-2002; 2002US-00255120.

XX 19-MAR-2001; 2001US-00811352.

PR 04-FEB-2002; 2002US-00067514.

XX (DECO-) DECODE GENETICS EHF.

XX Gretardottir S, Jonsdottir S, Reynisdottir ST, Thorleifsson G;

DR WPI; 2004-374932/35.

PT Diagnosing susceptibility to a stroke in an individual comprising
 PT screening for an at-risk haplotype in the phosphodiesterase 4D gene.

XX Disclosure; SEQ ID NO 578; 574pp; English.

XX The invention relates to a method of diagnosing susceptibility to a
 CC stroke in an individual comprising screening for an at-risk haplotype in
 CC the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
 CC an individual susceptible to stroke (affected) compared to a healthy
 CC individual (control), where the at-risk haplotype increases risk of
 CC stroke significantly. The composition, methods and kit are useful for
 CC diagnosing, predicting of clinical course and treating stroke using
 CC polymorphisms in the PDE4D gene. These may also be used in identifying
 CC agents that enhance or inhibit PDE4D polypeptide expression or activity.
 CC The present sequence represents a fragment of H. pylori strain J99 genome
 CC which is not referred to at all in the main body of the specification.

SQ Sequence 15 BP; 8 A; 1 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 730 TGTTCCTCAAT 743

Db 15 TGTTCCTCAAT 2

RESULT 245

ADO55514/c

ID ADO55514 standard; DNA; 15 BP.

XX ADO55514;

DT 29-JUL-2004 (first entry)

XX Human phosphodiesterase 4D (PDE4D) gene known microsatellite marker #12.

DE ds; stroke; phosphodiesterase 4D; PDE4D; human; microsatellite marker.

KW Homo sapiens.

OS US2004091865-A1.

XX 13-MAY-2004.

XX 25-SEP-2002; 2002US-00255120.

XX 19-MAR-2001; 2001US-00811352.

PR 04-FEB-2002; 2002US-00067514.

XX (DECO-) DECODE GENETICS EHF.

XX Gretardottir S, Jonsdottir S, Reynisdottir ST, Thorleifsson G;

PI WPI; 2004-374932/35.

DR Diagnosing susceptibility to a stroke in an individual comprising
 PT screening for an at-risk haplotype in the phosphodiesterase 4D gene.

XX Example 1; SEQ ID NO 26; 574pp; English.

XX The invention relates to a method of diagnosing susceptibility to a
 CC stroke in an individual comprising screening for an at-risk haplotype in
 CC the phosphodiesterase 4D (PDE4D) gene that is more frequently present in
 CC an individual susceptible to stroke compared to a healthy individual,
 CC where the at-risk haplotype increases risk of stroke significantly. The
 CC composition, methods and kit are useful for diagnosing, predicting of
 CC clinical course and treating stroke using polymorphisms in the PDE4D
 CC gene. These may also be used in identifying agents that enhance or
 CC inhibit PDE4D polypeptide expression or activity. The present sequence
 CC represents a human phosphodiesterase 4D (PDE4D) gene known microsatellite
 CC marker.

SQ Sequence 15 BP; 3 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.6%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 491 TCCCTGTCCCTGA 504

Db 14 TCCAGTCCCTGA 1

RESULT 246

ACA07606

ID ACA07606 standard; RNA; 17 BP.

XX ACA07606;

DT 03-JUN-2003 (first entry)

XX NFkB sub-unit modulating zymase substrate #5.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zymase;
 KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;

KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.

XX US2002177568-A1.

XX 28-NOV-2002.

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987112.

XX 18-MAY-1994; 94US-00245466.

XX 15-AUG-1994; 94US-00291932.

XX 23-DEC-1996; 96US-00777916.

XX (STIN/) STINCHOMB D T.

XX (MCSW/) MCSWIGGEN J.

XX (DRAP/) DRAPER K G.

XX Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression of
 a sequence encoding a subunit of nuclear factor kappa B useful for
 treating cancer, inflammatory disorders and autoimmune diseases.

XX Claim 3; Page 37; 72pp; English.

XX The invention describes an enzymatic nucleic acid molecule (I) which down
 regulates expression of a sequence encoding a subunit of nuclear factor
 kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberyze
 configuration. The enzymatic nucleic acid molecule is adapted to treat
 cancer and is useful for down-regulating REL-A activity in a cell, for
 treating a patient having a condition associated with the level of REL-A.
 (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 antisense nucleic acid molecules are useful for treating breast, lung,
 prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 multidrug resistant cancer. The method involves use of other drug
 therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 acid molecules are also useful for treating inflammatory disease such as
 rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 rejection, gene therapy applications, ischaemia/reperfusion injury/
 (central nervous system (CNS) and myocardial), glomerulonephritis,
 sepsis, allergic airway inflammation, inflammatory bowel disease or
 infection. This sequence represents the substrate of a novel enzymatic
 nucleic acid molecule

SQ Sequence 17 BP; 1 A; 6 C; 8 G; 0 T; 2 U; 0 Other;

Query Match 1.6%; Score 12.2; DB 1; Length 17;

Best Local Similarity 76.5%; Pred. No. 1.7e+02;

Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 61 GGGCCCCAGCTGGGACC 77

DB 1 GGGUGGCACGUGGGCCC 17

RESULT 247

AAF74725/C

ID AAF74725 standard; DNA; 12 BP.

XX

AC AAF74725;

XX 17-MAY-2001 (first entry)

XX Human smoothelin variant intron-exon splice recognition sequence #21.

DE Human smoothelin variant intron-exon splice recognition sequence #21.

XX Human; smoothelin; smoothelin B gene; smooth muscle cell promoter;

KW vascular contractile smooth muscle cell; gene therapy; PCR primer;

KW visceral contractile smooth muscle cell; cardiovascular; ss.

XX Homo sapiens.

OS EP1083231-A1.

XX 14-MAR-2001.

XX 09-SEP-1999; 99EP-00202943.

XX 09-SEP-1999; 99EP-00202943.

XX (INTR-) INTROGENE BV.

XX WPI; 2001-236858/25.

XX Nucleic acids encoding smooth muscle cell specific promoters, useful e.g.

PT for treating cardiovascular diseases or in targeting transgene expression

PT to smooth muscle cells expressing endogenous smoothelin proteins.

XX Example 3; Page 16; 51pp; English.

XX The present invention describes a nucleic acid delivery vehicle (I)

CC comprising a nucleic acid capable of expressing specifically in a

CC contractile smooth muscle cell, preferably a vascular contractile smooth

CC muscle cell and/or a visceral contractile smooth muscle cell. Also

CC described are smooth muscle cell specific promoters which can be

CC incorporated into a nucleic acid delivery vehicle, where the nucleic acid

CC delivery vehicle preferably comprises a virus-like particle such as an

CC adenovirus particle, an adeno-associated virus particle or a retrovirus

CC particle. (I) has cardiovascular activity and can be used in gene

CC therapy. The nucleic acid delivery vehicle is useful for the preparation

CC of a pharmaceutical for the treatment of a cardiovascular disease. The

CC promoter of the smoothelin gene (a smooth muscle cell specific promoter)

CC is useful for providing a particular nucleic acid with the capacity to

CC express proteins specifically in contractile smooth muscle cells. The

CC promoter may also be used in targeting transgene expression to smooth

CC muscle cells that express endogenous smoothelin protein, in

CC distinguishing subsets of smooth muscle cells, and in expressing foreign

CC genetic material specifically in contractile smooth muscle cells.

CC AAF74719 to AAF74756 represent human smoothelin variant intron-exon

CC splice recognition sites, which are used in an example from the present

CC invention

XX Sequence 12 BP; 1 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

SQ Query Match 1.6%; Score 12; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 99;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 606 CAGAAGCTGCAC 617

DB 12 CAGAAGCTGCAC 1

RESULT 248

AAS01800/C

ID AAS01800 standard; DNA; 12 BP.

XX AAS01800;

XX 12-SEP-2001 (first entry)

XX Human smoothelin gene intron-exon splice recognition sequence #7.

XX

KW Human; smoothenin; promoter; nucleic acid delivery vehicle; restenosis;
KW contractile smooth muscle cell; pharmaceutical; cardiovascular disease;
KW hypertension; atherosclerosis; transgene expression; oligo linker; ds;
KW percutaneous transluminal coronary angioplasty.
XX
OS Homo sapiens.
XX
XX WO200118048-A2.
XX
XX PD 15-MAR-2001.
XX
XX PF 08-SEP-2000; 2000WO-NL000638.
XX
XX PR 09-SEP-1999; 99EP-00202943.
XX PR 09-SEP-1999; 99US-0153284P.
XX
XX PA (INTR-) INTROGENE BV.
XX
XX PI Van Eijs GJMJ, Hateboer G, Havenga MJE;
XX WPI; 2001-244559/25.
XX
XX PT New nucleic acids encoding smooth muscle cell specific promoters, useful
XX for treating a cardiovascular disease or in targeting transgene
XX expression to smooth muscle cells expressing endogenous smoothenin
XX protein.
XX
XX PS Example 3; Page 45; 60pp; English.
XX
XX CC The sequence represents an intron-exon splice recognition sequence of the
XX human smoothenin gene. The smoothenin gene promoter, or its functional
XX part, derivative and/or analogue, can be used as part of a nucleic acid
XX delivery vehicle, comprising a nucleic acid capable of expressing
XX specifically in a contractile smooth muscle cell. The nucleic acid
XX delivery vehicle is useful for the preparation of a pharmaceutical for
XX the treatment of cardiovascular diseases, such as hypertension,
XX atherosclerosis and restenosis after percutaneous transluminal coronary
XX angioplasty. The promoter of a smoothenin gene is useful for providing a
XX particular nucleic acid with the capacity to express foreign genetic
XX material specifically in a contractile smooth muscle cell. The promoter
XX may also be used in targeting transgene expression to smooth muscle cells
XX that express endogenous smoothenin protein, in distinguishing subsets of
XX smooth muscle cells, and in expressing foreign genetic material
XX specifically in contractile smooth muscle cells
XX
XX SQ Sequence 12 BP; 1 A; 3 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 606 CAGAAGCTGCAA 617
DB 12 CAGAAGCTGCAA 1

RESULT 249
ABH93536/c
ID ABH93536 standard; DNA; 12 BP.
XX
XX AC ABH93536;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 293529 for detecting SNP TSC0015658.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX

XX 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI; 2001-657177/75.
XX DR
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 293529; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 735 TTCTCAATAAAA 746
DB 12 TTCTCAATAAAA 1

RESULT 250
ABI17243
ID ABI17243 standard; DNA; 12 BP.
XX
XX AC ABI17243;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 317216 for detecting SNP TSC0027870.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX DT 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX DR
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 317216; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 2 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 99;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 734 TTTCTCAATAA 745
 DB 1 TTTCTCAATAA 12
 RESULT 251
 ID ABI31739/c
 XX ABI31739 standard; DNA; 12 BP.
 AC ABI31739;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 331712 for detecting SNP TSC0036426.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 331712; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 7 A; 0 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 99;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 732 TTTTCTCAAT 743
 DB 12 TTTTCTCAAT 1
 RESULT 252
 ID ABI67794
 XX ABI67794 standard; DNA; 12 BP.
 AC ABI67794;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 367767 for detecting SNP TSC0056551.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 367767; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 99;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 716 ATACATTATCT 727

```

Db      .      |||||||
          1 ATACATTATCT 12

RESULT 253
ABH86717/c
ID ABH86717 standard; DNA; 12 BP.
XX
XX AC ABH86717;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 286710 for detecting SNP TSC0012789.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX PS Claim 1; SEQ ID NO 286710; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. A
XX CC oligonucleotide is used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 12 BP; 0 A; 1 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred.No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 470 GACCCACCCAA 481
Db 12 GACCCACCCAA 1

RESULT 254
ADM76066
ID ADM76066 standard; DNA; 12 BP.
XX
XX AC ADM76066;
XX
XX DT 03-JUN-2004 (first entry)
XX
XX DE NEPHA gene transcriptional control region Pax-4 binding site.

XX Human; NEPHA; ephrin receptor; brain; chromosome 1; apoptosis;
XX KW drug screening; antisense therapy; gene therapy; cancer; tumour;
XX KW lung cancer; ovarian cancer; breast cancer; cervical cancer;
XX KW prostate cancer; bladder cancer; stomach cancer; colorectal cancer;
XX KW cytosine; transcriptional control region; promoter;
XX KW transcription factor binding site; ds.
XX
XX OS Homo sapiens.
XX
XX PN JP2003289876-A.
XX
XX PD 14-OCT-2003.
XX
XX PF 05-APR-2002; 2002JP-00103497.
XX
XX PR 05-APR-2002; 2002JP-00103497.
XX
XX PA (TAKE ) TAKEDA CHEM IND LTD.
XX
XX PN WPI; 2004-038434/04.
XX
XX PT Novel antisense oligonucleotide useful as anticancer agent for preventing
XX PT cancer e.g. lung cancer, stomach cancer, breast cancer.
XX
XX PS Example 2; Page 19; 38pp; Japanese.
XX
XX CC The invention relates to antisense oligonucleotides (ADM76030 and
XX CC ADM76031) targeted to the human NEPHA gene (ADM76029), which encodes a
XX CC novel brain-derived ephrin receptor (ADM76028). The NEPHA protein has
XX CC 50.7% homology to the human EphA7 ephrin receptor and its gene is located
XX CC on chromosome 1. Ephrin receptors are overexpressed in various cancers
XX CC and it has been found that inhibition of NEPHA expression promotes
XX CC apoptosis. The invention also relates to the NEPHA transcriptional
XX CC control (promoter) region (ADM76037); recombinant vectors and host cells
XX CC comprising the NEPHA promoter operably linked to a reporter gene; a
XX CC method of screening for compounds which inhibit or activate transcription
XX CC of the NEPHA gene; and pharmaceutical compositions comprising an
XX CC antisense oligonucleotide or a transcriptional inhibitor or activator.
XX CC The antisense oligonucleotides and modulators of NEPHA transcription are
XX CC useful for inducing apoptosis for the treatment and/or prevention of
XX CC cancers in which NEPHA is overexpressed such as lung cancer, ovarian
XX CC cancer, breast cancer, cervical cancer, prostate cancer, bladder cancer,
XX CC stomach cancer and colorectal cancer. Sequences ADM76038-ADM76371
XX CC represent transcription factor binding sites within the transcriptional
XX CC control region of the NEPHA gene.
XX
XX SQ Sequence 12 BP; 1 A; 1 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred.No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 371 GGCCTGGTGGAG 382
Db 1 GGCCTGGTGGAG 12

RESULT 255
ABH41108/c
ID ABH41108 standard; DNA; 13 BP.
XX
XX AC ABH41108;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 241085 for detecting SNP TSC0058802.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.

```


CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 2 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 369 ATGGCGTGGTGG 380
 DB 2 ATGGCGTGGTGG 13
 RESULT 258
 ABH34624/c
 ID ABH34624 standard; DNA; 13 BP.
 XX AC ABH34624;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 234601 for detecting SNP TSC0057252.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPTG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 234601; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;
 Query Match 1.6%; Score 12; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 735 TTCTCAATAAA 746
 DB 12 TTCTCAATAAA 1
 RESULT 259
 ABF75057/c
 ID ABF75057 standard; DNA; 13 BP.
 XX AC ABF75057;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 175054 for detecting SNP TSC0043508.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 175054; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 3 A; 1 G; 2 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 369 ATGGCGTGGTGG 380
 DB 12 ATGGCGTGGTGG 1
 RESULT 260*
 ABH34625
 ID ABH34625 standard; DNA; 13 BP.
 XX AC ABH34625;
 XX DT 22-FEB-2002 (first entry)

```

XX Oligonucleotide SEQ ID NO 234602 for detecting SNP TSC0057252.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPITG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX Claim 1; SEQ ID NO 234602; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;

Query Match          1.6%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 735 TTCTCAATATAA 746
Db 2 TTCTCAATATAA 13
|||||
|||||

RESULT 261
AAS13442/c
ID AAS13442 standard; DNA; 14 BP.
XX
AC AAS13442;
XX
XX 18-DEC-2001 (first entry)
XX
XX DNA primer sequence for nanoparticle positioning #2.
XX
XX nanoparticle positioning; food industry; surgical implant;
KW autoimmune reaction; rejection; primer; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH misc_binding 1..5
FT /tag= a
FT /bound_moiety= "Nucleotides 5-1 of sequence appearing as
FT AAS13439"
FT

```

```

FT /note= "Forms double stranded region with nucleotides 5-1
FT of sequence appearing as AAS13439"
FT
FT misc_feature 6..8
FT /tag= b
FT /note= "Double stranded region"
FT
FT modified_base 7
FT /tag= c
FT /mod_base= OTHER
FT /note= "Other= G is linked to a Cell type 3 via a
FT disulphide linkage"
FT
FT misc_feature 9..10
FT /tag= d
FT /note= "May be multiple GC units"
FT
FT misc_feature 11..13
FT /tag= e
FT /note= "Double stranded region"
FT
FT modified_base 12
FT /tag= f
FT /mod_base= OTHER
FT /note= "Other= G is linked to a Cell type 4 via a
FT disulphide linkage"
FT
XX WO200160316-A2.
XX
XX 23-AUG-2001.
XX
XX 16-FEB-2001; 2001WO-SE000355.
XX
XX 18-FEB-2000; 2000SE-00000546.
XX
XX (OSCA/) OSCARSSON S.
XX (QUIST/) QUIST A.
XX (PAHL/) PAHLSSON C.
XX
XX Oscarsson S, Quist A, Pahlsson C;
XX WPI; 2001-570540/64.
XX
XX Positioning particles on a surface for separating macromolecules, cells,
XX bacteria or viruses, comprises contacting surface bound nucleic acid
XX polymers with particles labeled with complementary primer sequences.
XX
XX Example 1; Fig 1; 18pp; English.
XX
XX The invention relates to positioning particles or macromolecules on a
XX surface, involves arranging surface defects, attaching nucleic acid
XX polymers of known sequence to the surface defects, labeling the acid
XX particles/macromolecules with known nucleotide sequences in the form of
XX primers corresponding to specific locations on the bound nucleic acid
XX sequence, and contacting surface bound nucleic acid with the primers with
XX by which binding between corresponding base pairs occurs. The method is
XX useful for positioning particles or macromolecules, preferably bioactive
XX particles or macromolecules such as enzymes, hormones, signal substances,
XX antibodies and receptor molecules, cells or their parts, bacteria,
XX viruses or their parts, or pharmaceutically active substances, on a
XX surface. A two-dimensional or three-dimensional gradient is useful for
XX separating macromolecules, cells, bacteria or viruses and for detecting
XX macromolecules or creation of mixed separation surface where the upper
XX part of the surface is a hydrophobic surface and the lower part is an
XX ionic surface. Thus the gradients are useful for producing a mosaic or
XX pattern of different kind of bacteria on predetermined positions which
XX has applications in food industry. The method is useful for creating
XX novel biocompatible materials or to form an interface between an
XX artificial implant and a living organism e.g., creating a surface on an
XX implant (such as surgical implants such as stents), which surface
XX eliminates or minimises autoimmune reactions or rejection mechanisms.
XX Surfaces with artifacts produced by the above method have utility in
XX medicine, electronics, micromechanics, analysis and synthesis, etc. A
XX sensor incorporating the surface is useful in medical and analytical
XX applications for detecting trace amounts of specific compounds. The
XX present sequence is a primer sequence used to demonstrate the method of
XX the invention
XX

```

SQ Sequence 14 BP; 1 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 59 CGGGGCCCCAGC 70
 Db 14 CGGGGCCCCAGC 3

RESULT 262
 ABS98192/c
 ID ABS98192 standard; DNA; 14 BP.
 XX
 AC ABS98192;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human lactoferrin (LTF) gene PCR primer #7.
 XX
 KW Human; ss; primer: cytochrome P450 A1; CYP450A1; UGT2B4; MDR1; PCR;
 KW cytochrome P450 A2; CYP450A2; cytochrome P450 02B; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GSTL2; histamine-N-methyl transferase;
 KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 KW NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STM;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological.
 XX
 OS Homo sapiens.
 XX
 PN WO200257410-A2.
 XX
 PD 25-JUL-2002.
 XX
 XX 28-NOV-2001; 2001WO-US044838.
 PF
 XX 28-NOV-2000; 2000US-00724389.
 PR
 XX (DNAS-) DNA SCI LAB INC.
 PA
 XX Guida M, Hall J;
 PI
 XX WPI; 2002-698522/75.
 DR
 XX Isolated nucleic acid molecules having polymorphisms in known human genes
 PT e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers
 PT for locating, identifying and characterizing the genes responsible for
 PT disorder-related traits.
 XX
 PS Example 23; Page 146; 714pp; English.
 XX
 CC This invention relates to the sequence of an isolated nucleic acid
 CC molecule comprising at least one base variation from that of a known
 CC human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
 CC cytochrome P450 02B1 (CYP45002E1), adrenergic receptor beta1 (ADRB1),
 CC aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 CC (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 CC inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
 CC protein (FLAP), glutathione-S-transferase 12 (GSTL2), histamine-N-methyl
 CC transferase (HNMT), kallikrein 2, KLK2, nicotinamide -N-methyl
 CC transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
 CC sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl

transferrase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
 (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
 receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) seque
 The polymorphisms in the human genes cited in the invention are useful as
 genetic linkage markers for locating and characterizing the genes that
 are responsible for specific traits within the genome and eventually
 identifying the genes responsible for a variety of disorder-related
 traits as a result of their e.g., overexpression, constitutive
 expression, mutation or underexpression, which may be used in diagnosing
 and/or treating the disorders. The nucleic acid molecules comprising the
 polymorphic sequences contained in CYP450A1, CYP450A2, CYP45002E1, AHR,
 ARNT, EPHX2, GSTL2, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
 MDR1 and/or MDR3 are useful for screening individuals for altered drug
 metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
 AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 used to screen for altered cardiovascular function, in COX2 for altered
 susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 nervous system function, in FLAP and HNMT for altered pulmonary,
 immunological or haematological function, in KLK2 for altered serine
 protease activity in the prostate, in LTF for altered immunological or
 haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 peripheral nervous system function. The present sequence represents a PCR
 primer used to amplify the sequences of the invention

XX
 SQ Sequence 14 BP; 3 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 682 GCTGTGCTCTCC 693
 Db 14 GCTGTGCTCTCC 3

RESULT 263
 ADF78335/c
 ID ADF78335 standard; DNA; 14 BP.
 XX
 AC ADF78335;
 XX
 DT 26-FEB-2004 (first entry)
 XX
 DE Chromosomal abnormality detection-related APC small deletion DNA 81.
 XX
 KW chromosomal abnormality; maternal locus; genetic disorder; foetus;
 KW mutation; translocation; transversion; monosomy; trisomy; trisomy 21;
 KW chromosome 21; Down's Syndrome; aneuploidies; chromosome deletion;
 KW chromosome addition; chromosome amplification; chromosome translocation;
 KW chromosome rearrangement; single nucleotide polymorphism detection;
 KW SNP detection; pregnant female; APC; adenomatous polyposis coli; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003074723-A2.
 XX
 PD 12-SEP-2003.
 XX
 XX 28-FEB-2003; 2003WO-US006198.
 PF
 XX 01-MAR-2002; 2002US-0360232P.
 PR 11-MAR-2002; 2002US-00093618.
 PR 08-MAY-2002; 2002US-0378354P.
 XX
 XX (DHAL/) DHALLAN R.
 PA
 XX Dhallan R;
 PI
 XX WPI; 2003-845073/78.
 DR
 XX Detection of chromosomal abnormalities e.g. Down's Syndrome, non-

PT invasively in a fetus, comprises forming a ratio of amounts of alleles at
 PT a locus of interest and a different heterozygous locus.

PS Example 7; Page 159; 164pp; English.

XX This invention relates to a novel method of detecting chromosomal
 CC abnormalities by determining the sequence of alleles of a locus of
 CC interest from template DNA, determining which alleles are present and
 CC comparing to amounts of alleles at a different, selected heterozygous
 CC locus (for example on another chromosome or a maternal locus); relative
 CC amounts are expressed as a ratio indicating presence or absence of the
 CC abnormality. The method is useful for the detection of genetic disorders,
 CC especially in a foetus, including chromosomal abnormalities and
 CC mutations, for example translocations, transversions, monosomes,
 CC trisomies (for example trisomy 21 in which an additional copy of
 CC chromosome 21 results in Down's Syndrome) and other aneuploidies,
 CC deletions, additions, amplifications, translocations and rearrangements.
 CC It can be used to detect any alterations in a gene sequence, especially
 CC single nucleotide polymorphisms (SNPs), and may be used to detect
 CC numerous abnormalities simultaneously, for example if several SNPs are
 CC associated with a particular disease. The method provides a rapid, non-
 CC invasive method for determining the sequence of DNA from a foetus using a
 CC sample from a pregnant female, for example to detect genetic disorders as
 CC above or to determine if a foetus is a carrier of a disease or
 CC predisposed to a disease.

SQ Sequence 14 BP; 4 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 374 GTGGTGGAGATC 385
 Db 14 GTGGTGGAGATC 3

RESULT 264
 ADH53140/C
 ID ADH53140 standard; DNA; 14 BP.
 AC ADH53140;
 XX
 DT 25-MAR-2004 (first entry)
 DE Human APC (adenomatous polyposis coli) DNA fragment 80.
 XX
 KW sequence determination; recognition site; restriction endonuclease;
 KW human; APC; adenomatous polyposis coli; chromosome 5q21-22;
 KW colorectal cancer; ds.

OS Homo sapiens.

PN WO2003074740-A1.

PD 12-SEP-2003.

PF 28-FEB-2003; 2003WO-US006376.

PR 01-MAR-2002; 2002US-0360232P.

PR 11-MAR-2002; 2002US-00093618.

PR 08-MAY-2002; 2002US-0378354P.

PA (DHALL/) DHALLAN R.

PI Dhallan R;

XX WPI; 2003-756772/71.

PT Determining a sequence of a locus of interest comprises replicating a
 PT region of DNA comprising a locus of interest from a template
 PT polynucleotide by using a first and a second primer.

XX

PS Example 5; Page 137; 190pp; English.

XX The invention relates to a novel method for determining the sequence of a
 CC locus of interest which comprises replicating a region of DNA comprising
 CC a locus of interest from a template polynucleotide by using a first and a
 CC second primer where the second primer contains a sequence that generates
 CC a recognition site for a restriction enzyme such that digestion with the
 CC restriction enzyme generates a 5' overhang containing the locus of
 CC interest. The method may be useful for determining the sequences of
 CC multiple loci of interest concurrently and for determining the sequence
 CC of a mutant allele in the presence of a normal allele. The current
 CC sequence is that of the human APC (adenomatous polyposis coli) DNA
 CC fragment of the invention which is located on chromosome 5q21-22 and in
 CC which mutations are associated with colorectal cancer.

SQ Sequence 14 BP; 4 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 374 GTGGTGGAGATC 385
 Db 14 GTGGTGGAGATC 3

RESULT 265

ABT13746

ID ABT13746 standard; DNA; 14 BP.

AC ABT13746;

DT 07-FEB-2003 (first entry)

DE Population analysis related TAG sequence #52.

XX Qualitative; quantitative; analysis; population; invariable chain;
 KW nuclease; gene expression profile; ds.

OS Unidentified.

PN WO200266676-A2.

PD 29-AUG-2002.

PF 15-FEB-2002; 2002WO-FR000600.

PR 16-FEB-2001; 2001FR-00002183.

PA (CNRS) CNRS CENT NAT RECH SCI.

PI Pugnere D, Marti J, Manchon L, Piquemal D;

XX WPI; 2003-018634/01.

PT Analysis of nucleic acid populations, useful for comparing gene
 PT expression profiles, by sequencing and identifying tags based on nuclease
 PT recognition sites.

PS Example 2; Page 37; 51pp; French.

XX The invention relates to a novel method for qualitative or quantitative
 CC analysis of a population of nucleic acids in a sample where each nucleic
 CC acid contains many copies of an invariable chain of nucleotides,
 CC recognised by a nuclease. The number of bases separating two successive
 CC copies is constant and determined by the number of nucleotides between
 CC the invariable chain and the nuclease cutting site. The method is used to
 CC determine gene expression profiles in a population of cells, especially
 CC eukaryotes, e.g. where one population has been treated with a compound
 CC that may affect its physiology, or where one population represents normal
 CC cells and the other diseased cells. This polynucleotide sequence
 CC represents a nucleic acid of the population of the invention

XX

SQ Sequence 14 BP; 7 A; 1 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 738 TCAATAAAGTT 749
 Db 3 TCAATAAAGTT 14

RESULT 266
 ADR97911/C
 ID ADR97911 standard; DNA; 14 BP.
 XX
 AC ADR97911;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human APC DNA fragment containing deletion at codon 879.
 XX
 KW ds; chromosomal abnormality; detection; foetus; translocation;
 KW transversion; monosomy; trisomy; aneuploidy; deletion; addition;
 KW amplification; prenatal diagnosis; SNP; single nucleotide polymorphism;
 KW human; chromosome 5q21-22; adenomatous polyposis coli; mutation.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FN WO2004079011-A1.
 XX
 PD 16-SEP-2004.
 XX
 PF 29-AUG-2003; 2003WO-US027308.
 XX
 PR 28-FEB-2003; 2003WO-US006198.
 XX
 PA (RAVG-) RAVGEN INC.
 XX
 PI Dhallan R;
 XX
 WPI; 2004-677127/66.
 XX
 DR Detecting a chromosomal abnormality, e.g. translocations, transversions,
 XX monosomies, trisomies, aneuploidies, deletions, or arrangements, comprises
 PT determining the sequence of alleles of a locus of interest in the sample
 PT from template DNA.
 XX
 PS Example 7; Page 151; 429pp; English.
 XX
 CC This invention describes a novel method for detecting a chromosomal
 CC abnormality in a sample which comprises determining the sequence of
 CC alleles of a locus of interest in a sample from template DNA where
 CC determining the sequence of the alleles comprises amplifying the locus of
 CC interest, hybridising the amplified loci to GeneChip array, washing
 CC GeneChip array, staining the GeneChip array with detectable reagents, and
 CC scanning GeneChip array. The amplification method is self-sustained
 CC sequence reaction, ligase chain reaction, rapid amplification of cDNA
 CC ends, PCR and ligase chain reaction, Q-beta phage amplification, strand
 CC displacement amplification, or splice overlap extension PCR, preferably
 CC PCR. The determination of the sequence of the alleles comprises
 CC amplifying the locus of interest, fragmenting the amplicon, hybridising
 CC fragmented amplicons to CodeLink Arrays, extension reaction to
 CC incorporate a nucleotide and detecting incorporated nucleotides. The
 CC amplicon fragmentation is by exonuclease digestion. Detecting a
 CC chromosomal abnormality in a sample comprises determining the sequence of
 CC alleles of a locus of interest from template DNA, where determining the
 CC sequence of the alleles comprises using BeadArray Technology. The
 CC determination of the sequence of the alleles may also be done by
 CC amplifying the locus of interest, dephosphorylation of the unused
 CC reagents, in vitro transcription reaction of the products, RNase A
 CC cleavage of the products, mixing the products with CleanResin,
 CC transferring products to SpectroCHIP, and analysing the SpectroCHIP. The

dephosphorylation reaction is with shrimp alkaline phosphatase.
 Alternatively, the determination of the sequence of the alleles comprises
 amplifying the locus of interest, dephosphorylation of the unused
 reagents, hybridising a primer to the locus of interest, incorporating a
 nucleotide, mixing the products with CleanResin, transferring products to
 SpectroCHIP, and analysing the SpectroCHIP. The hybridisation of primer
 is adjacent to the locus of interest. The determination of the sequence
 of the alleles may also comprise amplifying the locus of interest,
 treating the products with exonuclease, single stranded DNA is annealed
 to an oligonucleotide, incorporating a nucleotide using the annealed
 template and primer, and detecting the incorporated nucleotide. The
 method is useful for detecting a chromosomal abnormality in a sample.
 Specifically, the method is useful for detecting chromosomal
 abnormalities in a fetus including translocations, transversions,
 monosomies, trisomies, and other aneuploidies, deletions, additions,
 amplifications, and arrangements. The method of the invention can also be
 used for prenatal diagnosis. This sequence represents a fragment of the
 human adenomatous polyposis coli (APC) gene which contains a nucleotide
 deletion.

Sequence 14 BP; 4 A; 7 C; 1 G; 2 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 374 GTGCTGGAGATC 385
 Db 14 GTGCTGGAGATC 3

RESULT 267
 ADS08595/C
 ID ADS08595 standard; DNA; 14 BP.
 XX
 AC ADS08595;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Human DNA oligonucleotide #84.
 XX
 KW Human; nucleic acid detection; cell lysis; chromosomal abnormality;
 KW cancer; carcinoma; bladder; breast; bronchus; colon; kidney; liver; lung;
 KW oesophagus; gall bladder; ovary; pancreas; stomach; cervix; thyroid;
 KW prostate; skin; small cell lung cancer; squamous cell carcinoma;
 KW leukaemia; lymphoma; myelodysplastic syndrome; fibrosarcoma;
 KW rhabdomyosarcoma; astrocytoma; neuroblastoma; glioma; schwannoma;
 KW melanoma; seminoma; teratocarcinoma; osteosarcoma; ds.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FN WO2004078994-A2.
 XX
 PD 16-SEP-2004.
 XX
 PF 01-MAR-2004; 2004WO-US006337.
 XX
 PR 28-FEB-2003; 2003WO-US006198.
 XX
 PA (RAVG-) RAVGEN INC.
 XX
 PI Dhallan R;
 XX
 WPI; 2004-662434/64.
 XX
 DR Detecting presence or absence of nucleic acid, containing mutation,
 XX involves isolating nucleic acid from sample containing cell lysis
 PT inhibitor, and detecting presence or absence of nucleic acid.
 XX
 PS Example 7; Page 160; 440pp; English.
 XX
 CC The invention relates to a method for detecting a nucleic acid, involving

CC isolating a nucleic acid from a sample, where an agent that impedes cell
 CC lysis was added to the sample, and detecting the presence or absence of
 CC the nucleic acid. The invention also relates to a method for detecting
 CC chromosomal abnormalities in a DNA sample and determining the sequence of
 CC foetal DNA from a sample of a pregnant female. The nucleic acid contains
 CC at least one mutation chosen from a single point mutation, multiple point
 CC mutations, an insertion, a frameshift, a truncation, a deletion, a
 CC duplication and a transversion. The method is useful for detecting
 CC nucleic acid in a sample obtained from a source chosen from bacteria,
 CC viruses, fungi, mycobacteria, protozoa, molds, yeasts, plants, humans,
 CC non-humans, multi-cellular parasites, animals and archaeobacteria. The
 CC method is useful for detecting, diagnosing or monitoring a disease such
 CC as cancer chosen from carcinoma of the bladder, breast, bronchus, colon,
 CC kidney, liver, lung, oesophagus, gall bladder, ovary, pancreas, stomach,
 CC cervix, thyroid, prostate and skin, small cell lung cancer, squamous cell
 CC carcinoma, haematopoietic tumours of lymphoid lineage, leukaemia, acute
 CC lymphocytic leukaemia, acute lymphoblastic leukaemia, B-cell lymphoma, T-
 CC cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell
 CC lymphoma, Burkett's lymphoma, haematopoietic tumours of myeloid lineage,
 CC acute and chronic myelogenous leukaemias, myelodysplastic syndrome and
 CC promyelocytic leukaemia, tumours of mesenchymal origin, fibrosarcoma and
 CC rhabdomyosarcoma, tumours of the central and peripheral nervous system,
 CC astrocytoma, neuroblastoma, glioma and schwannomas, melanoma, seminoma,
 CC teratocarcinoma and osteosarcoma. The method is also useful for
 CC monitoring response to treatment chosen from surgery, radiation,
 CC lifestyle change, dietary protocol and supplementation and administration
 CC of a drug. The drug is chosen from chemotherapeutic agents, anti-
 CC bacterial agents, anti-viral agents, anti-fungal agents, targeted-cancer
 CC drugs, cytotoxic agents, cytostatic agents and anti-proliferative agents.
 CC This sequence represents a DNA oligonucleotide used in the scope of the
 CC invention.

SQ Sequence 14 BP; 4 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 14;
 Best Local Similarity 100.0%; Pred. No. 1.3e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 374 GTGGTGGAGATC 385
 Db 14 GTGGTGGAGATC 3

RESULT 268
 AAX31657/c
 ID AAX31657 standard; DNA; 15 BP.
 XX
 AC AAX31657;

DT 21-MAY-1999 (first entry)

DE Tag sequence of a transcript increased in pancreatic cancer.

KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
 KW diagnosis; prognosis; treatment; ss.

OS Homo sapiens.

PN WO9853319-A2.

PD 26-NOV-1998.

PF 20-MAY-1998; 98WO-US010277.

PR 21-MAY-1997; 97US-0047352P.

PA (UYJO) UNIV JOHNS HOPKINS.

PI Vogelstein B; Kinzler KW;

XX WPI; 1999-070161/06.

XX Use of isolated gene transcripts - useful for developing products for the

PT diagnosis, prognosis and treatment of cancers, particularly colon and
 PT pancreatic cancer.

PS Claim 13; Page 67; 120pp; English.

XX AAX30947-31815 represent tag sequences of transcripts that are
 CC differentially expressed in colorectal cancer, in pancreatic cancer, or
 CC in both. The tag sequences can be used to identify genes by matching the
 CC tag to a gen data base member, or by using the tag sequences as probes to
 CC isolate unidentified genes from cDNA libraries. The tag sequences can
 CC also be used in a method for diagnosing colon or pancreatic cancer in a
 CC sample suspected of being neoplastic. The method comprises comparing the
 CC level of at least one transcript in a first sample of a tissue to a
 CC second sample, where the first sample is a colonic tissue suspected of
 CC being neoplastic and the second sample is a normal human colonic tissue.
 CC The transcript is identified by a tag selected from AAX30947-31815. The
 CC methods of the invention can be used in the diagnosis, prognosis and
 CC treatment of cancer

SQ Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 500 CCTGAGGGGCACA 511
 Db 14 CCTGAGGGGCACA 3

RESULT 269
 AAX31658/c
 ID AAX31658 standard; DNA; 15 BP.

XX
 AC AAX31658;

DT 21-MAY-1999 (first entry)

DE Tag sequence of a transcript increased in pancreatic cancer.

KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
 KW diagnosis; prognosis; treatment; ss.

OS Homo sapiens.

PN WO9853319-A2.

PD 26-NOV-1998.

PF 20-MAY-1998; 98WO-US010277.

PR 21-MAY-1997; 97US-0047352P.

PA (UYJO) UNIV JOHNS HOPKINS.

XX Vogelstein B, Kinzler KW;

XX WPI; 1999-070161/06.

XX Use of isolated gene transcripts - useful for developing products for the
 PT diagnosis, prognosis and treatment of cancers, particularly colon and
 PT pancreatic cancer.

PS Claim 13; Page 67; 120pp; English.

XX AAX30947-31815 represent tag sequences of transcripts that are
 CC differentially expressed in colorectal cancer, in pancreatic cancer, or
 CC in both. The tag sequences can be used to identify genes by matching the
 CC tag to a gen data base member, or by using the tag sequences as probes to
 CC isolate unidentified genes from cDNA libraries. The tag sequences can
 CC also be used in a method for diagnosing colon or pancreatic cancer in a
 CC sample suspected of being neoplastic. The method comprises comparing the
 CC level of at least one transcript in a first sample of a tissue to a

CC second sample, where the first sample is a colonic tissue suspected of
 CC being neoplastic and the second sample is a normal human colonic tissue.
 CC The transcript is identified by a tag selected from AAX30947-31815. The
 CC methods of the invention can be used in the diagnosis, prognosis and
 CC treatment of cancer

XX SQ Sequence 15 BP; 2 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 500 CCTGAGGGCACA 511
 |||||:|||||
 DB 14 CCTGAGGGCACA 3

RESULT 270

AAI67292/C

ID AAI67292 standard; DNA; 15 BP.

XX AC

XX AAI67292;

XX DT 11-FEB-2002 (first entry)

XX DE Human FKBP8 allele-specific oligonucleotide (ASO) probe.

XX DX

XX KW FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss;

XX KW immunosuppression; human; allele-specific oligonucleotide; ASO; probe.

XX OS Homo sapiens.

XX PN WO200172965-A2.

XX PD 04-OCT-2001.

XX PF 26-MAR-2001; 2001WO-US009718.

XX PR 24-MAR-2000; 2000US-0192125P.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Anastasio AE, Bentivegna SC, Choi JY, Klieem SE, Koshy B;

XX PI Stephens JC;

XX DR WPI; 2001-626261/72.

XX XX

XX PT New haplotypes of the FK506-binding protein 8 gene, useful for genotyping

XX PT that gene in individual and to design new therapy for associated disease

XX PT such as immunosuppression and cancer.

XX PS Claim 15; Page 13; 98pp; English.

XX XX

XX CC The invention relates to haplotyping the FK506-binding protein 8 (38KD)

XX CC (FKBP8) gene in an individual. The method involves determining the

XX CC identity of the nucleotide pair at one or more polymorphic sites selected

XX CC from P1 to P26 (described in the specification). The invention is useful

XX CC to improve the efficiency and reliability of several steps in the

XX CC discovery and development of drugs for treating diseases associated with

XX CC FKBP8 activity, for example immunosuppression and cancer. Sequences

XX CC AAI67274-299 represent allele-specific oligonucleotide (ASO) probes for

XX CC detecting FKBP8 gene polymorphisms

XX SQ Sequence 15 BP; 2 A; 5 C; 6 G; 1 T; 0 U; 1 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;

Best Local Similarity 85.7%; Pred. No. 1.5e+02;

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 457 GCCCCCCCGGTGGG 470

|||||:|||||

DB 15 GCACCCCRGTGGT 2

RESULT 271

AAI67293/C

ID AAI67293 standard; DNA; 15 BP.

XX AC

XX AAI67293;

XX DT 11-FEB-2002 (first entry)

XX DE Human FKBP8 allele-specific oligonucleotide (ASO) probe.

XX DX

XX KW FK506-binding protein 8; FKBP8; haplotyping; polymorphism; cancer; ss;

XX KW immunosuppression; human; allele-specific oligonucleotide; ASO; probe.

XX OS Homo sapiens.

XX PN WO200172965-A2.

XX PD 04-OCT-2001.

XX PF 26-MAR-2001; 2001WO-US009718.

XX PR 24-MAR-2000; 2000US-0192125P.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Anastasio AE, Bentivegna SC, Choi JY, Klieem SE, Koshy B;

XX PI Stephens JC;

XX DR WPI; 2001-626261/72.

XX XX

XX PT New haplotypes of the FK506-binding protein 8 gene, useful for genotyping

XX PT that gene in individual and to design new therapy for associated disease

XX PT such as immunosuppression and cancer.

XX PS Claim 15; Page 13; 98pp; English.

XX XX

XX CC The invention relates to haplotyping the FK506-binding protein 8 (38KD)

XX CC (FKBP8) gene in an individual. The method involves determining the

XX CC identity of the nucleotide pair at one or more polymorphic sites selected

XX CC from P1 to P26 (described in the specification). The invention is useful

XX CC to improve the efficiency and reliability of several steps in the

XX CC discovery and development of drugs for treating diseases associated with

XX CC FKBP8 activity, for example immunosuppression and cancer. Sequences

XX CC AAI67274-299 represent allele-specific oligonucleotide (ASO) probes for

XX CC detecting FKBP8 gene polymorphisms

XX SQ Sequence 15 BP; 2 A; 7 C; 4 G; 1 T; 0 U; 1 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;

Best Local Similarity 85.7%; Pred. No. 1.5e+02;

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 457 GCCCCCCCGGTGGG 470

|||||:|||||

DB 14 GCACCCCGGTGGG 1

RESULT 272

AAI6723/C

ID AAI6723 standard; DNA; 15 BP.

XX AC

XX AAI6723;

XX DT 30-MAR-2001 (first entry)

XX DE iGFBP3 oligonucleotide #143.

XX DX

XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;

XX KW cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;

XX KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;

XX KW IGF binding protein; iGFBP-2; iGFBP3; inflammation; psoriasis; pilaris;

XX KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;

KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU0000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 7; Page 45; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 1 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 10 AGCAGAGTCAGC 21
 DB 14 AGCAGAGTCAGC 3
 RESULT 273
 AAF451517/C
 ID AAF45517 standard; DNA; 15 BP.
 XX
 AC AAF45517;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP2 oligonucleotide #356.
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 XX
 XX neovascular condition of the retina; ss.

OS Homo sapiens.
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU0000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 6; Page 36; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 2 A; 5 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 340 CCCGACGAGCT 351
 DB 12 CCCGACGAGCT 1
 RESULT 274
 AAF46724/C
 ID AAF46724 standard; DNA; 15 BP.
 XX
 AC AAF46724;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP3 oligonucleotide #144.
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 XX
 XX neovascular condition of the retina; ss.
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX

```

PD 28-DEC-2000.
XX
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 7; Page 45; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAP45151 and AAP45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 1 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 12; DB 1; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 10 AGCAGAGTCAGC 21
XX |||||
XX Db 13 AGCAGAGTCAGC 2
XX
XX RESULT 275
XX AAF46722/c
XX ID AAF46722 standard; DNA; 15 BP.
XX
XX AC AAF46722;
XX
XX DT 30-MAR-2001 (first entry)
XX
XX DE IGFBP3 oligonucleotide #142.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200078341-A1.
XX
XX PD 28-DEC-2000.
XX
XX PF 21-JUN-2000; 2000WO-AU000693.
XX
XX PD 28-DEC-2000.
XX
XX PF 21-JUN-2000; 2000WO-AU000693.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX

```

```

PR 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 7; Page 45; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAP45151 and AAP45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 1 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 12; DB 1; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 10 AGCAGAGTCAGC 21
XX |||||
XX Db 15 AGCAGAGTCAGC 4
XX
XX RESULT 276
XX AAF45480
XX ID AAF45480 standard; DNA; 15 BP.
XX
XX AC AAF45480;
XX
XX DT 30-MAR-2001 (first entry)
XX
XX DE IGFBP2 oligonucleotide #319.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2000078341-A1.
XX
XX PD 28-DEC-2000.
XX
XX PF 21-JUN-2000; 2000WO-AU000693.
XX
XX PR 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX

```

```

PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 36; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 5 C; 7 G; 1 T; 0 U; 0 Other;
Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 222 CCGCAGTGCCG 233
DB 2 CCGCAGTGCCG 13
RESULT 277
AAF4515/c
ID AAF45515 standard; DNA; 15 BP.
XX
AC AAF45515;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #354.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 36; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 5 C; 7 G; 1 T; 0 U; 0 Other;
Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 222 CCGCAGTGCCG 233
DB 2 CCGCAGTGCCG 13
RESULT 278
AAF45478
ID AAF45478 standard; DNA; 15 BP.
XX
AC AAF45478;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #317.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 36; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 340 CCGGACGAGCT 351
DB 14 CCGGACGAGCT 3
RESULT 279
AAF45478
ID AAF45478 standard; DNA; 15 BP.
XX
AC AAF45478;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGFBP2 oligonucleotide #317.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
PN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU000693.
XX
PR 21-JUN-1999; 99US-0140345P.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
PT inhibits or reduces growth factor mediated cell proliferation and/or
PT inflammation.
XX
PS Example 6; Page 36; 201pp; English.
XX
CC The present invention relates to a method for ameliorating the effects of
CC skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
CC F45161). The method is useful for ameliorating the effects of psoriasis,
CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
CC hyperneovascular condition such as a neovascular condition of the retina,
CC brain or skin, growth factor-mediated malignancies, other sclerotic
CC disease, kidney disease, hyperproliferation of the inside of blood
CC vessels or any other hyperplasia
XX
SQ Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 340 CCGGACGAGCT 351
DB 14 CCGGACGAGCT 3

```

XX Example 6; Page 36; 201pp; English.

PS The present invention relates to a method for ameliorating the effects of

CC skin disorders. The method comprises contacting the skin with an

CC antisense oligonucleotide, (for Insulin-like Growth Factor, [IGF]-1

CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of

CC inhibiting or reducing growth factor mediated cell proliferation,

CC inflammation and/or other disorders. The present sequence is an

CC oligonucleotide which can be used to design the antisense

CC oligonucleotides of the present invention (see AAF45151 and AAF45153-

CC P45161). The method is useful for ameliorating the effects of psoriasis,

CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,

CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a

CC hyperneovascular condition such as a neovascular condition of the retina,

CC brain or skin, growth factor-mediated malignancies, other sclerotic

CC disease, kidney disease, hyperproliferation of the inside of blood

CC vessels or any other hyperplasia

XX SQ Sequence 15 BP; 1 A; 5 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 222 CCGCAGTGGCCG 233

Db 4 CCGCAGTGGCCG 15

RESULT 279

AAF45795/c

ID AAF45795 standard; DNA; 15 BP.

XX AC AAF45795;

XX 30-MAR-2001 (first entry)

DE IGFBP2 oligonucleotide #634.

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;

KW cystostatic; dermatological; cardiant; virucide; ophthalmological; keloid;

KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;

KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;

KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;

KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;

KW hyperneovascular condition; hyperplasia; kidney disease;

KW neovascular condition of the retina; ss.

XX OS Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering

PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that

PT inhibits or reduces growth factor mediated cell proliferation and/or

PT inflammation.

XX Example 6; Page 38; 201pp; English.

PS The present invention relates to a method for ameliorating the effects of

CC

CC skin disorders. The method comprises contacting the skin with an

CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1

CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of

CC inhibiting or reducing growth factor mediated cell proliferation,

CC inflammation and/or other disorders. The present sequence is an

CC oligonucleotide which can be used to design the antisense

CC oligonucleotides of the present invention (see AAF45151 and AAF45153-

CC P45161). The method is useful for ameliorating the effects of psoriasis,

CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,

CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a

CC hyperneovascular condition such as a neovascular condition of the retina,

CC brain or skin, growth factor-mediated malignancies, other sclerotic

CC disease, kidney disease, hyperproliferation of the inside of blood

CC vessels or any other hyperplasia

XX SQ Sequence 15 BP; 1 A; 2 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 1.5e+02;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 687 GCCTCCCCCGCC 698

Db 15 GCCTCCCCCGCC 4

RESULT 280

AAF45169/c

ID AAF45169 standard; DNA; 15 BP.

XX AC AAF45169;

XX 30-MAR-2001 (first entry)

DE IGFBP2 oligonucleotide #8.

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;

KW cystostatic; dermatological; cardiant; virucide; ophthalmological; keloid;

KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;

KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;

KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;

KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;

KW hyperneovascular condition; hyperplasia; kidney disease;

KW neovascular condition of the retina; ss.

XX OS Homo sapiens.

XX WO200078341-A1.

XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU000693.

XX 21-JUN-1999; 99US-0140345P.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wright CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering

PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that

PT inhibits or reduces growth factor mediated cell proliferation and/or

PT inflammation.

XX Example 6; Page 34; 201pp; English.

PS The present invention relates to a method for ameliorating the effects of

CC skin disorders. The method comprises contacting the skin with an

CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1

CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of

CC inhibiting or reducing growth factor mediated cell proliferation,

CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloide, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 5 A; 1 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 484 TTCCTCCTCCCT 495
 DB 15 TTCCTCCTCCCT 4

RESULT 281
 AAF45170/c
 ID AAF45170 standard; DNA; 15 BP.
 XX
 AC AAF45170;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP2 oligonucleotide #9.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 6; Page 34; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloide, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX

CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloide, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 5 A; 1 C; 9 G; 0 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 484 TTCCTCCTCCCT 495
 DB 14 TTCCTCCTCCCT 3

RESULT 282
 AAF45481
 ID AAF45481 standard; DNA; 15 BP.
 XX
 AC AAF45481;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP2 oligonucleotide #320.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 6; Page 36; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloide, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC

CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX Sequence 15 BP; 2 A; 5 C; 7 G; 1 T; 0 U; 0 Other;
 SQ

Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 222 CGCAGTGGCCG 233
 Db 1 CGCAGTGGCCG 12

RESULT 283
 AAF46725/c
 ID AAF46725 standard; DNA; 15 BP.
 XX
 AC AAF46725;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP3 oligonucleotide #145.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 7; Page 45; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 1 A; 4 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 10 AGCAGAGTCAGC 21
 Db 12 AGCAGAGTCAGC 1

RESULT 284
 AAF46287
 ID AAF46287 standard; DNA; 15 BP.
 XX
 AC AAF46287;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP2 oligonucleotide #1126.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 6; Page 41; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 0 A; 11 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 194 CCCCTGCCCCC 205
Db 4 CCCCTGCCCCC 15

RESULT 285
AAF45171/c
ID AAF45171 standard; DNA; 15 BP.
XX
XX
AC AAF45171;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP2 oligonucleotide #10.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 6; Page 34; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 6 A; 0 C; 9 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 12; DB 1; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 484 TTCCTCCTCCCT 495
Db 13 TTCCTCCTCCCT 2

```

```

RESULT 286
AAF45172/c
ID AAF45172 standard; DNA; 15 BP.
XX
XX
AC AAF45172;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGFBP2 oligonucleotide #11.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 6; Page 34; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 7 A; 0 C; 8 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 1.6%; Score 12; DB 1; Length 15;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 484 TTCCTCCTCCCT 495
Db 12 TTCCTCCTCCCT 1

```

```

RESULT 287
AAF45479

```

```

ID AAF45479 standard; DNA; 15 BP.
XX AC
XX AAF45479;
XX DT
XX 30-MAR-2001 (first entry)
XX DE IGFBP2 oligonucleotide #318.
XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX KW hyperneovascular condition; hyperplasia; kidney disease;
XX KW neovascular condition of the retina; ss.
XX OS Homo sapiens.
XX FN WO200078341-A1.
XX PD 28-DEC-2000.
XX PF 21-JUN-2000; 2000WO-AU000693.
XX PR 21-JUN-1999; 99US-0140345P.
XX PA (MURD-) MURDOCH CHILDRENS RES INST.
XX PI Wright CJ, Werther GA, Edmondson SR;
XX DR WPI; 2001-041421/05.
XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX PT inhibits or reduces growth factor mediated cell proliferation and/or
XX PS inflammation.
XX PS Example 6; Page 36; 201pp; English.
XX CC The present invention relates to a method for ameliorating the effects of
XX CC skin disorders. The method comprises contacting the skin with an
XX CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
XX CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX CC inhibiting or reducing growth factor mediated cell proliferation,
XX CC inflammation and/or other disorders. The present sequence is an
XX CC oligonucleotide which can be used to design the antisense
XX CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX CC F45161). The method is useful for ameliorating the effects of psoriasis,
XX CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,
XX CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX CC hyperneovascular condition such as a neovascular condition of the retina,
XX CC brain or skin, growth factor-mediated malignancies, other sclerotic
XX CC disease, kidney disease, hyperproliferation of the inside of blood
XX CC vessels or any other hyperplasia
XX SQ Sequence 15 BP; 1 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 222 CGCAGTGGCCG 233
DB 3 CGCAGTGGCCG 14
|||||

RESULT 288
AAF45799/c
ID AAF45799 standard; DNA; 15 BP.
XX AC AAF45799;
XX XX

ID AAF45479 standard; DNA; 15 BP.
XX AC AAF45514/c
XX ID AAF45514 standard; DNA; 15 BP.
XX AC AAF45514;
XX XX
XX 30-MAR-2001 (first entry)
XX DT IGFBP2 oligonucleotide #353.
XX DE
XX XX

Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 686 TGCTTCCCCGC 697
DB 12 TGCTTCCCCGC 1
|||||

RESULT 289
AAF45514/c
ID AAF45514 standard; DNA; 15 BP.
XX AC AAF45514;
XX XX
XX 30-MAR-2001 (first entry)
XX DT IGFBP2 oligonucleotide #353.
XX DE
XX XX

```

KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.
 XX
 XX WO200078341-A1.
 PN
 XX
 XX 28-DEC-2000.
 PD
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA

PI Wright CJ, Werther GA, Edmondson SR;
 XX
 XX WPI; 2001-041421/05.
 DR

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional), and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX Example 6; Page 36; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 1 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CCCGACGAGCT 351
 Db 15 CCCGACGAGCT 4

RESULT 290
 AAF45151/c
 ID AAF451516 standard; DNA; 15 BP.
 XX
 XX AAF451516;
 AC
 DT 30-MAR-2001 (first entry)
 XX
 XX IGFBP2 oligonucleotide #355.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;

KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

OS Homo sapiens.
 XX
 XX WO200078341-A1.
 PN
 XX
 XX 28-DEC-2000.
 PD
 XX
 XX 21-JUN-2000; 2000WO-AU000693.
 PF
 XX
 XX 21-JUN-1999; 99US-0140345P.
 PR
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.

PI Wright CJ, Werther GA, Edmondson SR;
 XX
 XX WPI; 2001-041421/05.

XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional), and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX Example 6; Page 36; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids, keratosis,
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia

XX Sequence 15 BP; 2 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 CCCGACGAGCT 351
 Db 13 CCCGACGAGCT 2

RESULT 291
 ABK95953
 ID ABK95953 standard; DNA; 15 BP.
 XX
 XX ABK95953;
 AC
 XX
 XX 24-SEP-2002 (first entry)
 DT
 XX
 XX Human LIPE gene polymorphism detection ASO probe #15.
 DE
 XX
 XX Human; lipase; hormone sensitive; LIPE; isogene; obesity; probe; ss;
 KW male sterility; polymorphism; allele-specific oligonucleotide; ASO.
 KW
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200240502-A2.
 PN
 XX
 XX 23-MAY-2002.
 PD

```
XX 16-NOV-2001; 2001WO-US043518.
XX
XX 16-NOV-2000; 2000US-0249302P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Anastasio AE, Bentivegna SC, Chew A, Koshy B, Rounds E;
XX
XX WPI; 2002-519369/55.
XX
XX Novel genetic variants of Lipase, Hormone-Sensitive isogenes, useful for
XX improving efficiency and reliability in drug development for treating
XX diseases associated with LIPE activity, e.g. obesity and male sterility.
XX
XX Claim 15; Page 14; 142pp; English.
XX
XX The present invention relates to a new polynucleotide comprising a
XX nucleotide sequence which comprises lipase, hormone sensitive (LIPE)
XX isogenes. The invention is useful in screening for drugs targeting LIPE
XX isogenes that are useful for treating obesity and male sterility. The
XX methods of the invention are useful for improving the efficiency and
XX reliability of several steps in the discovery and development of drugs
XX for treating diseases associated with LIPE activity. The polynucleotide
XX is useful in studying the expression and function of LIPE, and in
XX expressing LIPE protein for use in screening for candidate drugs to treat
XX diseases related to LIPE activity. It is also useful in studying the
XX effect of the variation on the biological activity of LIPE as well as on
XX the binding affinity of candidate drugs targeting LIPE for the treatment
XX of obesity and male sterility. The invention is useful for studying the
XX expression of LIPE isogenes in vivo, for in vivo screening and testing of
XX drugs targeted against LIPE protein, and for testing the efficacy of
XX therapeutic agents and compounds for treating obesity and male sterility
XX in a biological system. The present nucleic acid sequence represents one
XX of a collection (ABK95939-ABK95967) of allele-specific oligonucleotide
XX (ASO) probes that were used in the invention to detect polymorphisms in
XX the human LIPE gene
XX
XX Sequence 15 BP; 0 A; 8 C; 4 G; 2 T; 0 U; 1 Other;
SQ
Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.5e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 227 GTGGCGCGCGCCGC 240
DB |||||:|||||
2 GTGGCGCGCGCCGCC 15
RESULT 292
ABK95954
ID ABK95954 standard; DNA; 15 BP.
XX
XX AC ABK95954;
XX
XX 24-SEP-2002 (first entry)
XX
XX Human LIPE gene polymorphism detection ASO probe #16.
XX
XX Human; lipase; hormone sensitive; LIPE; isogene; obesity; probe; ss;
XX male sterility; polymorphism; allele-specific oligonucleotide; ASO.
XX
XX Homo sapiens.
XX
XX WO200240502-A2.
XX
XX 23-MAY-2002.
XX
XX 16-NOV-2001; 2001WO-US043518.
XX
XX 16-NOV-2000; 2000US-0249302P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
```

```
XX Anastasio AE, Bentivegna SC, Chew A, Koshy B, Rounds E;
XX
XX WPI; 2002-519369/55.
XX
XX Novel genetic variants of Lipase, Hormone-Sensitive isogenes, useful for
XX improving efficiency and reliability in drug development for treating
XX diseases associated with LIPE activity, e.g. obesity and male sterility.
XX
XX Claim 15; Page 14; 142pp; English.
XX
XX The present invention relates to a new polynucleotide comprising a
XX nucleotide sequence which comprises lipase, hormone sensitive (LIPE)
XX isogenes. The invention is useful in screening for drugs targeting LIPE
XX isogenes that are useful for treating obesity and male sterility. The
XX methods of the invention are useful for improving the efficiency and
XX reliability of several steps in the discovery and development of drugs
XX for treating diseases associated with LIPE activity. The polynucleotide
XX is useful in studying the expression and function of LIPE, and in
XX expressing LIPE protein for use in screening for candidate drugs to treat
XX diseases related to LIPE activity. It is also useful in studying the
XX effect of the variation on the biological activity of LIPE as well as on
XX the binding affinity of candidate drugs targeting LIPE for the treatment
XX of obesity and male sterility. The invention is useful for studying the
XX expression of LIPE isogenes in vivo, for in vivo screening and testing of
XX drugs targeted against LIPE protein, and for testing the efficacy of
XX therapeutic agents and compounds for treating obesity and male sterility
XX in a biological system. The present nucleic acid sequence represents one
XX of a collection (ABK95939-ABK95967) of allele-specific oligonucleotide
XX (ASO) probes that were used in the invention to detect polymorphisms in
XX the human LIPE gene
XX
XX Sequence 15 BP; 2 A; 10 C; 0 G; 2 T; 0 U; 1 Other;
SQ
Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.5e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 689 CTCGCCGCGCCACCT 702
DB |||||:|||||
1 CTCGCCGCGCCACCT 14
RESULT 293
AAL44242
ID AAL44242 standard; DNA; 15 BP.
XX
XX AC AAL44242;
XX
XX 08-NOV-2002 (first entry)
XX
XX Human interleukin 12A (IL-12A) allele specific oligonucleotide primer 10.
XX
XX Human; primer; interleukin 12A; IL-12A; drug screening; AIDS; malaria;
XX tuberculosis; cancer; haplotyping; genotyping; transgenic animal; ss.
XX
XX Homo sapiens.
XX
XX WO200229115-A1.
XX
XX 11-APR-2002.
XX
XX 05-OCT-2001; 2001WO-US031656.
XX
XX 06-OCT-2000; 2000US-0238693P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Armstrong B, Cappola G, Choi JV, Gilson CR, Klien SE, Koshy B;
XX Parks KE;
XX
XX WPI; 2002-315865/35.
XX
```

PT New interleukin 12A (IL-12A) gene polymorphic variants, for studying the
 PT expression and function of IL-12A and screening candidate drugs for
 PT treating AIDS and cancer.

XX Claim 15; Page 13; 72pp; English.

CC The invention comprises the amino acid and coding sequence of the human
 CC interleukin 12A (IL-12A) protein. Specifically the invention relates to
 CC the identification of polymorphisms within the human (IL-12A) gene
 CC sequence. The polymorphisms identified in the human IL-12A gene sequence
 CC are useful in studying the expression and function of IL-12A, and in
 CC screening drugs for the treatment of disorders such as AIDS, malaria,
 CC tuberculosis and cancer. The IL-12A polymorphisms may be used to
 CC haplotype and genotype the IL-12A gene of an individual. The IL-12A DNA
 CC sequences of the invention can be used to create transgenic animals for
 CC studying expression of the IL-12A isogenes in vivo. The present DNA
 CC sequence represents a human interleukin 12A (IL-12A) gene allele specific
 CC oligonucleotide primer

XX Sequence 15 BP; 3 A; 5 C; 4 G; 2 T; 0 U; 1 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;

Best Local Similarity 85.7%; Pred. No. 1.5e+02;

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 257 AGCGCGCAACTCAG 270

Db 2 AGCCTGCAACTCG 15

RESULT 294

ABN80605

ID ABN80605 standard; DNA; 15 BP.

AC ABN80605;

XX 19-JUL-2002 (first entry)

XX Human P450(cytochrome) oxidoreductase allele specific PCR primer #45.

XX Human; P450(cytochrome) oxidoreductase; POR; cancer; haplotype; SNP;
 KW single nucleotide polymorphism; flavoprotein; enzyme; PCR; primer; ss.

XX Homo sapiens.

XX WO200226768-A2.

XX 04-APR-2002.

XX 01-OCT-2001; 2001WO-US030877.

XX 29-SEP-2000; 2000US-0236449P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Kazemi A, Kliem SE, Lanz EM, Messer C, Tanguay DA;

XX WPI; 2002-394236/42.

XX New genetic variants comprising haplotypes of the P450 (cytochrome)
 PT oxidoreductase (POR) isogene, useful in improving the efficiency of drug
 PT screening protocols for compounds targeting POR.

XX Claim 14; Page 15; 141pp; English.

XX The present invention provides the protein, gene and cDNA sequences of
 CC human P450(cytochrome) oxidoreductase POR, and single nucleotide
 CC polymorphisms (SNPs) identified therein. The sequences can be used to
 CC haplotype the POR gene of an individual, and to establish whether POR is
 CC a suitable target for drugs to treat cancer and disorders associated with
 CC impaired protein synthesis in cells. The present sequence is an allele
 CC specific primer for the coding sequences of the invention

XX

SQ Sequence 15 BP; 0 A; 6 C; 6 G; 2 T; 0 U; 1 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;

Best Local Similarity 85.7%; Pred. No. 1.5e+02;

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 669 GCTGCGCCCACTGG 682

Db 2 GCTGCGCGCGCTSG 15

RESULT 295

AAS19927

ID AAS19927 standard; DNA; 15 BP.

XX AAS19927;

XX 26-MAR-2002 (first entry)

XX ASO primer #7 to detect human DNAL4 gene polymorphisms.

XX Human; single nucleotide polymorphism; SNP; DNAL4; chromosome 22q13.1;
 KW dynein axonemal light polypeptide chain 4; haplotyping; genotyping;
 KW neuroprotective; neurological disorder; allele-specific oligonucleotide;
 KW ASO; primer; ss.

XX Homo sapiens.

XX WO200179235-A2.

XX 25-OCT-2001.

XX 16-APR-2001; 2001WO-US012304.

XX 17-APR-2000; 2000US-0197460P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Bentivegna SC, Chew A, Choi JY, Koshy B;

XX WPI; 2002-075065/10.

XX Genotyping human dynein, axonemal light polypeptide chain 4 gene of
 PT individual, useful for determining haplotype of individual, comprises
 PT determining identity of nucleotide pair at specific polymorphic sites for
 PT two copies of gene.

XX Claim 16; Page 13; 79pp; English.

XX The present invention relates to novel single nucleotide polymorphisms
 CC (SNPs) in the human dynein, axonemal light polypeptide chain 4 (DNAL4)
 CC gene located on chromosome 22q13.1, and methods for haplotyping and/or
 CC genotyping the DNAL4 gene. The methods of the invention make use of
 CC allele-specific oligonucleotides (ASOs) as probes and primers and/or
 CC primer-extension oligonucleotides for detecting the DNAL4 gene
 CC polymorphisms. The polymorphisms and screened compounds are useful for
 CC the treatment of diseases associated with DNAL4 activity, such as
 CC neurological disorders. AAS19921-AAS19948 represent ASO primers for
 CC detecting human DNAL4 gene polymorphisms

XX Sequence 15 BP; 3 A; 2 C; 1 G; 8 T; 0 U; 1 Other;

Query Match 1.6%; Score 12; DB 1; Length 15;

Best Local Similarity 85.7%; Pred. No. 1.5e+02;

Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 713 TTGATACATTTC 726

Db 1 TTGATACCTTTATY 14

RESULT 296

ABL91848

```

ID  ABL91848 standard; DNA; 15 BP.
XX  ABL91848;
AC  ABL91848;
XX  11-JUL-2002 (first entry)
DT  11-JUL-2002 (first entry)
XX  Human LIPG gene allele specific oligonucleotide primer 27.
DE  Human; ss; allele specific oligonucleotide; primer;
XX  single nucleotide polymorphism; SNP; lipase endothelial isogene; LIPG;
KW  drug screening; atherosclerosis; cardiovascular disorder;
KW  LIPG haplotyping; LIPG genotyping.
XX  Homo sapiens.
OS  Homo sapiens.
XX  WO200216397-A2.
PN  WO200216397-A2.
XX  28-FEB-2002.
PD  17-AUG-2001; 2001WO-US026639.
XX  25-AUG-2000; 2000US-0227825P.
XX  (GENA-) GENAISSANCE PHARM INC.
PA  Duda A, Kazemi A, Kliem SE, Messer C;
XX  WPI; 2002-292055/33.
XX  Novel genetic variants of Lipase, Endothelial isogenes, useful for
PT  improving efficiency and reliability in drug development for treating
PT  diseases associated with LIPG activity, e.g. atherosclerosis.
XX  Claim 16; Page 14; 134pp; English.
PS  The invention comprises the DNA and amino acid sequence of the human
XX  lipase, endothelial (LIPG) isogene. Specifically, the invention relates
CC  to the discovery of 20 novel polymorphic sites within the LIPG gene. The
CC  LIPG coding sequence and protein are useful for screening drugs that can
CC  be used to treat atherosclerosis and other cardiovascular disorders. The
CC  LIPG coding sequence can also be used to haplotype and genotype the LIPG
CC  gene of an individual. The DNA sequences ABL91822 - ABL91861 represent
CC  LIPG gene allele specific oligonucleotide primers
XX  Sequence 15 BP; 4 A; 3 C; 6 G; 1 T; 0 U; 1 Other;
SQ  Query Match 1.6%; Score 12; DB 1; Length 15;
    Best Local Similarity 85.7%; Pred. No. 1.5e+02;
    Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY  23 AGCATGACCGAGCG 36
DB  ||||| |||||
    1 AGCATGACCGAGCS 14

RESULT 297
ABK64023/c
ID  ABK64023 standard; DNA; 15 BP.
XX  AC ABK64023;
XX  18-JUN-2002 (first entry)
DT  18-JUN-2002 (first entry)
XX  Human BF gene allele-specific oligonucleotide sequencing primer #30.
DE  Human; B-factor; properdin; BF; primer; ss; gene therapy; drug screening;
XX  antidiabetic; dermatological; diabetes; immunosuppressive;
KW  antiinflammatory; systemic lupus erythematosus.
XX  Homo sapiens.
OS  Homo sapiens.
XX  WO200218414-A2.
PN  WO200218414-A2.
XX  
```

```

PD  07-MAR-2002.
XX  29-AUG-2001; 2001WO-US027098.
XX  29-AUG-2000; 2000US-0228940P.
XX  (GENA-) GENAISSANCE PHARM INC.
PA  Anastasio AE, Finkel K, Kazemi A, Koshy B;
XX  WPI; 2002-304244/34.
XX  New genetic variants having polymorphisms in the B-Factor, Properdin (BF)
PT  gene, useful for studying the function of BF, and for treating disorders
PT  affected by expression or function of the BF isogene.
XX  Claim 17; Page 16; 151pp; English.
PS  The invention relates to single nucleotide polymorphisms in the gene
XX  encoding the human B-factor properdin protein (BF). A method for
CC  haplotyping the BF gene in an individual comprises identifying the
CC  nucleotide at one or more polymorphic sites and determining whether one
CC  of the copies of the gene is defined by one of the BF haplotypes given in
CC  the specification or whether both copies are defined by a haplotype pair.
CC  This method is useful in genotyping, whereby all possible haplotype pairs
CC  can be assigned to specific genotypes. An association between a trait and
CC  a haplotype or haplotype pair of the BF gene can be identified by
CC  comparing the frequency of the haplotype or haplotype pair in a
CC  population exhibiting the trait with the frequency of the haplotype or
CC  haplotype pair in a reference population, where a higher haplotype
CC  frequency in the trait population indicates the trait is associated with
CC  the haplotype or haplotype pair. BF and its corresponding DNA are used
CC  for studying the expression and function of BF, for use in screening for
CC  candidate drugs to treat diseases related to BF activity, such as
CC  diabetes and systemic lupus erythematosus. Sequences ABK63994-ABK64049
CC  represent allele-specific sequencing primers used to detect human BF gene
CC  polymorphisms
XX  Sequence 15 BP; 3 A; 3 C; 8 G; 0 T; 0 U; 1 Other;
SQ  Query Match 1.6%; Score 12; DB 1; Length 15;
    Best Local Similarity 100.0%; Pred. No. 1.5e+02;
    Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY  489 CCTCCCTGTGCC 500
DB  ||||| |||||
    12 CCTCCCTGTGCC 1

RESULT 298
ABK51277/c
ID  ABK51277 standard; DNA; 15 BP.
XX  AC ABK51277;
XX  13-AUG-2002 (first entry)
DT  13-AUG-2002 (first entry)
XX  Human Caspase-2, CASP2, allele specific probe #1.
DE  Human; ss; caspase-2; CASP2; apoptosis; cysteine protease;
KW  probe programmed cell death; chromosome 7q34-q35; tumour suppressor; SNP;
KW  single nucleotide polymorphism; haplotype; genotype; transgenic.
XX  Homo sapiens.
OS  Homo sapiens.
XX  WO200226767-A2.
PN  WO200226767-A2.
XX  04-APR-2002.
PD  27-SEP-2001; 2001WO-US030412.
XX  27-SEP-2000; 2000US-0235801P.
XX  
```


CC probe containing at least 10 consecutive nucleotides. SAGE tags, are
 CC diagnostic and prognostic markers of cancer, especially of the colon and
 CC pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
 CC SAGE tags of the invention
 XX
 SQ Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 500 CCTGAGGGCACA 511
 DB 14 CCTGAGGGCACA 3
 RESULT 301
 ABL36332/C
 ID ABL36332 standard; DNA; 15 BP.
 XX
 AC ABL36332;
 XX
 DT 22-APR-2002 (first entry)
 XX
 DE Human lysosomal acid phosphatase 2 (ACP2) allele-specific PCR primer 12.
 XX
 KW Human; ss; lysosomal acid phosphatase 2; ACP2; gene; chromosome 11;
 KW lysosome-specific enzyme; orthophosphoric monoester hydrolysis;
 KW Hodgkin's disease; HD; acid phosphatase deficiency;
 KW novel polymorphic site; ACP2 haplotype; ACP2 genotype; polymorphism;
 KW transgenic animal; primer; probe; primer-extension oligonucleotide; SNP;
 KW single nucleotide polymorphism.
 XX
 OS Homo sapiens.
 XX
 PN WO200194362-A2.
 FN
 XX
 PD 13-DEC-2001.
 XX
 PF 07-JUN-2001; 2001WO-US018457.
 XX
 PR 07-JUN-2000; 2000US-0210047P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Kliem SE, Messer C, Tanguay DA;
 XX
 DR WPI; 2002-154563/20.
 XX
 PT Novel genetic variants of acid phosphatase 2, lysosomal polypeptide gene
 PT useful in studying expression and function of the protein, and for
 PT screening drugs to treat diseases e.g. Hodgkin's disease.
 XX
 PS Claim 17; Page 14; 109pp; English.
 XX
 CC The invention comprises the human lysosomal acid phosphatase 2 (ACP2)
 CC nucleic acid and protein sequences. Specifically, the invention relates
 CC to the discovery of 22 novel polymorphic sites within the ACP2 gene. The
 CC invention also comprises methods for haplotyping and genotyping the ACP2
 CC gene in an individual. The ACP2 gene (located on chromosome 11) encodes a
 CC lysosomal-specific enzyme that catalyses the hydrolysis of
 CC orthophosphoric monoesters to alcohol and phosphate. The ACP2 gene and
 CC protein are pharmaceutically important in the treatment of Hodgkin's
 CC disease (HD) and acid phosphatase deficiency. The novel ACP2 gene
 CC polymorphisms of the invention are useful in haplotyping the ACP2 gene.
 CC ACP2 haplotyping is useful in validating ACP2 as a target (and designing
 CC drugs) for treating an ACP2-related disease or condition (e.g. Hodgkin's
 CC disease and acid phosphatase deficiency). The ACP2 gene polymorphisms are
 CC useful for ACP2 genotyping, which can also be used to develop diagnostic
 CC tests and therapeutic treatments. The ACP2 protein and nucleic acids of
 CC the invention are useful in the production of a transgenic animal which
 CC expresses ACP2 protein. The ACP2 nucleic acids of the invention are
 CC useful in the production of allele-specific oligonucleotides designed to

CC genotype each of the ACP2 polymorphisms. Nucleic acids ABL36299-ABL36320
 CC represent claimed ACP2 allele-specific probes. Nucleic acids ABL36321-
 CC ABL36364 represent claimed ACP2 allele-specific PCR primers. Nucleic
 CC acids ABL36365-ABL36408 represent claimed ACP2 primer-extension
 CC oligonucleotides
 XX
 SQ Sequence 15 BP; 2 A; 3 C; 5 G; 4 T; 0 U; 1 Other;
 Query Match 1.6%; Score 12; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 383 ATCACGGGCAAG 394
 DB 12 ATCACGGGCAAG 1
 RESULT 302
 AAS95898
 ID AAS95898 standard; DNA; 15 BP.
 XX
 AC AAS95898;
 XX
 DT 26-FEB-2002 (first entry)
 XX
 DE Human CALM1 gene allele-specific oligonucleotide #7.
 XX
 KW Calmodulin 1; CALM1; human; single nucleotide polymorphism; SNP;
 KW haplotyping; SCVA3; Alzheimer's disease; drug screening;
 KW calcium-dependent signal transduction; PCR primer; ss.
 KW
 OS Homo sapiens.
 XX
 PN WO200179218-A2.
 FN
 XX
 PD 25-OCT-2001.
 XX
 PF 09-APR-2001; 2001WO-US011509.
 XX
 PR 12-APR-2000; 2000US-0196340P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
 XX
 DR WPI; 2002-049190/06.
 XX
 PT New calmodulin-1 (CALM-1) isogene polymorphic variants, useful in
 PT expressing CALM1 protein for use in screening for candidate drugs to
 PT treat diseases related to CALM1 activity such as Alzheimer's disease.
 XX
 PS Claim 15; Page 13; 82pp; English.
 XX
 CC The invention relates to an isolated polynucleotide comprising a sequence
 CC selected from a polymorphic variant of calmodulin 1 (CALM1). The
 CC polymorphic variant comprises an CALM1 isogene defined by a haplotype
 CC selected from haplotypes 1-21 given in the specification. The
 CC polymorphisms are useful for studying the biological function of CALM1 as
 CC well as in identifying drugs targeting this protein for the treatment of
 CC a disorder related to its abnormal expression or function. The
 CC polymorphic variants may also be used in screening for compounds
 CC targeting CALM1 to treat a specific condition or disease predicted to be
 CC associated with CALM1 activity. Establishing CALM1 haplotype or haplotype
 CC pair of an individual is useful for improving the efficiency and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with SCVA3 activity, e.g. Alzheimer's
 CC disease and diseases involving defects in calcium-dependent signal
 CC transduction. Haplotyping the CALM1 gene in an individual is also useful
 CC in the design of clinical trials of candidate drugs for treating a
 CC specific condition or disease predicted to be associated with CALM1
 CC activity. AAS95892-AAS96018 represent human CALM1 allele- specific
 CC oligonucleotides and PCR primers of the invention
 XX

SQ Sequence 15 BP; 1 A; 7 C; 5 G; 1 T; 0 U; 1 Other;
Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.5e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 670 CTGCCGCGCACATGGC 683
Db 1 CCGCGCGCSACTGGC 14

Search completed: October 18, 2005, 09:43:13
Job time : 4 secs

Qy 483 TTTCTCTCTCTCTCTG 496
Db 1 TTTCTCTCTCTCTCTG 14

RESULT 303
ADG65423
ID ADG65423 standard; DNA; 15 BP.
XX
AC ADG65423;
XX
DT 11-MAR-2004 (first entry)
XX
DE UCP2 allele specific oligonucleotide probe seq id 19.
XX
KW anorectic; antidiabetic; immunomodulator; gene therapy; haplotyping;
KW uncoupling protein 2; mitochondrial; proton carrier; UCP2;
KW polymorphic site; haplotype; haplotype pair; obesity; diabetes;
KW immunological disorder; body mass defect; thermoregulation defect; human;
KW ASO; allele specific oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN US2003207284-A1.
XX
PD 06-NOV-2003.
XX
PF 16-JUL-2002; 2002US-00197019.
XX
PR 25-JAN-2001; 2001WO-US002485.
XX
PA (CHEW/) CHEW A.
PA (DENT/) DENTON R. R.
PA (GILS/) GILSON C. R.
PA (NAND/) NANDABALAN K.
PA (PARK/) PARKS K. E.
XX
PI Chew A, Denton RR, Gilson CR, Nandabalan K, Parks KE;
XX
WPI; 2004-051505/05.
XX
PT Haplotyping Uncoupling Protein 2 gene of an individual comprises
PT identifying the phased sequence of nucleotides at polymorphic sites of
PT the gene and assigning a haplotype or haplotype pair consistent with the
PT phased sequence.
XX
PS Disclosure; SEQ ID NO 19; 64pp; English.
XX
CC The invention describes haplotyping the uncoupling protein 2
CC (mitochondrial, proton carrier) (UCP2) gene of an individual comprising
CC identifying the phased sequence of nucleotides at polymorphic sites (PS) 1
CC -23 for at least one copy of the individual's UCP2 gene and assigning to
CC the individual a UCP2 haplotype or haplotype pair that is consistent with
CC the phased sequence. The composition and methods are useful in
CC haplotyping and/or genotyping the UCP2 gene in an individual to e.g.
CC screen for drugs targeting the UCP2 protein to treat a condition or
CC disease predicted to be associated with UCP2 activity. The disease or
CC condition may include obesity, diabetes, immunological disorders and
CC other diseases associated with defects in body mass and thermoregulation.
CC This sequence represents an allele specific oligonucleotide probe used
CC for detecting human uncoupling protein 2 (UCP2) gene polymorphisms.
XX
SQ Sequence 15 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 1 Other;
Query Match 1.6%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.5e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 18, 2005, 09:44:28 ; Search time 2 Seconds
(without alignments)
3.420 Million cell updates/sec

Title: US-10-605-498-91-COPY

Perfect score: 764

Sequence: 1 ggcacgaggagcagatcg.....aagtcaagaacacacg 764

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 222 seqs, 4477 residues

Total number of hits satisfying chosen parameters: 444

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 224 summaries

Database : pubdb:*

Published - Application - NA

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	23.4	3.1	25	1	US-10-719-900-265359
2	23.4	3.1	25	1	US-10-719-900-475563
3	23.4	3.1	25	1	US-10-719-900-618137
4	23.4	3.1	25	1	US-10-719-900-657749
5	23.4	3.1	25	1	US-10-719-900-858223
6	23	3.0	23	1	US-10-840-038-4
7	22.4	2.9	25	1	US-10-719-900-152005
8	22.4	2.9	25	1	US-10-719-900-653170
9	22.4	2.9	25	1	US-10-719-900-653171
10	22.4	2.9	25	1	US-10-719-900-855205
11	22.4	2.9	25	1	US-10-719-900-855206
12	22	2.9	22	1	US-10-840-038-5
13	21.8	2.9	25	1	US-10-719-900-51105
14	21.8	2.9	25	1	US-10-719-900-248862
15	21.8	2.9	25	1	US-10-719-900-265360
16	21.8	2.9	25	1	US-10-719-900-376560
17	21.8	2.9	25	1	US-10-719-900-415441
18	21.8	2.9	25	1	US-10-719-900-472172
19	21.8	2.9	25	1	US-10-719-900-475562
20	21.8	2.9	25	1	US-10-719-900-592386
21	21.8	2.9	25	1	US-10-719-900-618136
22	21.8	2.9	25	1	US-10-719-900-657748
23	21.8	2.9	25	1	US-10-719-900-830334
24	21.8	2.9	25	1	US-10-719-900-858224
25	21.8	2.9	25	1	US-10-719-956-435353
26	21.4	2.8	23	1	US-09-911-904-63
27	21	2.7	21	1	US-10-605-498-1
28	21	2.7	21	1	US-10-605-498-2
29	21	2.7	21	1	US-10-605-498-3
30	21	2.7	21	1	US-10-605-498-4
31	21	2.7	21	1	US-10-605-498-5
32	21	2.7	21	1	US-10-605-498-6
33	21	2.7	21	1	US-10-605-498-7

Sequence 8, Appli	1	US-10-605-498-8	21	2.7	21
Sequence 9, Appli	1	US-10-605-498-9	21	2.7	21
Sequence 10, Appl	1	US-10-605-498-10	21	2.7	21
Sequence 11, Appl	1	US-10-605-498-11	21	2.7	21
Sequence 12, Appl	1	US-10-605-498-12	21	2.7	21
Sequence 13, Appl	1	US-10-605-498-13	21	2.7	21
Sequence 14, Appl	1	US-10-605-498-14	21	2.7	21
Sequence 15, Appl	1	US-10-605-498-15	21	2.7	21
Sequence 16, Appl	1	US-10-605-498-16	21	2.7	21
Sequence 17, Appl	1	US-10-605-498-17	21	2.7	21
Sequence 18, Appl	1	US-10-605-498-18	21	2.7	21
Sequence 19, Appl	1	US-10-605-498-19	21	2.7	21
Sequence 20, Appl	1	US-10-605-498-20	21	2.7	21
Sequence 21, Appl	1	US-10-605-498-21	21	2.7	21
Sequence 22, Appl	1	US-10-605-498-22	21	2.7	21
Sequence 23, Appl	1	US-10-605-498-23	21	2.7	21
Sequence 24, Appl	1	US-10-605-498-24	21	2.7	21
Sequence 25, Appl	1	US-10-605-498-25	21	2.7	21
Sequence 26, Appl	1	US-10-605-498-26	21	2.7	21
Sequence 27, Appl	1	US-10-605-498-27	21	2.7	21
Sequence 28, Appl	1	US-10-605-498-28	21	2.7	21
Sequence 29, Appl	1	US-10-605-498-29	21	2.7	21
Sequence 30, Appl	1	US-10-605-498-30	21	2.7	21
Sequence 31, Appl	1	US-10-605-498-31	21	2.7	21
Sequence 32, Appl	1	US-10-605-498-32	21	2.7	21
Sequence 33, Appl	1	US-10-605-498-33	21	2.7	21
Sequence 34, Appl	1	US-10-605-498-34	21	2.7	21
Sequence 35, Appl	1	US-10-605-498-35	21	2.7	21
Sequence 36, Appl	1	US-10-605-498-36	21	2.7	21
Sequence 37, Appl	1	US-10-605-498-37	21	2.7	21
Sequence 38, Appl	1	US-10-605-498-38	21	2.7	21
Sequence 39, Appl	1	US-10-605-498-39	21	2.7	21
Sequence 40, Appl	1	US-10-605-498-40	21	2.7	21
Sequence 41, Appl	1	US-10-605-498-41	21	2.7	21
Sequence 42, Appl	1	US-10-605-498-42	21	2.7	21
Sequence 43, Appl	1	US-10-605-498-43	21	2.7	21
Sequence 44, Appl	1	US-10-605-498-44	21	2.7	21
Sequence 45, Appl	1	US-10-605-498-45	21	2.7	21
Sequence 46, Appl	1	US-10-605-498-46	21	2.7	21
Sequence 47, Appl	1	US-10-605-498-47	21	2.7	21
Sequence 48, Appl	1	US-10-605-498-48	21	2.7	21
Sequence 49, Appl	1	US-10-605-498-49	21	2.7	21
Sequence 50, Appl	1	US-10-605-498-50	21	2.7	21
Sequence 51, Appl	1	US-10-605-498-51	21	2.7	21
Sequence 52, Appl	1	US-10-605-498-52	21	2.7	21
Sequence 53, Appl	1	US-10-605-498-53	21	2.7	21
Sequence 54, Appl	1	US-10-605-498-54	21	2.7	21
Sequence 55, Appl	1	US-10-605-498-55	21	2.7	21
Sequence 56, Appl	1	US-10-605-498-56	21	2.7	21
Sequence 57, Appl	1	US-10-605-498-57	21	2.7	21
Sequence 58, Appl	1	US-10-605-498-58	21	2.7	21
Sequence 59, Appl	1	US-10-605-498-59	21	2.7	21
Sequence 60, Appl	1	US-10-605-498-60	21	2.7	21
Sequence 61, Appl	1	US-10-605-498-61	21	2.7	21
Sequence 62, Appl	1	US-10-605-498-62	21	2.7	21
Sequence 63, Appl	1	US-10-605-498-63	21	2.7	21
Sequence 64, Appl	1	US-10-605-498-64	21	2.7	21
Sequence 65, Appl	1	US-10-605-498-65	21	2.7	21
Sequence 66, Appl	1	US-10-605-498-66	21	2.7	21
Sequence 67, Appl	1	US-10-605-498-67	21	2.7	21
Sequence 68, Appl	1	US-10-605-498-68	21	2.7	21
Sequence 69, Appl	1	US-10-605-498-69	21	2.7	21
Sequence 70, Appl	1	US-10-605-498-70	21	2.7	21
Sequence 71, Appl	1	US-10-605-498-71	21	2.7	21
Sequence 72, Appl	1	US-10-605-498-72	21	2.7	21
Sequence 73, Appl	1	US-10-605-498-73	21	2.7	21
Sequence 74, Appl	1	US-10-605-498-74	21	2.7	21
Sequence 75, Appl	1	US-10-605-498-75	21	2.7	21
Sequence 76, Appl	1	US-10-605-498-76	21	2.7	21
Sequence 77, Appl	1	US-10-605-498-77	21	2.7	21
Sequence 78, Appl	1	US-10-605-498-78	21	2.7	21
Sequence 79, Appl	1	US-10-605-498-79	21	2.7	21
Sequence 80, Appl	1	US-10-605-498-80	21	2.7	21
Sequence 81, Appl	1	US-10-605-498-81	21	2.7	21

c 107	20.8	2.7	25	1	US-10-719-900-152006	Sequence 152006,	180	13.8	1.8	17	1	US-09-927-046-1306	Sequence 1306, Ap
c 108	20.8	2.7	25	1	US-10-809-189-92419	Sequence 92419, A	c 181	13.8	1.8	17	1	US-09-927-046-1904	Sequence 1904, Ap
c 109	20.2	2.6	25	1	US-10-719-900-51106	Sequence 51106, A	c 182	13.8	1.8	17	1	US-09-927-046-1905	Sequence 1905, Ap
c 110	20.2	2.6	25	1	US-10-719-900-72371	Sequence 72371, A	c 183	13.8	1.8	17	1	US-09-740-332-4378	Sequence 4378, Ap
c 111	20.2	2.6	25	1	US-10-719-900-147040	Sequence 147040,	c 184	13.8	1.8	17	1	US-09-817-879-4378	Sequence 4378, Ap
c 112	20.2	2.6	25	1	US-10-719-900-24861	Sequence 24861,	c 185	13.8	1.8	17	1	US-10-060-756A-170	Sequence 170, App
c 113	20.2	2.6	25	1	US-10-719-900-347106	Sequence 347106,	c 186	13.8	1.8	17	1	US-10-163-552-650	Sequence 650, App
c 114	20.2	2.6	25	1	US-10-719-900-376561	Sequence 376561,	c 187	13.8	1.8	17	1	US-10-156-306-5029	Sequence 5029, App
c 115	20.2	2.6	25	1	US-10-719-900-415444	Sequence 415444,	c 188	13.8	1.8	17	1	US-10-238-700-484	Sequence 484, App
c 116	20.2	2.6	25	1	US-10-719-900-472173	Sequence 472173,	c 189	13.8	1.8	17	1	US-10-061-201-1223	Sequence 1223, Ap
c 117	20.2	2.6	25	1	US-10-719-900-581985	Sequence 581985,	c 190	13.8	1.8	17	1	US-10-382-248-80	Sequence 80, Appl
c 118	20.2	2.6	25	1	US-10-719-900-592387	Sequence 592387,	c 191	13.8	1.8	17	1	US-10-676-154-599	Sequence 599, App
c 119	20.2	2.6	25	1	US-10-719-900-611646	Sequence 611646,	c 192	13.8	1.8	17	1	US-10-712-672-332	Sequence 332, App
c 120	20.2	2.6	25	1	US-10-719-900-685015	Sequence 685015,	c 193	13.8	1.8	17	1	US-10-669-841-6971	Sequence 6971, Ap
c 121	20.2	2.6	25	1	US-10-719-900-685016	Sequence 685016,	c 194	13.8	1.8	17	1	US-10-723-361-2329	Sequence 2329, Ap
c 122	20.2	2.6	25	1	US-10-719-900-819345	Sequence 819345,	c 195	13.8	1.8	17	1	US-10-723-361-2330	Sequence 2330, Ap
c 123	20.2	2.6	25	1	US-10-719-900-830335	Sequence 830335,	c 196	13.8	1.8	17	1	US-10-723-361-2331	Sequence 2331, Ap
c 124	20.2	2.6	25	1	US-10-809-189-92432	Sequence 92432, A	c 197	13.8	1.8	17	1	US-10-723-361-10669	Sequence 10669, A
c 125	20.2	2.6	25	1	US-10-719-956-364445	Sequence 364445,	c 198	13.8	1.8	17	1	US-10-723-361-10670	Sequence 10670, A
c 126	20.2	2.6	25	1	US-10-719-956-435352	Sequence 435352,	c 199	13.8	1.8	17	1	US-10-494-343-325	Sequence 325, App
c 127	20	2.6	20	1	US-10-605-498-82	Sequence 82, Appl	c 200	13.8	1.8	17	1	US-10-498-462-1759	Sequence 1759, Ap
c 128	20	2.6	20	1	US-10-713-808-13	Sequence 13, Appl	c 201	13.8	1.8	17	1	US-10-498-462-1760	Sequence 1760, Ap
c 129	19	2.5	19	1	US-10-605-498-87	Sequence 87, Appl	c 202	13.8	1.8	17	1	US-10-724-270-484	Sequence 484, App
c 130	19	2.5	19	1	US-10-605-498-90	Sequence 90, Appl	c 203	13.8	1.8	17	1	US-10-724-270-5305	Sequence 5305, Ap
c 131	18.4	2.4	21	1	US-10-472-779-1	Sequence 1, Appl	c 204	13.8	1.8	17	1	US-10-890-776A-170	Sequence 170, App
c 132	18	2.4	18	1	US-10-605-498-77	Sequence 77, Appl	c 205	13.4	1.8	16	1	US-10-712-672-1489	Sequence 1489, Ap
c 133	17.8	2.3	21	1	US-10-605-498-89	Sequence 89, Appl	c 206	13	1.7	15	1	US-09-918-728B-11	Sequence 11, Appl
c 134	17.8	2.3	22	1	US-10-472-779-2	Sequence 2, Appl	c 207	13	1.7	16	1	US-10-712-672-1490	Sequence 1490, Ap
c 135	17	2.2	17	1	US-10-339-793-168	Sequence 168, App	c 208	13	1.7	21	1	US-10-605-498-50	Sequence 50, Appl
c 136	16.8	2.2	17	1	US-10-751-736-34691	Sequence 34691, A	c 209	12.8	1.7	16	1	US-09-829-855-10	Sequence 10, Appl
c 137	15.8	2.1	19	1	US-09-990-613-0	Sequence 0, Appl	c 210	12.8	1.7	16	1	US-09-829-855-110	Sequence 110, App
c 138	15.8	2.1	19	1	US-10-605-498-83	Sequence 83, Appl	c 211	12.8	1.7	16	1	US-10-455-013-17	Sequence 17, Appl
c 139	15.8	2.1	21	1	US-10-605-498-7	Sequence 7, Appl	c 212	12.8	1.7	16	1	US-10-455-013-29	Sequence 29, Appl
c 140	15.4	2.0	17	1	US-09-866-108-10667	Sequence 10667, A	c 213	12.8	1.7	16	1	US-10-179-940-539	Sequence 539, App
c 141	15.4	2.0	17	1	US-10-211-689-82	Sequence 82, Appl	c 214	12.8	1.7	16	1	US-10-627-250-17	Sequence 17, Appl
c 142	15.4	2.0	17	1	US-10-723-361-10667	Sequence 10667, A	c 215	12.8	1.7	16	1	US-10-627-250-29	Sequence 29, Appl
c 143	15.4	2.0	19	1	US-10-844-072-10	Sequence 10, Appl	c 216	12.8	1.7	16	1	US-10-712-672-1775	Sequence 1775, Ap
c 144	15.4	2.0	19	1	US-10-844-072-133	Sequence 133, App	c 217	12.8	1.7	16	1	US-10-607-077A-10	Sequence 10, Appl
c 145	15.4	2.0	19	1	US-10-922-340-10	Sequence 10, Appl	c 218	12.8	1.7	16	1	US-10-607-077A-110	Sequence 110, App
c 146	15.4	2.0	19	1	US-10-922-340-133	Sequence 133, App	c 219	12.8	1.7	16	1	US-10-776-934-107	Sequence 107, App
c 147	14.8	1.9	18	1	US-10-450-472-50	Sequence 50, Appl	c 220	12.8	1.7	16	1	US-10-776-934-568	Sequence 568, App
c 148	14.4	1.9	16	1	US-10-179-940-466	Sequence 466, App	c 221	12.8	1.7	16	1	US-10-776-934-569	Sequence 569, App
c 149	14.4	1.9	17	1	US-09-866-108-10666	Sequence 10666, A	c 222	12.8	1.7	16	1	US-10-776-934-570	Sequence 570, App
c 150	14.4	1.9	17	1	US-09-866-108-10668	Sequence 10668, A	c 223	12.8	1.7	16	1	US-10-776-934-571	Sequence 571, App
c 151	14.4	1.9	17	1	US-10-060-830-218	Sequence 218, App	c 224	12.8	1.7	16	1	US-10-730-771-330	Sequence 330, App
c 152	14.4	1.9	17	1	US-10-060-830-219	Sequence 219, App							
c 153	14.4	1.9	17	1	US-10-156-306-5028	Sequence 5028, Ap							
c 154	14.4	1.9	17	1	US-10-238-700-2848	Sequence 2848, Ap							
c 155	14.4	1.9	17	1	US-10-723-361-10666	Sequence 10666, A							
c 156	14.4	1.9	17	1	US-10-723-361-10668	Sequence 10668, A							
c 157	14.4	1.9	17	1	US-10-498-462-2204	Sequence 2204, Ap							
c 158	14.4	1.9	17	1	US-10-498-462-2204	Sequence 2204, Ap							
c 159	14.4	1.9	17	1	US-10-724-270-1527	Sequence 1527, Ap							
c 160	14.4	1.9	18	1	US-10-349-143-6095	Sequence 6095, Ap							
c 161	14.4	1.9	18	1	US-10-702-817-27	Sequence 27, Appl							
c 162	14	1.8	17	1	US-09-818-875-4230	Sequence 4230, Ap							
c 163	14	1.8	17	1	US-09-818-875-4231	Sequence 4231, Ap							
c 164	14	1.8	17	1	US-09-780-533A-765	Sequence 765, App							
c 165	14	1.8	17	1	US-09-780-533A-1791	Sequence 1791, Ap							
c 166	14	1.8	17	1	US-10-209-787-4230	Sequence 4230, Ap							
c 167	14	1.8	17	1	US-10-209-787-4231	Sequence 4231, Ap							
c 168	14	1.8	17	1	US-10-261-185-4230	Sequence 4230, Ap							
c 169	14	1.8	17	1	US-10-261-185-4231	Sequence 4231, Ap							
c 170	14	1.8	17	1	US-10-681-074-4230	Sequence 4230, Ap							
c 171	14	1.8	17	1	US-10-681-074-4231	Sequence 4231, Ap							
c 172	13.8	1.8	17	1	US-09-866-108-2329	Sequence 2329, Ap							
c 173	13.8	1.8	17	1	US-09-866-108-2330	Sequence 2330, Ap							
c 174	13.8	1.8	17	1	US-09-866-108-2331	Sequence 2331, Ap							
c 175	13.8	1.8	17	1	US-09-866-108-10669	Sequence 10669, A							
c 176	13.8	1.8	17	1	US-09-866-108-10670	Sequence 10670, A							
c 177	13.8	1.8	17	1	US-09-866-108-1425	Sequence 1425, Ap							
c 178	13.8	1.8	17	1	US-09-825-805-772	Sequence 772, App							
c 179	13.8	1.8	17	1	US-09-780-533A-2414	Sequence 2414, Ap							

ALIGNMENTS

RESULT 1

US-10-719-900-265359
; Sequence 265359, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10719, 900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 265359
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-265359

Query Match 3.1%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
OY 417 ATGGCTACATCTCCCGGTCTTAC 441
|||||
Db 1 ATGGCTACATCTCTCGGTCTTAC 25

RESULT 2
US-10-719-900-475563/c
; Sequence 475563, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 475563
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-475563

Query Match 3.1%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 405 GCGAGGACGAGATGGCTACATCTC 429
|||||
Db 25 GCGAGGACGAGATGGCTACATCTC 1

RESULT 3
US-10-719-900-618137
; Sequence 618137, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 618137
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-618137

Query Match 3.1%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 309 GCGCGGTGTCCCTGGATGTCACCA 333
|||||
Db 1 GCGCGGTGTCCCTGGACGTCACCA 25

RESULT 4
US-10-719-900-657749/c
; Sequence 657749, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900

OY 417 ATGGCTACATCTCCCGGTCTTAC 441
|||||
Db 1 ATGGCTACATCTCTCGGTCTTAC 25

RESULT 5
US-10-719-900-858223/c
; Sequence 858223, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 858223
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-858223

Query Match 3.1%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 17;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 308 TGGCGCGTGTCCCTGGATGTCACCC 332
|||||
Db 25 TGGCGCGTGTCCCTGGACGTCACCC 1

RESULT 6
US-10-840-038-4/c
; Sequence 4, Application US/10840038
; Publication No. US20050009137A1
; GENERAL INFORMATION:
; APPLICANT: Adams, John
; APPLICANT: Chen, Hong
; TITLE OF INVENTION: An Intracellular Estradiol Binding Protein, a Polynucleotide
; TITLE OF INVENTION: Encoding the Same and Cell Lines Overexpressing the Same
; FILE REFERENCE: 81476-302961
; CURRENT APPLICATION NUMBER: US/10/840,038
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 60/468,717
; PRIOR FILING DATE: 2003-05-07
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-840-038-4
```

Query Match 3.0%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 38 CGCGTCCCTCTCTCGCTCTGGG 60
|||||
DB 23 CGCGTCCCTCTCTCGCTCTGGG 1

RESULT 7
US-10-719-900-152005/c
; Sequence 152005, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 152005
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-152005

Query Match 2.9%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 22;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 406 GCAGGACGAGCGTGCCTACATCTC 429
|||||
DB 25 GCAGGACGACATGGCTACATCTC 2

RESULT 8
US-10-719-900-653170
; Sequence 653170, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 653170
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-653170

Query Match 2.9%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 22;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 376 GGTGGAGTACCGGCAAGCACGA 399
|||||
DB 1 GGTGGAGTACGAGGCAAGCACGA 24

RESULT 9
US-10-719-900-653171
; Sequence 653171, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 653171
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-653171

Query Match 2.9%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 22;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 376 GGTGGAGTACCGGCAAGCACGA 399
|||||
DB 1 GGTGGAGTACCTGGCAAGCACGA 24

RESULT 10
US-10-719-900-855205
; Sequence 855205, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 855205
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-855205

Query Match 2.9%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 22;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 502 TGAGGGCACACTGACCGTGGAGGC 525
|||||
DB 1 TGAGGGCACACTAACCGTGGAGGC 24

RESULT 11
US-10-719-900-855206
; Sequence 855206, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 855206
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-855206

Query Match 2.9%; Score 22.4; DB 1; Length 25;

```
Best Local Similarity 95.8%; Pred. No. 22;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 502 TGAGGGGCACACTGACCGTGGAGGC 525
Db 1 TGAGGGGCACACTTACCGTGGAGGC 24

RESULT 12
US-10-840-038-5
; Sequence 5, Application US/10840038
; Publication No. US2005009137A1
; GENERAL INFORMATION:
; APPLICANT: Adams, John
; APPLICANT: Chen, Hong
; TITLE OF INVENTION: An Intracellular Estradiol Binding Protein, a Polynucleotide
; FILE REFERENCE: 81476-302961
; CURRENT APPLICATION NUMBER: US/10/840,038
; CURRENT FILING DATE: 2004-05-06
; PRIOR APPLICATION NUMBER: US 60/468,717
; PRIOR FILING DATE: 2003-05-07
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-840-038-5

Query Match 2.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 38 CGCGTCCCTTCCTCGCTCTGC 59
Db 1 CGCGTCCCTTCCTCGCTCTGC 22

RESULT 13
US-10-719-900-51105/c
; Sequence 51105, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 51105
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-51105

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 414 AGCATGGCTACATCTCCCGTCTT 438
Db 25 AACATGGCTACATCTCTCGTCTT 1

RESULT 14
US-10-719-900-248862
; Sequence 248862, Application US/10719900
```

```
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 248862
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-248862

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 425 ATCTCCCGTGTCTTCACGCGGAAT 449
Db 1 ATCTCGGTGCTTCACCGGAAAT 25

RESULT 15
US-10-719-900-265360
; Sequence 265360, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 265360
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-265360

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 417 ATGGCTACATCTCCCGTGTCTTAC 441
Db 1 ATGGCTACATCTGTCGGTGTCTTAC 25

RESULT 16
US-10-719-900-376560
; Sequence 376560, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 376560
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
```

US-10-719-900-376560

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 429 CCCGGTCTTCACGGGGAATACAC 453

Db 1 CTCGGTCTTCACCCGGAATACAC 25

RESULT 17

US-10-719-900-415441
; Sequence 415441, Application US/10719900
; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 415441

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-415441

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 413 GAGCATGCTACATCTCCGGTCT 437

Db 1 GAACATGGCTACATCTCTCGGTCT 25

RESULT 18

US-10-719-900-472172/c

; Sequence 472172, Application US/10719900
; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 472172

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-472172

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 407 CAGGACGAGCATGGCTACATCTCCC 431

Db 25 CAGGACGACATGGCTACATCTCTC 1

RESULT 19

US-10-719-900-475562/c

; Sequence 475562, Application US/10719900
; Publication No. US20050026164A1

; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 475562
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-475562

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 405 GGCAGGACGAGCATGGCTACATCTC 429

Db 25 GGCAGGACGAACTTGGCTACATCTC 1

RESULT 20

US-10-719-900-592386

; Sequence 592386, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 592386

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-592386

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 409 GGACGAGCATGGCTACATCTCCCGG 433

Db 1 GGACGACATGGCTACATCTCTCGG 25

RESULT 21

US-10-719-900-618136

; Sequence 618136, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 618136

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-618136

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 309 GCGCGGTGCTCCGTGATGTCACCA 333
|||
Db 1 GCGCGGTGCTCCGAGACGTCAACCA 25

RESULT 22
US-10-719-900-657748/c
; Sequence 657748, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 657748
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-657748

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 308 TGGCGCGTGTCCCGATGTCAACC 332
|||
Db 25 TGGCGCGTGTCCGTGACGTCAACC 1

RESULT 23
US-10-719-900-830334
; Sequence 830334, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 830334
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-830334

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 428 TCCCGGTGCTTCAACGCGGAATACA 452
|||
Db 1 TCTCGGTGCTTCAACCGGAATACA 25

RESULT 24
US-10-719-900-858224/c
; Sequence 858224, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 858224
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-858224

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 362 ACCAAGGATGCGTGTGGAGATCA 386
|||
Db 25 ACCAAGGAGCGCTGTGGAGATCA 1

RESULT 25
US-10-719-956-435353
; Sequence 435353, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 435353
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-435353

Query Match 2.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 26;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 261 GGCAACTCAGCAGCGGTCTCGGA 285
|||
Db 1 GGCAACTCAGCAGCGGTCTCAGA 25

RESULT 26
US-09-911-904-63
; Sequence 63, Application US/09911904
; Publication No. US20030096234A1
; GENERAL INFORMATION:
; APPLICANT: Farr, Spencer B.
; APPLICANT: Pickett, Gavin G.
; APPLICANT: Neft, Robin Eileen
; APPLICANT: Dunn, II, Robert Thomas
; TITLE OF INVENTION: CANINE TOXICITY GENES
; FILE REFERENCE: 40074200200
; CURRENT APPLICATION NUMBER: US/09/911,904
; CURRENT FILING DATE: 2002-04-09
; PRIOR APPLICATION NUMBER: US 60/220,057
; PRIOR FILING DATE: 2000-07-21
; NUMBER OF SEQ ID NOS: 386
; SOFTWARE: Fast-SEQ for Windows Version 4.0
; SEQ ID NO 63
; LENGTH: 23
; TYPE: DNA

```
; ORGANISM: Canis familiaris
US-09-911-904-63

Query Match          2.8%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 25;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 73 GGACCCCTTCGCGACTGGTACC 95
Db 1 GGACCCCTTCGCGACTGGTACC 23

RESULT 27
US-10-605-498-1/c
; Sequence 1, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-1

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGCACGAGGAGCAGAGTCAGC 21
Db 21 GGCACGAGGAGCAGAGTCAGC 1

RESULT 28
US-10-605-498-2/c
; Sequence 2, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-2

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 31 CGAGCGCGCGTCCCTTC 51
Db 21 CGAGCGCGCGTCCCTTC 1

; ORGANISM: Canis familiaris
US-09-911-904-63

Query Match          2.8%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 25;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 73 GGACCCCTTCGCGACTGGTACC 95
Db 1 GGACCCCTTCGCGACTGGTACC 23

RESULT 27
US-10-605-498-1/c
; Sequence 1, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-1

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGCACGAGGAGCAGAGTCAGC 21
Db 21 GGCACGAGGAGCAGAGTCAGC 1

RESULT 28
US-10-605-498-2/c
; Sequence 2, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-2

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 31 CGAGCGCGCGTCCCTTC 51
Db 21 CGAGCGCGCGTCCCTTC 1

; ORGANISM: Canis familiaris
US-09-911-904-63

Query Match          2.8%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 25;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 73 GGACCCCTTCGCGACTGGTACC 95
Db 1 GGACCCCTTCGCGACTGGTACC 23

RESULT 27
US-10-605-498-1/c
; Sequence 1, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-1

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GGCACGAGGAGCAGAGTCAGC 21
Db 21 GGCACGAGGAGCAGAGTCAGC 1

RESULT 28
US-10-605-498-2/c
; Sequence 2, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-2

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 31 CGAGCGCGCGTCCCTTC 51
Db 21 CGAGCGCGCGTCCCTTC 1
```

```
RESULT 31
US-10-605-498-5/c
; Sequence 5, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-5

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 41 GTCCCTTCGCTCTGCGG 61
Db 21 GTCCCTTCGCTCTGCGG 1

RESULT 32
US-10-605-498-6/c
; Sequence 6, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-6

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 CGCTCTGCGGGGCCCGACT 71
Db 21 CGCTCTGCGGGGCCCGACT 1

RESULT 33
US-10-605-498-7/c
; Sequence 7, Application US/10605498
```

```
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-7
```

```
Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 61 GGGCCCCAGCTGGGACCCCTT 81
Db 21 GGGCCCCAGCTGGGACCCCTT 1
```

```
RESULT 34
US-10-605-498-8/c
; Sequence 8, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-8
```

```
Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 71 TGGGACCCCTTCGCGGACTGG 91
Db 21 TGGGACCCCTTCGCGGACTGG 1
```

```
RESULT 35
US-10-605-498-9/c
; Sequence 9, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
```

```
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-9

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 81 TCCGCGACTGGTACCGCGATA 101
Db 21 TCCGCGACTGGTACCGCGATA 1

RESULT 36
US-10-605-498-10/c
; Sequence 10, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-10

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 91 GTACCCGCATAGCGCGCTCTT 111
Db 21 GTACCCGCATAGCGCGCTCTT 1

RESULT 37
US-10-605-498-11/c
; Sequence 11, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
```

```
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-11

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 101 AGCGCGCTCTTCGACCGAGGCC 121
Db 21 AGCGCGCTCTTCGACCGAGGCC 1

RESULT 38
US-10-605-498-12/c
; Sequence 12, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-12

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 111 TCGACCGAGCGCTTCGGGCTGC 131
Db 21 TCGACCGAGCGCTTCGGGCTGC 1

RESULT 39
US-10-605-498-13/c
; Sequence 13, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-13

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 121 CTTGGGCTGCCCGGCTGCC 141
Db 21 CTTGGGCTGCCCGGCTGCC 1

RESULT 40
US-10-605-498-14/c
; Sequence 14, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-14

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 131 CCCGGCTGCCGGGAGGTGG 151
Db 21 CCCGGCTGCCGGGAGGTGG 1

RESULT 41
US-10-605-498-15/c
; Sequence 15, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-15

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 121 CTTGGGCTGCCCGGCTGCC 141
Db 21 CTTGGGCTGCCCGGCTGCC 1

RESULT 42
US-10-605-498-16/c
; Sequence 16, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-16

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 151 GTCGCACTGGTTAGCGCGCAG 171
Db 21 GTCGCACTGGTTAGCGCGCAG 1

RESULT 43
US-10-605-498-17/c
; Sequence 17, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-17

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 161 TTAGCGGCGCAGCAGCTGGCCA 181
Db 21 TTAGCGGCGCAGCAGCTGGCCA 1

RESULT 44
US-10-605-498-18/c
; Sequence 18, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-18

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 171 GCAGCTGGCGCAGCTACGTGC 191
Db 21 GCAGCTGGCGCAGCTACGTGC 1

RESULT 45
US-10-605-498-19/c
; Sequence 19, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-19

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 181 AGGCTACGTGGCGCCCTGCC 201
Db 21 AGGCTACGTGGCGCCCTGCC 1

RESULT 46
US-10-605-498-20/c
; Sequence 20, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-20

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 191 CGCCCCCTGCCCCCGCGGCC 211
Db 21 CGCCCCCTGCCCCCGCGGCC 1

RESULT 47
US-10-605-498-21/c
; Sequence 21, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-21

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 201 CCCCCGCGCCATCGAGGCC 221
Db 21 CCCCCGCGCCATCGAGGCC 1

RESULT 48
US-10-605-498-22/c
; Sequence 22, Application US/10605498
; Publication No. US20040127441A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: USC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-22

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 211 CATCGAGAGCCCCCGCAGTGGC 231
Db 21 CATCGAGAGCCCCCGCAGTGGC 1

RESULT 49
US-10-605-498-23/c
; Sequence 23, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: USC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-23

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 221 CCCGAGTGGCGCGCGCGCGCC 241
Db 21 CCCGAGTGGCGCGCGCGCGCC 1

RESULT 50
US-10-605-498-24/c
; Sequence 24, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
```

```
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: USC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-24

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 231 CCGCGCCCGCGCTACAGCGCGG 251
Db 21 CCGCGCCCGCGCTACAGCGCGG 1

RESULT 51
US-10-605-498-25/c
; Sequence 25, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: USC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-25

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 241 CTACAGCGCGCGCTCAGCGG 261
Db 21 CTACAGCGCGCGCTCAGCGG 1

RESULT 52
US-10-605-498-26/c
; Sequence 26, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: USC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
```

; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-26

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 251 GCGCTCAGCGGCAACTCAGC 271
Db 21 GCGCTCAGCGGCAACTCAGC 1

RESULT 53

US-10-605-498-27/c
; Sequence 27, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-27

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 261 GCGCACTCAGCGGGGTCT 281
Db 21 GCGCACTCAGCGGGGTCT 1

RESULT 54

US-10-605-498-28/c
; Sequence 28, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 28
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-28

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 271 CAGCGGGTCTCGGAGATCCG 291
Db 21 CAGCGGGTCTCGGAGATCCG 1

RESULT 55

US-10-605-498-29/c
; Sequence 29, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-29

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 281 TCGGAGATCCGGCACACTGCG 301
Db 21 TCGGAGATCCGGCACACTGCG 1

RESULT 56

US-10-605-498-30/c
; Sequence 30, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 30
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-30

```
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 291 GGCACACTGGCGACCGCTGGC 311
DB 21 GGCACACTGGCGACCGCTGGC 1

RESULT 57
US-10-605-498-31/c
; Sequence 31, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-31

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 301 GGACCGCTGGCGCGTGCCT 321
DB 21 GGACCGCTGGCGCGTGCCT 1

RESULT 58
US-10-605-498-32/c
; Sequence 32, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 32
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-32

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 331 CGCGTGTCCCTGGATGCAAC 331
DB 21 CGCGTGTCCCTGGATGCAAC 1

RESULT 59
US-10-605-498-33/c
; Sequence 33, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-33

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 TGGATGTCAACCACTTCGCC 341
DB 21 TGGATGTCAACCACTTCGCC 1

RESULT 60
US-10-605-498-34/c
; Sequence 34, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-34

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 331 CCACCTTCGCCCGGACGAGCT 351
DB 21 CCACCTTCGCCCGGACGAGCT 1
```

```
RESULT 61
US-10-605-498-35/c
; Sequence 35, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 35
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-35

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      341  CCGGACGAGCTGACGGTCAAG 361
Db      21  CCGGACGAGCTGACGGTCAAG 1

RESULT 62
US-10-605-498-36/c
; Sequence 36, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-36

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      351  TGACGGTCAGACCAAGGNTG 371
Db      21  TGACGGTCAGACCAAGGATG 1

RESULT 63
US-10-605-498-37/c
; Sequence 37, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
```

```
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-37

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      361  GACCAAGGATGGCGTGGTGA 381
Db      21  GACCAAGGATGGCGTGGTGA 1

RESULT 64
US-10-605-498-38/c
; Sequence 38, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-38

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      371  GCGGTGGTGGAGATCACCGGC 391
Db      21  GCGGTGGTGGAGATCACCGGC 1

RESULT 65
US-10-605-498-39/c
; Sequence 39, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
```

; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-39

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 381 AGATCACCGGCAAGCAGGAGG 401
Db 21 AGATCACCGGCAAGCAGGAGG 1

RESULT 66

US-10-605-498-40/c
; Sequence 40, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-40

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 391 CAAGCACGAGGCGGCAGGA 411
Db 21 CAAGCACGAGGCGGCAGGA 1

RESULT 67

US-10-605-498-41/c
; Sequence 41, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02

; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 41
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-41

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 401 GAGCGCAGGACGAGCATGCC 421
Db 21 GAGCGCAGGACGAGCATGCC 1

RESULT 68

US-10-605-498-42/c
; Sequence 42, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-42

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 411 ACGAGCATGGCTACATCTCCC 431
Db 21 ACGAGCATGGCTACATCTCCC 1

RESULT 69

US-10-605-498-43/c
; Sequence 43, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43

; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-43

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 421 CTACATCTCCGGTCTTCAC 441
Db 21 CTACATCTCCGGTCTTCAC 1

RESULT 70

US-10-605-498-44/c
; Sequence 44, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 44
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-44

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 431 CGGTGCTTCACGCGGAATAC 451
Db 21 CGGTGCTTCACGCGGAATAC 1

RESULT 71

US-10-605-498-45/c
; Sequence 45, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 45
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-45

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 441 CGCGAAATACACGCTGCCCC 461
Db 21 CGCGAAATACACGCTGCCCC 1

RESULT 72

US-10-605-498-46/c
; Sequence 46, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 46
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-46

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 451 CACGCTGCCCCCGGTGTGGA 471
Db 21 CACGCTGCCCCCGGTGTGGA 1

RESULT 73

US-10-605-498-47/c
; Sequence 47, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 47
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-47

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 461 CCGGTGTGACCCCA 481

```
Db 21 CCGGTGGACCCCA 1
|||||
RESULT 74
US-10-605-498-48/c
; Sequence 48, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 48
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-48
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 471 ACCCCACCAAGTTTCCTCT 491
|||||
Db 21 ACCCCACCAAGTTTCCTCT 1
|||||
RESULT 75
US-10-605-498-49/c
; Sequence 49, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 49
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-49
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 481 AGTTTCCTCCCTCCCTGCCCC 501
|||||
Db 21 AGTTTCCTCCCTCCCTGCCCC 1
|||||
RESULT 76
US-10-605-498-50/c
; Sequence 50, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-50
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 501 CTGAGGGCACACTGACCGTGG 521
|||||
Db 21 CTGAGGGCACACTGACCGTGG 1
|||||
RESULT 77
US-10-605-498-51/c
; Sequence 51, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 51
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-51
Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 501 CTGAGGGCACACTGACCGTGG 521
|||||
Db 21 CTGAGGGCACACTGACCGTGG 1
|||||
RESULT 78
US-10-605-498-52/c
; Sequence 52, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
```

```
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 52
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-52

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 511 ACTGACCGTGGAGGCCCCCAT 531
Db 21 ACTGACCGTGGAGGCCCCCAT 1

RESULT 79
US-10-605-498-53/c
; Sequence 53, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 53
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-53

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 521 GAGGCCCCCATGCCAAGCTA 541
Db 21 GAGGCCCCCATGCCAAGCTA 1

RESULT 80
US-10-605-498-54/c
; Sequence 54, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
```

```
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 54
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-54

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 531 TGCCCAAGCTAGCCACGAGT 551
Db 21 TGCCCAAGCTAGCCACGAGT 1

RESULT 81
US-10-605-498-55/c
; Sequence 55, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 55
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-55

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 AGCCACGCGAGTCCCAACGAGT 561
Db 21 AGCCACGCGAGTCCCAACGAGT 1

RESULT 82
US-10-605-498-56/c
; Sequence 56, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; FILE REFERENCE: UBC.P-031
```

; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 56
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-56

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 551 TCACACGAGATCACCATCCCA 571
DB 21 TCACACGAGATCACCATCCCA 1

RESULT 83

US-10-605-498-57/c
; Sequence 57, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-57

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 TCACATCCCGTCCACCTTCG 581
DB 21 TCACATCCCGTCCACCTTCG 1

RESULT 84

US-10-605-498-58/c
; Sequence 58, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 58
; LENGTH: 21

; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-58

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 571 AGTCACCTTCGAGTCGGGGC 591
DB 21 AGTCACCTTCGAGTCGGGGC 1

RESULT 85

US-10-605-498-59/c
; Sequence 59, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 59
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-59

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 581 GAGTCGGGGCCGACGTTGGG 601
DB 21 GAGTCGGGGCCGACGTTGGG 1

RESULT 86

US-10-605-498-60/c
; Sequence 60, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-60

Query Match 2.7%; Score 21; DB 1; Length 21;

```
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 591 CCAGCTTGGGGGCCGAGAAG 611
Db 21 CCCAGCTTGGGGGCCGAGAAG 1

RESULT 87
US-10-605-498-61/c
; Sequence 61, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-61

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 601 GGGCCGAGAGCTGCAAAATC 621
Db 21 GGGCCGAGAGCTGCAAAATC 1

RESULT 88
US-10-605-498-62/c
; Sequence 62, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-62

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 611 GCTGCAAAATCCGATGAGACT 631
Db 21 GCTGCAAAATCCGATGAGACT 1

RESULT 89
US-10-605-498-63/c
; Sequence 63, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 63
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-63

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 621 CCGATGAGACTGCCGCCAAGT 641
Db 21 CCGATGAGACTGCCGCCAAGT 1

RESULT 90
US-10-605-498-64/c
; Sequence 64, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 64
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-64

Query Match 2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 631 TGCCGCCCAAGTAAAGCCTTAG 651
Db 21 TGCCGCCCAAGTAAAGCCTTAG 1

RESULT 91
US-10-605-498-65/c
```

```
; Sequence 65, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 65
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-65

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 641 TAAAGCCTTAGCCGGATGCC 661
Db 21 TAAAGCCTTAGCCGGATGCC 1

RESULT 92
US-10-605-498-66/c
; Sequence 66, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-66

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 651 GCCCGATGCCACCCCTGCT 671
Db 21 GCCCGATGCCACCCCTGCT 1

RESULT 93
US-10-605-498-67/c
; Sequence 67, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 67
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-67

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 661 CCACCCCTGCTGCGCCACTG 681
Db 21 CCACCCCTGCTGCGCCACTG 1

RESULT 94
US-10-605-498-68/c
; Sequence 68, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 68
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-68

Query Match          2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 671 TGCCGCCACTGGCTGTGCTC 691
Db 21 TGCCGCCACTGGCTGTGCTC 1

RESULT 95
US-10-605-498-69/c
; Sequence 69, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
```

```
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-69
```

```
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 681 GGCTGTGCTCCCGCCGACC 701
Db 21 GGCTGTGCTCCCGCCGACC 1
```

RESULT 96

```
US-10-605-498-70/c
; Sequence 70, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 70
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-70
```

```
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 691 CCCCCGCCACCTGTGTCT 711
Db 21 CCCCCGCCACCTGTGTCT 1
```

RESULT 97

```
US-10-605-498-71/c
; Sequence 71, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
```

```
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 71
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-71
```

```
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 701 CTGTGTCTCTTTTGATACAT 721
Db 21 CTGTGTCTCTTTTGATACAT 1
```

RESULT 98

```
US-10-605-498-72/c
; Sequence 72, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 72
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-72
```

```
Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 711 TTTTGATACATTTATCTCTCG 731
Db 21 TTTTGATACATTTATCTCTCG 1
```

RESULT 99

```
US-10-605-498-73/c
; Sequence 73, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 21
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-10-605-498-73

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 721 TTTATCTCTCTGTTTCTCAA 741
Db 21 TTTATCTCTCTGTTTCTCAA 1

RESULT 100
US-10-605-498-74/c
; Sequence 74, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 74
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-74

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 731 GTTTTCTCAATAAAGTTCA 751
Db 21 GTTTTCTCAATAAAGTTCA 1

RESULT 101
US-10-605-498-75/c
; Sequence 75, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 75
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-75

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 741 AATAAGTTCAAAGCAACCACTG 764
Db 21 AATAAGTTCAAAGCAACCACTG 1

RESULT 102
US-10-605-498-76/c
; Sequence 76, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 76
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-76

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 744 AAAGTTCAAAGCAACCACTG 764
Db 21 AAAGTTCAAAGCAACCACTG 1

RESULT 103
US-10-605-498-78/c
; Sequence 78, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 78
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-78

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 365 AAGATGCGCTGGTGGAGATC 385
Db 21 AAGATGCGCTGGTGGAGATC 1
```

```
RESULT 104
US-10-605-498-79/c
; Sequence 79, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,498
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 79
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-79

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 265 ACTCAGCAGCGGGTCTCGGA 285
Db 21 ACTCAGCAGCGGGTCTCGGA 1

RESULT 105
US-10-605-498-80/c
; Sequence 80, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,498
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 80
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-80

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 264 AACTCAGCAGCGGGTCTCGG 284
Db 21 AACTCAGCAGCGGGTCTCGG 1

RESULT 106
US-10-605-498-81/c
; Sequence 81, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,498
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 81
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-81

Query Match      2.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 26 ATGACCGAGCGCGCGTCCCC 46
Db 21 ATGACCGAGCGCGCGTCCCC 1

RESULT 107
US-10-719-900-152006/c
; Sequence 152006, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 152006
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-152006

Query Match      2.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 34;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 406 GCAGGACGAGCATGGCTACATCTC 429
Db 25 GCAGGACGAGCATGGCTACATCTC 2

RESULT 108
US-10-809-189-92419
; Sequence 92419, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
```

```
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 92419
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-92419

Query Match          2.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 34;
Matches 22; Conservative 0; Mismatches 0; Gaps 0;

Qy 499 CCCTGAGGGCACACTGACCGTGA 522
Db 2 CCCTGAGGGCACACTTCCGTGA 25

RESULT 109
US-10-719-900-51106/c
; Sequence 51106, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 51106
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-51106

Query Match          2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 0; Gaps 0;

Qy 414 AGCATGGCTACATCTCCCGGTGCTT 438
Db 25 AACATGGCTACAACCTCTCGGTGCTT 1

RESULT 110
US-10-719-900-72371
; Sequence 72371, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 72371
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-72371

Query Match          2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 0; Gaps 0;

Qy 425 ATCTCCCGGTGCTTCACCGGAAAT 449
Db 1 ATCTCTCGGTGCATCACCCGAAAT 25

RESULT 113
US-10-719-900-347106
; Sequence 347106, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
```

```
Qy 447 AATACAGCTGCCCGCGGTGGA 471
Db 1 AATACAGCTCCCTCCAGGTGGA 25

RESULT 111
US-10-719-900-147040/c
; Sequence 147040, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 147040
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-147040

Query Match          2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 0; Gaps 0;

Qy 257 AGCCGCAACTCAGCAGCGGTCT 281
Db 25 AACCGACAGCTCAGCAGCGGTCT 1

RESULT 112
US-10-719-900-248861
; Sequence 248861, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 248861
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-248861

Query Match          2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 0; Gaps 0;

Qy 425 ATCTCCCGGTGCTTCACCGGAAAT 449
Db 1 ATCTCTCGGTGCATCACCCGAAAT 25

RESULT 113
US-10-719-900-347106
; Sequence 347106, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
```

; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 347106
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-347106

Query Match 2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 132 CCCGGTCCGAGGAGGTGTCGCA 156
||||| ||||| ||||| ||||| |||||
Db 1 CCCGGTCCCGATGAGTGTGCGCA 25

RESULT 114

US-10-719-900-376561
; Sequence 376561, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 376561

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-376561

Query Match 2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 429 CCCGGTCTTCACGCGGAATACAC 453
||||| ||||| ||||| ||||| |||||
Db 1 CTCGGTCTTCAGCGGAATACAC 25

RESULT 115

US-10-719-900-415444
; Sequence 415444, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 415444

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-415444

Query Match 2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 413 GAGCATGGCTACATCTCCCGTGCT 437
||||| ||||| ||||| ||||| |||||
Db 1 GAACATGGCTACTTCTCTCGTGCT 25

RESULT 116

US-10-719-900-472173/c
; Sequence 472173, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 472173

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-472173

Query Match 2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 407 CAGGACGAGCATGCTACATCTCCC 431
||||| ||||| ||||| ||||| |||||
Db 25 CAGGACGAACATCGCTACATCTCTC 1

RESULT 117

US-10-719-900-581985
; Sequence 581985, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 581985

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-581985

Query Match 2.6%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 40;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 444 GGAATACACGCTGCCCGCGTGCT 468
||||| ||||| ||||| ||||| |||||
Db 1 GGAATACACGCTCCCTCCAGGTGT 25

RESULT 118

US-10-719-900-592387
; Sequence 592387, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

: PRIOR APPLICATION NUMBER: 60/427,808

— 100 —

; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-77

Query Match 2.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 42;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 226 AGTGGCCGCGCCGCCCTA 243
|||
Db 18 AGTGGCCGCGCCGCCCTA 1

RESULT 133
US-10-605-498-89
; Sequence 89, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 89
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-605-498-89

Query Match 2.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 57;
Matches 16; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 576 CTTTCAGTCGCGGCCGAGC 596
|||
Db 1 CCUUCGUGCGGGGCCGUCG 21

RESULT 134
US-10-472-779-2/c
; Sequence 2, Application US/10472779
; Publication No. US20040097539A1
; GENERAL INFORMATION:
; APPLICANT: TERASHITA, Zen-ichi
; APPLICANT: NARUO, Ken-ichi
; APPLICANT: UCHIKAWA, Osamu
; APPLICANT: NAKANISHI, Atsushi
; TITLE OF INVENTION: HSP inducing agent
; FILE REFERENCE: 2890 USOP
; CURRENT APPLICATION NUMBER: US/10/472,779
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: PCT/JP02/02946
; PRIOR FILING DATE: 2002-03-27

; PRIOR APPLICATION NUMBER: JP 2001-92704
; PRIOR FILING DATE: 2001-03-28
; NUMBER OF SEQ ID NOS: 3
; SEQ ID NO 2
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer for amplifying HSP27 gene
US-10-472-779-2

Query Match 2.3%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 62;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 413 GAGCATGGCTACATCTCCCG 433
|||
Db 21 GAACATGGCTACATCTCTCG 1

RESULT 135
US-10-339-793-168
; Sequence 168, Application US/10339793
; Publication No. US20030180764A1
; GENERAL INFORMATION:
; APPLICANT: Lynx Therapeutics, Inc.
; APPLICANT: Shang, Jin
; APPLICANT: Bowen, Benjamin
; TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
; FILE REFERENCE: 37-000310US
; CURRENT APPLICATION NUMBER: US/10/339,793
; CURRENT FILING DATE: 2003-01-08
; NUMBER OF SEQ ID NOS: 443
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 168
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-339-793-168

Query Match 2.2%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 559 GATCACCATCCAGTCA 575
|||
Db 1 GATCACCATCCAGTCA 17

RESULT 136
US-10-751-736-34691
; Sequence 34691, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34691
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-34691

```
Query Match          2.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 75;
Matches 15; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      170 AGCAGCTGGCCAGGTACT 189
      |||:|||||:|||||:|:
Db      2 AGGAGCUGGCCAGGCUACUU 21

RESULT 137
US-10-605-613-0
; Sequence 0, Application US/09990613
; Publication No. US20030096219A1
; GENERAL INFORMATION:
; APPLICANT: Wu, Reen
; APPLICANT: Chen, Yin
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR THE
; TITLE OF INVENTION: ANALYSIS OF MUCIN GENE EXPRESSION AND IDENTIFICATION OF
; TITLE OF INVENTION: DRUGS HAVING THE ABILITY TO INHIBIT MUCIN GENE EXPRESSION
; FILE REFERENCE: UC072.001A
; CURRENT APPLICATION NUMBER: US/09/990,613
; CURRENT FILING DATE: 2001-11-21
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-990-613-0

Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 83;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      403 GCGCAGCAGCAGCATGCG 421
      |||||:|||||:|||||
Db      1 GCGCACCACGAGCATGCG 19

RESULT 138
US-10-605-498-83
; Sequence 83, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 83
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-605-498-83

Query Match          2.1%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 83;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      266 CTCAGCAGCGGGTCTCGG 284
      |:|||||:|:|:|
Db      1 CUCUCGUGCGGGGUCUGG 19
```

```
RESULT 139
US-10-605-498-7
; Sequence 7, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; TITLE OF INVENTION: Cancers
; FILE REFERENCE: UBC-P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; CURRENT FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-7

Query Match          2.1%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 97;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      60 GGGCCCCAGCTGGGACCC 78
      |||||:|||||:|||||
Db      3 GGGGTCCCAGCTGGGCCC 21

RESULT 140
US-09-866-108-10667
; Sequence 10667, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10667

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 12 CAGAGTCAGCCAGCATG 28
||||| |||||||
Db 1 CAGAGCCAGCCAGCATG 17
||||| |||||||

RESULT 141
US-10-211-689-82/c
; Sequence 82, Application US/10211689
; Publication No. US2003023247A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, John II
; APPLICANT: Anderson, David W.
; APPLICANT: Boldog, Ferenc L.
; APPLICANT: Burgess, Catherine E.
; APPLICANT: Casman, Stacie J.
; APPLICANT: Edinger, Shlomit R.
; APPLICANT: Gangolli, Esha A.
; APPLICANT: Gorman, Linda
; APPLICANT: Guo, Xiaojia (Sasha)
; APPLICANT: Khrantsov, Nikolai V.
; APPLICANT: Lepley, Denise M.
; APPLICANT: MacDougall, John R.
; APPLICANT: Pena, Carol A.
; APPLICANT: Peyman, John A.
; APPLICANT: Patturajan, Meera
; APPLICANT: Rieger, Daniel K.
; APPLICANT: Shinkets, Richard A.
; APPLICANT: Smithson, Glennda
; APPLICANT: Spytek, Kimberly A.
; APPLICANT: Vernet, Corine A. M.
; APPLICANT: Vosse, Edward Z.
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-416B
; CURRENT APPLICATION NUMBER: US/10/211,689
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: 60/311751
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 60/310,802
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 60/310,795
; PRIOR FILING DATE: 2001-08-08
; PRIOR APPLICATION NUMBER: 60/311,292
; PRIOR FILING DATE: 2001-08-09
; PRIOR APPLICATION NUMBER: 60/361,159
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/373,050
; PRIOR FILING DATE: 2002-04-16
; PRIOR APPLICATION NUMBER: 60/380,970
; PRIOR FILING DATE: 2002-05-15
; PRIOR APPLICATION NUMBER: 60/311,979
; PRIOR FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 60/381,030
; PRIOR FILING DATE: 2002-05-16

; PRIOR APPLICATION NUMBER: 60/323,944
; PRIOR FILING DATE: 2001-09-21
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 132
; SOFTWARE: Curasequid version 0.1
; SEQ ID NO 82
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-211-689-82

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 399 AGGAGCGGAGGACGAG 415
||||| |||||||
Db 17 AGGAGCAGCAGGACGAG 1
||||| |||||||

RESULT 142
US-10-723-361-10667
; Sequence 10667, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10667

Query Match 2.0%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 77;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 12 CAGAGTCAGCCAGCATG 28
||||| |||||||

```
Db      1 CAGAGCCAGCCAGCATG 17

RESULT 143
US-10-844-072-10
; Sequence 10, Application US/10844072
; Publication No. US20050159376A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
; TITLE OF INVENTION: Androgen Receptor Gene Expression Using Short Interfering Nuclei
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/157 (MBHB04-428)
; CURRENT FILING DATE: 2004-05-12
; PRIOR APPLICATION NUMBER: US 10/844,072
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 718
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-844-072-10

Query Match      2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 92;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      228 TGGCGCGCGCCGCTTAC 244
          :|||||||:|||||:
Db      1 UGGCGCGCGCUCGCCUAC 17

RESULT 144
US-10-844-072-133/C
; Sequence 133, Application US/10844072
; Publication No. US20050159376A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
; TITLE OF INVENTION: Androgen Receptor Gene Expression Using Short Interfering Nuclei
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/157 (MBHB04-428)
; CURRENT FILING DATE: 2004-05-12
; PRIOR APPLICATION NUMBER: US 10/844,072
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 718
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-844-072-10

Query Match      2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 92;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      228 TGGCGCGCGCCGCTTAC 244
          :|||||||:|||||:
Db      1 UGGCGCGCGCUCGCCUAC 17

RESULT 145
US-10-922-340-10
; Sequence 10, Application US/10922340
; Publication No. US20050170371A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
; TITLE OF INVENTION: Androgen Receptor Gene Expression Using Short Interfering Nuclei
; FILE REFERENCE: 400/222 (04-428-A)
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: US 10/922,340
; PRIOR FILING DATE: 2004-05-12
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: PCT/US04/13456
; PRIOR FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US 10/780,447
; PRIOR FILING DATE: 2004-02-13
; PRIOR APPLICATION NUMBER: US 60/292,217
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/362,016
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: US 60/306,883
; PRIOR FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/311,865
; PRIOR FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: US 10/727,780
; PRIOR FILING DATE: 2003-12-03
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 718
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 133
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-844-072-133

Query Match      2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      228 TGGCGCGCGCCGCTTAC 244
          :|||||||:|||||:
Db      19 TGGCGCGCGCTGCGCTAC 3

RESULT 145
US-10-922-340-10
; Sequence 10, Application US/10922340
; Publication No. US20050170371A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
; TITLE OF INVENTION: Androgen Receptor Gene Expression Using Short Interfering Nuclei
; FILE REFERENCE: 400/222 (04-428-A)
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: US 10/922,340
; PRIOR FILING DATE: 2004-05-12
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: PCT/US04/13456
; PRIOR FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US 10/780,447
; PRIOR FILING DATE: 2004-02-13
; PRIOR APPLICATION NUMBER: US 60/292,217
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/362,016
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: US 60/306,883
; PRIOR FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/311,865
; PRIOR FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: US 10/727,780
; PRIOR FILING DATE: 2003-12-03
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```

; NUMBER OF SEQ ID NOS: 750
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-922-340-10

Query Match          2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 82.4%; Pred. No. 92;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 228 TGGCGCGCGCGCTTAC 244
      :|||||||:|||||
Db 1 UGGCGCGCGCTCGCTTAC 17

RESULT 146
US-10-922-340-133/c
; Sequence 133, Application US/10922340
; Publication No. US20050170371A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Vaish, Narendra
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of 5-Alpha Reductase and
; TITLE OF INVENTION: Androgen Receptor Gene Expression Using Short Interfering Nuclei
; FILE REFERENCE: 400/222 (04-428-A)
; CURRENT APPLICATION NUMBER: US/10/922,340
; CURRENT FILING DATE: 2004-08-20
; PRIOR FILING DATE: 2004-05-12
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: PCT/US04/13456
; PRIOR FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US 10/780,447
; PRIOR FILING DATE: 2004-02-13
; PRIOR APPLICATION NUMBER: US 60/292,217
; PRIOR FILING DATE: 2001-05-18
; PRIOR APPLICATION NUMBER: US 60/362,016
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: US 60/306,883
; PRIOR FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/311,865
; PRIOR FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: US 10/727,780
; PRIOR FILING DATE: 2003-12-03
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 750
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 133
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-922-340-133

Query Match          2.0%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 92;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 228 TGGCGCGCGCGCTTAC 244
      :|||||||:|||||
Db 19 TGGCGCGCGCTCGCTTAC 3
```

```

RESULT 147
US-10-450-472-50/c
; Sequence 50, Application US/10450472
; Publication No. US20040132094A1
; GENERAL INFORMATION:
; APPLICANT: Boreau Pharma A/S
; TITLE OF INVENTION: Combinatorial libraries of proteins having the scaffold structure
; FILE REFERENCE: BOR00003/WO
; CURRENT APPLICATION NUMBER: US/10/450,472
; CURRENT FILING DATE: 2003-12-08
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-450-472-50

Query Match          1.9%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 99;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 86 GACTGGTACCGCATAGC 103
      |||||:|||||:|
Db 18 GACCGGTACCGCATCGC 1

RESULT 148
US-10-179-940-466/c
; Sequence 466, Application US/10179940
; Publication No. US20040018618A1
; GENERAL INFORMATION:
; APPLICANT: Abrams, Mark A.
; APPLICANT: Bauer, S. C.
; APPLICANT: Braford-Goldberg, Sarah R.
; APPLICANT: Caparon, Mair H.
; APPLICANT: Easton, Alan M.
; APPLICANT: Klein, Barbara K.
; APPLICANT: McKearn, John P.
; APPLICANT: Olin, Peter O.
; APPLICANT: Paik, Kuman
; APPLICANT: Polazzi, Joseph O.
; TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
; NUMBER OF SEQUENCES: 549
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Carol M. Nielsen, Gardere Wynne Sewell LLP,
; STREET: 1601 Elm Street, Suite 3000
; CITY: Dallas
; STATE: Texas
; COUNTRY: USA
; ZIP: 75201-4761
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/179,940
; FILING DATE: 19-Jun-2002
; CLASSIFICATION: Unknown
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/981044
; FILING DATE: 24-NOV-1992
; APPLICATION NUMBER: PCT/US93/11198
; FILING DATE: 22-NOV-1993
; APPLICATION NUMBER: US 08/411796
; FILING DATE: 09-APR-1995
; APPLICATION NUMBER: US 08/559390
; FILING DATE: 15-NOV-1995
; ATTORNEY/AGENT INFORMATION:
```

```
; NAME: Carol M. Nielsen
; REGISTRATION NUMBER: 37,676
; REFERENCE/POCKET NUMBER: 126181-1056 (C2713/1)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (713)276-5383
; TELEFAX: (713)276-5555
; INFORMATION FOR SEQ ID NO: 466:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 466:
US-10-179-940-466

      Query Match          1.9%; Score 14.4; DB 1; Length 16;
      Best Local Similarity 93.8%; Pred. No. 91;
      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      565 CATCCCACTCACCTTC 580
Db      16 CATTCCAGTCACCTTC 1

      RESULT 149
US-09-866-108-10666
; Sequence 10666, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 10666
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10668

      Query Match          1.9%; Score 14.4; DB 1; Length 17;
      Best Local Similarity 93.8%; Pred. No. 1e+02;
      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

; SEQ ID NO 10666
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10666

      Query Match          1.9%; Score 14.4; DB 1; Length 17;
      Best Local Similarity 93.8%; Pred. No. 1e+02;
      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

Qy 13 AGAGTCAGCCAGCATG 28
|||||
Db 1 AGAGCCAGCCAGCATG 16

RESULT 151

US-10-060-830-218/c
; Sequence 218, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 218
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-218

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 11 GCAGAGTCAGCCAGCA 26
|||||
Db 17 GCAGAGTCAGCCTGCA 2

RESULT 152

US-10-060-830-219/c
; Sequence 219, Application US/10060830
; Publication No. US20030032154A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; APPLICANT: Nguyen, Cung-Tuong
; TITLE OF INVENTION: HUMAN LCCL DOMAIN CONTAINING PROTEIN
; FILE REFERENCE: PB0169
; CURRENT APPLICATION NUMBER: US/10/060,830
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761

; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/325,062
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 1123
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 219
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-830-219

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 11 GCAGAGTCAGCCAGCA 26
|||||
Db 16 GCAGAGTCAGCCTGCA 1

RESULT 153

US-10-156-306-5028
; Sequence 5028, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5028
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5028

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 14; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 193 CCCCTGCCCCCGCC 208
|||||
Db 1 CCCCUUGCCCCCGCC 16

RESULT 154

US-10-238-700-2848/c
; Sequence 2848, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2848
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2848

Query Match 1.9%; Score 14.4; DB 1; Length 17;

```
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 227 GTGGCCGCGCCGCT 242
Db 16 GTGGCCGCGCCGCT 1

RESULT 155
US-10-723-361-10666
; Sequence 10666, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10666
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10668

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 AGAGTCAGCCAGCATG 28
Db 1 AGAGCCAGCCAGCATG 16

RESULT 157
US-10-498-462-2203
; Sequence 2203, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; PRIOR FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2203
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2203

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 56 CTGCGGGGGCCCGACT 71
Db 2 CTGAGGGGGCCCGACT 17

RESULT 156
US-10-723-361-10668
; Sequence 10668, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
```

```
APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 10668
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10668

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 13 AGAGTCAGCCAGCATG 28
Db 1 AGAGCCAGCCAGCATG 16

RESULT 157
US-10-498-462-2203
; Sequence 2203, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; PRIOR FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 2203
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2203

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 56 CTGCGGGGGCCCGACT 71
Db 2 CTGAGGGGGCCCGACT 17
```

RESULT 158
US-10-498-462-2204
; Sequence 2204, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-08-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2204
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-2204

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 56 CTGCGGGGCCCGCAGCT 71
||| ||||| ||||| |||||
Db 1 CTGAGGGGGCCCGCAGCT 16

RESULT 159
US-10-724-270-1527/c
; Sequence 1527, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1527
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1527

Query Match 1.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 227 GTGGCCGGCCCGCCT 242
||| ||||| ||||| |||||
Db 16 GTGGCCGGCCCGCCT 1
RESULT 160
US-10-349-143-6095/c
; Sequence 6095, Application US/10349143
; Publication No. US2004000584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6095
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-8894 for SEQ 2161,
US-10-349-143-6095

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 701 CTGTGTGTTCTTTGA 716
||| ||||| ||||| |||||
Db 18 CTGTGTGTTCTTCTGA 3

RESULT 161
US-10-702-817-27
; Sequence 27, Application US/10702817
; Publication No. US2004014747A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1 EXPRESSION
; FILE REFERENCE: ISPH-0797
; CURRENT APPLICATION NUMBER: US/10/702,817
; CURRENT FILING DATE: 2003-11-06
; PRIOR APPLICATION NUMBER: US 09/106,038
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: PCT/US99/13763
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: 09/695,451
; PRIOR FILING DATE: 2000-10-24
; NUMBER OF SEQ ID NOS: 247
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-702-817-27

Query Match 1.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 487 CTCCTCCCTGTCCCT 502

Db 2 CTCCTCCCTGTCCCT 17

RESULT 162

US-09-818-875-4230/c
; Sequence 4230, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gampier, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-818-875-4230

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCGAGTCCA 554

Db 15 AGCCACGCGAGTCCA 2

RESULT 163

US-09-818-875-4231
; Sequence 4231, Application US/09818875
; Publication No. US20030051270A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gampier, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; TITLE OF INVENTION: Stranded Oligonucleotides
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/09/818,875
; CURRENT FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-818-875-4231

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCGAGTCCA 554

Db 3 AGCCACGCGAGTCCA 16

RESULT 164

US-09-780-533A-765
; Sequence 765, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowirra, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 765
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-765

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 164 GCGCGCAGCAGCTG 177

Db 3 GCGCGCAGCAGCTG 16

RESULT 165

US-09-780-533A-1791
; Sequence 1791, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowirra, Bharat
; APPLICANT: Haerberli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00,878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1791
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-1791

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;

```
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 164 GCGGCGCAGCAGCTG 177
Db 2 GCGGCGCAGCAGCUG 15

RESULT 166
US-10-209-787-4230/c
; Sequence 4230, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-4230

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCGAGTCCA 554
Db 15 AGCCACGCGAGTCCA 2

RESULT 167
US-10-209-787-4231
; Sequence 4231, Application US/10209787
; Publication No. US20030217377A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4
; CURRENT APPLICATION NUMBER: US/10/209,787
; PRIOR FILING DATE: 2002-07-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-209-787-4231

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCGAGTCCA 554
Db 3 AGCCACGCGAGTCCA 16

RESULT 168
US-10-261-185-4230/c
; Sequence 4230, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4230
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-4230

Query Match 1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 541 AGCCACGCGAGTCCA 554
Db 15 AGCCACGCGAGTCCA 2

RESULT 169
US-10-261-185-4231
; Sequence 4231, Application US/10261185
; Publication No. US20040014057A1
; GENERAL INFORMATION:
; APPLICANT: Kmiec, Eric B.
; APPLICANT: Gamper, Howard B.
; APPLICANT: Rice, Michael C.
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations with Modified Single
; FILE REFERENCE: Napro-4CON
; CURRENT APPLICATION NUMBER: US/10/261,185
; CURRENT FILING DATE: 2002-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/09761
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/192,176
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/192,179
; PRIOR FILING DATE: 2000-03-27
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
```

```
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; NUMBER OF SEQ ID NOS: 4385
; SOFTWARE: Friedman macro Napro4
; SEQ ID NO 4231
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-261-185-4231

Query Match      1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      541 AGCCACGCGAGTCCA 554
Db      3 AGCCACGCGAGTCCA 16

RESULT 170
US-10-681-074-4230/c
; Sequence 4230, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: Napro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4230
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-4230

Query Match      1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      541 AGCCACGCGAGTCCA 554
Db      15 AGCCACGCGAGTCCA 2

RESULT 171
US-10-681-074-4231
; Sequence 4231, Application US/10681074
; Publication No. US20040175722A1
; GENERAL INFORMATION:
; APPLICANT: KMEC, ERIC B.
; APPLICANT: VAN BRABANT, ANJA
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR REDUCING SCREENING IN
; TITLE OF INVENTION: OLIGONUCLEOTIDE-DIRECTED NUCLEIC ACID SEQUENCE ALTERATION
; FILE REFERENCE: Napro-18 US
; CURRENT APPLICATION NUMBER: US/10/681,074
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: US 60/453,360
; PRIOR FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/416,983
; PRIOR FILING DATE: 2002-10-07
; NUMBER OF SEQ ID NOS: 4375
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4231
```

```
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-681-074-4231

Query Match      1.8%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      541 AGCCACGCGAGTCCA 554
Db      3 AGCCACGCGAGTCCA 16

RESULT 172
US-09-866-108-2329/c
; Sequence 2329, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AROMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 2329
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2329

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      551 TCCACGAGATCACCAT 567
```

Db 17 TCCAGCGACATCACCAT 1

RESULT 173

US-09-866-108-2330/C

; Sequence 2330, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US 09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Acomica Sequence Listing Engine

; SEQ ID NO 2330

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-2330

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 GTCCACGACGATCACC 566

DB 17 GTCCACGACGATCACC 1

RESULT 174

US-09-866-108-2331/C

; Sequence 2331, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US 09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Acomica Sequence Listing Engine

; SEQ ID NO 2330

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-2330

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 550 GTCCACGACGATCACC 566

DB 17 GTCCACGACGATCACC 1

RESULT 175

US-09-866-108-10669

; Sequence 10669, Application US/09866108

; Patent No. US20020048800A1

; GENERAL INFORMATION:

; APPLICANT: GU, Yizhong

; APPLICANT: JI, Yonggang

; APPLICANT: PENN, Sharron G.

; APPLICANT: HANZEL, David K.

; APPLICANT: RANK, David R.

; APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

; FILE REFERENCE: AEOMICA-7

; CURRENT APPLICATION NUMBER: US 09/866,108

; CURRENT FILING DATE: 2001-05-25

; PRIOR APPLICATION NUMBER: US 60/207,456

; PRIOR FILING DATE: 2000-05-26

; PRIOR APPLICATION NUMBER: GB 24263.6

; PRIOR FILING DATE: 2000-10-04

; PRIOR APPLICATION NUMBER: US 60/236,359

; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: PCT/US01/00666

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00667

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00664

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00669

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00665

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00668

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00663

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00662

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00661

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: PCT/US01/00670

; PRIOR FILING DATE: 2001-01-30

; PRIOR APPLICATION NUMBER: US 60/234,687

; PRIOR FILING DATE: 2000-09-21

; PRIOR APPLICATION NUMBER: US 60/266,860

; PRIOR FILING DATE: 2001-02-05

; NUMBER OF SEQ ID NOS: 15752

; SOFTWARE: Acomica Sequence Listing Engine

; SEQ ID NO 2330

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-866-108-2331

Query Match 1.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.2e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 549 AGTCCACGACGATCACC 565

DB 17 AGTCCACGACGATCACC 1

;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Acomica Sequence Listing Engine
;; SEQ ID NO 10669
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-10669

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 14 GAGTCAGCCAGCATGAC 30
||| ||||| ||||| |||||
Db 1 GAGCCAGCCAGCATGGC 17

RESULT 176
US-09-866-108-10670
;; Sequence 10670, Application US/09866108
;; Patent No. US2002004800A1
;; GENERAL INFORMATION:
;; APPLICANT: GU, Yizhong
;; APPLICANT: JI, Yonggang
;; APPLICANT: PENN, Sharron G.
;; APPLICANT: HANZEL, David K.
;; APPLICANT: RANK, David R.
;; APPLICANT: CHEN, Wenheng
;; APPLICANT: SHANNON, Mark
;; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
;; FILE REFERENCE: ACOMICA-7
;; CURRENT APPLICATION NUMBER: US/09/866,108
;; CURRENT FILING DATE: 2001-05-25
;; PRIOR APPLICATION NUMBER: US 60/207,456
;; PRIOR FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: GB 24263.6
;; PRIOR FILING DATE: 2000-10-04
;; PRIOR APPLICATION NUMBER: US 60/236,359
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30

;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Acomica Sequence Listing Engine
;; SEQ ID NO 10670
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-10670

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 15 AGTCAGCCAGCATGACC 31
||| ||||| ||||| |||||
Db 1 AGCCAGCCAGCATGGCC 17

RESULT 177
US-09-864-785-1425/c
;; Sequence 1425, Application US/09864785
;; Patent No. US20020177568A1
;; GENERAL INFORMATION:
;; APPLICANT: Ribozyme Pharmaceuticals, Inc.
;; APPLICANT: Stinchcomb, Dan
;; APPLICANT: Draper, Ken
;; APPLICANT: McSwiggen, Jim
;; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
;; TITLE OF INVENTION: Levels of NF-Kappa B
;; FILE REFERENCE: 400/022 (MBHB00-812-D)
;; CURRENT APPLICATION NUMBER: US/09/864,785
;; CURRENT FILING DATE: 2001-05-23
;; NUMBER OF SEQ ID NOS: 3929
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 1425
;; LENGTH: 17
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1425

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 16 GGGCCAGCTGGGACCC 78
||| ||||| ||||| |||||
Db 17 GGGCCAGCTGGGACCC 1

RESULT 178
US-09-825-805-772
;; Sequence 772, Application US/09825805

```
; Publication No. US20030004122A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Oligonucleot
; FILE REFERENCE: MBH00-831-F (400/009)
; CURRENT APPLICATION NUMBER: US/09/825,805
; CURRENT FILING DATE: 2001-09-27
; PRIOR FILING DATE: 2001-09-27
; PRIOR FILING DATE: 2000-05-23
; PRIOR APPLICATION NUMBER: 09/578,223
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/476,387
; PRIOR FILING DATE: 1999-12-30
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1558
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 772
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-825-805-772

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 123 TCGGGCTGCCCGGCTG 139
:|||||:|||||:
Db 1 UCGGGCUGGUCGCGUG 17

RESULT 179
US-09-780-533A-2414
; Sequence 2414, Application US/09780533A
; Publication No. US20030060611A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Chowrira, Bharat
; APPLICANT: Haeblerli, Pete
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
; FILE REFERENCE: MBH00.878-A (400/011)
; CURRENT APPLICATION NUMBER: US/09/780,533A
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: US 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 6679
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2414
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-533A-2414

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 462 CCGGTGTGACCCACC 478
```

```
Db 1 CCGGUGGACCCCGCC 17
||| |:|:||||| |||
RESULT 180
US-09-927-046-1306
; Sequence 1306, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1306
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1306

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.2e+02;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 506 GGCACACTGACCGTGA 522
|||||:|||||:
Db 1 GGCACAGUAGUGGA 17

RESULT 181
US-09-927-046-1904/c
; Sequence 1904, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chlori
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1904
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1904

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 423 ACATCTCCCGTGCTTC 439
|||||:|||||:
Db 17 ACATCTCCCTGTGATTC 1

RESULT 182
```

```
US-09-927-046-1905/c
; FILE REFERENCE: US09927046
; Sequence 1905, Application US/09927046
; Publication No. US20030064946A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc
; APPLICANT: McSwiggen, Jim
; APPLICANT: Thompson, Jim
; APPLICANT: McKenzie, Tim
; APPLICANT: Ayers, Dave
; APPLICANT: Grupe, Andrew
; APPLICANT: Szymkowski, Edmund
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Calcium Activated Chloride Channel-1
; TITLE OF INVENTION: Channel-1
; FILE REFERENCE: 249/021
; CURRENT APPLICATION NUMBER: US/09/927,046
; CURRENT FILING DATE: 2001-08-09
; NUMBER OF SEQ ID NOS: 5450
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1905
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-927-046-1905

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 422 TACATCTCCCGTGCTT 438
Db 17 TACATCTCCCGTGATT 1

RESULT 183
US-09-740-332-4378
; Sequence 4378, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4378
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-4378

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 677 CACTGCGCTGCTGCC 693
Db 1 CCCUGGCAGUGCCUCCC 17

RESULT 184
US-09-817-879-4378
; Sequence 4378, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection
```

```
; FILE REFERENCE: MBHB00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4378
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-4378

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 677 CACTGCGCTGCTGCC 693
Db 1 CCCUGGCAGUGCCUCCC 17

RESULT 185
US-10-060-756A-170/c
; Sequence 170, Application US/10060756A
; Publication No. US20030046717A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/060,756A
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4804
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 170
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-756A-170

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 295 CACTGCGGACCGCTGGC 311
Db 17 CACTGCGGCGCGGTGGC 1

RESULT 186
US-10-163-552-650
; Sequence 650, Application US/10163552
; Publication No. US20030105051A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Nucleic acid treatment of diseases or conditions related to level
; FILE REFERENCE: MBH01-1653-A (400/014)
; CURRENT APPLICATION NUMBER: US/10/163,552
; CURRENT FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 1997
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 650
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-163-552-650

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 123 TCGGGCTGCCCGGCTG 139
Db 1 UCGGGCUGGCGGCGUG 17

RESULT 187
US-10-156-306-5029
; Sequence 5029, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5029
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5029

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 1.2e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 194 CCCCTGCCCGCCGCGC 210
Db 1 CCCUUGCCCGCGCC 17

RESULT 188
US-10-238-700-484
; Sequence 484, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 484
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
```

```
US-10-238-700-484

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 35.3%; Pred. No. 1.2e+02;
Matches 6; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 708 TTCTTTTGATACATTTA 724
Db 1 UCCUUUGAUAUUUA 17

RESULT 189
US-10-061-201-1223
; Sequence 1223, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 1223
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-1223

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 557 GAGATCACCATCCAGT 573
Db 1 GAGATCAGCAGCCAGT 17

RESULT 190
US-10-382-248-80/c
; Sequence 80, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
```

```
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 80
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-382-248-80

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      664 CCCCTGCTGCCGCCACT 680
Db      17 CCCCTTCTGCAGCCACT 1

RESULT 191
US-10-676-154-599/c
; Sequence 599, Application US/10676154
; Publication No. US20040081996A1
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE REFERENCE: M0656/7045(HCL/MAT)
; CURRENT FILING DATE: 2003-09-29
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; PRIOR FILING DATE: 1999-09-24
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 599
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-10-676-154-599

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      746 AGTTCARAGCACACC 762
Db      17 AGTCAAGCAACACC 1

RESULT 192
US-10-712-672-332/c
; Sequence 332, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
```

```
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 332
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-332

Query Match      1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      254 CTCAGCCGCAACTCAG 270
Db      17 CTCAGCCGCACTCAG 1

RESULT 193
US-10-669-841-6971
; Sequence 6971, Application US/10669841
; Publication No. US2004012746A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP
; FILE REFERENCE: 400/042US (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/359,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6971
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-6971
```



```
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2331
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2331

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 549 AGTCCAGCGACATCACC 565
Db 17 AGTCCAGCGACATCACC 1

RESULT 197
US-10-723-361-10669
; Sequence 10669, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10670
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10670

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 15 AGTCAGCGACGATGACC 31
Db 1 AGCCAGCGACGATGCC 17

RESULT 199
US-10-494-343-325
; Sequence 325, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shanon, Mark
; APPLICANT: Phann, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
```

```
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 14 GAGTCAGCCAGCATGAC 30
Db 1 GAGCCAGCCAGCATGCC 17

RESULT 198
US-10-723-361-10670
; Sequence 10670, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10670
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10670

Query Match
Best Local Similarity 1.8%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 15 AGTCAGCGACGATGACC 31
Db 1 AGCCAGCGACGATGCC 17

RESULT 199
US-10-494-343-325
; Sequence 325, Application US/10494343
; Publication No. US20040248138A1
; GENERAL INFORMATION:
; APPLICANT: Shanon, Mark
; APPLICANT: Phann, Thuymy
; TITLE OF INVENTION: HUMAN AGIOMOTIN-LIKE PROTEIN 1
; FILE REFERENCE: PB0184
; CURRENT APPLICATION NUMBER: US/10/494,343
; CURRENT FILING DATE: 2004-04-30
; PRIOR APPLICATION NUMBER: US to be assigned
```

;
; PRIOR FILING DATE: to be assigned
; PRIOR APPLICATION NUMBER: PCT/US2002/035129
; PRIOR FILING DATE: 2002-11-01
; PRIOR APPLICATION NUMBER: US 60/334,773
; PRIOR FILING DATE: 2001-11-01
; NUMBER OF SEQ ID NOS: 870
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 325
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-494-343-325

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 243 ACAGCGCGCGCTCAGC 259
Db 1 ACATCCGCTCGCTCAGC 17

RESULT 200
US-10-498-462-1759/c
; Sequence 1759, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1759
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-1759

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 520 GGAGGCCGCCATGCCCA 536
Db 17 GGAGGCCACCCAGGCCCA 1

RESULT 201
US-10-498-462-1760/c
; Sequence 1760, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1760
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-10-498-462-1760

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 519 TGGAGGCCCCCATGCC 535
Db 17 TGGAGGCCACCCAGGCC 1

RESULT 202
US-10-724-270-484
; Sequence 484, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; TITLE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 484
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-484

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 35.3%; Pred. No. 1.2e+02;
Matches 6; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 708 TTCTTTTGATACATTTA 724
Db 1 UCCUUUGAUAUUUA 17

RESULT 203
US-10-724-270-5305
; Sequence 5305, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; TITLE OF INVENTION: RAS, HER2 and HIV
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26

PRIOR APPLICATION NUMBER: PCT/US02/16840
PRIOR FILING DATE: 2002-05-29
PRIOR APPLICATION NUMBER: US 60/318,471
PRIOR FILING DATE: 2001-09-10
PRIOR APPLICATION NUMBER: US 60/296,249
PRIOR FILING DATE: 2001-06-06
PRIOR APPLICATION NUMBER: US 60/294,140
PRIOR FILING DATE: 2001-05-29
PRIOR APPLICATION NUMBER: US 10/238,700
PRIOR FILING DATE: 2002-09-10
PRIOR APPLICATION NUMBER: US 10/163,552
PRIOR FILING DATE: 2002-06-06
PRIOR APPLICATION NUMBER: US 10/157,580
PRIOR FILING DATE: 2002-05-29
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2002-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/417,012
PRIOR FILING DATE: 2003-04-16
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 6810
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5305
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-724-270-5305

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.2e+02;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 123 TCGGCTGCCCGCGTGTG 139
:|||||:|||||:
DB 1 UCGGCGUGCUCGCGUG 17

RESULT 204
US-10-890-776A-170/c
Sequence 170, Application US/10890776A
Publication No. US20050129683A1
GENERAL INFORMATION:
APPLICANT: Zhang, Jian
FILE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
CURRENT APPLICATION NUMBER: US/10/890,776A
CURRENT FILING DATE: 2004-07-14
PRIOR APPLICATION NUMBER: US 10/060,756
PRIOR FILING DATE: 2002-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 09/864,761
PRIOR FILING DATE: 2001-05-23
PRIOR APPLICATION NUMBER: US 60/327,898
PRIOR FILING DATE: 2001-10-09
NUMBER OF SEQ ID NOS: 4809
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 170
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-890-776A-170

Query Match 1.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 295 CACTGCGACCGCTGGC 311
:|||||:|||||:
DB 17 CACTGCGCGCGGTGGC 1

RESULT 205
US-10-712-672-1489
Sequence 1489, Application US/10712672
Publication No. US20040102413A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Chowrira, Bharat
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
FILE REFERENCE: MSHB00-882-C (400/019)
CURRENT APPLICATION NUMBER: US/10/712,672
CURRENT FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US/09/653,225
PRIOR FILING DATE: 2000-08-31
PRIOR APPLICATION NUMBER: 60/197,769
PRIOR FILING DATE: 2000-04-14
PRIOR APPLICATION NUMBER: 60/150,713
PRIOR FILING DATE: 1999-08-31
NUMBER OF SEQ ID NOS: 5586
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1489
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-10-712-672-1489

Query Match 1.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 197 CTGCCCCCGCGGCC 211
:|||||:|||||:
DB 2 CCGCCCCCGCGGCC 16

RESULT 206
US-09-918-728B-11/c
Sequence 11, Application US/09918728B
Publication No. US20030105308A1
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleoside Triphosphates and Their Incorporation into Oligonucleo
FILE REFERENCE: MSHB00-831-H (400/033)
CURRENT APPLICATION NUMBER: US/09/918,728B
CURRENT FILING DATE: 2002-04-03
NUMBER OF SEQ ID NOS: 127
SOFTWARE: PatentIn version 3.0
SEQ ID NO 11
LENGTH: 15
TYPE: RNA
ORGANISM: Homo sapiens
US-09-918-728B-11

Query Match 1.7%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 685 GTGCTCCCCCGC 697
:|||||:|||||:
DB 15 GTGCTCCCCCGC 3

```
RESULT 207
US-10-712-672-1490
; Sequence 1490, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/553,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1490
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1490

Query Match      1.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 199 GCCCCCCCGCGCC 211
Db 1 GCCCCCCCGCGCC 13

RESULT 208
US-10-605-498-50
; Sequence 50, Application US/10605498
; Publication No. US20040127441A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rocchi, Palma
; APPLICANT: Signaevsky, Maxim
; TITLE OF INVENTION: Compositions and Methods for Treatment of Prostate and Other
; FILE REFERENCE: UBC.P-031
; CURRENT APPLICATION NUMBER: US/10/605,498
; PRIOR FILING DATE: 2003-10-02
; PRIOR APPLICATION NUMBER: US 60/415,859
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: US 60/463,952
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 91
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-605-498-50

Query Match      1.7%; Score 13; DB 1; Length 21;
Best Local Similarity 76.2%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 495 TGTCCCTCAGGCGCACACTGA 515
Db 1 TGTGCCCTCAGGCGCACAGGA 21

RESULT 209
US-10-712-672-1490
; Sequence 1490, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/553,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1490
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-1490

Query Match      1.7%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 199 GCCCCCCCGCGCC 211
Db 1 GCCCCCCCGCGCC 13

RESULT 210
US-09-829-855-110
; Sequence 110, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 110
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-110

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 525 CCCCCCATGCCCGAGCT 540
Db 1 CCCCCGTGCCGAGCT 16

RESULT 211
US-10-455-013-17
; Sequence 17, Application US/10455013
; Publication No. US20040010810A1
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KLAPHOLZ, SUE
US-10-455-013-17

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 56 CTGCGGGGCGCCGAGCT 71
Db 1 CTGCGGTGCCGAGCT 16

RESULT 212
US-09-829-855-110
; Sequence 110, Application US/09829855
; Patent No. US20020065609A1
; GENERAL INFORMATION:
; APPLICANT: Matthew, Ashby N.
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY-1
; CURRENT APPLICATION NUMBER: US/09/829,855
; CURRENT FILING DATE: 2001-04-10
; PRIOR APPLICATION NUMBER: US 60/196063
; PRIOR FILING DATE: 2000-04-10
; PRIOR APPLICATION NUMBER: US 60/196258
; PRIOR FILING DATE: 2000-04-11
; NUMBER OF SEQ ID NOS: 244
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 110
; LENGTH: 16
; TYPE: DNA
; ORGANISM: unknown
; FEATURE:
; OTHER INFORMATION: unidentified soil organism
US-09-829-855-110

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 56 CTGCGGGGCGCCGAGCT 71
Db 1 CTGCGGTGCCGAGCT 16
```

APPLICANT: BRENNER, DANIEL G.
APPLICANT: CAPON, DANIEL J.
TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
FILE REFERENCE: CELL 4.6 CON 2
CURRENT APPLICATION NUMBER: US/10/455,013
CURRENT FILING DATE: 2003-06-04
PRIOR APPLICATION NUMBER: 09/019,523
PRIOR FILING DATE: 1998-02-05
PRIOR APPLICATION NUMBER: 08/234,145
PRIOR FILING DATE: 1994-04-28
PRIOR APPLICATION NUMBER: 08/112,848
PRIOR FILING DATE: 1993-08-27
PRIOR APPLICATION NUMBER: 08/031,801
PRIOR FILING DATE: 1993-03-15
PRIOR APPLICATION NUMBER: 07/919,297
PRIOR FILING DATE: 1992-07-24
PRIOR APPLICATION NUMBER: 07/610,515
PRIOR FILING DATE: 1990-11-08
PRIOR APPLICATION NUMBER: 07/466,008
PRIOR FILING DATE: 1990-01-12
NUMBER OF SEQ ID NOS: 33
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 17
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide
US-10-455-013-17

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 68 AGCTGGGACCCCTTCC 83
||||| |||||
Db 1 AGCTGGAACCCCTTGC 16

RESULT 212
US-10-455-013-29
Sequence 29, Application US/10455013
Publication No. US20040010810A1
GENERAL INFORMATION:
APPLICANT: KUCHERLAPATI, RAJU
APPLICANT: JAKOBOVITS, AYA
APPLICANT: KLAPHOLZ, SUE
APPLICANT: BRENNER, DANIEL G.
TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
FILE REFERENCE: CELL 4.6 CON 2
CURRENT APPLICATION NUMBER: US/10/455,013
CURRENT FILING DATE: 2003-06-04
PRIOR APPLICATION NUMBER: 09/019,523
PRIOR FILING DATE: 1998-02-05
PRIOR APPLICATION NUMBER: 08/234,145
PRIOR FILING DATE: 1994-04-28
PRIOR APPLICATION NUMBER: 08/112,848
PRIOR FILING DATE: 1993-08-27
PRIOR APPLICATION NUMBER: 08/031,801
PRIOR FILING DATE: 1993-03-15
PRIOR APPLICATION NUMBER: 07/919,297
PRIOR FILING DATE: 1992-07-24
PRIOR APPLICATION NUMBER: 07/610,515
PRIOR FILING DATE: 1990-11-08
PRIOR APPLICATION NUMBER: 07/466,008
PRIOR FILING DATE: 1990-01-12
NUMBER OF SEQ ID NOS: 33
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 29
LENGTH: 16
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide
US-10-455-013-29

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 68 AGCTGGGACCCCTTCC 83
||||| |||||
Db 1 AGCTGGAACCCCTTGC 16

RESULT 213
US-10-179-940-539/c
Sequence 539, Application US/10179940
Publication No. US20040018618A1
GENERAL INFORMATION:
APPLICANT: Abrams, Mark A.
Bauer, S. C.
Braford-Goldberg, Sarah R.
Caparon, Mair H.
Easton, Alan M.
Klein, Barbara K.
McKearn, John P.
Olines, Peter O.
Paik, Kuman
Polazzi, Joseph O.
TITLE OF INVENTION: Interleukin-3 (IL-3) Mutant Polypeptides
NUMBER OF SEQUENCES: 549
CORRESPONDENCE ADDRESS:
ADDRESSEE: Carol M. Nielsen, Gardere Wynne Sewell LLP,
STREET: 1601 Elm Street, Suite 3000
CITY: Dallas
STATE: Texas
COUNTRY: USA
ZIP: 75201-4761
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/179,940
FILING DATE: 19-Jun-2002
CLASSIFICATION: Unknown
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/981044
FILING DATE: 24-NOV-1992
APPLICATION NUMBER: PCT/US93/11198
FILING DATE: 22-NOV-1993
APPLICATION NUMBER: US 08/411796
FILING DATE: 09-APR-1995
APPLICATION NUMBER: US 08/559390
FILING DATE: 15-NOV-1995
ATTORNEY/AGENT INFORMATION:
NAME: Carol M. Nielsen
REGISTRATION NUMBER: 37,676
REFERENCE/DOCKET NUMBER: 126181-1056 (C2713/1)
TELECOMMUNICATION INFORMATION:
TELEPHONE: (713)276-5383
TELEFAX: (713)276-5555
INFORMATION FOR SEQ ID NO: 539:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (synthetic)
SEQUENCE DESCRIPTION: SEQ ID NO: 539:
US-10-179-940-539

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 565 CATCCAGTCACCTTC 580
Db 16 CATCCAGTCACCGTC 1

RESULT 214

US-10-627-250-17
; Sequence 17, Application US/10627250
; Publication No. US20040093622A1
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KLAPHOLZ, SUE
; APPLICANT: BRENNER, DANIEL G.
; APPLICANT: CAPON, DANIEL J.
; TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
; FILE REFERENCE: CELL 4.4 CPA RCE
; CURRENT APPLICATION NUMBER: US/10/627,250
; CURRENT FILING DATE: 2003-07-24
; PRIOR APPLICATION NUMBER: US/08/031,801
; PRIOR FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 07/919,297
; PRIOR FILING DATE: 1992-07-24
; PRIOR APPLICATION NUMBER: PCT/US91/00245
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/610,515
; PRIOR FILING DATE: 1990-11-08
; PRIOR APPLICATION NUMBER: 07/466,008
; PRIOR FILING DATE: 1990-01-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide

US-10-627-250-17

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 68 AGCTGGGACCCCTTCC 83
Db 1 AGCTGGACCCCTTGC 16

RESULT 215

US-10-627-250-29
; Sequence 29, Application US/10627250
; Publication No. US20040093622A1
; GENERAL INFORMATION:
; APPLICANT: KUCHERLAPATI, RAJU
; APPLICANT: JAKOBOVITS, AYA
; APPLICANT: KLAPHOLZ, SUE
; APPLICANT: BRENNER, DANIEL G.
; APPLICANT: CAPON, DANIEL J.
; TITLE OF INVENTION: GENERATION OF XENOGENEIC ANTIBODIES
; FILE REFERENCE: CELL 4.4 CPA RCE
; CURRENT APPLICATION NUMBER: US/10/627,250
; CURRENT FILING DATE: 2003-07-24
; PRIOR APPLICATION NUMBER: US/08/031,801
; PRIOR FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 07/919,297
; PRIOR FILING DATE: 1992-07-24
; PRIOR APPLICATION NUMBER: PCT/US91/00245

; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/610,515
; PRIOR FILING DATE: 1990-11-08
; PRIOR APPLICATION NUMBER: 07/466,008
; PRIOR FILING DATE: 1990-01-12
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: polylinker

US-10-627-250-29

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 68 AGCTGGGACCCCTTCC 83
Db 1 AGCTGGACCCCTTGC 16

RESULT 216

US-10-712-672-1775
; Sequence 1775, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrira, Bharat
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1775
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens

US-10-712-672-1775

Query Match 1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.4e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 677 CACTGGCTGTGCTTCC 692
Db 1 CAGUGGUGUGCCACC 16

RESULT 217

US-10-607-077A-10
; Sequence 10, Application US/10607077A
; Publication No. US20040110183A1
; GENERAL INFORMATION:
; APPLICANT: Ashdy, Matthew
; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
; FILE REFERENCE: ASHBY/1 DIV
; CURRENT APPLICATION NUMBER: US/10/607,077A
; CURRENT FILING DATE: 2003-06-25
; PRIOR APPLICATION NUMBER: US 09/829855
; PRIOR FILING DATE: 2001-04-10

; PRIOR APPLICATION NUMBER: PCT/US01/11609
 ; PRIOR FILING DATE: 2001-04-10
 ; PRIOR APPLICATION NUMBER: US 60/196063
 ; PRIOR FILING DATE: 2000-04-10
 ; PRIOR APPLICATION NUMBER: US 60/196258
 ; PRIOR FILING DATE: 2000-04-11
 ; NUMBER OF SEQ ID NOS: 244
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 10
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Unknown
 ; FEATURE:
 ; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
 ; OTHER INFORMATION: microbes in soil sample collected
 ; OTHER INFORMATION: in Wyoming, USA
 US-10-607-077A-10

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 525 CCCCCTGCCCCAGCT 540
 ||||| ||||| |||||
 Db 1 CCCCCTGCCCCAGCT 16

RESULT 218
 US-10-607-077A-110
 ; Sequence 110, Application US/10607077A
 ; Publication No. US20040110183A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ashby, Matthew
 ; TITLE OF INVENTION: Methods for the Survey and Genetic Analysis of Populations
 ; FILE REFERENCE: ASHBY/1 DIV
 ; CURRENT APPLICATION NUMBER: US/10/607,077A
 ; CURRENT FILING DATE: 2003-08-25
 ; PRIOR APPLICATION NUMBER: US 09/829855
 ; PRIOR FILING DATE: 2001-04-10
 ; PRIOR APPLICATION NUMBER: PCT/US01/11609
 ; PRIOR FILING DATE: 2001-04-10
 ; PRIOR APPLICATION NUMBER: US 60/196063
 ; PRIOR FILING DATE: 2000-04-10
 ; PRIOR APPLICATION NUMBER: US 60/196258
 ; PRIOR FILING DATE: 2000-04-11
 ; NUMBER OF SEQ ID NOS: 244
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 110
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Unknown
 ; FEATURE:
 ; OTHER INFORMATION: ribosomal DNA sequence tag isolated from
 ; OTHER INFORMATION: microbes in soil sample collected
 ; OTHER INFORMATION: in Wyoming, USA
 US-10-607-077A-110

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 56 CTGCGGGGCCAGCT 71
 ||||| ||||| |||||
 Db 1 CTGCGGTGCCGAGCT 16

RESULT 219
 US-10-776-934-107/c
 ; Sequence 107, Application US/10776934
 ; Publication No. US20050014712A1
 ; GENERAL INFORMATION:
 ; APPLICANT: HANSEN, BO
 ; APPLICANT: THRUE, CHARLOTTE ALBAEK

; APPLICANT: WESTERGAARD, MAJKEN
 ; APPLICANT: PETERSEN, KAMILLE DUMONG
 ; APPLICANT: WISSENBACH, MARGIT
 ; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
 ; FILE REFERENCE: 58610(71432)
 ; CURRENT APPLICATION NUMBER: US/10/776,934
 ; CURRENT FILING DATE: 2004-02-10
 ; PRIOR APPLICATION NUMBER: 60/446,372
 ; PRIOR FILING DATE: 2003-02-10
 ; PRIOR APPLICATION NUMBER: 60/523,591
 ; PRIOR FILING DATE: 2003-11-19
 ; NUMBER OF SEQ ID NOS: 741
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 107
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic oligonucleotide
 US-10-776-934-107

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 161 TTAGGCGGCAGCAGCT 176
 ||||| ||||| |||||
 Db 16 TTGGAGGCAGCAGCT 1

RESULT 220
 US-10-776-934-568/c
 ; Sequence 568, Application US/10776934
 ; Publication No. US20050014712A1
 ; GENERAL INFORMATION:
 ; APPLICANT: HANSEN, BO
 ; APPLICANT: THRUE, CHARLOTTE ALBAEK
 ; APPLICANT: WESTERGAARD, MAJKEN
 ; APPLICANT: PETERSEN, KAMILLE DUMONG
 ; APPLICANT: WISSENBACH, MARGIT
 ; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
 ; FILE REFERENCE: 58610(71432)
 ; CURRENT APPLICATION NUMBER: US/10/776,934
 ; CURRENT FILING DATE: 2004-02-10
 ; PRIOR APPLICATION NUMBER: 60/446,372
 ; PRIOR FILING DATE: 2003-02-10
 ; PRIOR APPLICATION NUMBER: 60/523,591
 ; PRIOR FILING DATE: 2003-11-19
 ; NUMBER OF SEQ ID NOS: 741
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 568
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic oligonucleotide
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (1)..(4)
 ; OTHER INFORMATION: beta-D-oxy-LNA modified base
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (13)..(16)
 ; OTHER INFORMATION: beta-D-oxy-LNA modified base
 ; FEATURE:
 ; NAME/KEY: misc feature
 ; LOCATION: (1)..(16)
 ; OTHER INFORMATION: phosphorothioate linkage
 US-10-776-934-568

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 161 TTAGGCGGCAGCAGCT 176
 |||||
 Db 16 TTGGAGGCAGCAGCT 1

RESULT 221

US-10-776-934-569/c
 ; Sequence 569, Application US/10776934
 ; Publication No. US20050014712A1
 ; GENERAL INFORMATION:
 ; APPLICANT: HANSEN, BO
 ; APPLICANT: THRU, CHARLOTTE ALBAEK
 ; APPLICANT: WESTERGAARD, MAJKEN
 ; APPLICANT: PETERSEN, KAMILLE DUMONG
 ; APPLICANT: WISSENBACH, MARGIT
 ; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
 ; FILE REFERENCE: 58610(71432)
 ; CURRENT APPLICATION NUMBER: US/10/776,934
 ; CURRENT FILING DATE: 2004-02-10
 ; PRIOR APPLICATION NUMBER: 60/446,372
 ; PRIOR FILING DATE: 2003-02-10
 ; PRIOR APPLICATION NUMBER: 60/523,591
 ; PRIOR FILING DATE: 2003-11-19
 ; NUMBER OF SEQ ID NOS: 741
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 569
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (1)..(4)
 ; OTHER INFORMATION: beta-D-oxy-LNA modified base
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (13)..(15)
 ; OTHER INFORMATION: beta-D-oxy-LNA modified base
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: (1)..(16)
 ; OTHER INFORMATION: phosphothioate linkage
 US-10-776-934-569

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 161 TTAGGCGGCAGCAGCT 176
 |||||
 Db 16 TTGGAGGCAGCAGCT 1

RESULT 222

US-10-776-934-570/c
 ; Sequence 570, Application US/10776934
 ; Publication No. US20050014712A1
 ; GENERAL INFORMATION:
 ; APPLICANT: HANSEN, BO
 ; APPLICANT: THRU, CHARLOTTE ALBAEK
 ; APPLICANT: WESTERGAARD, MAJKEN
 ; APPLICANT: PETERSEN, KAMILLE DUMONG
 ; APPLICANT: WISSENBACH, MARGIT
 ; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
 ; FILE REFERENCE: 58610(71432)
 ; CURRENT APPLICATION NUMBER: US/10/776,934
 ; CURRENT FILING DATE: 2004-02-10
 ; PRIOR APPLICATION NUMBER: 60/446,372
 ; PRIOR FILING DATE: 2003-02-10
 ; PRIOR APPLICATION NUMBER: 60/523,591
 ; PRIOR FILING DATE: 2003-11-19

; NUMBER OF SEQ ID NOS: 741
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 570
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic oligonucleotide
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (1)..(4)
 ; OTHER INFORMATION: beta-D-oxy-LNA modified base
 ; FEATURE:
 ; NAME/KEY: modified_base
 ; LOCATION: (13)..(15)
 ; OTHER INFORMATION: beta-D-oxy-LNA modified base
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: (5)..(13)
 ; OTHER INFORMATION: phosphothioate linkage
 US-10-776-934-570

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 161 TTAGGCGGCAGCAGCT 176
 |||||
 Db 16 TTGGAGGCAGCAGCT 1

RESULT 223

US-10-776-934-571/c
 ; Sequence 571, Application US/10776934
 ; Publication No. US20050014712A1
 ; GENERAL INFORMATION:
 ; APPLICANT: HANSEN, BO
 ; APPLICANT: THRU, CHARLOTTE ALBAEK
 ; APPLICANT: WESTERGAARD, MAJKEN
 ; APPLICANT: PETERSEN, KAMILLE DUMONG
 ; APPLICANT: WISSENBACH, MARGIT
 ; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
 ; FILE REFERENCE: 58610(71432)
 ; CURRENT APPLICATION NUMBER: US/10/776,934
 ; CURRENT FILING DATE: 2004-02-10
 ; PRIOR APPLICATION NUMBER: 60/446,372
 ; PRIOR FILING DATE: 2003-02-10
 ; PRIOR APPLICATION NUMBER: 60/523,591
 ; PRIOR FILING DATE: 2003-11-19
 ; NUMBER OF SEQ ID NOS: 741
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 571
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Artificial sequence
 ; FEATURE:
 ; OTHER INFORMATION: Synthetic oligonucleotide
 ; FEATURE:
 ; NAME/KEY: misc_feature
 ; LOCATION: (1)..(16)
 ; OTHER INFORMATION: phosphothioate linkage
 US-10-776-934-571

Query Match 1.7%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 1.4e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 161 TTAGGCGGCAGCAGCT 176
 |||||
 Db 16 TTGGAGGCAGCAGCT 1

RESULT 224

```
US-10-730-771-330/c
; Sequence 330, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 330
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-330

Query Match      1.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      464 GGTGTGAGACCCACCC 479
          |||||
Db      16  GGTGAGGACCCAGCC 1

Search completed: October 18, 2005, 09:44:31
Job time : 3 secs
```

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)